0001654954-24-01065110-Q CEL SCI CORP 20240814202408141627321627321627320 0001654954-24-010651 10-Q 58 20240630 20240814 20240814 CEL SCI CORP 0000725363 2836 840916344 CO 0930 10-Q 34 001-11889 241208474 8229 BOONE BLVD . SUITE 802 VIENNA VA 22182 7035069460 8229 BOONE BLVD. SUITE 802 VIENNA VA 22182 INTERLEUKIN 2 INC 19880317 10-Q 1 cvm_10q.htm FORM 10-Q cvm_10q.htm0000725363false--09-30Q320240.012000000000.016000000000542578844742230400005800080620300000.0300000.0100000.000007253632023-10-012024-06-300000725363us-gaap:SubsequentEventMembercvm:MrKerstenMember2024-07-012024-07-180000725363us-gaap:SubsequentEventMembersrt:ChiefExecutiveOfficerMember2024-07-110000725363us-gaap:SubsequentEventMember2024-07-012024-07-290000725363us-gaap:SubsequentEventMember2024-07-290000725363cvm:UnvestedRestrictedStockMember2022-10-012023-06-300000725363cvm:UnvestedRestrictedStockMember2023-10-012024-06-300000725363cvm:OptionsMember2022-10-012023-06-300000725363cvm:OptionsMember2023-10-012024-06-300000725363cvm:LandlordMember2023-01-012023-01-110000725363cvm:ErgomedMember2023-04-012023-06-300000725363cvm:ErgomedMember2022-10-012023-06-300000725363us-gaap:LeaseAgreementsMember2022-10-012023-06-300000725363us-gaap:LeaseAgreementsMember2023-10-012024-06-300000725363cvm:ErgomedMember2023-10-012024-06-300000725363cvm:OfficerandDirectorMember2023-10-012023-10-280000725363cvm:OfficerandDirectorMember2024-04-012024-06-300000725363cvm:OfficerandDirectorMember2023-10-012024-06-300000725363cvm:OfficerandDirectorMember2024-05-012024-05-040000725363cvm:ConsultingAgreementsMember2023-04-012023-06-300000725363cvm:ConsultingAgreementsMember2024-04-012024-06-3000007253632024-02-012024-02-2900007253632023-11-012023-11-300000725363cvm:EquityProceedsFromSaleCommonStockMember2023-05-012023-05-310000725363cvm:EquityProceedsFromSaleCommonStockMember2023-10-012024-06-300000725363cvm:EquityProceedsFromSaleCommonStockMember2024-06-3000007253632023-11-3000007253632024-02-290000725363cvm:RestrictedStocksMembercvm:ConsultantsMember2022-10-012023-06-300000725363cvm:ConsultingAgreementsMember2023-09-300000725363cvm:ConsultingAgreementsMember2024-06-300000725363cvm:RestrictedStocksMembercvm:ConsultantsMember2023-04-012023-06-300000725363cvm:RestrictedStocksMembercvm:ConsultantsMember2024-04-012024-06-300000725363cvm:ConsultingAgreementsMember2023-10-012024-06-300000725363cvm:RestrictedStocksMembercvm:ConsultantsMember2023-10-012024-06-300000725363cvm:ConsultingAgreementsMember2022-10-012023-06-300000725363cvm:ConsultingAgreementsOtherMember2023-10-012024-06-300000725363cvm:SeriesRRMember2022-10-012022-10-280000725363cvm:SeriesSSMember2023-10-012024-06-300000725363srt:MinimumMembercvm:ConsultantsMember2024-06-300000725363cvm:ConsultantsOptionMember2024-06-300000725363cvm:SeriesRRMember2024-06-300000725363cvm:SeriesNNMember2024-06-300000725363cvm:SeriesMMMember2024-06-300000725363cvm:SeriesYMember2024-06-300000725363cvm:SeriesXMember2024-06-300000725363cvm:SeriesUUMember2024-06-300000725363cvm:SeriesNMember2024-06-300000725363srt:MaximumMembercvm:ConsultantsMember2023-10-012024-06-300000725363srt:MinimumMembercvm:ConsultantsMember2023-10-012024-06-300000725363cvm:SeriesRRMember2023-10-012024-06-300000725363cvm:SeriesNNMember2023-10-012024-06-300000725363cvm:SeriesMMMember2023-10-012024-06-300000725363cvm:SeriesYMember2023-10-012024-06-300000725363cvm:SeriesXMember2023-10-012024-06-300000725363cvm:SeriesUUMember2023-10-012024-06-300000725363cvm:SeriesNMember2023-10-012024-06-300000725363cvm:NonEmployeesMember2023-04-012023-06-300000725363cvm:NonEmployeesMember2024-04-012024-06-300000725363cvm:NonEmployeesMember2022-10-012023-06-300000725363cvm:NonEmployeesMember2023-10-012024-06-300000725363us-gaap:EmployeeStockMember2023-10-012024-06-300000725363us-gaap:EmployeeStockMember2022-10-012023-06-300000725363us-gaap:EmployeeStockMember2023-04-012023-06-300000725363us-gaap:EmployeeStockMember2024-04-012024-06-300000725363cvm:IncentiveStockBonusPlansMember2024-06-300000725363us-gaap:StockCompensationPlanMember2024-06-300000725363cvm:StockBonusPlansMember2024-06-300000725363cvm:NonQualifiedStockOptionsPlansMember2024-06-300000725363cvm:IncentiveStockBonusPlanMember2024-06-300000725363us-gaap:RetainedEarningsMember2024-06-300000725363us-gaap:AdditionalPaidInCapitalMember2024-06-300000725363us-gaap:CommonStockMember2024-06-300000725363us-gaap:RetainedEarningsMember2024-04-012024-06-300000725363us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000725363us-gaap:CommonStockMember2024-04-012024-06-3000007253632024-03-310000725363us-gaap:RetainedEarningsMember2024-03-310000725363us-gaap:AdditionalPaidInCapitalMember2024-03-310000725363us-gaap:CommonStockMember2024-03-3100007253632024-01-012024-03-310000725363us-gaap:RetainedEarningsMember2024-01-012024-03-310000725363us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000725363us-gaap:CommonStockMember2024-01-012024-03-3100007253632023-12-310000725363us-gaap:RetainedEarningsMember2023-12-310000725363us-gaap:AdditionalPaidInCapitalMember2023-12-310000725363us-gaap:CommonStockMember2023-12-3100007253632023-10-012023-12-310000725363us-gaap:RetainedEarningsMember2023-10-012023-12-310000725363us-gaap:AdditionalPaidInCapitalMember2023-10-012023-12-310000725363us-gaap:CommonStockMember2023-10-012023-12-310000725363us-gaap:RetainedEarningsMember2023-09-300000725363us-gaap:AdditionalPaidInCapitalMember2023-09-300000725363us-gaap:CommonStockMember2023-09-3000007253632023-06-300000725363us-gaap:RetainedEarningsMember2023-06-300000725363us-gaap:AdditionalPaidInCapitalMember2023-06-300000725363us-gaap:CommonStockMember2023-06-300000725363us-gaap:RetainedEarningsMember2023-04-012023-06-300000725363us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000725363us-gaap:CommonStockMember2023-04-012023-06-3000007253632023-03-310000725363us-gaap:RetainedEarningsMember2023-03-310000725363us-gaap:AdditionalPaidInCapitalMember2023-03-310000725363us-gaap:CommonStockMember2023-03-3100007253632023-01-012023-03-310000725363us-gaap:RetainedEarningsMember2023-01-012023-03-310000725363us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000725363us-gaap:CommonStockMember2023-01-012023-03-3100007253632022-12-310000725363us-gaap:RetainedEarningsMember2022-12-310000725363us-gaap:AdditionalPaidInCapitalMember2022-12-310000725363us-gaap:CommonStockMember2022-12-3100007253632022-10-012022-12-310000725363us-gaap:RetainedEarningsMember2022-10-012022-12-310000725363us-gaap:AdditionalPaidInCapitalMember2022-10-012022-12-310000725363us-gaap:CommonStockMember2022-10-012022-12-3100007253632022-09-300000725363us-gaap:RetainedEarningsMember2022-09-300000725363us-gaap:AdditionalPaidInCapitalMember2022-09-300000725363us-gaap:CommonStockMember2022-09-3000007253632022-10-012023-06-3000007253632024-06-3000007253632023-09-3000007253632024-08-08iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pure UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549Â FORM 10-QÂ (Mark One)â˜’QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934Â For the quarterly period ended June 30, 2024Â ORÂ â˜TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934Â For the transition period from ________________ to _______________.Â Commission File Number 001-11889Â CEL-SCI CORPORATIONÂ Â ColoradoÂ 84-0916344State or other jurisdiction incorporationÂ (IRS) Employer Identification NumberÂ Â 8229 Boone Boulevard, Suite 802Â Vienna, Virginia 22182Â Address of principal executive officesÂ Â (703) 506-9460Â Registrant's telephone number, including area codeÂ Securities registered pursuant to Section 12(b) of the Act:Â Title of Each ClassÂ Trading Symbol(s)Â Name of Each Exchange on Which RegisteredCommon StockÂ CVMÂ NYSE AmericanÂ Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) had been subject to such filing requirements for the past 90 days. Yes â˜’Â Â No â˜Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes â˜’Â Â No â˜Â Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filerâ€, â€œsmaller reporting companyâ€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act:Â LargeÂ acceleratedÂ filerâ˜AcceleratedÂ filerâ˜Non-accelerated filerâ˜’ SmallerÂ reportingÂ companyâ˜’Â Â Emerging growth companyâ˜Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜Â Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act). Yes â˜Â Â Â No â˜’Â Class of StockÂ Â No. Shares OutstandingÂ DateCommon Â 61,493,229Â August 8, 2024Â Â Â Â TABLE OF CONTENTS Â PART I FINANCIAL INFORMATIONÂ Item 1.Â Â PageÂ Â Â Â Â Â Condensed Balance Sheets at June 30, 2024 (unaudited) and September 30, 2023Â 3Â Â Â Â Â Condensed Statements of Operations for the nine months ended June 30, 2024 and 2023 (unaudited)Â 4Â Â Â Â Â Â Â Condensed Statements of Operations for the three months ended June 30, 2024 and 2023 (unaudited)Â 5Â Â Â Â Â Condensed Statements of Stockholdersâ€™ Equity for the nine months ended June 30, 2024 and 2023 (unaudited)Â 6Â Â Â Â Â Condensed Statements of Cash Flows for the nine months ended June 30, 2024 and 2023 (unaudited)Â 8Â Â Â Â Â Â Â Notes to Condensed Financial StatementsÂ (unaudited)Â 10Â Â Â Â Â Item 2.Management's Discussion and Analysis of Financial Condition and Results of OperationsÂ 19Â Â Â Â Item 3.Quantitative and Qualitative Disclosures about Market RisksÂ 29Â Â Â Â Item 4.Controls and ProceduresÂ 29Â Â Â Â Â PART IIÂ Â Â Â Â Â Item 2.Unregistered Sales of Equity Securities and Use of ProceedsÂ 30Â Â Â Â Â Item 5.Other InformationÂ 30Â Â Â Â Â Â Item 6.ExhibitsÂ 30Â Â Â Â Â Â SignaturesÂ 31Â Â Â 2Table of Contents CEL-SCI CORPORATIONCONDENSED BALANCE SHEETSÂ Â Â Â Â Â Â Â JUNE 30,Â Â SEPTEMBER 30, Â ASSETSÂ 2024Â Â 2023Â Â Â (UNAUDITED)Â Â Â Â Current assets:Â Â Â Â Â Â Cash and cash equivalentsÂ $384,652Â Â $4,145,735Â Prepaid expensesÂ Â 551,337Â Â Â 520,368Â Supplies used for R&D and manufacturingÂ Â 2,555,249Â Â Â 2,248,072Â DepositsÂ Â 51,129Â Â Â 4,245Â Â Â Â Â Â Â Â Total current assetsÂ Â 3,542,367Â Â Â 6,918,420Â Â Â Â Â Â Â Â Â Â Finance lease right of use assetsÂ Â 7,800,909Â Â Â 9,131,987Â Operating lease right of use assetsÂ Â 1,548,010Â Â Â 1,698,243Â Property and equipment, netÂ Â 8,613,316Â Â Â 10,188,126Â Patent costs, netÂ Â 173,028Â Â Â 197,704Â DepositsÂ Â 2,319,101Â Â Â 2,319,101Â Supplies used for R&D and manufacturingÂ Â 71,589Â Â Â 74,669Â Â Â Â Â Â Â Â Â Â Total assetsÂ $24,068,320Â Â $30,528,250Â Â Â Â Â Â Â Â Â Â LIABILITIES AND STOCKHOLDERS' EQUITYÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Current liabilities:Â Â Â Â Â Â Â Â Accounts payableÂ $1,369,441Â Â $2,009,786Â Accrued expensesÂ Â 1,272,149Â Â Â 1,049,581Â Due to employeesÂ Â 696,487Â Â Â 557,244Â Finance lease obligation, current portionÂ Â 1,949,245Â Â Â 1,771,804Â Operating lease obligation, current portionÂ Â 219,019Â Â Â 197,431Â Â Â Â Â Â Â Â Â Total current liabilitiesÂ Â 5,506,341Â Â Â 5,585,846Â Â Â Â Â Â Â Â Â Finance lease obligations, net of current portionÂ Â 8,477,784Â Â Â 9,949,565Â Operating lease obligations, net of current portionÂ Â 1,486,138Â Â Â 1,652,949Â Other liabilitiesÂ Â 125,000Â Â Â 125,000Â Â Â Â Â Â Â Â Â Total liabilitiesÂ Â 15,595,263Â Â Â 17,313,360Â Â Â Â Â Â Â Â Â Commitments and contingencies (refer to Note E)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â STOCKHOLDERS' EQUITYÂ Â Â Â Â Â Â Preferred stock, $0.01 par value; 200,000 shares authorized; 0 shares issued and outstandingÂ Â -Â Â Â -Â Common stock, $0.01 par value; 600,000,000 shares authorized; 54,257,884 and 47,422,304 shares issued and outstanding at June 30, 2024 and September 30, 2023, respectivelyÂ Â 542,578Â Â Â 474,223Â Additional paid-in capitalÂ Â 515,832,848Â Â Â 499,832,063Â Accumulated deficitÂ Â (507,902,369)Â Â (487,091,396)Â Â Â Â Â Â Â Â Â Total stockholders' equityÂ Â 8,473,057Â Â Â 13,214,890Â Â Â Â Â Â Â Â Â Â TOTAL LIABILITIES AND STOCKHOLDERS' EQUITYÂ $24,068,320Â Â $30,528,250Â Â Â Â Â Â Â Â Â See notes to condensed financial statements.Â Â 3Table of Contents CEL-SCI CORPORATIONCONDENSED STATEMENTS OF OPERATIONSNINE MONTHS ENDED JUNE 30, 2024 and 2023(UNAUDITED)Â Â Â Â Â Â Â Â 2024Â Â 2023Â Â Â Â Â Â Â Operating expenses:Â Â Â Â Â Â Research and developmentÂ $13,684,204Â Â $17,203,823Â General and administrativeÂ Â 6,547,866Â Â Â 6,804,729Â Total operating expensesÂ Â 20,232,070Â Â Â 24,008,552Â Â Â Â Â Â Â Â Operating lossÂ Â (20,232,070)Â Â (24,008,552)Â Â Â Â Â Â Â Â Interest expense, netÂ Â (571,102)Â Â (493,522)Other expenseÂ Â (7,801)Â Â (61,525)Â Â Â Â Â Â Â Â Â Net lossÂ Â (20,810,973)Â Â (24,563,599)Modification of warrantsÂ Â (659,456)Â Â (171,552)Â Â Â Â Â Â Â Â Net loss available to common shareholdersÂ $(21,470,429)Â $(24,735,151)Â Â Â Â Â Â Â Â Net loss per common share â€“ basic and dilutedÂ $(0.42)Â $(0.57)Weighted average common shares outstanding â€“ basic and dilutedÂ Â 51,479,454Â Â Â 43,761,395Â Â Â Â Â Â Â Â Â See notes to condensed financial statements.Â Â 4Table of Contents CEL-SCI CORPORATIONCONDENSED STATEMENTS OF OPERATIONSTHREE MONTHS ENDED JUNE 30, 2024 and 2023(UNAUDITED)Â Â Â Â Â Â Â Â 2024Â Â 2023Â Â Â Â Â Â Â Operating expenses:Â Â Â Â Â Â Research and developmentÂ $4,703,160Â Â $5,727,789Â General and administrativeÂ Â 1,967,075Â Â Â 2,453,968Â Total operating expensesÂ Â 6,670,235Â Â Â 8,181,757Â Â Â Â Â Â Â Â Â Operating lossÂ Â (6,670,235)Â Â (8,181,757)Â Â Â Â Â Â Â Â Interest expense, netÂ Â (190,705)Â Â (181,670)Other income (expense)Â Â 4,382Â Â Â (3,854)Â Â Â Â Â Â Â Â Â Net lossÂ Â (6,856,558)Â Â (8,367,281)Modification of warrantsÂ Â (659,456)Â Â -Â Â Â Â Â Â Â Â Â Net loss available to common shareholdersÂ $(7,516,014)Â $(8,367,281)Â Â Â Â Â Â Â Â Net loss per common share â€“ basic and dilutedÂ $(0.14)Â $(0.19)Weighted average common shares outstanding â€“ basic and dilutedÂ Â 53,994,384Â Â Â 44,254,363Â Â Â Â Â Â Â Â Â See notes to condensed financial statements.Â Â 5Table of Contents CEL-SCI CORPORATIONSTATEMENTS OF STOCKHOLDERSâ€™ EQUITY(UNAUDITED)Â Â Â Â Â Â Â AdditionalÂ Â Â Â Â Â Â Common StockÂ Paid-InÂ Â AccumulatedÂ Â Â Â Â Shares Â Â AmountÂ Â CapitalÂ Â DeficitÂ Â TotalÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â BALANCES AT SEPTEMBER 30, 2023Â Â 47,422,304Â Â $474,223Â Â $499,832,063Â Â $(487,091,396)Â $13,214,890Â 401(k) contributions paid in common stockÂ Â 17,724Â Â Â 177Â Â Â 48,730Â Â Â -Â Â Â 48,907Â Stock issued to nonemployees for serviceÂ Â 88,573Â Â Â 886Â Â Â 201,421Â Â Â -Â Â Â 202,307Â Proceeds from the sale of common stockÂ Â 2,490,000Â Â Â 24,900Â Â Â 4,955,100Â Â Â -Â Â Â 4,980,000Â Equity based compensation â€“ employeesÂ Â -Â Â Â -Â Â Â 1,383,909Â Â Â -Â Â Â 1,383,909Â Share issuance costsÂ Â -Â Â Â -Â Â Â (470,229)Â Â -Â Â Â (470,229)Net lossÂ Â -Â Â Â -Â Â Â -Â Â Â (6,709,524)Â Â (6,709,524)BALANCES AT DECEMBER 31, 2023Â Â 50,018,601Â Â $500,186Â Â $505,950,994Â Â $(493,800,920)Â $12,650,260Â Â 401(k) contributions paid in common stockÂ Â 27,373Â Â Â 274Â Â Â 53,211Â Â Â -Â Â Â 53,485Â Stock issued to nonemployees for serviceÂ Â 162,744Â Â Â 1,627Â Â Â 379,243Â Â Â -Â Â Â 380,870Â Proceeds from the sale of common stockÂ Â 3,875,000Â Â Â 38,750Â Â Â 7,711,250Â Â Â -Â Â Â 7,750,000Â Equity based compensation â€“ employeesÂ Â -Â Â Â -Â Â Â 1,432,540Â Â Â -Â Â Â 1,432,540Â Share issuance costsÂ Â -Â Â Â -Â Â Â (717,621)Â Â -Â Â Â (717,621)Net lossÂ Â -Â Â Â -Â Â Â -Â Â Â (7,244,891)Â Â (7,244,891)BALANCES AT MARCH 31 , 2024Â Â 54,083,718Â Â $540,837Â Â $514,809,617Â Â $(501,045,811)Â $14,304,643Â Â 401(k) contributions paid in common stockÂ Â 45,722Â Â Â 457Â Â Â 60,120Â Â Â -Â Â Â 60,577Â Stock issued to nonemployees for serviceÂ Â 70,444Â Â Â 704Â Â Â 154,951Â Â Â -Â Â Â 155,655Â Purchase of stock by officers and directorsÂ Â 58,000Â Â Â 580Â Â Â 80,040Â Â Â -Â Â Â 80,620Â Equity based compensation â€“ employeesÂ Â -Â Â Â -Â Â Â 728,120Â Â Â -Â Â Â 728,120Â Net lossÂ Â -Â Â Â -Â Â Â -Â Â Â (6,856,558)Â Â (6,856,558)BALANCES AT JUNE 30, 2024Â Â 54,257,884Â Â $542,578Â Â $515,832,848Â Â $(507,902,369)Â $8,473,057Â Â See notes to condensed financial statements.Â Â 6Table of Contents CEL-SCI CORPORATIONSTATEMENTS OF STOCKHOLDERSâ€™ EQUITY (continued) (UNAUDITED)Â Â Â Â Â Â Â AdditionalÂ Â Â Â Â Â Â Common StockÂ Paid-InÂ Â AccumulatedÂ Â Â Â Â Shares Â Â AmountÂ Â CapitalÂ Â DeficitÂ Â TotalÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â BALANCES AT SEPTEMBER 30, 2022Â Â 43,448,317Â Â $434,484Â Â $486,625,816Â Â $(454,897,093)Â $32,163,207Â Warrant exercisesÂ Â 217,752Â Â Â 2,177Â Â Â 445,114Â Â Â -Â Â Â 447,291Â Equity based compensation â€“ employeesÂ Â -Â Â Â -Â Â Â 1,703,931Â Â Â -Â Â Â 1,703,931Â 401(k) contributions paid in common stockÂ Â 21,331Â Â Â 213Â Â Â 49,965Â Â Â -Â Â Â 50,178Â Stock issued to nonemployees for serviceÂ Â 40,236Â Â Â 402Â Â Â 91,221Â Â Â -Â Â Â 91,623Â 2014 incentive stock forfeitedÂ Â (2,000)Â Â (20)Â Â (11,080)Â Â -Â Â Â (11,100)Net lossÂ Â -Â Â Â -Â Â Â -Â Â Â (7,853,509)Â Â (7,853,509)BALANCES AT DECEMBER 31, 2022Â Â 43,725,636Â Â $437,256Â Â $488,904,967Â Â $(462,750,602)Â $26,591,621Â Equity based compensation â€“ employeesÂ Â -Â Â Â -Â Â Â 1,743,288Â Â Â -Â Â Â 1,743,288Â 401(k) contributions paid in common stockÂ Â 23,627Â Â Â 236Â Â Â 54,629Â Â Â -Â Â Â 54,865Â Stock issued to nonemployees for serviceÂ Â 38,562Â Â Â 386Â Â Â 100,249Â Â Â -Â Â Â 100,635Â Net lossÂ Â -Â Â Â -Â Â Â -Â Â Â (8,342,809)Â Â (8,342,809)BALANCES AT MARCH 31 , 2023Â Â 43,787,825Â Â $437,878Â Â $490,803,133Â Â $(471,093,411)Â $20,147,600Â Equity based compensation â€“ employeesÂ Â -Â Â Â -Â Â Â 1,551,319Â Â Â -Â Â Â 1,551,319Â 401(k) contributions paid in common stockÂ Â 12,855Â Â Â 129Â Â Â 52,534Â Â Â -Â Â Â 52,663Â Stock issued to nonemployees for serviceÂ Â 36,523Â Â Â 365Â Â Â 135,304Â Â Â -Â Â Â 135,669Â Proceeds from the sale of common stockÂ Â 913,234Â Â Â 9,132Â Â Â 1,543,365Â Â Â -Â Â Â 1,552,497Â 2014 Incentive Stock ForfeitedÂ Â (2,000)Â Â (20)Â Â (11,080)Â Â -Â Â Â (11,100)Share issuance costsÂ Â -Â Â Â -Â Â Â (271,968)Â Â -Â Â Â (271,968)Net lossÂ Â -Â Â Â -Â Â Â -Â Â Â (8,367,281)Â Â (8,367,281)BALANCES AT JUNE 30 , 2023Â Â 44,748,437Â Â $447,484Â Â $493,802,607Â Â $(479,460,692)Â $14,789,399Â Â See notes to condensed financial statements.Â Â 7Table of ContentsÂ CEL-SCI CORPORATIONCONDENSED STATEMENTS OF CASH FLOWSNINE MONTHS ENDED JUNE 30, 2024 and 2023(UNAUDITED)Â Â Â Â Â Â Â Â Â 2024Â Â 2023Â Â Â Â Â Â Â Â Net lossÂ $(20,810,973)Â $(24,563,599)Adjustments to reconcile net loss to net cash used in operating activities:Â Â Â Â Â Â Â Â Depreciation and amortizationÂ Â 2,977,603Â Â Â 2,959,681Â Non-cash lease expenseÂ Â 5,008Â Â Â 12,788Â Share-based payments for servicesÂ Â 778,571Â Â Â 473,723Â Equity-based compensationÂ Â 3,544,569Â Â Â 4,976,338Â Common stock contributed to 401(k) plan (Increase)/decrease in assets:Â Â 162,969Â Â Â 157,706Â Prepaid expensesÂ Â (15,708)Â Â Â 208,419Â Supplies used for R&D and manufacturingÂ Â (304,097)Â Â (24,491)DepositsÂ Â (46,884)Â Â (2,342,951)Increase/(decrease) in liabilities:Â Â Â Â Â Â Â Â Accounts payableÂ Â (592,370)Â Â 66,616Â Accrued expensesÂ Â 167,568Â Â Â 243,800Â Due to employeesÂ Â 139,243Â Â Â 28,173Â Â Â Â Â Â Â Â Â Â Net cash used in operating activitiesÂ Â (13,994,502)Â Â (17,803,797)Â Â Â Â Â Â Â Â Â CASH FLOWS FROM INVESTING ACTIVITIES:Â Â Â Â Â Â Â Â Purchases of property and equipmentÂ Â (75,122)Â Â (361,892)Expenditures for patent costsÂ Â (13,211)Â Â -Â Â Â Â Â Â Â Â Â Â Net cash used in investing activitiesÂ Â (88,333)Â Â (361,892)Â Â Â Â Â Â Â Â Â CASH FLOWS FROM FINANCING ACTIVITIES:Â Â Â Â Â Â Â Â Proceeds from issuance of common stockÂ Â 12,730,000Â Â Â 1,552,497Â Payments of stock issuance costsÂ Â (1,173,577)Â Â (213,796)Proceeds from the purchase of stock by officers and directorsÂ Â 80,620Â Â Â -Â Proceeds from the exercise of warrantsÂ Â -Â Â Â 447,291Â Payments on obligations under finance leasesÂ Â (1,315,291)Â Â (1,157,371)Â Â Â Â Â Â Â Â Â Net cash provided by financing activitiesÂ Â 10,321,752Â Â Â 628,621Â Â Â Â Â Â Â Â Â Â NET DECREASE IN CASH AND CASH EQUIVALENTSÂ Â (3,761,083)Â Â (17,537,068)Â Â Â Â Â Â Â Â Â CASH AND CASH EQUIVALENTS, BEGINNING OF PERIODÂ Â 4,145,735Â Â Â 22,672,138Â Â Â Â Â Â Â Â Â Â CASH AND CASH EQUIVALENTS, END OF PERIODÂ $384,652Â Â $5,135,070Â Â Â Â Â Â Â Â Â Â See notes to condensed financial statements.Â Â 8Table of ContentsÂ CEL-SCI CORPORATIONCONDENSED STATEMENTS OF CASH FLOWSNINE MONTHS ENDED JUNE 30, 2024 and 2023(UNAUDITED)Â Â Â 2024Â Â 2023Â SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:Â Â Â Â Â Â Assets purchased under finance leasesÂ $20,797Â Â $-Â Finance lease obligation included in accounts payableÂ $1,296Â Â $927Â Property and equipment included in current liabilitiesÂ $2,770Â Â Â -Â Consulting services paid with issuance of common stockÂ $738,832Â Â $327,927Â Accrued consulting services to be paid with common stockÂ $110,000Â Â $110,000Â Financing costs included in current liabilitiesÂ $91,975Â Â $58,172Â Â Â Â Â Â Â Â Â Â Cash paid for interestÂ $706,517Â Â $809,495Â Â Â Â Â Â Â Â Â Â See notes to condensed financial statements.Â Â 9Table of ContentsÂ CEL-SCI CORPORATIONNOTES TO CONDENSED FINANCIAL STATEMENTSNINE MONTHS ENDED JUNE 30, 2024 AND 2023 (UNAUDITED)Â A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESÂ Basis of PresentationÂ The accompanying condensed financial statements of CEL-SCI Corporation (the â€œCompanyâ€) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Companyâ€™s annual report on Form 10-K for the year ended September 30, 2023.Â In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments (all of which are of a normal recurring nature) and disclosures necessary for a fair presentation of the Companyâ€™s financial position as of June 30, 2024 and the results of its operations for the nine months then ended. The condensed balance sheet as of September 30, 2023 is derived from the September 30, 2023 audited financial statements.Â Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Companyâ€™s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.Â Summary of Significant Accounting Policies:Â Cash and Cash Equivalents â€“ Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.Â Property and Equipment â€“ Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.Â Supplies used for R&D and manufacturing â€“ Supplies are consumable items kept on hand to support the Companyâ€™s R&D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.Â Patents â€“ Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.Â Leases â€“ The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.Â Â 10Table of ContentsÂ Share-Based Compensation â€“ Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, Compensation â€“ Stock Compensation (â€œASC 718â€). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.Â The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the â€œPlansâ€. All Plans have been approved by the Companyâ€™s stockholders.Â The Companyâ€™s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Companyâ€™s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.Â The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.Â Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.Â Research and Development Costs â€“ Research and development costs are expensed as incurred.Â Management accrues Clinical Research Organization (â€œCROâ€) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. Â Net Loss Per Common Share â€“ The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share.Â Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period.Â The Companyâ€™s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.Â Income Taxes â€“ The Company accounts for income taxes in accordance with the provisions of ASC 740, Income Taxes, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards.Â Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.Â The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.Â The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of June 30, 2024 and September 30, 2023.Â Â 11Table of ContentsÂ Impairment of long-lived assets â€“ CEL-SCIâ€™s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCIâ€™s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.Â Use of Estimates â€“ The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.Â These estimates are based on managementâ€™s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year.Â Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.Â The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. Â Recently Adopted Accounting StandardsÂ In June 2016, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update No. 2016-13, Financial Instruments â€“ Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (â€œASU 2016-13â€). ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no impact on the Companyâ€™s financial position, results of operations, or cash flows. Â New Accounting PronouncementsÂ In November 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (â€œASU 2023-07â€), which expands disclosures about a public entityâ€™s reportable segments and requires more enhanced information about a reportable segmentâ€™s expenses, interim segment profit or loss, and how a public entityâ€™s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is assessing the effect of this update on the condensed financial statement disclosures. Â In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Improvements to Income Tax Disclosures, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.Â B. LIQUIDITYÂ The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and conducting clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine, the Companyâ€™s lead investigational therapy, to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from any regulatory agency for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.Â Â 12Table of ContentsÂ To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.Â Due to the Companyâ€™s recurring losses from operations and future liquidity needs, there is substantial doubt about the Companyâ€™s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.Â C. STOCKHOLDERSâ€™ EQUITYÂ Proceeds from the Sale of Common StockÂ In February 2024, the Company sold 3,875,000 shares of common stock at a public offering price of $2.00 per share and received proceeds of approximately $7.0 million, net of issuance costs of approximately $0.7 million.Â In November 2023, the Company sold 2,490,000 shares of common stock at a public offering price of $2.00 per share and received proceeds of approximately $4.5 million, net of issuance costs of approximately $0.5 million.Â In April 2023, the Company sold 794,117 shares of common stock at a public offering price of $1.70 per share and received proceeds of approximately $1.4 million. The Company granted the underwriters a 30-day option to purchase up to 119,117 additional shares of common stock to cover over-allotments. The underwriter fully exercised this option in May 2023, resulting in additional proceeds to the Company of approximately $200,000. The Company incurred issuance costs of approximately $0.2 million related to this offering.Â Equity CompensationÂ Underlying share information for equity compensation plans as of June 30, 2024 is as follows:Â Name of PlanÂ Total Shares Reserved Under PlansÂ Incentive Stock Option PlansÂ Â 138,400Â Non-Qualified Stock Option PlansÂ Â 17,787,200Â Stock Bonus PlansÂ Â 1,283,760Â Stock Compensation PlansÂ Â 634,000Â Incentive Stock Bonus PlanÂ Â 640,000Â Â Â 13Table of ContentsÂ Â Stock option activity:Â Â Â Nine months ended June 30,Â Â Â Â 2024Â Â Â 2023Â Options grantedÂ Â 1,967,500Â Â Â 6,500Â Options exercisedÂ Â -Â Â Â -Â Options forfeitedÂ Â 293,000Â Â Â 179,832Â Options expiredÂ Â 27,075Â Â Â 58,787Â Â Â Â Three Months Ended June 30,Â Â Â Â 2024Â Â Â 2023Â Options grantedÂ Â 1,964,500Â Â Â 2,000Â Options exercisedÂ Â -Â Â Â -Â Options forfeitedÂ Â 240,000Â Â Â 57,500Â Options expiredÂ Â 40Â Â Â 13,383Â Â On March 1, 2024, the Company accelerated the vesting of 234,332 stock options issued to directors to vest on April 19, 2024. The Company concluded that the change in vesting of the options should be treated as a modification in accordance with ASC 718. As such, the Company revalued the options as of March 1, 2024 (the modification date) and subtracted any compensation cost already recognized prior to the modification date. This resulted in remaining compensation cost of approximately $260,000 that was amortized on a straight-line basis over the remaining service period. The remaining compensation cost of approximately $101,000 as of March 31, 2024 was expensed during the three months ended June 30, 2024.Â Share-Based Compensation Expense:Â Â Â Nine months ended June 30,Â Â Â 2024Â Â 2023Â EmployeesÂ $3,544,569Â Â $4,976,338Â Non-employeesÂ $600,841Â Â $473,723Â Â Â Â Three Months Ended June 30,Â Â Â 2024Â Â 2023Â EmployeesÂ $728,120Â Â $1,540,219Â Non-employeesÂ $230,678Â Â $188,001Â Â Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods.Â Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts. Â Â 14Table of ContentsÂ Warrants and Non-Employee OptionsÂ The following chart represents the warrants and non-employee options outstanding at June 30, 2024:Â Warrant/OptionsÂ Issue DateÂ Shares Issuableupon Exercise of Warrants/ OptionsÂ Â Exercise PriceÂ Â Expiration DateÂ Series NÂ 8/18/2008Â Â 85,339Â Â $3.00Â Â 8/18/2026Â Â Series UUÂ 6/11/2018Â Â 93,603Â Â $2.80Â Â 6/30/2026Â Series XÂ 1/13/2016Â Â 120,000Â Â $9.25Â Â 7/13/2026Â Series YÂ 2/15/2016Â Â 26,000Â Â $12.00Â Â 8/15/2026Â Series MMÂ 6/22/2017Â Â 333,432Â Â $1.86Â Â 6/22/2026Â Series NNÂ 7/24/2017Â Â 200,087Â Â $2.52Â Â 7/24/2026Â Series RRÂ 10/30/2017Â Â 234,009Â Â $1.65Â Â 10/30/2026Â Consultant OptionsÂ 7/28/2017 â€" 9/2/2023Â Â 110,000Â Â $1.39- $2.18Â Â 7/27/2027 - 9/1/2028Â Â 1. Equity WarrantsÂ Changes in Equity WarrantsÂ No warrants recorded as equity were exercised during the nine months ended June 30, 2024. The following warrants recorded as equity were exercised during the nine months ended June 30, 2023.Â WarrantsÂ Warrants ExercisedÂ Â Exercise PriceÂ Â ProceedsÂ Series RRÂ Â 17,752Â Â $1.65Â Â $29,291Â Series SSÂ Â 200,000Â Â $2.09Â Â 418,000Â Â Â Â 217,752Â Â Â Â Â Â $447,291Â Â No warrants recorded as equity expired during the nine and three months ended June 30,2024. On February 5, 2023, 600 Series TT warrants, with an exercise price of $2.24, expired.Â On May 4, 2024, the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $659,455, which was recorded as a deemed dividend in the financial statements for the nine and three months ended June 30, 2024. The Series N, X, MM, NN, RR and UU warrants are held by current Officers of the Company.Â On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024. The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend. The Series RR warrants are held by current Officers of the Company.Â 2. Options and Shares Issued to ConsultantsÂ During the nine months ended June 30, 2024 and 2023, the Company issued 321,761 and 115,321 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $1.84 and $2.45 during the nine months ended June 30, 2024 and 2023, respectively. During the three months ended June 30, 2024 and 2023, the Company issued 70,444 and 36,523 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $1.33 and $2.41 during the three months ended June 30, 2024 and 2023, respectively.Â No options were issued to a consultant during the nine months ended June 30, 2024. During the nine months ended June 30, 2023, 5,000 options with an exercise price of $11.61 issued to a consultant expired.Â Â 15Table of ContentsÂ During the nine months ended June 30, 2024 and 2023, the Company recorded total expense of approximately $601,000 and $474,000, respectively, relating to the share-based compensation under various consulting agreements. During the three months ended June 30, 2024 and 2023, the Company recorded total expense of approximately $231,000 and $188,000, respectively, relating to the share-based compensation under these consulting agreements. On June 30, 2024 and September 30, 2023, consulting fees of approximately $221,000 and $205,000, respectively, are included in current assets as prepaid expenses and will be amortized over the remaining service periods.Â D. RELATED PARTY TRANSACTIONSÂ During the nine and three months ended June 30, 2024, certain officers and directors purchased 58,000 shares of restricted common stock at an aggregated fair market value of approximately $80,620. No restricted shares of the Companyâ€™s common stock were purchased by related parties during the nine and three months ended June 30, 2023.Â On May 4, 2024, the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $659,455, which was recorded as a deemed dividend in the financial statements for the three months ended June 30, 2024. The Series N, X, MM, NN, RR and UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Companyâ€™s CEO, Geert Kersten, is a beneficiary.Â On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024 (Note C). The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend.Â E. COMMITMENTS AND CONTINGENCIESÂ Clinical Research AgreementÂ Under co-development and revenue sharing agreements with Ergomed, Ergomed agreed to contribute up to $12 million towards the Companyâ€™s Phase 3 Clinical Trial in the form of discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreements in accordance with ASC 808, Collaborative Arrangements. The Company determined the payments to Ergomed are within the scope of ASC 730, Research and Development. Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its statements of operations. Since the inception of the agreement with Ergomed, the Company has incurred research and development expenses of approximately $35.8 million for Ergomedâ€™s services. This amount is net of Ergomedâ€™s discount of approximately $11.9 million. During the nine months ended June 30, 2024 and 2023, the Company recorded, net of Ergomedâ€™s discount, approximately $0.1 million for each period as research and development expense related to Ergomedâ€™s services. During the three months ended June 30, 2024 the Company did not record any research and development expense related to Egromedâ€™s services and during three months ended June 30, 2023, the Company recorded, net of Ergomedâ€™s discount, less than $0.1 million as research and development expense related to Ergomedâ€™s services.Â Lease AgreementsÂ The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Companyâ€™s specifications so that it can be used by the Company to manufacture Multikine for the Companyâ€™s Phase 3 clinical trial and sales of the drug if approved by any regulatory agency. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain.Â The San Tomas lease is classified as a finance lease on the Companyâ€™s balance sheet, as well as several other smaller finance leases for office equipment. The finance right of use assets are being depreciated using the straight-line method over the underlying lease terms. Total cash paid related to finance leases during the nine months ended June 30, 2024 and 2023 was approximately $2.0 and $1.9 million, respectively, of which approximately $0.7 and $0.8 million was for interest, respectively, in each nine-month period. As of June 30, 2024, the weighted average discount rate of the Companyâ€™s finance leases is 8.46% and the weighted average time to maturity is 4.34 years.Â Â 16Table of ContentsÂ On January 11, 2023, the Company was required to deposit approximately $2.3 million to its landlord, equivalent to one yearâ€™s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned.Â Approximate future minimum lease payments under finance leases as of June 30, 2024 are as follows:Â Three months ending September 30, 2024Â $666,000Â Year ending September 30,Â Â Â Â Â 2025Â Â 2,747,000Â Â 2026Â Â 2,838,000Â Â 2027Â Â 2,929,000Â Â 2028Â Â 3,021,000Â Â 2029Â Â 255,000Â Â Total future minimum lease obligation Â Â 12,456,000Â Â Less imputed interest on finance lease obligationsÂ Â (2,029,000)Â Net present value of financing lease obligationsÂ Â 10,427,000Â Â Less net present value of financing lease obligations â€" current portionÂ Â (1,949,000)Â Net present value of financing lease obligations - non-current portionÂ $8,478,000Â Â The Company leases two facilities under operating leases. The lease for the Companyâ€™s office headquarters will expire on November 30, 2025.Â The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on February 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. The Company incurred lease expense for operating leases of approximately $0.3 million for both the nine months ended June 30, 2024 and 2023. Total cash paid related to operating leases during the nine months ended June 30, 2024 and 2023 was approximately $0.3 million for each period. The weighted average discount rate of the Companyâ€™s operating leases is 10.19% and the weighted average time to maturity is 7.16 years. Â As of June 30, 2024, approximate future minimum lease payments under operating leases are as follows: Â Three months ending September 30, 2024Â $90,000Â Year ending September 30,Â Â Â Â 2025Â Â 366,000Â 2026Â Â 287,000Â 2027Â Â 277,000Â 2028Â Â 285,000Â 2029Â Â 294,000Â ThereafterÂ Â 746,000Â Total future minimum lease obligationÂ Â 2,345,000Â Less imputed interest on operating lease obligationÂ Â (640,000)Net present value of operating lease obligationsÂ Â 1,705,000Â Less net present value of operating lease obligations - current portionÂ Â (219,000)Net present value of operating lease obligations - non-current portionÂ $1,486,000Â Â Â 17Table of ContentsÂ G. PATENTSÂ During the nine and three months ended June 30, 2024 and 2023, there was no impairment of patent costs. The weighted average amortization period for patents is approximately 8 years. For the nine months ended June 30, 2024 and 2023, amortization of patent costs totaled approximately $25,000 and $29,000, respectively. For the three months ended June 30, 2024 and 2023, amortization of patent costs totaled approximately $7,000 and $9,000, respectively. The total estimated future amortization is as follows:Â Three months ending September 30, 2024Â $8,000Â Year ending September 30,Â Â Â Â 2025Â Â 29,000Â 2026Â Â 25,000Â 2027Â Â 22,000Â 2028Â Â 19,000Â 2029Â Â 16,000Â ThereafterÂ Â 54,000Â TotalÂ $173,000Â Â H. LOSS PER COMMON SHAREÂ Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. The Companyâ€™s potentially dilutive shares, which include outstanding common stock options, common stock warrants and unvested restricted stock are not included in the computation of diluted net loss per share if their effect would be anti-dilutive.Â The following table provides a reconciliation of the numerators and denominators of the basic and diluted loss per-share computations:Â Â Â Nine Months EndedÂ Â Three Months EndedÂ Â Â June 30,Â Â June 30,Â Loss per share â€" basic and dilutedÂ 2024Â Â 2023Â Â 2024Â Â 2023Â Net loss available to common â€" basic and dilutedÂ $(21,470,429)Â $(24,735,151)Â $(7,516,014)Â $(8,367,281)Weighted average shares outstanding â€" basic and dilutedÂ Â 51,479,454Â Â Â 43,761,395Â Â Â 53,994,384Â Â Â 44,254,363Â Basic and diluted loss per common shareÂ $(0.42)Â $(0.57)Â $(0.14)Â $(0.19)Â In accordance with the contingently issuable shares guidance of ASC 260, Earnings Per Share, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of June 30 :Â Â Â 2024Â Â 2023Â Options and WarrantsÂ Â 17,497,453Â Â Â 13,824,365Â Unvested Restricted StockÂ Â 147,250Â Â Â 147,250Â TotalÂ Â 17,644,703Â Â Â 13,971,615Â Â J. SUBSEQUENT EVENTS Â On July 11, 2024, Geert Kersten, the Companyâ€™s Chief Executive Officer and a director, loaned the Company $200,000.Â Â On July 18, 2024, Mr. Kersten loaned the Company an additional $250,000.Â Â These amounts were repaid on July 30, 2024.Â On July 29, 2024, the Company sold 3,715,000 shares of common stock at an offering price of $1.00 per share, and pre-funded warrants to purchase up to 7,130,000 shares of common stock, at an offering price of $0.99 per pre-funded warrant, for gross proceeds of approximately $10.8 million. Â Â 18Table of ContentsÂ Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONSÂ Company OverviewÂ and Product CandidatesÂ CEL-SCI Corporation is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the bodyâ€™s natural defense system. CEL-SCI is currently focused on the development of the following product candidates and technologies:Â 1)Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers; and2)L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS, with several product candidates under development for the potential treatment of rheumatoid arthritis.Â Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in this report as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review under the Companyâ€™s future anticipated regulatory submission for approval. None of the Companyâ€™s product candidates have been approved for sale, barter or exchange by the Food and Drug Administration (FDA) or any other regulatory agency for any use to treat disease in humans nor has the safety or efficacy of these products been established for any use. There can be no assurance that obtaining marketing approval from the FDA in the United States and by comparable agencies in most foreign countries will be granted.Â MULTIKINE, THE PHASE III CLINICAL TRIAL RESULTS, AND PATH FORWARDÂ Immunotherapy is a large, high growth market. Immunotherapies use the patientâ€™s own immune system to fight disease. These â€œtargeted therapiesâ€ are at the forefront of modern cancer research. A recent Bloomberg report from January 2023 asserted that:Â The global cancer immunotherapy market is expected to reach USD $196.45 billion by 2030, registering CAGR of 7.2% during the forecast period, according to a new report by Grand View Research, Inc. The rising adoption of immunotherapy over other therapy options for cancer owing to its targeted action is anticipated to increase the adoption during the forecast period. Moreover, increasing regulatory approvals from authoritarian establishments for novel immunotherapy used for oncology is also expected to further fuel the market growth. (https://www.bloomberg.com/press-releases/2023-01-18/cancer-immunotherapy-market-worth-196-45-billion-by-2030-grand-view-research-inc)Â CEL-SCI hopes to participate in this growing market with its lead investigational therapy MultikineÂ® (Leukocyte Interleukin, Injection). Multikine is unique among approved cancer immunotherapies because it is given first, right after diagnosis, before any other treatment including surgery.Â Multikine has been tested in approximately 740 patients in Phase 1, 2 and 3 clinical studies conducted in the U.S., Canada, Europe, Israel and Asia. In these studies, it has been administered in multiple doses by various routes and various frequencies to determine its safety and efficacy. The data from these studies allowed CEL-SCI to determine the patient population most responsive to Multikine and most likely to benefit from it. The target population is newly diagnosed advanced primary head and neck cancer patients with no lymph node involvement (determined via PET imaging) and with low PD-L1 tumor expression (determined via biopsy), two features that physicians routinely assess at baseline as part of standard practice.Â In the target patient population CEL-SCI believes Multikine significantly extended life. In the Phase III study, CEL-SCI observed a 73% survival rate with Multikine vs. only 45% without Multikine at 5 years after treatment, and a Hazard ratio of 0.35 (95% CIs [0.19, 0.66]).Â Â 19Table of ContentsÂ CEL-SCI completed a bias analysis for the target population in the Phase III study in preparation for submission of data to regulatory agencies including the FDA for confirmatory registration study.Â The detailed data on parameters including patient age, sex, race, tumor locations, and staging demonstrate balance between the treatment and control arms.Â Therefore, no bias was found, which supports confidence in Multikineâ€™s efficacy results.Â CEL-SCI applied to the FDA for a 212-patient randomized controlled confirmatory registration study focusing only on those patients in the target population, this accounts for approximately 100,000 patients worldwide per year. In May 2024, CEL-SCI announced that the FDA indicated CEL-SCI may move forward with a confirmatory registration study of Multikine in the target population.Â What is Multikine and who is it for? Multikine is a biological medicinal immunotherapy comprised of a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment before the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikineâ€™s rationale for use is to incite a locoregional immune response against the tumor before the local immune system has been compromised by the standard of care and/or disease progression.Â The Multikine target population is not yet treated adult patients with resectable locally advanced primary squamous cell carcinoma of the head and neck (SCCHN) in the oral cavity and who have:Â Â Â·No lymph node involvement (via PET imaging)Â Â·Low PD-L1 tumor expression (TPS<10) (via biopsy)Â PD-L1 is a protein receptor on the tumor surface that helps the tumor repel cells of the immune system. CEL-SCI believes that patients with tumors having low PD-L1 would be more likely to respond to Multikine because their tumors have lower defenses against the patientâ€™s immune system. CEL-SCI estimates that patients with tumors having low PD-L1 represent about 70% of locally advanced primary SCCHN patients.Â Targeting low PD-L1 also differentiates Multikine from other immunotherapies. For example, checkpoint inhibitors like Keytruda and Opdivo appear to best serve patients having high PD-L1, because these drugs work by blocking PD1/PD-L1 receptors interaction; when this interaction (PD1/PD-L1) happens it leads to inactivation/death of the immune cells attacking the tumor. These checkpoint inhibitors appear to act best when tumors express high levels of PD-L1 receptors (usually TPS >20 to TPS >50). While none of these drugs are currently approved as a first-line treatment before surgery, even if such approvals were to come in the future, we believe the large majority of patients in this group having low PD-L1 would still be expected to need Multikine.Â CEL-SCI believes Multikine leads to longer survival with no safety issues. Clinical investigations of Multikine, presented at

ESMO (Europe Society for Medical Oncology) in October 2023, have demonstrated in the randomized controlled Phase III trial (RCT) the following in the target population:Â Â Â·risk of death cut in half at five years versus the control;Â Â·28.6% absolute 5-year overall survival benefit versus control (p=0.0015);Â Â·0.349 hazard ratio vs control (95% CIs [0.18, 0.66], Wald p=0.0012);Â Â·>35% rate of pre-surgery reductions and/or downstages (p<0.01); andÂ Â·low PD-L1 tumor expression (vs high PD-L1 where Keytruda and Opdivo work best).Â There were no demonstrable safety signals or toxicities observed in approximately 740 Multikine-treated subjects across multiple clinical trials. Adverse event (AE) and serious adverse event (SAE) incidences were not significantly different among treatment and control groups. There were no Multikine-related deaths, no Multikine-related delays of surgery, no Multikine-related interference with post-surgical treatment, and only two discontinuations. Multikine-related AEs before surgery were local and resolved after surgery. Although the literature reports that some of Multikineâ€™s components may be toxic when administered systemically (e.g., TNFÎ±, IFN Î³, IL-1Î²), these toxicities did not emerge with Multikine, even at doses many times higher than those administered in the Phase III trial, primarily due to Multikineâ€™s delivery by local injection and dosage.Â Â 20Table of ContentsÂ CEL-SCI published its data as abstracts and posters at the annual conferences for the 2022 American Society of Clinical Oncology (ASCO), 2022 and 2023 European Society for Medical Oncology (ESMO), and the 2023 European Head and Neck Societyâ€™s (EHNSâ€™s) annual European Conference On Head And Neck Oncology (ECHNO) and the 2023 European Society for Therapeutic Radiology and Oncology (ESTRO) and 2023 American Head and Neck Society (AHNS). These publications can be accessed at http://www.cel-sci.com.Â Multikine works by inducing pre-surgical responses. CEL-SCI observed statistically significant pre-surgical responses after Multikine treatment, and therefore CEL-SCI believes in the following: Â Â â¢Multikine causes pre-surgical responses;Â â¢Pre-surgical responses lead to longer life;Â â¢Therefore, selecting more patients predicted to have a pre-surgical response should lead to much better survival in the target population.Â A â€œpre-surgical responseâ€ is a significant change in disease before surgery. CEL-SCI saw two kinds of responses in the Phase III trial. First, there were â€œreductionsâ€ in the size of the tumorâ€"a reduction of 30% or more qualified as a â€œpre-surgical reduction,â€ or â€œPSRâ€ for short. Second, there were disease â€œdownstagesâ€ (e.g., the disease improved from Stage IV to Stage III) pre-surgery. CEL-SCI calls this a â€œpre-surgical downstagingâ€ or â€œPSDâ€ for short. CEL-SCIâ€™s 2022 ESMO cancer conference presentation reported on PSR, and CEL-SCIâ€™s new 2023 ESMO presentation reported on PSD.Â Across the whole Phase III trial, PSRs were seen in 8.5% of Multikine patients compared to none in the control group. PSDs were seen in 22% of Multikine patients as compared to 13% in the control group. Because Multikine was the only therapy given to these patients before surgery, it is CEL-SCIâ€™s strong belief that Multikine had to be the cause of the higher rates of PSR and PSD.Â These data are presented visually below. The taller blue columns show PSR and PSD rates in all 529 Multikine-treated patients in the Phase III trial, and the gray columns show PSR and PSD rates for all 394 control patients. Â Â Â 21Table of ContentsÂ It was not enough for us to show that Multikine likely leads to PSRs and PSDs as compared to a control group, CEL-SCI also had to test if PSRs and PSDs lead to improved survival. CEL-SCIâ€™s Phase III trial demonstrated that PSR patients were 72% likely to be alive after five years, whereas control patients were only about 49% likely to be alive after five years. Patients with PSD saw similar improvement in CEL-SCIâ€™s Phase III trial.Â Their five-year chance of survival was approximately 68%. Therefore, CEL-SCI believes that the Phase III trial demonstrated that those patients who had PSR or PSD resulting from Multikine lived longer than those who were not treated with Multikine. It is important to note that these results are from the entire Phase III study population, not from a subgroup. The likelihood of living at least five years is shown in the graphic below for patients with PSR (blue), patients with PSD (orange) and control patients who did not receive Multikine (gray). Â Â Multikine cut the 5-year risk of death in half in the target population. CEL-SCIâ€™s results show that Multikine can cut the risk of death in half at five years versus the control group in the target population. Survival increased from 45% in the control group to 73% in the Multikine group, at five years. This means the risk of death fell to 27% in the Multikine group from 55% in the control, shown below.Â Â 22Table of ContentsÂ Â Another way to see the survival benefit of Multikine in the target population is the Kaplan-Meier curve from our ESMO â€™23 poster, shown below. On the vertical axis is the probability of survival and the horizontal axis is time in months. The blue Multikine line is far above the green control line, meaning the chance of survival is much higher in the Multikine group at every point in time compared to the control. These results had a low (log rank) p-value of 0.0015, which is very significant as a statistical matter. Â Â 23Table of ContentsÂ CEL-SCIâ€™s physician consultants tell CEL-SCI that the early separation of these two survival curves (e.g., at 12 months) adds validation to the potential positive effects of Multikine.Â Another measure of survival benefit is called the â€œhazard ratio,â€ which compares the rate of an event (chances) of dying between two different groups. Here, in the Multikine target population, the hazard ratio was 0.35, which means that deaths occurred in the Multikine group about one-third as frequently as in the control group. It is also important to note that the hazard ratioâ€™s 95% confidence interval remained far below 1.0 (which would mean parity between the compared groups). In the case of Multikine, statistically speaking, there is a 95% chance that the hazard ratio would fall between 0.18 and 0.66 if Multikine were tested in the target population in another study. A hazard ratio of 0.66 as the â€œso called worst case scenarioâ€ (the upper limit of the 95% confidence interval - for the hazard ration - in this case) is still below (better) than the hazard ratio required for most drug approvals. Â CEL-SCI completed a bias analysis for the target population in the Phase III study in preparation for submission of data to regulatory agencies including the FDA for confirmatory registration study.Â The detailed data on parameters including patient age, sex, race, tumor locations, and staging demonstrate balance between the treatment and control arms.Â Therefore, no bias was found, which supports confidence in Multikineâ€™s efficacy results.Â Â These positive survival outcomesâ€"increased overall survival, reduced risk of death, widely separated Kaplan-Meier curves with early separation, low hazard ratio, low p-values, low confidence intervalsâ€"CEL-SCI believes were driven by high PSR/PSD rates in the target population, as shown in the graphic below:Â Â Â CEL-SCI relies on all of these data together to support its plan to request accelerated/conditional approval in the new target population without waiting until the completion of another clinical trial.Â CEL-SCIâ€™s regulatory strategy going forward is to seek approval of Multikine following full enrollment of our confirmatory study wherever possible.Â Â CEL-SCI applied to the FDA for a 212-patient randomized controlled confirmatory registration study focusing only on those patients in the target population, this accounts for approximately 100,000 patients worldwide per year. In May 2024, CEL-SCI announced that the FDA indicated CEL-SCI may move forward with a confirmatory registration study of Multikine in the target population.Â Â 24Table of ContentsÂ Â Â Â·The confirmatory study will be a randomized controlled trial with two arms: Multikine treatment plus standard of care versus standard of care alone. CEL-SCI expects to commence enrollment in Q4 2024 / Q1 2025Â and reach full enrollment in Q2 2026.Â Â Â Â Â·If approved as a pre-surgical treatment, CEL-SCI believes Multikine should be added to the standard of care for the target population in this unmet medical need.Â Â Â Â Â·CEL-SCI believes that the confirmatory study has a high likelihood of success based on the large survival benefit that has already been observed in the target population from the completed Phase III study. The planned confirmatory study will be much smallerâ€"less than a quarter the size of the prior studyâ€" and will focus on the patients who saw the greatest survival benefit when treated with Multikine.Â Why Do We Believe Our Confirmatory Study Will Be Successful?Â Â Â 25Table of ContentsÂ An â€œunmet needâ€ is a factor for approval considered by all major regulatory bodies worldwide. In the Multikine target population, there is also a great unmet need for improved survival. The current standard of care provides only about a 50/50 chance of surviving five years, whereas Multikine could increase that survival rate to over 70% in the target population based on the Phase III data. Chemotherapy (in addition to radiotherapy following surgery) has improved survival outcome for some head and neck patients, but chemotherapy is only indicated for high-risk patients, who are not likely to fall within the Multikine target population. Currently available immunotherapies are given after surgery or where surgery is not indicated, in contrast to Multikine, which is given before surgery to patients with resectable tumors. Available checkpoint inhibitors work best on tumors with high PD-L1 expression, whereas Multikine works best in tumors with low PD-L1 expression. Therefore, Multikineâ€™s target population is underserved, and will continue to be underserved, by current therapies, but Multikine can meet the need for improved survival.Â The major regulatory bodies with whom we are working, U.S. FDA, Health Canada, European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) all have conditional approval pathways designed for situations where the target population has not been fully tested prospectively and there is strong data supporting clinical benefit for patients. The reason is that regulators understand that in many cases patients should not have to wait for additional data before being offered the chance to benefit from a new drug, especially if the drug has shown to be safe. Every situation is different and depends on the specific facts.Â IN CONCLUSIONÂ Â Â·Strong survival data: Multikine-treated patients in the target population had a 73% 5-year survival vs a 45% 5-year survival in the control group who did not receive Multikine in the Phase III study. In addition, no safety signals or toxicities versus standard of care. The Hazard ratio is 0.35 with an upper limit of 0.66.Â Â Â Â Â·Addressing an unmet medical need: Multikine focuses on the 70% of patients not well served by the two leading approved drugs for head and neck cancer, Keytruda and Opdivo. Multikineâ€™s proposed indication is a pre-surgical treatment in head & neck cancer, where no drug is currently approved.Â Â Â Â Â·Multikineâ€™s Target Population: The confirmatory registration study will focus on newly diagnosed locally advanced primary head and neck cancer patients with no lymph node involvement (determined via PET scan) and with low PD-L1 tumor expression (determined via biopsy).Â Â Â Â Â·FDA pathway: CEL-SCI is aiming to begin enrollment for a 212-patient confirmatory registration study in Q4 2024 / Q1 2025Â with full enrollment expected about Q2 2026. Potential to seek early approval after full enrollment.Â Liquidity and Capital ResourcesÂ Since inception, the Company has financed its operations through the issuance of equity securities, convertible notes, loans and certain research grants. The Company will likely continue to generate net operating losses as it continues the development of Multikine and brings other drug candidates into clinical trials. Until such time as the Company becomes profitable, any or all of these financing vehicles or others may be utilized to assist the Companyâ€™s capital requirements. Â Capital raised by the Company has been expended primarily for patent applications, research and development, administrative costs, the construction and upgrade of the Companyâ€™s manufacturing and laboratory facilities and clinical trials. The Company does not anticipate realizing significant revenues until entering into licensing arrangements for its technology and know-how or until it receives regulatory approval to sell its products (which could take several years). Thus, the Company has been dependent upon the proceeds from the sale of its securities to meet all of the Companyâ€™s liquidity and capital requirements and anticipates having to do so in the future.Â The cost of the confirmatory registration study is estimated to be about $30 million. The Company will be required to raise additional capital or find additional long-term financing to continue with its research efforts. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. Â However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations. Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Companyâ€™s ability to continue as a going concern. Â Â 26Table of ContentsÂ Under a co-development agreement, Ergomed agreed to contribute up to $12 million towards the completed Phase 3 study where it performed clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specified maximum amount. Approximately $11.9 million of the committed $12 million contribution has been realized as of June 30, 2024.Â During the nine months ended June 30, 2024, the Companyâ€™s cash decreased by approximately $3.8 million. Significant components of this decrease included cash used to fund the Companyâ€™s regular operations of approximately $13.9 million and approximately $1.3 million in payments on finance lease obligations offset by net proceeds from the November 2023 and February 2024 financing of $11.4 million.Â During the nine months ended June 30 , 2023, the Companyâ€™s cash decreased by approximately $17.5 million. The significant component of this decrease included cash used to fund the Companyâ€™s regular operations of approximately $17.8 million, which includes the approximate $2.3 million deposit made to the Companyâ€™s landlord as a result of falling below certain cash requirements per the San Tomas lease. Other components of this decrease include approximately $0.4 million used to make leasehold improvements and acquire research and development equipment, and approximately $1.2 million in payments on the Companyâ€™s finance leases.Â During the nine months ended June 30, 2024, no warrants were exercised. During the nine months ended June 30 , 2023, 217,752 warrants were exercised at a weighted average exercise price of $2.05 for total proceeds of approximately $0.5 million.Â Results of Operations and Financial ConditionÂ The Company incurred a net operating loss of approximately $20.2 million for the nine months ended June 30, 2024. This net operating loss consists of significant non-cash expenses including approximately $4.1 million in share-based compensation to employees and non-employees, and approximately $3.0 million in depreciation and amortization expense. The Company incurred a net operating loss of approximately $6.7 million for the three months ended June 30, 2024. This net operating loss consists of significant non-cash expenses including approximately $1.0 million in share-based compensation to employees and non-employees, and approximately $1.0 million in depreciation and amortization expense.Â During the nine months ended June 30, 2024, research and development expenses decreased by approximately $3.5 million, or 20%, compared to the nine months ended June 30 , 2023. Major components of this decrease include an approximately $2.4 million decrease in expenses related to the Phase 3 study, a decrease of approximately $1.1 million of employee stock compensation expense and an approximately $0.1 million decrease in other research and development costs which is offset by $0.1 million increase in costs incurred to prepare for the potential commercial sale of Multikine.Â Â 27Table of ContentsÂ During the three months ended June 30, 2024, research and development expenses decreased by approximately $1.0 million, or 18%, compared to the three months ended June 30 , 2023. Major components of this decrease include an approximately $0.9 million decrease in expenses related to the Phase 3 study, a decrease of approximately $0.5 million of employee stock compensation expense which is offset by $0.4 million increase in costs incurred to prepare for the confirmatory Registration Study and potential commercial sale of Multikine.Â During the nine months ended June 30, 2024, general and administrative expenses decreased by approximately $0.3 million, or 4%, compared to the nine months ended June 30 , 2023. This decrease is primarily due to an approximately $0.5 million decrease in consulting fees and a decrease of approximately $0.4 million of employee stock compensation expense, which is offset by increase of approximately $0.6 million in other general and administrative costs.Â During the three months ended June 30, 2024, general and administrative expenses decreased by approximately $0.5 million, or 20%, compared to the three months ended June 30 , 2023. This decrease is primarily due to an approximately $0.3 million decrease in consulting fees, an decrease of approximately $0.4 million of employee stock compensation expense which is offset by netÂ increase of approximately $0.2 million in other general and administrative expenses.Â During the nine months ended June 30, 2024, net interest expense increased by approximately $0.1 million compared to the nine months ended June 30, 2023. While the amount of interest paid on the Companyâ€™s lease liabilities are approximately $0.7 million and $0.8 million for the nine months ended June 30, 2024 and 2023, the Company earned approximately $0.2 million less in interest income during the nine months ended June 30, 2024 compared to the nine months ended June 30, 2023. Net interest expense, which consists primarily of interest paid on lease liabilities, are approximately $0.2 for both the three months ended June 30, 2024 and June 30 , 2023.Â Research and Development ExpensesÂ The Companyâ€™s research and development efforts involve Multikine and LEAPS. The table below shows the research and development expenses associated with each project.Â Â Â Nine months ended,Â Â Three months ended,Â Â Â June 30,Â Â June 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â MULTIKINEÂ $13,615,922Â Â $16,919,843Â Â $4,681,127Â Â $5,661,214Â LEAPSÂ Â 68,282Â Â Â 283,980Â Â Â 22,033Â Â Â 66,575Â TOTALÂ $13,68 and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of the Companyâ€™s clinical trials and research programs are primarily based upon the amount of capital available to the Company and the extent to which the Company has received regulatory approvals for clinical trials. The inability of the Company to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent the Company from completing the studies and research required to obtain regulatory approval for any products which the Company is developing. Without regulatory approval, the Company will be unable to sell any of its products. Since all of the Companyâ€™s projects are under development, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.Â Â 28Table of ContentsÂ Critical Accounting EstimatesÂ Managementâ€™s discussion and analysis of the Companyâ€™s financial condition and results of operations is based on its unaudited condensed financial statements. The preparation of these financial statements is based on the selection of accounting policies and the application of significant accounting estimates, some of which require management to make judgments, estimates and assumptions that affect the amounts reported in the financial statements and notes.Â The Company believes some of the more critical estimates that affect its financial condition and results of operations are in the areas of leases and share-based compensation.Â The measurement of the finance and operating lease right-of-use asset and lease liabilities requires the determination of an estimated lease term and an incremental borrowing rate, which involves complex judgment by management. Significant judgment is required by management to develop inputs and assumptions used to determine the incremental borrowing rate for lease contracts. The fair value of the stock options is calculated using the Black-Scholes option pricing model which requires various judgmental assumptions including volatility and expected option life. The compensation cost is recognized as expense over the requisite service or vesting period. Performance-based options are valued using a Monte-Carlo simulation model, which requires inputs based on estimates, including the likelihood of the occurrence of performance and market conditions, volatility and expected option life.Â For more information regarding the Companyâ€™s critical accounting estimates, see Part II, Item 7 of the Companyâ€™s Annual Report on Form 10-K for the year ended September 30, 2023. The application of these critical accounting estimates has been discussed with the Audit Committee of the Companyâ€™s Board of Directors.Â Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKSÂ The Company does not believe that it has any significant exposure to market risk.Â Item 4. CONTROLS AND PROCEDURESÂ Evaluation of Disclosure Controls and ProceduresÂ Under the direction and with the participation of the Companyâ€™s management, including the Companyâ€™s Chief Executive Officer and Chief Financial Officer, the Company carried out an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of June 30, 2024. The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic reports with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and regulations, and that such information is accumulated and communicated to the Companyâ€™s management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. The Companyâ€™s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching its desired disclosure control objectives.Â The Companyâ€™s Chief Executive Officer and Chief Financial Officer has concluded that the Companyâ€™s disclosure controls and procedures were not effective as of June 30, 2024 due to the material weaknesses described in the Company's Annual Report on Form 10-K for the year ended September 30, 2023.Â Changes in Internal Control over Financial ReportingÂ There were no changes in the Companyâ€™s internal control over financial reporting that occurred during the three months ended June 30, 2024 that have materially affected, or are reasonably likely to materially affect, the Companyâ€™s internal control over financial reporting.Â Â 29Table of ContentsÂ PART IIÂ Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.Â During the nine months ended June 30, 2024, the Company issued 321,761 restricted shares of common stock to consultants for investor relations services and clinical drug and corporate development.Â The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 with respect to the issuance of these shares. The individuals who acquired these shares were sophisticated investors and were provided full information regarding the Companyâ€™s business and operations. There was no general solicitation in connection with the offer or sale of these securities. The individuals who acquired these shares acquired them for their own accounts. The certificates representing these shares bear a restricted legend which provides they cannot be sold except pursuant to an effective registration statement or an exemption from registration. No commission or other form of remuneration was given to any person in connection with the issuance of these shares.Â Item 5. Other InformationÂ None of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period ending June 30, 2024.Â Item 6. ExhibitsÂ Number Â ExhibitÂ Â Â 31 Â Rule 13a-14(a) CertificationsÂ Â Â 32 Â Section 1350 CertificationsÂ Â 30Table of ContentsÂ SIGNATURESÂ Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.Â Â CEL-SCI CORPORATIONÂ Â Â Â Date: Â August 14, 2024By:Â Â /s/Â Geert KerstenÂ Â Â Geert KerstenÂ Â Â Â Principal Executive Officer*Â Â Â * Also signing in the capacity of the Principal Accounting and Financial Officer.Â Â 31Â EX-31 2 cvm_ex31.htm CERTIFICATIONS cvm_ex31.htmEXHIBIT 31 Â CERTIFICATIONS Â I, Geert Kersten, certify that: Â 1. I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation; Â Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â Â 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:Â Â a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â Â b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â Â Â c) evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and Â Â Â Â d) disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; andÂ 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): Â Â a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â Â Â b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Â Date: August 14, 2024 By: /s/ Geert Kersten Â Â Â Geert Kersten Â Â Â Principal Executive Officer Â Â Â Â Â Â CERTIFICATIONS Â I, Geert Kersten, certify that: Â 1. I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation; Â Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â Â 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:Â Â a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â Â Â b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â Â Â c) evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and Â Â Â Â d) disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; andÂ 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):Â Â a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â Â Â b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Â Date: August 14, 2024 By: /s/ Geert Kersten Â Â Â Geert Kersten Â Â Â Principal Financial Officer Â EX-32 3 cvm_ex32.htm CERTIFICATIONS cvm_ex32.htmEXHIBIT 32 Â In connection with the Quarterly Report of CEL-SCI Corporation (the â€œCompanyâ€) on Form 10-Q for the period ending June 30, 2024 as filed with the Securities and Exchange Commission (the â€œReportâ€), Geert Kersten, the Principal Executive and Principal Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge: Â Â (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â Â Â Â (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of the Company. Â Â By: /s/ Geert Kersten Â Â Â Geert Kersten Â Â Â Principal Executive and Â Â Â Principal Financial Officer Â Â Date: August 14, 2024 Â EX-101.SCH 4 cvm-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - CONDENSED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - LIQUIDITY link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - STOCKHOLDERS EQUITY link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - PATENTS link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - LOSS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - STOCKHOLDERS EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - PATENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - LOSS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - STOCKHOLDERS EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - STOCKHOLDERS EQUITY (Details 1) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - STOCKHOLDERS EQUITY (Details 2) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - STOCKHOLDERS EQUITY (Details 3) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - STOCKHOLDERS EQUITY (Details 4) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - PATENTS (Details) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - PATENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - LOSS PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - LOSS PER COMMON SHARE (Details 1) link:presentationLink link:calculationLink link:definitionLink 000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 cvm-20240630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name Document Quarterly Report Document Transition Report Entity Interactive Data Current CONDENSED BALANCE SHEETS Current assets: Cash and cash equivalents Prepaid expenses Supplie used for R&D and manufacturing Deposits current Total current assets [Assets, Current] Finance lease right of use assets Operating lease right of use assets Property and equipment, net Patent costs, net Deposits Supplies used for R&D and manufacturing Total assets [Assets] LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable Accrued expenses Due to employees Finance lease obligation, current portion Operating lease obligation, current portion Total current liabilities [Liabilities, Current] Finance lease obligations, net of current portion Operating lease obligations, net of current portion Other liabilities Total liabilities [Liabilities] STOCKHOLDERS' EQUITY Preferred stock, $.01 par value; 200,000 shares authorized; 0 shares issued and outstanding Common stock, $.01 par value; 600,000,000 shares authorized; 54,257,884 and 47,422,304 shares issued and outstanding at June 30, 2024 and September 30, 2023, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity [Stockholders' Equity Attributable to Parent] TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY [Liabilities and Equity] Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) Operating expenses: Research and development General and administrative Total operating expenses [Operating Expenses] Operating loss [Operating Income (Loss)] Interest expense, net Other expense [Other Nonoperating Expense] Net loss [Net Income (Loss) Attributable to Parent] Modification of warrants Net loss available to common shareholders [Net Income (Loss) Available to Common Stockholders, Basic] Net loss per common share - basic and diluted Weighted average common shares outstanding - basic and diluted STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED) Statement [Table] Statement [Line Items] Equity Components [Axis] Common Stock Additional Paid-In Capital Retained Earnings (Accumulated Deficit) Balance, shares [Shares, Issued] Balance, amount Warrant exercises shares Warrant exercises amount Equity based compensation - employees 401(k) contributions paid in common stock shares 401(k) contributions paid in common stock amount Stock issued to nonemployees for service shares Stock issued to nonemployees for service amount 2014 incentive stock forfeited shares 2014 incentive stock forfeited amount Net Income (Loss) Proceeds from the sale of common stock shares Proceeds from the sale of common stock amount Share issuance costs Purchase of stock by officers and directors sahres Purchase of stock by officers and directors amount Balance, shares Balance, amount CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) Net loss [Net Income (Loss), Including Portion Attributable to Noncontrolling Interest] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Non-cash lease expense Share-based payments for services Equity-based compensation Common stock contributed to 401(k) plan (Increase)/decrease in assets: Prepaid expenses [Increase (Decrease) in Prepaid Expense] Supplies used for R&D and manufacturing [Increase (Decrease) in Inventories] Deposits [Increase (Decrease) in Deposits] Increase/(decrease) in liabilities: Accounts payable [Increase (Decrease) in Accounts Payable] Accrued expenses [Increase (Decrease) in Accrued Liabilities] Due to employees [Increase (Decrease) in Employee Related Liabilities] Net cash used in operating activities [Net Cash Provided by (Used in) Operating Activities] CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of property and equipment [Payments to Acquire Property, Plant, and Equipment] Expenditures for patent costs [Payments to Acquire Intangible Assets] Net cash used in investing activities [Net Cash Provided by (Used in) Investing Activities] CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock Payments of stock issuance costs [Payments of Stock Issuance Costs] Proceeds from the purchase of stock by officers and directors [Increase (Decrease) Due from Officers and Stockholders] Proceeds from the exercise of warrants Payments on obligations under finance leases [Repayments of Debt and Lease Obligation] Net cash provided by financing activities [Net Cash Provided by (Used in) Financing Activities] NET DECREASE IN CASH AND CASH EQUIVALENTS [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect] CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS, END OF PERIOD SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Assets purchased

under finance leases Finance lease obligation included in accounts payable Property and equipment included in current liabilities Consulting services paid with issuance of common stock Accrued consulting services to be paid with common stock Financing costs included in current liabilities Cash paid for interest BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] LIQUIDITY LIQUIDITY [LIQUIDITY] STOCKHOLDERS EQUITY STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] PATENTS PATENTS Intangible Assets Disclosure [Text Block] LOSS PER COMMON SHARE LOSS PER COMMON SHARE Earnings Per Share [Text Block] SUBSEQUENT EVENTS SUBSEQUENT EVENTS Subsequent Events [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Cash and Cash Equivalents Property and Equipment Supplies used for R&D and manufacturing Patents Leases Stock-Based Compensation Research and Development Costs Net Loss Per Common Share Income Taxes Impairment of long-lived assets Use of Estimates Recently Adopted Accounting Standards New Accounting Pronouncements Schedule of future minimum payments under finance leases Schedule of future minimum payments under operating leases Schedule of equity compensation plans Schedule of Stock option activity Schedule of Stock-Based Compensation Expense Schedule of warrants and non-employee options outstanding Schedule of derivative liabilities Schedule of total estimated future amortization Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations Schedule of anti-dilutive securities Award Type [Axis] Incentive Stock Bonus Plan [Member] [Incentive Stock Bonus Plan [Member]] Non-Qualified Stock Option Plans [Member] Stock Bonus Plans [Member] Stock Compensation Plan [Member] Incentive Stock Bonus Plan [Member] Remaining Options/shares Under Plans Options Granted Options Forfeited Option Exercised Options Expired Sale of Stock [Axis] Employees Non-employees Stock Based Compensation Expense Class Of Warrant Or Right Axis Range Axis Related Party Transactions By Related Party Axis Series N [Member] Series UU [Member] Series X [Member] Series Y [Member] Series MM [Member] Series NN [Member] Series RR [Member] Minimum [Member] Consultants [Member] Maximum [Member] Consultants Options [Member] Issue Date Shares Issuable Upon Exercise Of Warrant/options Exercise Price Expiration Date Series SS [Member] Equity Warrants Exercised Equity Warrants Exercise Price Proceeds From Equity Warrants Exercised Trading Activity [Axis] Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis Plan Name Axis Common Stock sale [Member] Restricted Stock [Member] Consultants [Member] Consulting Agreements [Member] Consulting Agreements Other [Member] Incremental cost Weighted average grant date fair value Options issued Consulting fees inclued prepaid expenses Common stock issued for service, shares Common stock shares issued Public offering price Proceeds from issuance of common stock Amortization cost Issuance cost of common stock Net of issuance costs Sale of common stock at a public offering price Additional purchase of common stock Stock options Total expense Officer And Director [Member] Incremental cost Purchase of newly issued shares by insiders Purchase of restricted common stock fair value Three months ending September 30, 2024 2025 2026 2027 2028 2029 Total future minimum lease obligation Less imputed interest on finance lease obligations [Finance Lease, Liability, Undiscounted Excess Amount] Net present value of financing lease obligations Less net present value of financing lease obligations - current portion [Less net present value of financing lease obligations - current portion] Net present value of financing lease obligations - non-current portion Three months ending September 30, 2024 [Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year] 2025 [Lessee, Operating Lease, Liability, to be Paid, Year One] 2026 [Lessee, Operating Lease, Liability, to be Paid, Year Two] 2027 [Lessee, Operating Lease, Liability, to be Paid, Year Three] 2028 [Lessee, Operating Lease, Liability, to be Paid, Year Four] 2029 [Lessee, Operating Lease, Liability, to be Paid, Year Five] Thereafter Total Future Minimum Lease Obligation Less Imputed Interest On Operating Lease Obligation [Lessee, Operating Lease, Liability, Undiscounted Excess Amount] Net Present Value Of Operating Lease Obligation Net present value of lease finance lease obligations - current portion [Net present value of lease finance lease obligations - current portion] Net present value of lease finance lease obligations - non-current portion Title of Individual [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Ergomed [Member] Landlord [Member] Lease Agreements [Member] Net Of Discount Interest amount Lease expense for operating leases Total cash payment for oprating lease Annual increase to interest payments Weighted average time of maturity of operating leases Research and development expenses Weighted average discount rate operating lease Clinical service trial Financing arrangement deposit base rent amount Three months ending September 30, 2024 [Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year] 2025 [Finite-Lived Intangible Asset, Expected Amortization, Year One] 2026 [Finite-Lived Intangible Asset, Expected Amortization, Year Two] 2027 [Finite-Lived Intangible Asset, Expected Amortization, Year Three] 2028 [Finite-Lived Intangible Asset, Expected Amortization, Year Four] 2029 [Finite-Lived Intangible Asset, Expected Amortization, Year Five] Thereafter [Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five] Total [Other Indefinite-Lived Intangible Assets] Amortization expense Weighted average amortization period for patents Net loss available to common shareholders - basic and diluted Loss per share- basic and diluted Weighted average shares outstanding - basic and diluted Basic and diluted loss per common share Options and Warrants Unvested Restricted Stock [Member] Antidilutive Securities Subsequent Event Type Axis Subsequent Event [Member] Chief Executive Officer [Member] Mr. Kersten [Member] Public offering price [Class of Warrant or Right, Exercise Price of Warrants or Rights] Pre funded warrants offering price Sale of common stock at a public offering price Proceeds from newly issued shares Pre-funded warrants to purchase common stock Amount of loan Additional loan amount Amount of expense for amortization of deferred issuance costs associated with an own-share lending arrangement. EX-101.CAL 6 cvm-20240630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 7 cvm-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 8 cvm-20240630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE GRAPHIC 9 cvm_10qimg15.jpg begin 644 cvm_10qimg15.jpg
M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# 4$! 0$ P4$! 0&!0$&" <' ")" < \@%1(5(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @("#_P 1" '< ?8# 2(A$! Q$!_\0 M'P 04! 0$! 0$ P0%!@<('"0H+_\0 M1 @ 0(01!1(A,4$&\$U%A!R)Q%#*!D:((T*QP152T D,V)R@@D*
M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! 0 $" P0%!@<('"0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H6 M)R@I*C4V-S@Y.D-$149'2$E*4U155E-865IC9&5F9VAI:G-T=79W>'EZ@H.$
[illegible]

MYQ=U:?V'XC_P#0S>'O_!+-_P#)5=;10!R7V'XC_P#0S>'O_!+-_P#) M5*MC\1MPW>)O#Q'?&BS?_)5=910 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110
4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !17S/)K7Q U#XX^(+3P[?^(K@Z;XBM M87BRATJ"P,"-,L@;G?R2-O/(K1L?CAXJO/#NN>)%*Q_V5#I]Y>VBO&H?
B%X\NO$D&@VVG^'HKJSTVVU74FNKF2.-TGE M95CA;'!55Y9A@M@8&:S;'XP>)M0\2:RMKX;\[0K.;4+59_+E#0O;1E@\CGY' M'92-]\KD4 >[T5\PZ]\8OB)-\/M4NK:'2-(U+^Q-+UZUN;??*
(X;J8(8V#C! M?ISTP3W ->AVOQ \50_%]'P?XDTVPTRTG/DVLY27&H.(=[-#)R@(;MT444 %%%% !17S1XRUCQ_=?&KQ-H_@_4/$4M_8_V8VGU)M1UW6?L_A<-H=G+J5JMP(Y 8)+1&
(>1S\C*F*1M7E> M,]: /=J*\+L?B?X^UB31+&STSPY7UWH2^)+@W5Q*D MVD")"KXX?J2QX'"% M6;/XL>(]0^(U_I-CX;\[0[+49=+FF2.0Z0[_..:3[FW=A=O7!!]J /:Z*^7 MK[XV?
$+4/ASJ>H0V>DZ3>W'A7_A(K&YMR\I@59Q$ZLK@@L0(LPB< JC!A@1O@L,D'I0![1110 M444 %%%% !1110 5RUY?>.8[Z9;#PUI%Q:AB(I)M8DB=U[$J+=@I]LGZUU-1 MNZQH9'8*BC)8G H
Y;^TOB)_P!"EH7_(/)?_D6C^TOB)_T6A?7_P"#R7_P"1 M:\TOQ[JVGW/B/Q,(;(]J)>LKG4M/_M)"MMN@;;&(3XBT/_(3NJ,Q3/QE_ MH<-W2W:ZM?7"VEX;2(8 W$190"7W9W,3A20!V /0?
[2^(G_0I:%_X/)? M_D6C^TOB)_P!"EH7_(/)?_D6A^*#R7_ .1:O^'+$^Z\U3PMI>H:I#%#%\W-'!()(U2_\ R+76T4 < ME_:7Q$_Z%%+0O_!Y+_P#(M']I??$3_*%%+0O\ P>2_(M=;10!R7T]$3_*%%+0O\
P>2__(M'JH$3_H4M'_\DO_R+1+M:7Q$_P"A2Z+_ ,'DO_R+76T4 2_\ R+76T4 2__(M8'B#XC?\ "+_$=]J&U=\ M-2X:^!.^X9W1"1D=;+&S$8#BUM\-?\ 7'1AXA5?#1\
PZAXHTF2WU-I+V2:SL\,;:WMY MC&SMN89(&W(&23G XH Z(^TOB)_T*6A?^#R7_P"1:/[2^($_$*6A?\ @\E_ M^1:9/XXTNWUVTTV6UNUAO?EMKPHOE3-G9M6I9E9V7C<87C<1L5N<8R,5#N9\>:;XJO%MK
M2PU"T:6S6_MS>0A!/ S;=RX)Z'L<'D4 6?[2^(G_ $*6A?\ @\E_^1:/[2^(_MG_0I:%_X/)?_)%KK:* .2_M+XB?J"EH7_@\E_ D6C^TOB)_P!"EH7_ (/) M?_D6NMHH Y+^TOB)_P!"EH7_
(/)? _D6C^TOB)_T6A?7_^#R7_P"1:ZVB@#DO M[2^(G_0I:%_X/)?_D6H M+XB?\ 0I:%_X/)?_)%KK:* .2 M+XB?\ 0I:%_ M_P"#R7_Y%H_M+XB?]"EH7_@\E_ D6NMHH Y+^TOB)_T6A?7_^#R7_P"1:/[2
M^(G_$*6A?\ @\E_^1:ZVB@#DO M[2^(G_$*6A?\ @\E_^1:/[2^(G_0I:%_X M/)?_)%KK:* .2_M+XB?\ 0I:%_X/)?_D6H_M+XB?]"EH7"EH7_@\E_ D6C^TOB)_P!"EH7_(/)?_D6NMHH Y+^TOB)_T6A?7_^#R7_P"1:/[2
M^(G_$*6A?\ @\E_^1:ZVB@#DO M[2^(G_0I:%_X M/)?_)%KK:* .2_M+XB?]"EH7_@\E_ D6C^TOB)_T6A?7_^#R7_P"1:/[2^(G_0I:%_X/)?_D6NMHH Y+^TOB)_P!"EH7_(/)?_D6CM+XB?\ 0I:%_X/)?_)%KK:* .2_M \T^T?7:?ZE?:?X\'V6/:NMHH Y+^TOB)_P!"EH7_
M8&6.21(P[8+%8P6./0"@#E-8\'WVNWNGWVL?#7PS>7&G*$6[R:U-\BJ054_Z M-A@^ 0&R,BFMX-O)?$-WKQ^&/AK^TKQ9%GF_MR;Y_79(=OV; ++P6 R1WJG
MJ7Q4D@BTRSL=0TE[N>SFO+BYF6X6$!)/+\L(%,BMG.XL!LP2>HKJ/%'BZ[TG M0-$O+5;"*?5IXH!=7,^;2VWH7W,Z_>'&%Z!B1TH Q9/!E])8R64GPQ\,/;2: M;%I#QMKG;:0FS= M@VV-
VT8W8W8[UUO@GQ3_ ,)3X=DOG\AI[6ZFLIGM)/,AD>-L;XV[JPP1]<5U MU ')VE\1/\ H4M"_P#!Y+_\BT7VE\1/\^A2T+_ P>2_\ R+76T4 2_ (M=;10!Y:VGBZRUW4-
XUBSTJSU+X6^%KFWTJ(06:/K\ECN$A@:)=WE&,CS Y'J!C!/<9Z74O%FH0^!-$UJUL8X]5UI[2"&VGD MS'#+.5^^R\E5!)XZX]Z ,*'P;?6]]MK%\,?"P@736T@1G6IF7[(S;C^@VWW2 MW-
06O@>ZT_5K+5K?X:^&H[RQ5%MY/[?N&V%*HV#;8+*I(#$$@=Z[+P?K]YK M5CJ"ZM;PPZCIE]+87'V=B8W9,$.N>0"K X/3FNMH Y+^TOB)_P!"EH7_(/)?M?D6@:C\0]PW>$]" [D:Y+_\BUUM%
!1110 4444 %%%% !5:6&:.:)XI462- MP596&0>H(U9HH YG7O&D^(/#CZJ)<6Z0P"/RX3^BAK?C V<87CC'0@D=#6 M9I6T9@(W3+0+@+UOXZSMM6^WSI<3+<6L0BWJ@12L07:ORCJ!D\UW-%
%6&&.WA2&& M-8XT4*J(,*H'0 =A5JBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y M=_"UC-XINM=0\!]J-Q-P6S6\RJ\8\J1I%< C[VYOPP,5SEU\+;&29+JTU1X+P M2WC---
:PW&4N)O.90KJ0"K8VMU],8T6+Q1_9,R0#1M#%[YC1"0^= M)(0O!ZA50G'?=[54T@QQJGE^)))=076[+3IK:&VNKR-=,9K'2ETI1(%PZ!PV\X'WN/I7-'XL--ID%YIOAFXO2;&ZOIU%U&@B
M2WF,4@!/WB2I*XZCTJ>^*$%OJBPP:-:HL$D(N+F:8"146U^TLRQ %B-G)P, M^U 'IM%<-X+\<6_"6ZMX[$VKPPQ7"E)EF1HY =OS+P'&.5[<5W- !1110 4 M444 %%%% !1110 4444 %%%%
!1110 5@Z]IMYJVGI#^L7.DW,4JS1W$ 5N M1_"RMPRD'D&HO&FL7&@^#-1U2S17NHT"0!NGF.P1<_BPKF/$FO>*O#_BC1UD MU*UDL+Z\ALXX/L;;70@"226?.)Q.U<8. .2>
!G_"L&AC%SIWB:[M-8G%P MM]?_ &>)S=K.X>0%"-JX(&W'3WK5D\%W$>AIH>F>(KJSL[=(([6]X(IDB2-- MI5E9?W@;J<]"!C%%8MKXHU[2/B VC^)M6LOLK64]Y.QMFMX;4*Z*6L4K'1]K\ M'?W77 /
.*E\2:OXB74]D*+*+*!-BMS+/:.+6@Q2\^<^.:!.:6<0!TA-F^*X^I-I(O]$:^GBJV]5X*IE5K.+@V5Q'EY+&M9EEBNTO+1&AZVB+1+^V!@)]NK\4;2#_WMB/,G8M#_O&3@J[>FU(*V*@^XS^?V4
M2WF,4@!/WB2I*XZCTJ>^*$%OJBPP:-:HL$D(N+F:8"146U^TLRQ %B-G)P, M^U 'IM%<-X+\<6_"6ZMX[$VKPPQ7"E)EF1HY =OS+P'&.5[<5W- !1110 4 M444 %%%% !1110 4444 %%%%
M)KB']Z%&*/;YBDDJY)8J&]I!R\!/BN=+/P(I<'*J!Y3&[@Q$B#%3VG$%%BQ5$WA2]Z8=M,^'Z]\P/,ZTHD"K5QPTF^R(*#6?$:&^$%6[HRH@&BBQ$-1#(%@,]-@I5HP:=]SA.>C$>%B5-+0!K2$(EBFRR[]'@)%SW@!4)@^#;K(R*=J&O-J*8P
RSRW&H-1.L_FA P\HC:N!'&!CD8[Y-76\ Q+X;M]!M]270Y7&>NS\&:MBBB@ HHHH **** "BBB@ KE+SQIIEC>S6 MV!@F-O-'-#\T4AC$D:'!(RX. M%P>6^7KQ0!I_\+ T?_H$^)/
G[W_XU1_PL#1_^@3XD_PH#"?O?_ (U71P3 M?;13>6T?P*&V.,N1G!'K5J@#DO^%@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E$%@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E
G_A/WO_^#R7_P"1:H_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E
M3187<4>@WR/E)"R,I\KT9@?H*?K(/ .:WJ\NK3:?XNMKR1K:3S;?1+U2KP%_ M+< PD9Q*X.0ZC9VY&M)T_2\Q7L,QU5G)+V$Z1,PMP!UDRC9'I@ M]Q5ZX^(T,CVUM8Z;
<079U*RM+BWOH_+>.*Y9@L@)YPK<'D$'(H A\.ZQH/A MR!H8(_&MXI1(%WHMZXA1!A54"$ #W.2>Y-=#_PL#1_^@3XD_PH#"?O?_ (U4 M.A^.M"US61I=EYZNZ226\DB8CNDC?8[1G/(!QU
X((XKLZ .2_X6!H_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E
$G_A/WO\ \:KK:* .2_X6!H_ $"?2?G_A/WO_^#R7_P"1:H_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/
$G_A/WO\ M\:KK:* .2_X6!H_ $"?2?G_A/WO_^#R7_P"1:H_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/
[7*F'/!13@$ [02*]BK)U?^VA8_P#$A6R> M[W#B]9Q'M[_=!.: /-M)7PGI.KV^I+:^-+K[&DL=E;7>CWLL5FLA&\1CR<\@ M ?,6P.!6P?$7AEO%$'B!M'\3M=P6K6D*G0;WRXT9@S%5\KACA03Z
"N:;XL: MM':6D5Q#H=K=73W4T5Q-/*+>2VA<1B10%+DN^[!Q@*NX]7LM]KUYX=LM0T M>/2UNID2:07,[/"JE2>ZL;&;1KTV
MEK<2AMTBIY.1DN_<@;VP!FMGPOXDT7P[X5TW1%TWQ'(;2$([CP]? ._5F'[K MNQ)K=#ZYJGB/PI#K&J6MOFXDD\[C,S%)80Q"2#< 0& W#V(KJZ .2_X6!H M_P#T"?$G_A/WO_QJC_A8A&C_]
GQ)_P"$_>__ !JNMHH Y+_A/WO_^#R7_P"1:H_P"E@:/_P"E&JZVB@#DO ^X2:X6!H_W_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E@:/_P"E
<]+=X;UBX6\U>W\8J]RD!U&RMM'O1:WDD0&!"RF$G@M&0/NE<@#.:]EKE@?GB;POX2NM;AABE,+Q(3.Y2*(/[J&1R 3M7=N.!G XH MXVU;PG:^((M8:#QI=&"266UM;G1:V[NKN0&T;O+Y+E0
MZDM_&5DM[EM?06>BWL<5[$I.U)!Y!I:0'O!G!O.Q:P8OAA5H!Kt1Z/;"X MN[NV.ZUSX[KMVR.2=N<&.1&(HDL.D4 (/2W7C/5;QT.MN8P<2:TXFO?9"Q+K->'S>S M8LA@!I>7>VN*(I#I%6XM.PPQW,HDD
XSO!SD/_"VOB8[Z]XN+I.]Y%98]-P(IB1]{(Y)@+GRN)V6)Y48#3MKN39^*76E6Y:%0Q;4D%W\KDI]E@# <-"cY@H T)I@QHX!5-P]ZW=*2:&BNxm@y8
C(KH5\4^&WL)M037K%K*%@DEP+A=BL>@) "@#%C4 3O)Y Q 7\9ZU< X6;V?\ H==&_P# Q/\ &M23Q%*/H/^ Y'_ (6;V?^AUT;_ P #8/\ _C0H_
(6;V?^AUT;_ P #$_QH_P"%F#W M H==&_\ Q/\:ZZB@#D?^%F_#W_H==&_\ \#$_QH_X6;V?^AUT;_ P #F_QH_P"% MF_#W_H==&_\ Q/\:ZZB@#D?^%F_#W_H==&_\ \#$_QH_X6;V?^AUT;_ P #$
M==&_\#$_QH_X6;V?^AUT;_ P #$_QH_P"% MF_#W_H==&_\ Q/\:ZZB@#D?^%F_#W_H==&_\ \#$_QH_X6;V?^AUT;_ P #$_QH_P"% MF_#W_H==&_\ Q/\:ZZB@#D?^%F_#W_H==&_\ Q/\
#$_QH_P"%F_#W_H==&_\ Q/\:ZZB@#D?^%F_#W_H==&_\ Q/\:ZZB@#D?^%F_#W M7G P MPQUZLYLWOO&FC>5;EF9%N8\R$JON6SD!2=P'JX>U8-O<_#E/&K^&XK[CXE:09:%G)K"BI"\&PX/
8A9&!P P)X)4/,+P#0ZZ-X&)C5Z5Q5X9A@AF MGU[3H8IU#Q.]RBB1[*Z@#D?^%F_#W_H==&_\ Q/\:ZZB@#D?^%F_#W_H==&_\ \#$_QH_X6;V?^AUT M;_ P #$_QH_P"F_#W_H==&_\ Q/\:ZZB@#D?^%F_#W_
'71O\ P,3_!KK MJ .1_X6;V?^AUT;_ P #$_QH_P"% MF_#W_H==&_\ Q/\:ZZB@#D?^%F_#W_H==&_\ Q/\:ZZB@#D?^%F_#W_H==&_\ \#$_QH_X6;V?^AUT;_ P #$_QH_P"% MF_#W_H==&_\ Q/\
.1_X6;V?\ H==&_P# Q/\ &C_ A9OP]O_ A9OP]O_ Q/\:ZZB@#D?^%F_#W_H==&_\ Q/\:ZZB@#D?^%F_#W_H==&_\ \#$_QH_X6;V?^AUT;_ P #$_QH_P"% MF_#W_H==&_\ Q/\
]7T&)TN#X8B:7I[W<30_:8KN,0&&X)7ZX MS@]KMM/T>AT4 >+:M'P]\SQN#F^4?34Z!N3*DNKV-SDN_% <55>UX@ [J-, M8Z&EA N3R[1<+X'9RUMF9_H :DB>A<+\>?I3.:I\@-X2]@X0,C$%A+I%O
<^E6?^%F_#W_H==&_\ \#$_QH_X6;V?^AUT;_ P #$_QH_P"%F_#W_H==&_\ Q/\:ZZB@#D?^%F_#W_H==&_\ Q/\:ZZB@#D?^%F_#W_H==&_\ Q/\:ZZB@#D?^%F_#W_H==&_\ Q/\
:YKQ5XJ^'OB31DL1\0M)LIH;B%*[@F6YC)&X9=R$X9N&:>2:Y=8'@<2JBLJP%L)@1)@@YZYSN-:2:IX'M?"\ M?AVP^*VFQV5O;006Z3M!.H,9.XR!O]8'R 5XQCC%=H/'%NOB>RT&[T'6;2:^
MF>&WFFM@(I"BEB\0>+-'\-76D6NJ3.L^KWB65K%&F=B!DCL MH)&6Z#(]: .1\)^OAQX65TN:V?QUH]U]KHW_@8G^-==10!R/"S?A3H_P"F_#W_H==&_\ Q/\:ZZB@#D?^%F_#W_H=
HHHH **** "BBB@ HHHH \4TGX9(O#]AI=WI+6YU=;2_ MM;L7ER]Q GFEGB:-7R%^8*&"A00QSG%16?9'Q=!J'JO3:;;7$L%U9W*Z=/=H M?M'EPR1/EEC5%(+AE^7'':O<** /%M>^'^O:M?
P7CZ/:K;W>F"PN-.L[X016 MA\XOD-Y9+*0W.P*!?Q%UUO=F\2^F?M4G, 0J,J?NQP6.[:6ZA-P[BLFW ML)^+^/%*9ZYX=5H[.\U258%_THR"%%DCCGD#$?>;$L@7L7 KL+KQ]EXG_L.
MX>1)=NYYRG[J-O+:0.0(S=F*1NWT6EU@#Q1I^F^"YO%D\-R;&*W^T[!'^]9@#TPI M/4Y% 7/P[UVP;4;2D:;A&ttingIC^II=8'M3 MO^$/\>6)F;K_(ETM)+:9!
<+#Y:%_(EN&D"D*'(V)8\-MQG=@#BNLL_B%I-MQ*#[_'&BS&LB@,4))*4[Q8:YS$IE8)P]CGN'Z8!IR8(&G:*OP*AQ]J:$@!:C>*I2;C*JCOL?FJ)1TZ]*&GZ#@\.#@[GFMHAC:,^V=<^T^AV@
DMQ>/,@W;1QM89(' M7M7L6GPR6^E6EO-@RQ0HCX.>0H!K(_X3#@O+38@O+C636T26^CNTU%4BFMW5XU,:;W MW,#Q@4EQXJT>VOG@@DN"Z\J(IZI)-'AHT@4X#$^_./7:?2@#I:*XB3XB:"\-U
M\>,MW_9K 8A$/^D;S)>S9G[P;@CV-=W=M(()D62-UZ_I&0?RH MM4444 %%%% !1110 4444 %%%% !1110 4444 <;XTT?4M4L-N=':W2W2M
M1AU"."5_+6<)D,F[!VICZC:E+!$G"X5N?!\'+#^JUiP/)5YP!9 N-DHVLSUL-X%?9?5T\\[*>W2"SWRKG\O|VK$#X_#?*O:/HQV#H8N'X<0(/8(U?DS[R$V78@,N+HU+S8P$B1\<"TR:^(SDE@'3B^ITX[#4>8C
M7QIKFK6MK#KWN]8DWC!R8S~Y3;<N+3j^UH9C*_%>;%L)=;;L0\EYW)X4$=*8)R=0JL2'\&G2/I8=-\V/I(YTQJ6XJD&B0*$7NE9
M7QIKFK6MK#KWUJM+R2XT^22RGM/.%DD,BR2)'+N&NX^Z@$;7<J33+O4ZVK]B2%N5Q7K)!I6[V%L)@T
!1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 >?>+O\ \B+6*M)UYOWS9+DIX<ORTHBLS[KSZ!GIE8B!2.2E+XUBH%IPJIS8>E%SO\U=?%#7O#\D$?8CAWSYG8ZB,=1OWH[J4>W1A2@)5N?A$)L\%R98Q=YE38NHJ9NS2O(FP=9J=[4#XBS90
4+/18=,MA MJ5A>I14FH?:'=H21+)Y!!)4J O3Y.V:J2_#WQMJS7_]HPVEO+I=U9F1)8U MBFD>ZAF4*B("L;+&P.XEOF.Q.*LV/C+0]2TN\O++\65K19GDMMZB8"-BK';@X94X]P.10!POB;P+XD
M\86^GM'H^G^&#\@M!#=33R013B19AY*JJS%% 97*[& YV=^U7=2[\'*-(]L%TZ1KI98]1E\NW:%@RL C.SYSC:%5B3[4 >'DU)M9@M&H8A^T-,T6SR?*V; H8LV<=_7FNW'"Z7JWA_P 'GF@Z MQ*Y*=.9
<,"9H%8^4Q .S:".V*ATGQ]I.KWME?ECJ=K;ZBK26-[N2N"&!#)+/**WW411U)Y_ $T M <7%HWC:3Q['XFN-#2A%XFUJ%"7F"29+XF'4E/^I1(SGR)0I9CSQCDSDMXSLT?QEX
MCU*PA_L>VB%O:;V$%F[W,YM-?&(W,/JNW'*QZ4 =%16?/J*$$%&J)}@Y(+=DNH3$@,?4GNVY%.%QVKWL$;?Z!)*F9X55O/aI!R$*9Mg$<4,9DDDFD=MJ@BCDL2 ;CQUH^H:
MQX8+==B1JA8<$XC!)'&3[5$_Q%T);*&6&SU6XNJ)986L(2)VN86C F]/ MX< @YSSN&,YK0N/%VCV A2T\3+,]Q87BQ&V\B-GDN##+@1JB#DLQ)XH ZFBL+ M1=:@URP:[MX;JV*2-#)#=P-#)&Z]05/\QD'L:W: "BBB@ HHHH **** "BBB
M@ HHKD[WP+H&H7TU]9V.A/#/5+N6 MST[7;F[N(E9GCA\1WC%0IP2<3=C6A%X\(S7<]O#-J O!]I;275U]JD,$2EWD?7?;T*H'4D^=4C?#[PE''TS-JJQJ MNXL=%_J+^#R*+^_4*\+_47_'E]_J
\>H MZ^BN0_X5QX7 ,HO_P#R*T_]@ P7 _'E]_J\>HZ^L_]/\X"+M_J\>H MZ^BN0_X5QX7/@ MOO\ X]J1_PKCPU_P@_H__JP%_M?[D
S/%W@F+Q%]\%U;!X3)G[7+Y[!,+&RI^[Z%CO*[NR%O454TGPCK5Q\-]?\ M.ZS'Y[W[NV9E:0#MN_"M!O!@M;]-/DNM1%XZ&18#K][O M*CJP7SLXI9O!?
@FWTU]2GO=0BL8U+M<-X@O!&JCN6[&&* .1T_X2^* MO@@Z^ MU 6HF9696:ELENSN=9CE=DO@?7P@UUU:K<-D9I(S*D8UZ[W],GW >=R.1S[U:;X>^%% M*ACJP+' !UR]Y/\ W^H XC6/ ?
B*2ZOWL=/B"?VG8ZHLD$T2/=+' (GA^92 MP8;P6!4\=#6EI/@.^EM4T_4+, M!TK<_P"$'\Y+3Y+3J7J]I[PHH+M[B4% WBIK8SWI{*1T52JH6$%G8S)/+%IE/
P[#H>F6C6&GO->7$XFBNW6+9% MY:#E06P6BNWC@9'ZLFBI)*FHZ=1V>1V37,*/*(8FCDP458U(W<#T M%>C?*\\PZ4V+U3#7D$IS2"^$WVL=/7#LNVK$&"ZW7#XH*J(4A@J\Q5{!NZ\XQ
<,"9H%8^4Q .S:".V*ATGQ]I.KWME?ECJ=K;ZBK26-[N2N"&!#)+/**WW411U)Y_ $T M <7%HWC:3Q['XFN-#2A%XFUJ%"7F"29+XF'4E/^I1(SGR)0I9CSQCDSDMXSLT?QEX
MCU*PA_L>VB%O:;V$%F[W,1BQYN^/JNW'/QZ4 =%16?/J*$$%&J)}@Y(+=DNH3$@,?4GNVY%.%QVKWL$;?Z!)*F9X55O/aI!R$*9Mg$<4,9DDDFD=MJ@BCDL2 ;CQUH^H:
MQX8+==B1JA8<$XC!)'&3[5$_Q%T);*&6&SU6XNJ)986L(2)VN86C F]/ MX< @YSSN&,YK0N/%VCV A2T\3+,]Q87BQ&V\B-GDN##+@1JB#DLQ)XH ZFBL+ M1=:@URP:[MX;JV*2-#)#=P-
#)&Z]05/\QD'L:W: "BBB@ HHHH **** "BBB M@ HHKD[WP+H&H7TU]9V.A/#/5+N6 MST[7;F[N(E9GCA\1WC%0IP2<3=C6A%X\(S7<]O#-J O!]I;275U]JD,$2EWD?7?;T*H'4D^=4C?#[PE''TS-
JJQJ MNXL=%_J+^#R*+^_4*\+_47_'E]_J\>H MZ^BN0_X5QX7 ,HO_P#R*T_]@ P7 _'E]_J\>HZ^L_]/\X"+M_J\>H MZ^BN0_X5QX7/@

```
M5<;XLO+I==\*Z3;SO"E[J),SH<%DCC:39]"0OY4?:/BA_P! GPO_ .#"X_\ MC%9&KZ?\2-7DTZ:33O#,4VGW2W<+KJ%QU (*G]ST*L0: &Z7;ZQI M>(KZZM)+6VEA\LB'[(',@VQ[1QPH^8Y)
(IW@%7W:[K9UO4+O19[G[/IPO[DS M;DBRKRJ3_??=CV13WJK;>$O$UIKUUKUMX1\'Q:I=JRSW2WUSOD#=03Y/(JY_ M9/C0Z=8Z=_PB_@\6>GO'):PB]N L#)]PJ/(XQVH
Y7PU\2DUKXI7ETNM2W&G MSZ5))9Z);Q,TJ".;&\IC)E=1\0CJ?]I_V#X2^VB(P"?[?<;Q&3NVY\CIGF ML[4/"_BC5M9AUC4O!_@VYU"#;LGDO;@M\IRN?W/.#R,YQ0!3M[R^T_XHZ)<1
M^(KV^TC6);M6NI+E)+:0!V6V2)?]68PC?/WVD'DUF^-/B,J_$70](M?$:Z9 M::?JUM!=M? ZCJT%O)(AVGRQND9<]MPCV_C3?M'Q0_Z/(A?_P &Q\8K'UK3?B M-K5M;12Z:BDM;J*[AD6_N"4DC8,/\
ECR#R"/0F@^CJ5]K6@^-O%\E[XFN M&L8_#S:A KPKY5@0\@!55&7("Y)/)Q4?PSU#7(=:OM+\13WMM*^G6EY':WUX MMTS%RRO,LB\*&88V>HR.M3?\(GXC_P"$BG\0?\(;X;,59U9)IKVX+R*PP5.
M8>01VZ4RQ\'^(-,MY;6Q\$^#;>&66.9U6]N/F>-MT9YA_A(R!T% #[)=4M?B M(T^GZ]J^M6UFMS)K6?GMP2,PV\,8&/,7(X7D ?-RPJCXZU*\GTBX\1Z+K&KV M<]A!%+)8B1;8Z:A9BUS-
"WS2953\AZA3CDYJUIG@S7]%U@ZMI?:GP;9WID>4 MRPWURI+OGW'. <@']SR,\X M.10!SVA>(M6N/&$6N:E=JD=G=:_/I,)CND, W".)K?&0"%W%\[MW.,&NQ\4 M2ZQ#X_\
!5U9Z[.FF7=X]O)80JOE2C[/*^YFZMRJX'08S6(3X. M\'_VJX(:Z^VW&XY7:3_J,N.,]<5!=>!]=O/[,^U>"?!&;ZZ;Q5XOTB:=YX;&]BDA:1MQ19856-
I8'C61HV92H=>J^XJQ10!Y!X>UW6M'N]8N=6UJ^UR* M+Q"H,$4PC01H[0@2':H)8&0_45?O?B3?+=S6>E^'$NKB*XU"(^==^4NVTVY
M;.T_>W<#W7T@G0;K3]2L&CGC34+X:E*\4[I(MR"A61&!RA!C4C'I3+'P#X M:T_YHK6=GS=,TDMS([,;C'G$DGDMM'T[4 .G-7--\?:AJ'B6P\.KX?C34&FNX;XFZ_=P" Q99#MR MX83 @<8[UMS>
O#=@;)"UK*GE6D%E&Z3NKQI"^^(JP.0RMR&ZU)I?@S0M'N[ M6\L[>9KNV$^+B69I'D,S(TK.2?F8F->3TQQ0!2TKQ!=\)5XWCU"VNM*A2[W"99Y5C19&V_(P+H3C(P M>.E=1-X)T>3Q-<^(%N-
2@N;ID:YAAO)$@N-B[1OB!VL-O!XYJG#\-?"\-G<6 MGD7E %3Q%XZU;POX?BNM4TBPAOPD M\LMJ=0R9(XAG,6%+-N'J!M[UF_\ "<:]-J^LQS0QPZ;!J>E6]F]N_P"]*W/E M$BO,"/\ EISCZ#UK.U0?\
"M/"C?:T:UN9(+B.6$0-=2&.W25MT@A?7.(JQZ[<5 MNV6BV.GZMJ&IVL;)6FQ< \#CTH VZ*** "BBB@ HHHH **** M/,/%GB[Q!X=\8%_)FDTM458X%M\QS;HI#N,G9A*(EVY^ZQ..],O/'EY;_"K4 M-?
LV,VIV$<<<,AN(?+432;-LFT'[F)5<>J]<&N[OM+LM2N;2:ZA\XVI=HT9CL MRRE"2O0G6 STR:S['P?H-GH-]H0M6N;&_R+A+J1I3*I0(%)8YP$55 [!10! MQNN>(-
>^'.H(U_JEQXGM)]*O+UHKA(XI$FMPC?*R@ (P?&"#M('/-:.J?$*\ MT34M-L]1TVR5[AK=+F&&^\R:$S2%%(4)R!P23C.3CI5V'X<>'$M[R&Z^WZA] MLLVL&>]O))GCMSUC1F.4!P,XY.!Z5;O_
'H.I:P^J7,=UYLDD$L<=U(D4K MPD&)F0!'*X'Y4 8:ZEKNJ]<*4_\$NTK+S@)Y>!;0 <^&\NGEA-,#/G!R<0W.G!>!RS?%*$*Q8PG?]K@Z.)2/UX+*G]@<%LNK[[IS5;V;'G);]3T#Y8J<#4IM#$H0*JV_)6DXJY9Y%O<#NG+_<%+[(Q7Z?VG%$(X1B2,A;9B0<7NN&8HFE]*5`&>#4@A`O*^70(!(_DH=/]H;$N+@5F!!+!X0_7@/"PJV/)>(QH:!8SH2#8#B<&0?Z!^,%%]2*4(QPUI`#L<>P0]+![BN`QE$[GO=DF5`)&7/0"=<H6Y8VBO'<"P9G*0F<@X6QV&]I)`EW=Q?I8L!9N9,S@V7VW',YJ,1Q/:P0-!*H-EQ
:P>:?+^,?$+Y&*D=7:^[M'B.`;M@ZG8EJ8RU1#>Y&!@1]VNE/M_@@N0*/NS_1?-^,SP8FN1E+F:+W2U`W7*&4(UA*U2B+,V)K0>4MGB#@OA9]18?7,@H!7V^+,B>2JD)0QV2_$DK+=UIR"H/9,94GUT5%YZ;O<:;U[T/Y+$0A#5@_(9DD"&\(,3B6<'OF(@:$>^JZC,$V*8CVYQX+^<&,XR#5M;G0MK&Z[[N$09!(NH.=;5Q*FF9+01-;C9%#N((#0;@8.+;V:LJ*)T]>4'`'[Y)HJ)N&I+M+C!!CJ]B7U?@.-P?@9,>'NE(XV<_@M(4:MY)A<;`A8$/"`&RYD.ULCK4/($"DOX`D-S$'FG;@-,Y4,)B.M\;+_$G;N_JNE;>"):W!/[U-,:!#'J^U!Q,&#I3:HN.1+[8(DZBY)N
M:9LC-<;'.#T:1RVHAA\I&)#X<''D@I=(-L).\$:*>W,T]ODO;(!2H>$"7Y.S8SC`!TV2:%7/J-.+&MZ5.L6FXW"R%H2OJ)Z_).*%9*F0FB6K?)>&N=T+WLO%LY%PSWHQ($@EZV+,\'HX-"T8T0*K\(,V9%[B@P%A-]&7J=UE`&6WO!6`4,<\R=^D:GI&+LI,`0K=DPH/JDVGB68M?UZRWVE1`6&@K.YJS\..G89K3-RS6M>CB=1;#?D(GJMLOO5EZ%?T)I8]%@(G0!,3H!=8>XKIK;LRH?UU4V7%:T?I=)(MRD!=3P5_=8F>O#Z3L7DFY3)%"S:N4Q3D(^"@.BK>*OT21^Q\,N#IA.Y.<.ZQ9/3L,VH>1Q@#VG07EA?$7=GT0H3HJ,KL4`VBT^3T7&'I=,!?%/R#/K@EVPD[I@=@[V"R[/+H4:HSCY:]]?)L\3&:]K>0?<7%`;G;6#%'KE!ND)-[N>I9G%0GU0[C8Q!GJ9OT;.IVN!\$=A>P[0_*DNV:EHNX:8'IS:1B4>]0EH;0JI=I7;0BUH3?$<8*^=:,!XR=0?XOBYJ='TT#8NZL!O\+*DSOVW+JPU/LXY!Y*[Y<RO2DE9T/,NB6>EV;:@QIXP:=!.@+H]M7<_8:%EA0<E.YHTF4H/6<#`5/)QJ/+46QH,+9/..KU*$T`M!KSP))0MNNRH;G:IOQ;HE=LZF>Q2XZT%I.S!*R'C7`_PSUH]V$*<D4,D`$UW`UR2*^,H`>C`9DA>,`-\?_P`_EDT#[[SL[1LGKB?%>W.J6U6K$X?;MB>=;DR[R!HY4$?+Z+*HSW^R[UI&'_+V[(^L(Y5U7/1/2)P5\TRBE!7E5#U9+Z2?;.F%S@YQR5NUW;2*QB]Y*0_)'2E.$+MTV.(@Q=Y\Q=3GPO87TB=LW8(?+D]'0]RV4`RNE$W60QYL(J]7,^M=>*+W'W%+S$:E5:-[MYSS_@+U+LOS-=3+7UH4!^*<UP*9%9)$NU]GYR;PO!!%;=HM0X;\O;T<?TN=@-ITZT(@(P$Y`)LT&D>?7DJNZ>I+&#T^T9&16+5_0M]3?!TN
```

M6DFI2W4.K3W"^7'!+,97#Q9#EQN91C@_*<]:3QUX)UC6O$]I<:/Y8T_5HDT[M7=TFQOLR2>:K*/XF^_'C^[(?2@#MX?$6A7&K?V3!K%G)J&W?]F693)C&<[7PMI8T:.-]VT1JY!E;"-P/89R<5S]
MOX.\06OQ-CU"PT=;33?[5>^G=[F.:UD0Q%/,CC8>;%.?E!VD)C/7-+\0/#.L MZWK5U(O@NUUI3;*NEZG:7PL;NPEP=P>3(8KNPPVY[@J: .@N_'$DFL-HWAOP
MW?:W>P6T5U=J'2V6U60$QHYD(_>$ G9C@=<5%_PLS2[C1=,N=+TV^OM5U.YE MLH-)"K'.DT6?.60L=J!,?,V2.1C.16+I.B>./!>K76I1::GBQ]7LK3[<\=TE
MO*EY#$(V?]Y@,CX!]00>#FJ=GX)\6:)+I/C""WM-1U^+4#+Z^O].2;RXW2[V[MHXI&&-R;(\$X#8;ID4 =YX>\2W&M75_I^H:+=Z/J=@4\Z"-2#\PY(!(!KH M?#LWBW4;K4KSQ)I\&E6;[([.P659ID
!WO(Z_+EB1A1G '7FN$M]!\?:-X%N M?AGI^@P7,#1S65KKCW:+%';R%L/)%]\NJL1@ @D#D9H](D\4>&8KFWM9?$% MA'/<%!%$]PH=RX!3)SR""/7-1Z3XJTW5-7U/2U;[/;ZA\+[]=#\8V-KI]K/-
>1Z=!IL\K+YC+;QQ*26QE<%"157QKI^L>%8O M$.O0P0?VFNNPZIH#^9DWLTD*PO:[!\P)4,#V((/8T >KZMXETO2?#5_K[3+< MVUGN5A
P8O(&V>6/]HOA<>IITOB+1;6_M=+U#5+.SU.Y4,EG+.HD)/8#///' MO7%^(O#,F@_!*UTRW5KA])DM;ZZV\F?RYTFG;W)P[56N/#FM1^*-=EA\+Z=X
MALO$%]:WT6H74R!;5$5!M=3\YV["R;,\MVYH]"7Q%H;ZXVA+K%FVJ*,FT$R M^:,_=SGIS5>/Q5X;FOFL8O$%A)=*CR-"MPA8*A(>U7M)^'^IV-CX3+:9917
M=AXAO=1O71EW&&4W.#NQ\Q(ECR/* .LTGX@>#]:\/VVN6>O68L+AVCCDEE$ M>67JN">N.<>E:R>(M#DUE]%CUBS?4T7F:=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D! end GRAPHIC 10 cvm_10qimg9.jpg begin 644 cvm_10qimg9.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# 4$! 0$ P4$! 0$!04&' T(" <' M"! +# D-$Q
4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_ MVP!# 04&!@@"' \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @("#_P 1" %& 94# 2(A$!
Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %]0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B7J#4(&6AXB)BI*3E)66EYB9J*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0
M1$ @$"! 0 #!! <%! 0 0)W Q M$$!2$Q\R!40=A<1,B,H$(%$*1H';!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#[+HHHH ** M** "BBO%?
VAKS6+/P+H8B:)J%U:75WX@LK4_9KU[1I5'=8UH^';=O^$:T5[C7+=%=6CU+SVA2!3D[4 1I&)W$+B@#Z M3HKPCP'\5/'VN1:FNL>^?[1FCMX+RQ33)(;=[B-VPWR2W##"\$/N&X9X!K)^ M+>I?
$+0]1\/>*/#5Q=Z+-XO5?#-QI.H78=-/N9B?)N4",R"10&R5..%Z\T ? M1M%^-GB;XD>,O .O_P_F"N?".EMKK>']+M[FYO-6D-6:_W9+9,E38.#_E_GP> M3,
"I_$7QVUK2_'=K9:3:V%_I7V^QL;V%K619;5KA5.#<>9L9QN. L;# Y:@# MZ,HKRCP$XR\:>+_&/BR.\M]%@\.:%K%YI"& 2_:Y'B*&.24 VL<]R>@&.?,
MO$FN7FJ:I\7M0U[Q[JGAW4O"AQHEE:Z@UK\O"[G?Q[G<&G$";S7P/F#=<+&10! M245\S&_KQUI%IH*BZEH]W#B3Q'H^E7.AI)](JRW,SK'N)HMX\N(Y=I94,XD:4!+-5E\.Z=IMMJDNCZ?
MM;FXFFN?N?+&Z-6 .4!P^;DD#BN M:N/B1XB\9>'_RVL0KI=KH>H:5\[-/TF;[&S0K.F"WS)O;;=G@=KN8&X@Y?M4 M?!N^N'TGXAW%#?U?.WD>+5)!?519)W+B%%%%9<#D*/05YCX%\0>(M(\>^';?
QAJ&J: MSJ6KR7+66N:7XF%YIVIX1W >R'$487;@JHP0#ZT ?5]%%?-^@ _'[5=:L:?"]M_ M[#GO-4T74]2U&^W9F:UFMT+1IMWDH%&QR&Y"*N6_P 7/'.%K MH$7A?7'1;HZ: /H2BOG:P\P]M?>
-6\0>&[Z; MP_I)/%W@ M^YC MUBW32]1T?QUIFGR/9[H!/(%$S!OF3>^W@X#X*[V%>B?&;6/$FD^/ANGANX)NKK7 MO*:T:\>VANAY3'9*RAOES_LGZ4 >T45\G\ "6^)%N/&K^*;>.ZGA\9:79K8 M/J%Q-
;V0DV@^4ZF,X&?DV_+@*_A5WPC\O'7B0_VE-X7L;?0[RTOY;>0G:UK+!%\)(BLQE M)FSY9# 1H5/J.: /IBBO-OAGX@\8>*_AW;>)_%46CV_IIVL=U9QZB3'?@?=?%?O6K._UY;6QNY([F?
Q)=3M*1<6_AK5=4TFSTV_M[K3C*;-ENI MTC,4@+DAP&R*&Y'..U>N7TWBBW^%>LW'B*XL8=*8O!]W?K>)XH.J6=WM4#[2H M!)MY-WW0,#!(]* /L"BODCX:^*O$FF^(;VZ6\U: V?
@N/4VTCQ)K)F&&KW++N M6YAD=F6*+C!X8W8&L9K:UIXH!*+V&^(\N\NSOG,U#JG\-JK-_C@>)*,.@D(@SF&#J\,I+7@(,Q)(Q8>>&3+SS2Y&4/M(X:^\ 'GKC;)RKY\:@GJ'_%.\AA@OV5(T6W[CFVAZ@K:X.%G.ZGAHGG> T\MR(&FV\6%@
W8C5?0FJ7A3XV/K[4O"MYX@T70M:>Q$VJ0PKI_G"[1[-&R0Q*R\ #/#!7*/LNHM/TN60BW3>H59 MMS$-(/7"\Y&.*I?%%\7:E\
<_$V@^')/%EW?)H-O)I4&BZBUO!:73.0)IAYB MKL]<@Y].X /JFBODCQUK'C30]8U/6/%%&MW6O:5I=C9PW2^'/$HTRXT:X$2^< MS6_'G,[G:[H7]@:=IUWHQ759+=8I'LS)@P
M;MCEV"!E*G)8@H7%)K6)6X MDB51I(-XVOL8C*Y'!QU%X1VN@Z_9 ;VLM'LK9M3GK M6U10:SNE>&/"?A-NYT/PJI>B^:#)P1)ODDQ@=57IDE2 M *\HL?AW+-+_ #_3I_$D.L.+
(-7ATNSLUM+::&VET]8VCD/D%2@WI(BMN+$GRU M/J ;>N:E\+=>MH-3\4:!J;6UTEG"FHZ#+++<),P+*B1O$9.0^>!CBM'3]#^' M?BYE\46OAW11N-XC^V2Z>@GC>)L!&WJ'1D9-6.8.",N$?
PSX^U:"PMIKS6TT MR#7K6YLYK^2V.HVL*PR"9V904*[V4*&#-@G/&*JZIX-\20^'8-+;P_=ZKJ&F MW]W-Y_EP7-IK+$,MQ<1/+&58YP2I'EL&VC:5H]:N3H/A'1M5UG[/:7:;I
M+^]EAA"8Y'S2,%&79]GHTUL)06 M0!G4D'Y3\(\&J)\GX7VEUJ-H$$GS:?>ZA;0$R(L4,\4DP!]+*H5C[A:Y' MQ=X6U+6/+&RD3-13(2\& NWAEVY#953N'R\YH].M
M4\-^*+R/6/[-MKV[T>[GM8+FXM@9+:5&V*2>6S*\KC(ZXI]WX\/>H:[#X:Q6 MOO!!*<<>**S,/[KCB]!%!&Z[;E%,:7+@?HQJTSXGD"SQ+\>O@IFX#&K/GAS>&Ds?XW(!+TV]WH$>]&&M>!@T^42XR657W
X.<8H]9T_3_ ?K>F:OXT@NWCO]/GLE5#,<2;VC(P MV[Y598P?0\=JX_7/#_#/ (LO/BU;ZU!H MKPK:ZM:LE[:1PJLMCL"R&65G\TG)/6@#U:STK3-/UZT?Y/_PK_RJ7=#17YT?I#_IYKY_(H]9_?W5L>_Y\ ?
=L#ECWQ\Y-8&CZ%X*T7TQ6&Y>BZ%?4B@*WKZG(*L*D:AV^:VRS+%?`o,

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

M!=H (&.&//S"N]KYB^ O_)1I_P#KPD_]#2OIV@ HHHH **** "BBB@ HHHH M\TUS7O$=GXHN[*W>Y4O'(EE;161D20[$,;E]IZN74Y("@?C7I8SCGK7E?B>1 MO[>O[.Z\2V< #-/_ +Z%.\J/
M_GFOY4>7'_SS7\J &^?;_P#/>/\ [Z%95])'+J%G";HK&WF%A'*4S@#&2#6O MY4?_#S7\JS[J./^V-/_':])>WL*I;DRV%^R:?_ ,_DW_@8_P#\51]DT_\ MY_)O_Q__BJO^5'_
'%_*CRH_P#GFOY4KON.R[%#[]I__/Y-_P"!C_\ Q5'V M33_^?R;_,_#'_P#BJO\ E1_\U_*CRH_^>:_E1=]PLNQF:?+'%->0_:MZ), MN^7>0"BGJ3GJ36C]HM_^>\?_ 'T*J6<W_3-*N^5'_P \U_*A
M@AOVBW_Y[Q_]]"C[1;_\JX_^^C_YYK^5'E1_\U_*D,;]HM_^>\?_?0H M^T6_/>/_OH4[RH_^>:_E1Y4?_/-?/RH ;HM_P#GO'_WT*/M/%O\ \JX_^^A3 MO*C_ .>:_E1Y4?\ SS7\J &_:+_=@_P#?
0H^T6^/]'_WT*Y=Y4?\ SS\ MJ/\CQ_JU_*D,\.&^(GB$@@C^AT _1U^FX'*^$/&K2Z9H-M\G\C7CYM_N\OE^:.[?[Q'Y_D=K16KX572=4U74--OK6=[B*TDN(F63:@VCN M.I.3ZXIGA2XT?4-8AT;4[. 3328(Z>\:(L#P%B51\SY]37YV?5&;171Z?9Z' M-9ZA'<6Y6XAN+B!Q-9T/
M[XHO]U"=OX&&@#B== P"1>OO^N1KS*O3M=_Y%X^Z_ZY&O,: /5O@.ZI\1)R[!1 M@@D'Q_&E?3/VBW_ ,?\?20_?0KYG ZJWQG$G#*"/L$G7_ 'TKZ:\]/_GFOY4 M-
^T6_P#SWC'_[Z%'VBW_Y[Q_]]"G>5'_SS7\]/^7 .>:_E0 W[1;_ P#/>/\ M[Z%%+++Y\'_ #VC_P"^A2^5'_SS7\]7RH_[B_EO @ _M1110 4444 >::C?7VE^(M M8ET_5+N#3S<++>Q:6DT-
J_EH&W.7#'Y0I.%.,UZ6.GK7F&M+^)JNM77]FSM MIEE(O]HPKJ#0_:B(T9F\G;AAM*CEEW[<<]_35*LH*G(]J '452:YMX[=YVN(MUA3.Z0L JXX.3T&*:]]9+;Q7#W<(AF(6.3S!MAS0!?HJN)(VE:-6!=<
M%E!Y&>F?RJQ0 4A.!D\"HI)%B7X^6 M'*1=Y.F;?[O\ C5B.-(V(N! .I** "BBB@!*CIKLL:%V8*H'I)P *\VOOC9\ M.;&<*ELY=<:5XFVL\,#NA/LP&&#,.#]J1A\3L>G50N?^0Q8?27 M0KSW_A??PS_Z"__ ("R?X57D7 .7PP:YBG;5[C=%NVXM),<]>U;+*UE]A_<9 M>WI/[2^1]:HKRW_A??PS_Z"__ ("R?X57D7 .7PP:YBG;5[C=%NVXM),<]>U;+*UE]A_<9 M>WI/[2^1]:HKRW_A??PS_P"@M/\ DG^"_OOX9_]!:_
,!)/\7U:M_ M(_N'[:G_[SU&G5P7A?XF^$/&6K2Z9H-]+<744G96@ $! SDCU85WG:L M)0E!\LE9FL91DKQ=RE9_\?NH_P#79?\ T6E7JHV?_'[J/_79?_1:5>H8T%%% M%(84444 %%%%% !0>E%!Z4
?#GC[ )*XC_["%Q_Z;N;_S71^/C_ ,7'\1_1_]
MA&X_]&-7-%X<)N,(>B$CUW_?HSH_SH(-_XHHA(_HM-/_XW1-N_+/\N_6/8$HS%3?G9:[aNI4P%KI4S@D$-]CXXKN0:M D+HLJ&LYK'^8^V/0<\%I]V2J(aI>W**R72B!)
[... remaining lines of encoded data ...]
0^*U[IUGHMZ/"NO>&+>QO;F25HUM7CF!7)R'V+PJ\ G)QS7 MT/10!\Z>!_#FJ>+OB)+KOCJUU.+4M'UR>>SLVLWB2UAC!C@_TACB2+!R$CQN M8EFW <==\?IF/P5U[1+/1[_5]1U*#
[/:VUG:23L6WK\QV*0H7[W..G%>NT4 M^?^\DSB'"LOD'_1*.:CR.D_IW4]ZI*RA[C/?QB]@N1K?\#*\\V*\[#E(]!3^ 0A40LH7,Z&-Y0)O8I.R6&H^/*0U0EIIV9DB.W*Q,D$"L\/@F+K_GWHT ?2.4?!UGU.+3!@ 3Z"@%NA
/[)]Y+9VF;>\T;2H#'C3A3VN+F5Z[86?:-GC.KFN90Y_T[3BLO<[1GGL\PC"/IF5^K@<C'2>ADT#@OGCQ:?@HE#S5VJ4?+G84*@CNQ&,-&4-(I&8Y@?+@WMVAT)5UV@[M1\;9\6[8Q(?J2QR'R/;WL@R-OM;W'^NQ4O?3E*8NG$NU4*
MN%%?6E% 'S%I7?QD6%0"(O"?A76=+U33_#F@*$8[>\9S)]Q<3-'T88' "DOC MG@3$#*UXZ+P#H-S\;=7U!=$O#H\/I1W.I6KPW.FW3 0FUWGB:Q_,H!8@)= M#U[HH] **** "BBB@ HHHH ****
"BBB@ HHHH *\M\17VI6?Q-CNF2*9;>. M".PLY878S>8Q$KQL.%<< D]A[UZE28&0>] 'BMMIMG?:K;:7=0S17TVH/K MRH5;RCDH6&&!/EE1STK;*W1TWQ,FGR:7<2->*6AFEX:*)@7SM P 3]

[&,$ M@8XKT_'7WI<#.>] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 45#-,(83(P) QP.])YLW_/J?\ OH4 3T5! MYT__ #ZG_OH4>=/_
,^I_P"^A0!/14'FS?\ /J?^^A1YT_\ SZG_ +Z% $]% M0>=/_P ^I_[Z%'G3_P#/J?\ OH4 3T5!YT__ #ZG_OH4>;-_SZG_ +Z% $]% M0>=/_P ^I_[Z%)'/NF\EHRC;=W)SQ0!8HHHH **** "BBB@ HHHH
**** "B MBB@ HHHH **** "BBB@ HHHH **** #M24=JK37"P[=R M2-DX^1"V/RJ6[*[&E5+^\Z?(?E^OI1S+N%F7,453 M^V+ME;R9?W9P1L.3]/6E-VOF1IYU'/N'*RW15+
[8GE/]Y,V$ M.TCRSD_0=ZH:AXBTC2;B/"/4[H6K3G6NK6 M=]IL-*CKSCMD?G34HO1,EZ;FYFDKE?^ M$]\)^29/[57 ;;CRVS^6.E/_ .$X*^;Y7]KQYV[L[6Q^>.M.XKG3T5E6NK6 M=]IL-
:&6:WF.$98VY[9QUQ5G[0OFO%Y>/<=F6L48JI]L3$1\F7]Z<#Y M#\OU]*7[6G[W]S+^[Z(?F^GK1SQ[A9EK%%%N?:NOW,O[SI\A^7Z^E)]M39 M*WDS?
NS@C8M',NX69;XI:J?:E\R./RY,R#.=AP/J>U,^VIY3R>3-A#MQ MY9R?H.]'/'N*Q=YI*]BX7SEB\N3YEW9V' ^I]:9]NC\@S>3/@-MV^6=WY>E' M-
%=1V9=I<55^T+YYB\FOI]6?1=G8=OY^M1_H_)$WDS8+;<>6=P_#THYHKJ%F7\ M452^TKYLD?ER91=Q.PX/T,B/B8K=SHI/%?AV]5/&6UU6*6:1U5S .26 MP;!T^7G'X5TC>/&=9%?
P;JC"0@N#82?,1W/R\]!5)A8CN/%,KH)HU=)9^)I)O"-[KSVF?LV_%LI_>KMXQ/(X6[D=A7.?\ M"<1^N_X0G4-VW9G^S9,[?3[O2I%^($BM(R^#]44R]N182?-VY^7FF(DN-
!SGUK,A\=+;HJ0^"M2B4,74)IT@ 8]_N]:?-X\6XECEN/!>I2R M1*,^GR$J?8]>* 'GO]>?V?)M:U M)A]D>VMXSZ\D"I31XVADE;=X)O0TS@NTFGN 3V+$K^M= M]#96I6&9K*%)511P@^3'(/L:
,S2]6DU319WFDAM;R+SHY K*49DWC/,W(MSS7 0R74G@Z"T_\ MBW6YL;R)YKQM3?R;T;-Q59.JG'51T->HM::?;LGEO)M)7.<'\237(ZQXDTG3^)3;>$[N]B1M^(M-9H,^HPN,T
9EUJ%\O M]G:M!?7<-I>VL>^TW$R01L N,D[)YM4E@?_A'=9MO"I0*NGRXO M^524>GZ;JVG;Q;M<;;=Q74;,48QMG:P[$=C6E7A$.J:EINI#5M6TO6(;WJ$ B M/ITOEW2C^!.OHW4?2O6?
#>OP^)-#CU2&UN+1BS1R6]S&4DAD4X96'L::)-Z MBBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%% M%%% !1110 4444 %%%% !1110 4444 1CO7-Z\ WB'2%8
CRI^# VSKI!WKG- M>_Y&+1_^N4_\XZJG\1C5^#[BW]CMO^>*_P?(I5L[8,/W*=?[HJEK&L0:+8- M>7^&2*+#3!&&J(^[A>K =P.;;H6KKKFG P!I0VYBM96S;LS@M+'C(<@?=SV!
MYQ6]SD<5:]C3T;_D$K_OR?\ HQJU>]96C>?J7_ ()7'Y/_1C5J]ZYG3.V'PK MT0ZBBB@T"BBB@ HHHH **** "BBB@ HHHH **** "N=\0?\ (<\,?]A!O 2> M:NBKG/$/_(<\+\ 81;_-)YJ
.CHI**BX["T4E%%PL+124F:+B*-Y(F^&%W M"H3OLG__=34[6UO)<+.\8:11M!/.!4].X%1+-% M<23,9Y1_$_0?0=!5RDHI7 6BDHHN MFO;S39K'SQJT]G=2WZ$>7"8@GF
@YRGRCON]]D.DZ]IFOI]6@Z+##%/\T M8B*@E$WC);)^7<,G(Z*,4 >ET444 %%%% $5<[KW_(Q:/\ ]PTB]M!);30I.I22V"A"Q12X&WC:&R!WP*U/$>C3:MI\8LI+6WN MHI4D\RZA$D;*N?
D8=P/\VKG)M;=3GE\+-'1 MO^02O^_P"C&K5K*5^\3.FG\4[ )!*'P[ ]YBZ%ZKT^F\?(Y[D=KT=VCY BO\)B9BW3P?[YHP_C.VMQ?J0ZUZ^'%*UH5P'\;I?!YFZCJDH!TC=:
D8=P/\VKG)M;=3GE\+-'1 MO^02O^_P"C&K5K*5^\3.FG\4[ )!*'P[ ]YBZ%ZKT^F\?(Y[D=KT=VCY BO\)B9BW3P?[YHP_C.VMQ?J0ZUZ^'%*UH5P'\;I?!YFZCJDH!TC=:
GRAPHIC 13 cvm_10qimg11.jpg begin 644 cvm_10qimg11.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ # VP! 4$! 0$ P4$! 0&!04 T(" <' M"! + # D-$Q 4$Q(0$Q%14%%Q@9%!<A(2&B,:'!X?
(2$A%!DD)R0@)AT@(2#_MVP! 04&!@4&!@'" \(" \@%)5(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @("#_P 1" %G G # 2(A$! Q$! \0 M'P 04! 0$! 0$ $"

>T;:6ESVV0^2^YX1?V-]X@\:7D.L;] M<;:JBZALLX%T^9WAA5AL:.16";2.22.YS78?%"'3[BST"TUBWDETMM21KJ15 M=@BJI(SLYY.!7HV**3]7:TV!0T:[GS[XPCCNKB?21,M38R:XOMR Q+GK[
M5ZGMYJE?V=OJ6GSV-RA>&9"CJ&*D@^XY%7[2]D3[/=GC&F0Z3J'B70;C15OK MO6X+6:_OI[GSD::41X",&P/]8W0# Q4?A.OFO-;M=8N-.2>]M?[/F MBD=MAS#([-LQG@ #L,5ZUHOAG2-
\QM/MF624!7DEE;5V Z#H.NV^9UD5A(6+%2']">WI7(W3:3XCO?$$D M::A>>([J_:'3TB\Y5MUCPBR@C" AB37NY'!':L_3-/L]+T^.QL8?)MXLI$!
M)QDDGK[DU"EJY=6:..BB>1ZU%_;>I:Q8W\>I7'BM)TATI8_-1(8P%VS*PP@(M.YF)^E5;Y])\0:EXE\Y-0U#7Y+C[%IL#*"!@#>QR?:DU!KG19=1N/L[RQV-C9Z(LT@D*H'&Z64[/F('&2.:]F
MO1BE[3R#V;[GSQ#I_E^$/%R?OY[(EDM;;$=K-$F-P,DH1B6P >O?TKI;J!;) MYV\$VEQ';6&CR7-N(ED^>65@N0&Y+!%) ^E>Q8HP*'4;Z"5.W4\/7[+:QW^L M>#4U)[1-+DAN9Y?-
_P!+NG*]G#\EU))) XS70^'_K!H/CO2K;3UNH_(TEF MOIGFDD%PY*JH;<2"00QKT_M1VL3:L6HI:G%W^+SXJ:79W S#9V$MY"IZ&4N M$W?4*3^=<5KVBKK,G>)?
$4MO>R:A+J"66F]9)$D(RH'50<#G<#==6H98LD%0PPPIP?>M,CFM:PN6]GGGB>Q\2/J4/]FPZU/&L"]TE MEJ4-NC,.N5=2<^])=:M)X;^'MQ)X@BO#<2+(D<5ZXO))'(^4$QKC'X5Z)24<
M^UUL')K=,\^TC6-#T'X26%V\ADM([41;?L[GS),'*[-N>6R.F*S-#L]4U;X3 MZ79^%-0ALYF:-XT\4D>N,<>]=#]&EV.K1Q1WUOY\44@E$;.=I8=-P[X]#Q6O3E/FU[A&'*>/V.
M@K]:Z39:]'=SVFFZ0;V>,R2())YF+%3@C=@ \=J[I'X26MS;^ =*CN_,\PQM(M$E)+(K,2]*0.:["DHUNLI*K0I M+-@CGC[@ZC-:FJ:7?>'[SQ4WA&*\MD@L;:%V4O,2[/EY54GYF6/TKV6BGSNY
M/LT>5_#?1[6'6;[5-.UZ2_MVA6*2-+.6"-WSG>3(QW/ZX]:MW.G>(-:^(6L7 M>FZL-+MK2VBL/,>U\QGW?.Y0D@#&1SS7I%%)S;DY H))(\6NO">FI;^)I9+& MZGM-&LDL+%/,D4R2!2[/\N-
Q+N.:R/&4EY/:G1[Q7^WZ58PQVY>WN)I;F1D& M9 4(10&XW)XKZ!Q3=M$:C3NT-TU:R/%=9MO)XMTVSN#-KMU!#;VSZ?*MQ') M$P W31RKA#UR2WI5,Z?
>:]XQD75O$%Q8ZRFH'R8%T^9I((E?Y-D@;9L*CDX[MG->\TVFIVZ"=._4S-4U2UT?3Y-0OC+Y$>-YBB:0@$XSA03BN(\+R3:WX]O-: M6XN-3TN& K:7=S;^2('9OFCB&!N&T#+$9[5Z53?
6HC+E3TW*<;M'D/CXK<^, M(@$97U;2*)8UT:2.=-Y+9\R*2/Y=V.I;@8JL]GI0\1^,]372[AO$EI'FSC*RI MMB0@!E/W6R2?RKVFC%6IV25B7"[N>-V>K2:E%H\/A];RZ_L+2);HM)#(@EN#
M&&$5*UO?,72O#EY-%&V\G[=,' M.UL]U13^+?2O5C6=IFGV>E:=!I^GPK!;0KM1%[#^OUK1]92YG=%QCRJP4444 MB@HHHH **** "BBB@ HHHH **Q $$DL.@7!_P 3 M#4/_):@#5HK+_L6/\
Z"&H?^!#4?V+'_T$-0_\"&H U**R_P"Q8_\ H(:A M_P"!#4?V+'_T$-0_\"&H U**R_[%C_Z"&H?^!#4?V+'_-!#4/\ P(:@#4HK M+_L6/_H(:A X$-1_8L?_$$-0_\ AJ -2BLO^Q8_P#H(:A X$-1_8L?_00U
M#_P(:@#4HK+_+%C_P"@AJ'_($-1_8L?_00U M#_P(:@#4HK+_L6/_H(:A X$ M-1_8L?\ T$-0_P# AJ -2BLO^Q8_^@AJ'_@0U'BQ_\ 00U M#_P "&H U**R_M[%C_,@AJ'_@0U'BQ_J!#4/_ AJ -2BLO\
L6/_*"&H?\ @0U'BQ_]!#4 M/_ AJ -2BLO^Q8_^@AJ'_@0U'BQ_P#00U#_,"&H U**R_[%C_Z"&H?^!#4 M?V+'_P!!#4/_ (:@#4HK+_L6/\ Z"&H?^!#4?V+'_T$-0_\"&H U**RCHL>
M/^0AJ'_@0U8T@#JZ*Y3:W_/MK_P#W]_\ KT;6_P"?7;7_^_O\]>@#JZ*Y*1A% M$TDD.O*B@LQ\SH!^:-<&FP7?Q'1CZJ!210ZYN&Z$9H VJ*R P"Q8_\ H(:A M_P"!#4?V+'_T$-0_\"&H
U**R_[%C_Z"&H?^!#4?V+'_-!#4/\ P(:@#4HK M+_L6/_H(:A X$-1_8L?_$$-0_\ AJ -2BLO^Q8_P#H(:A X$-1_8L?_00U M_P(:@#4HK+_+%C_P"@AJ'_($-1_8L?_00U M#_P(:@#4HK+_L6/_H(:A X$
M-1_8L?\ T$-0_P# AJ -2BLO^Q8_^@AJ'_@0U9]_;P6#0(;K5)F*D*H)Q). M!DT=!=)17*;6_Y]M?^@O'_^VO_/MK_ '] _^O0! MU=%C:W M_/MK_P#W]_\ KT =717*;6_Y]M?
_ O P!>C:W_P!]_\ Z] 'Z] '5TR M:>3I]@@F_MFW_[[$>24[=V,XV/M6CX?:9K"=%SS'KT?L$/\ ]NH@_$(5L#I6 M'KTL<_ABYFA821NBLK*L5U-O#VE_P!E MR0(0RF;SE)S'DY QWKHZOO\ A'-
)'W;4J,YPLE@EF@@^_"PD@ ^MTL%%^6)]CNFX;CKK7GZTLM -Y85M;:!^HD(#)D^ MTL%%^6)]CNFX;CKK7GZTLM -Y85M;:!^HD(#)D^ MTL%%^6)]CNFX;CKK7GZTLM -Y85M;:!^HD(#)D^
M_P"$5+-OD*AL;M!?ES@9KT7_A'-)]YW_[N/N__?Y \:.)TMO&\]UXIU2X\10R M064>FO&BHJB=>=I!4AB6/WLY'2O0=* Y UC_P!<$_\ 015-O#>CLI5K5BIX
M(,KX/ZUI1QI#&L4:A44!54= !0!-1110 4444 %%%% !1110 4444 %%%% ! M61]/ (Y M[67_ '[? &C;KW /:R []O\ XT[^V+?_)][O_P'; "D_MBW_P?>[\!V_P MHYO)!==QNI17/:.JF,[?
G*D#'IS7CNCP?%K1-2AN9[,OHET\: M<%:19ORU[-<7GDZ5->HH^2)?2&I64^6.!G!Z?2O-K#XD:]] M%RVEFTTNSU)(3=2?;9'2-8P,I(.?XF/9@<8YQ2W*,>TL_BM9W*(.^YN;H6UJ[+*
M3,Z\0GH@(;YN^?.'%!W2V?^7?FO?C!:Q;/0@^E=#X M7\7WB1;?)TZOTLM=GC^SSW!6[0JN2Q'0'0CC..NW!K$$M?B]:R6]Q=36&R?&+ -P +%EQZ $-
Y[2X&I74NH6YU$RVT6EQE=D.S"I*-ZLPSW4Y!YY%8O] MC^/VLD6*WU,#Q@#O+7-V;W=;O:[?]2G.-^. =H(;DFO;Z* . T>W%M#9K'I^I M:?]_U9R0,D],]B3GK73^'\
CUN_^OR;_P!"HUC_(_-)_Z^ MQ_Z"U'A_CUN_P#K\F_P"H V**** "BBB@ HHHH R-?T !NM+D<1B=A^?3S MSCICWKTBB@#D-4T&QL_",<)1Y&L8(X8W9R#A2,9
.*Z_M6/XD_Y%N[^@ P#0 MA6P.E '-:AH-N\L5U:VK22^=OD7[0R[OW[XJ*:RAMX'FDT.0(BEFO=DG _&N MHJ*2-)8VCD4,C A@>A%)2DOA:1/+V.V/1-)DC606[8(##]Z_^-2?V#I?_/LW M_?
U_\:4:/IRJ%$. . -[?XU!IZM:ZE=V(_U?$T?S$D \$<^XHYI=6_O%MNBG M/##HNK6EU'B.TES!*'E;)Y5N>.V/QK7_M73?^@C;?\ ?U:M.B2+MD0./0C(MIGV2U_Y]X_\
OD4W)2MS7N78DBD2;-9(V5T89#*^@U)7.K;ZQI.FNEM);2Q0 M!F1#VVXC)..#5R/7\'):XVLR@R21'YWAR].9W+?^!#'K9I!;JVUUI!"=0": WD$Q9 MR P]MJ5-FG9@%%%%%% HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LC4K*ZN;BSN M+.:*,2V=FQ*A96!7'8BM>B@#*\OQ!_S\V'_?I_\ XJCR_$'_#\V'_?I_P#X
MJM6B@#*\OQ!_S\V'_?I__BJ/+\0?\ -A_P!^G_\ BJU:* .=H==D1E>?3V5A M@J86((_[ZK)'A&%;(68TC0!;B3S1%)B.T/\ WL9ZUUU% '+_-@7'VY[[['H M.!K=/+:;[*=[+C&W.>F.*?
<:'<7B(EW:Z-.JQ^4HDM"*25J^<M^4CC@954?2 M'\B.T$\A^>2%#GJ(G/+JQ'YB3C$/J^@Z\@#VDT_J.\ZKIKN.JAC MKT^RJH[1^\J\D1\BCU
M\;JRGN\I,IL:ICJ+V:A?Q\#F\P.K9&>? M$`J=(V9A'8MHa([9T00@J0L]$E!>GU.B7]A7Q:)W<7YDZY&7/^B]W;L`X>VHJH7Q#)4F[:8G5]=7\/:D=QV+4F^3%E6F^:#N+U`:...

[&!@$\ D56T_XK07'F/+ M8_:+<3MF:*14V1,VV/"DYD;UV]* /5**\HNOC)8V>G13W'A^]%S)+M%NKJWR M;-^_<./N_P /6KFI?$"_E,MGING_-G;Y(8XM1O5)A028^=AP. >F[K0!Z71
M7E6H^.M87PWHUY;R65K//6GV/C;Q!>IJ4T*: M>[FRGNK:T<,K6AB8#;,023NSGH.E 'J+?=-9GA__) %I_NG_P!"-<98^+-4 ME\8:5:WN_\ (3T3_KZ_]IM6\OWJP==__MY">B?]?7_M-JWTZU*^(UG\,?
1_F2T4451D%%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 5C>'O\ CTN_^OR; P!"K9K&\/?\ M>EW_-?DW_H5 &S1110 4444 %%%% !1110 4444 %%%%
!7&>/+75;K1K=- M-CNYHA.#NEDCCEC:.55=&&&5AD$?2J MW]BZ/_T";/\ [\+_(4 \>%V\HADSM^0CH1Z=33]UF9#(7\-ER,% MLC.,Y J:U].VZ1:V"0'3[,:!8[_"%YRQ/I[U<_L71_^@39_P?A?\
"@#G M1): MB3PUEB2?F')/6G17%O#>27D,_AV.YD 5YDOFT.1Y()(QI=FI92N?(7C/X5%8Z#H]O80VIT^SE:%0C- MY"\D#Z4 9%#-I-Z>DBV,WANU64[I!"P0.??'6FPR6<-S%<02>&XIHD\N.1& 9
M%_N@CH/:NC_L71_^@39_]^%_PJE!X>TF'4KNX:QLV%SMVIY"_+M&#VH Q]UB M+V:\#^&A=3J4DER*C6WTE+%K%8_"RVC-O: !0A;UQTS74_V+H_\ MT";/ OPO^%9\WA_29-
1MKH65F@MMP9/?G<,#- %./4!&8S'?>'T,2[%VR8V M+Z#G@<=*]I[=.\V*0^(R'@+)OES&3U(J,UTW]BZ/_T";/\ [\+_(53U#0- M'NM/FM%T*RB>92BMY"\'J ,;4V,\0AF;PU)&&#!6((R,
=>U6;B^6\M)+6[MO/#%\]LXVM%))N1AZ$$$XK8CT31TB1#I=FQ50I/D+V'TIYTC1E!9M+LP!U)@7_ M H YN9[*>..9 #WS M'O\ C6I8^'=>)MI;MFL;.7SYC,H\A?E! &.GM5W^Q=" Z!-G_-^%_P * .>6
M>V6[6]2?PXMTL?E+,& =4_N@]<>U:6FWVEV>EP6LNL6+O&N&99E)SGCFF-X M>T?^UTOOL=F$6(P>7Y*\L6S^=:7]BZ/_ - FS_[\+_(U_A0 ?VUH_\ \ T%K/_ O\
MK_C1 ;6C_P#06L_^ P"O^-4=1\/Z1>6;6JZ?9!Q.Q5@?7(7/# ^E6UT?164,NE MV3]Q"A_I0 _^VM'_P@M9]_P!?\/[:T?_ *"UG^_Q%_ L;1_ !H$VG M ?A?
*HV.@Z1:PO"UA9RMYC/GR%XW$D#I0!>_MK1_P@H+H+6?_ '_ 7 &C^VM'_ M_@M9 \ ?]?\/[%T?\ Z!-G_P!^%_PJ_^F PJFGA_24U.;[.GV962-8POD+P03]_M %S^VM'_ M@M9 \ ?]?\/[:T?\
Z"UG P!_U_QH L71_P#H$V?_ 'X7_"J]= M[X=TBX6&GVW2@V_"Y@ ;6C_P#06L_^ P"O^-4]_M:/_ -!:S [_ M * XTG]CZ.1QI5F1_P!1<%"@P2,>E %G^VM'_ M%G-V^Z&T@ZVX@2,JG
MUG_W_7 &C^VM'_ Z"UG^P/_ 5X/6/Z^/"Z%=\ZV]^M Z6Q#SV^&[%$_7 Q_T7-(?(\ ^,ZE
... (remaining lines of the encoded data dump, including the embedded header "GRAPHIC 14 cvm_10qimg12.jpg begin 644 cvm_10qimg12.jpg", continue to the foot of the page)

M/Y%M<"20B.2<^5L4%B &+[0,8&[M4DOPS^%OAK1[NZDT"RTW3+:[369F,LBQ M0S0[F64#=A=NYN!@<]*X*YOTO6EM/#^O:GXC\-QWVAS"[OI'G,=X=07S$5V M/^K"LR=$./NY(KT?
XH!7\.Z3#-F\)VY!!$A^;@Y X&![5YI\3->N+/4O&JZIXHU70IK#2EF\/PV4\D" MW+F)S))\@_>L) %(.0H .!G-;7VC4CX@\=ZW=7VOWL>A0P2V>F65PT:R$V*N MP51]]F8G@Y /.,T >QUBZIJFGZ/%!-
]%PEI#-.ELLKYV^8YVHI/;)( )XR0. M]>'^%]2\6ZY_PD^F>'?$DEPRZ3:ZIIK1;A<7J+=+*Y,1GF52P?8J.H^4 G@' M-:]OJS^,O@[XV\:TUQ;Z-K-C,^GV5RTC2!WR.?N>@H]KHK, MT-
KQ_#FF/J.1>M:Q&?/7S-@W?KFM,@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M
"BBB@"E>V=MJ.GW.FWUNEQ:W,;0S12#*R(PPRD>A!(J+3=/@TO3+73;42BW MM8UAC\V1I&VJ,#+,23OW)S6E10 4444 8E]HMCJ.J;=J5Y"TMQIKO);@NVV- MV7;7VYP6"E@"0<;CCK6W110
4444 %%%% !1110 5C:SI-AKFC7FDZI:K=6E MW&8I8FR RGW'(/H1R#R*V:* .3U3P3HNM20'5'U&YABB2%[9M0G$$ZJ?&_B'QYK7Q8U MOP[X#U#5X9M*CTVV@2UA5K-
;B27S9Y+EV4A56WVC;D$D\FO3?B$OQ";2K;_M\(5^]BLOF[9YV/M!BX_X]]_[O?U_P!9\M_]G.P/D%#A=O<"N*R?A?\ VAX7&L&Q\&>(].\ZMK< M-
OH^FW41,NG1FW'FSRJ]DQPF53W/)SCF@@W:BOC_ ,^#?B9'9ZU#INB^(-* M\2'P_J5OK.H74["+5:YY@;=H'+D,VS=AP!M!QFIE\&Z]-X&\4C2O#_BC0/#3 M7^F3V6A7-I-*%
ME@OO.FECM9'+M:P-(QBB)+,1M4C@LV,F3BO2Z "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBHI9ECP,%F/W5'4T .=UC0N[!5'4FJP: MXD^;/$:=BZY)_#
(Q21PLSB6X(9ARJ#[]?XGWJ[0!7V7?_/>/_OT?_BJ-EW_S MWC_[]'_XJK%% %?9=__)_/>/_+]'_P"*HV7?_/>/_OT?_BJL44 5]EW_]X_M_P#OT?\ XJC9=__)_/>/_+]'_P"*JQ10!7V7?_/>/_OT?_BJ-EW_
,]X_P#O MT?\ X]K%% %?9=_\]X_^_1_^*HV7?_/>/_OT?_BJL44 5]EW_P]X\ OT?_]K(C9=_\]X_^_1_^*JQ10!7V7?_SWC_ _1_P#BJ-EW_SWC_P]X_]K M%% %?9=_\]X_^_1_^*HV7?_SWC_
_1_P#BJL44 5]EW_SWC_[]'_XJC9=_ M\]X_^_1_^*JQ10!7V7?_ #WC_P"_1_\ BJ-EW_SWC_[]'_XJK%% %?9=_P#/ M>/\ []'_ .*HV7?_ #WC_P"_1_\ BJL44 5]MW_SVB_[]'_XJDV7?_/Q'_WZ
M/_Q5>3>,OCEX9*ZK%+K@:'=:PJ(C)'7,&+Y_F&M_8E!"(_ "NN&"Q$QV.YL.\VL*\$U',J]%YE[N@-*WXOZW\KFRYAX7!9X),UP)$*FRY%^R]_G%N80T!$MXXNWIK.(L3V17U&[H"I95VPCLUZN&W\!#E=XG)AV%N$SGTBIEPP9S8&7LVL;S&Y+#]?P<,)G9:W;O3$9J5OT7B(8_2%8M%)M=KXU=Y^TLG8ZRS9F<"W$2G89,I'
2O%9/VEM$EB>.3PO=LC*58?;%Y!"_"G+^TQHJ(JKX5NP MJC&/"\#\JU6(O*5E#\B/K5%OXOS/98M%>&6:''4)(I)V#RND:*TA P"Q ^8 MX &3V%6?[,O/^@U<_DO^%>)_\--
Z1_T*]U_X$+ A1_PTYI(&3X7N@/\ KX7_M H^HXG^3\@^LT?YOS/;_P"R[S_H,W/Y+_A2_P!F7G_09N?R7_"N:^'?CZU_M(GA^XU:UL);*.&Y-MLE<,6(56R"/][*[FN&2E"3C+=='3'EDN:)E-I=X$)_M
MJZZ>B_X4_3OM4FF6DTRA=X49B8^22]ZTF^X?I5/2?^0)8?!^J?_H(I7NAV MLR;9=_)/>/_+]'_P"*HV7?_/>/_OT?_BJL44BBOLN_\>)?'H(_%58HH W5_+O\GO_ MY[Q]C_]P^\ "_/%58HH K[:~ _S*
%4;+O_GO' WZ/_Q56** *^R[_\ M\^'?_ >/ WZ/_ ,51MN_>T? '[/^6** "BBB@ HHHH **** "BN9@\20S:W#ID M^GW]B]R9%MI+F$*DY098+@DC@$_,!D#BFZ?XNMM0L7U'^R[^UTY(7G-W.L8C
M*+G)P'+=CVH ZBBN3M?%6GW:EC;WEO/]HBM_LLT8$NZ0!D. 2,;26SG@*V>F M*ZR@ HK,]*69@]CJ357]]\'C='#Z]&?_?K0 23,[F* !F'#.?NK_B?:IHH M5BRV2G[S']:>B+&@1%"]L.@%%/H ****
"BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@#-U+4K'.2=/EU#4KJ.UM85W22RMM517RY\3/ MCE?>:(#-
H_A5Y;#3#E)+G[LUP/;^XOMU/?'2O5OC[SX"M#F&,G"7LXG,9HKI]]?W% *C:G]Q?RK]/ZMYGB^V\ MCF**Z?:G]Q?RHVI_<7\]/JWF'MO(Y9W5%W,:IRS-(?1?2M+7P!>18 '[OM]:
MR*\ZM>,G$ZZ>]YCZ^_9C_P"28ZA V$W_/1<=>Y=Z\-_9C_YC]'_83?_P!% MQU[CWKX#%QI>]+I+0 A1'\ N, 'HU% 'F]]X5NK9KN338;QHX## MY9-
UF>Y!*"8]['*D0KY:\C&7Y&M^=!10!&T:/MWJ&VG(SZU)110 4444 %%023)$!NR6/"],.2WT MJ/RI1NFD:/T2-L8^I[T 6Z*K*?91_S M\3_]_*/LH_Y^) \ OY0!9HJM]E'_
#\3_P#?RC[*/^?B?_OY0!9HJM]E'_/Q M/_W\H^RC_GXG_P"_E %FBJWV4?/_Q/_- */LH_Y^) ^ E %FBJWV4?\ $_M_?RC[*/^?B?_]L\'_W\H^RC_GXG_[^4 6:K*?91_S\3_]
M_*/LH_Y^) \ OY0!9HJM]E'_#\3_P#?RC[*/^?B?_OY0!9HJM]E'_/Q/_W\ MH^RC_GXG_P"_E %FBJWV4?/_Q/_-*/LH_Y^) \ OY0!9HJM]E'_Y$_P#?RC[*/^?B?_OY0!9HJM]E'_
%^)"$ML7Q\Y#W3ZD R &JNW4"GTT +11FHGR:1+#Q2RK\#OPRUS27=KL^ %$<JMGL1%I9[IG#I-RAW M$0R!<.KV@QO+FO&:P33Z M4O4YU23&4R%Y&A8;U@A/ F,0\2Y;!%A))5D[;
M_\UVRJ)H?OHJ.\1.^,K@&J5!T[)X9N$I%GKPLAFH7=$^6KZ]#4:\LLSUC0Y@9[9D&@Y?2V8F=7T[3Z5 R1[D(JG?'<6A\2#G\YKH<VEBH\HK^:A]K3A%8+\2F.8_K+QE2EG6F[7Z=3TL@K\9M3MQM%/E]KNVR6ZD7[WQ
&*$$8R,@CWJ \\(_J]]KUKJ&L7%AY5]5%M:(622Y# MH4PY).% .<#.2 >,4W2#.%M&TDX+-1!S@8%SW29)&0BXP. MI]/M0!7L?&5@Q&F^S#XW0?*
[EB!C8A.??;_>KM(9H;&U/!5-]>[5]\[>5 M@HGXJ&SZ$>,,!K (1K*5N3F :GR/&HA\&5H]:E(VZJ/C(VUN6B&X0&%5<('M/E1'(?)8^8=4C9)'LK%<.#*SIGL:PU3H'VBP>Q^C8KP]ZGQHKH\
M*,K%)WT^V0Q=J^DeM[[-'_S-4I@0#2F0 _@UE&A]=LBDM@*^N5>5$&D^W,A/^\Z5+:0JJVYRO@+C)X'!R 2LS1+,\LXLSZ\DJDU2MB^L+'OOD#%
]E&E?*]L^... !1F=EZ%J!>9V_+NUU']@3>,K0KHN0)__<_JO\D?O:9U&$*H@3A<X9ZJ<6T<D;Q_2G0R -HG@[Q0)ZB%,G4HJI=X&L=;L\H0:D>D8Q#N*T&GZ[:<7H:9T\U$\\
(9A&A.2?K6QK#XJZL-RZ6]W,^\B5$0ME"N3NI%*]]\=EWQF**KN:V@$9Q?\#^H!>?0\@VK! 2HQ+_E6X!=7K?2M5HS\9A-]KLK$9N$A4'E$VJ\Q^T)R\S\%1QL\=/>FJ\=JZ\^G=9*W

end GRAPHIC 15 cvm_10qimg13.jpg begin 644 cvm_10qimg13.jpg

M0S+J%Q^Z%J%7:F/W%K+;+V[K,6/N!VKPW]H[28M!TOX?Z'#,\T6GV,EHDCXW M.$6)03CC)Q7U[7RM^UE_R$_"7_7*Y_G'7;@'>LOG^1C4243E_#.@>$;_.*^
M&I=5T_18;5IK:.\>29/-O&>5@Q697#HP&-\3IM"C(;G-1#X9>$8M&M-2U*\> MUD;SWFM8=4BE8A8)I53.S"$-&]?Q?>]:\5VKDG:,G@G%)Y<8.0BY^E>]["=V
MU.U_Z[G.I)6NCWN'X<^!+73=5-K=1WS75OLCN+K4(%%@[/;E(^F3)MD<^9T M!XZU6N?AG\/;'5([:^UBYC2YN+.W01:A$1 TJRE]S%!N ,2J"0N#(,UX;Y:9 MSL7/TH"
(.B*/PI>PG_.PYEV/6M6*>&[KXC6&BQV@L+=- CN386]Y%YMQ=K$ M3Y!F^YYC,,%L=NE2>+]"\&:5I'ASPUIEU L=QK<\=]JK21RRQQ@QKABHZ('8 M<':2A/.>/(MJA=H4 >F*
JCHH%4],KJ\MAU1?#'PO<7.N+))+ID=G"YA M$NLV\A(61D?:B\J^Q>"5(W=\BJ^I^!/AW!I'BJXL=4U%[C2)7MXE%S#)RL0
M=96&!N1V.T8Z;3U/%>.>7'Q\B\=.*7:O'RCCIQTK3V_YV/F78]>\+?#OP?K M'AW1+_4M9FMVO?::X6[A5/.:5T>V"$;E=44/O/&#TZ5M6/@#P-K&B:3HMI>
M_9;C6;A;BVGDGCDFMG:S$ABD8#E 5?L,$BO!RJDDE0<^U6K#4+[2[B2XTVZD MLYI(GA>2$[6*,,,N?0CK1[&;NU/T$I)=!^J+IZZU?)I!E;3EG=;9IB"[1AB%
M+$8Y(P;IT=!@45V)65B6%%%%,04444 %%%% !1110 4444 %:VC?:_/E_\ M'O\ Q[NGX>]0Z?IKW9\R3*0COW;Z5TD<<<42QO*P%1>@%=N&A)M2>B/GLSO-. M,'3BN9O?LO\
@BT445ZA\AJ%%%% :A1110&H4444!J%%%% :A1110&H4444! MJ%%%% :A1110+4+3:*[3P'\]7\>:MY=L#;::"P^T7C+E5_V5_O-
[=N]&I)\+:/%I.BVH@MDZGJSMW9CW)]:Z"OSG'XF.)K<\8V7XOU/TC+\+ M+#4>24KO\%Z#]***XCTPHHHH **** "BBB@ HHHH ***R=0U*STRS-U?W"P1 MI@%V]2< =22> !R:
-2O/\ OI*_#/Q(GT^;Q]ZK6"NL7V681C#XSG@Y^Z M*Z(>(-);*PNOI2A\F_E%O;L6QYLAS\@'7=\IX[8.:=-XAT>&]FL9M2@BN(%: M20.6?\,O\ PW_Y[:S_.!@_P#B:/\ MAE_X;_\ /;6/_P?
$UZ:OBKP_;;R=6A8W3;8P,CG=MPW'RG=P-V,GBM*VU M"QO+R\L[6\CFGLW$=Q&AR8F*A@#Z'!!&M?K%5:9')'L>/_/#+_P_-P#G MMK/_(&#_P")H_X9@^&^_;6_P?
_$U[A11]9J_S,?)'L>'_P###+_PW_P"> MVL_^!@^)H_X9?^AO\ \]M9_P# P?\ Q->X44?6:6:\O_PY([CP__AE_X; \ M]M9_\H#*/]9J_32_P"&`
MUG_P,'Q-#',/PU_P"">VL_^!@^)KV^BE]9K@SL.Q/XAH\K:'$X-?ECS^V\/ \ K$^J\O ~ V[:S_P"!@^@_ \ M]M9_P#"
MUG_P,"Q-#_#,/PU_P ">VL_^!@^)KV^BE]9K:SL.2/8K:X9?^&^_ \ SVUG M_P #!_J\ $T?\,O\ PW_Y[:S_
.!@_P#B:]OHH^M5YV'L>'?>>/?_P#K_P#J*@^/#Y1!E\1ETQU:^_Y?'_%*?U:^+ ^_X^;U:^P#W(Y+@OMZ,P^#PJT]J,P4S:?&#.5
*O[,/PW5@WF:PV.QO!@_P#CM>]WFNZ9I]!];V5Y>107%P1Y;,W)R M< GT!/)QD\4ECK^DWCW<4.H1.]H"TQS@(H!;)X(!4@D<9!H^L5M^9BY[[6 M/.A^SWX%4!5EU(<
"X"_CM+-PS[X'_.?C4_\ P)',37<_\ "6>'/LR7 M"L4DODJ6R#NP#R^O#[&ZQ]T\H?,W)X<;;Q_>^8;:X_>@ M,\=:U^M8C=G+2HO[".! X9\\#??\]M2 _@?!_!-
#/G@; GMJ7 ($# M_P"]KUB.021B1<[6 (R"#^1]:E]=Q'\[^\G^SL-(CR' AGOP/\ \]M2_P# MD?\ Q-'_ SWX' Y[:E_X$C .)KUZBE]=Q'\[^\/[/PW\B/(AGOP/_SV MU+_P)' Q-'_#/?@?
_GMJ7 @?2@/_B:]>HH^NXC\Q^NXC^= _PSWX'_/;4O_ \"1_\ U[:E_X$C_ .)KUZBE]=Q'\[^\/[/PW\B/(AGOP/_SV MU+_P)' Q-'_#/?@?
GMJ7_@?2@/_B:]>HH^NXC^=_>'[!X[:E_X$C_XFC_AGOP/\ \]M2_P#_M_.)M2_\ D?_.!-'_#/?@? Y[:E_P"!I:E:E_P"!-'_#/?_)[:E_P#`!-'_#/?
B:]>HI_7L1_ O#^\S\-(CR' AGOP/\ \]M2_P# D?\ Q-'_ SWX' Y[:E_X$C_ .)KUZBCZRZBCZBCZ]M2_P#!'_#@-/%_
R(\?_P"&&?7NIX_Z^1 7\37HNDZ_T+IVAZ7T\ EVJ6MI"NU$08ZUMTRL*N(JU4E4DVC>CA:-%MTXI7):***R,D**** "BBB@ HHHH * M*** "BBB@
KG/$&EW&J6EJ;,2..YM+E+J(2 ['9<_*V,0"">1T,#S71T4+1W M \UM_!>J7+V5]>7B6M_!J#WDD"*LL*[IS(QC)&X%EVC)QTZ#FJWC*XTQO$,V MFZYXDT73WNK9H=-@GN]DD;,OS2-
&1\Q8@+G(PN<B_"[6+/PWI]K>?$;Q/%=Q6T:2"VNH_*1PH!"[HR M=HZ#)Z5HK\--85@P^*7BW/O/"1_Z+H+K'F7W>=CTBBO/?^%=ZS_P!%%%2_ M]_+?_P"-4/"
"N]9_P"BI>*_?&]SY[]_S'=]CT*BO/O^%=-U_T5.@N+'/J,`-PS\5M/7?\_D\_P-%+M)M$\M&X/^`--(3_&T/`%/TN@A0\K"O&]I&
"N]9_P"BI>*_^EO_A/E*SY]_S'=]CT*BO/^%=-U_+,_P+ +^:_`-56_P"%:_^L%LP*&R!&4Q)-/
[a;]@T&*+R)94E3* M<2"0&'O71617_--EBNA_*SE22^=_Q&GH=+:7ZT_:W.TR<:6@G@EKN=+0,Q66:-@G+%WXBL8S(N>T1W$U0A#(D2S11@6]:2*
&1\Q8@+G(PN<B_"[6+/PWI]K>?$;Q/%=Q6T:2"VNH_*1PH!"[HR M=HZ#)Z5HK\--85@P^*7BW/O/"1_Z+H+K'F7W>=CTBBO/?^%=ZS_P!%%2;I%[$/
&1\Q8@+G(PN<B_"[6+/PWI]K>?$;Q/%=Q6T:2"VNH_*1PH!"[HR M=HZ#)Z5HK\--85@P^*7BW/O/"1_Z+H+K'F7W>=CTBBO/?^%=ZS_P!%%%

(SYQT4+5_P_&RV%E9W5_/> M:1=Z;.9));V&.U$SQ.?*\HC)D63')(;<,C Q4NM97L-4[]3S>_T^XTV6WCN= MFZ>WBNDV'/R2+N7/O@\T:GI]QI.KW>EW>S[1:2M#
(4.5W#K@]ZU_%4;LNA7R ME'@FTFTC5T=6RZ1!74@'((/!SBNR\0W&IR:SXHN-3U"UF*2Q7*P)'/&T&).#S/M)*PN2]SROM[9Q^-&:]4U.\L8[:YN+.&[N?#)L- MD4!OH$M"#$
%$>W>)@_/]_<,YP'RA@3:(I)18]P M8]C)Y@'/7(P/2K]L^W]?YC=-+J>==L]LXS[UKW&@S6FG07=UJ%C\)/;?:TM7 MD82F,Y*G&W&6QPN<].F;[^\O+".!KBSANKGPS]@"+;F^@CM"/*
&.J7$PDR M?[Y89SCFLV\UBXNYY$NM5:Y6/P@!'YDVX+,8$SC)X?(^O%/VLGL@Y$NIPNH: M?=:7?/8WL82=51RH.X89 Z_1A56NO\ B!-J%WXCAU>]:YM[BUMVM9A<"3@
M0Q[L8)*_/G(..RD@>YN+A;:*!I-KLS D-_N\8)]2*C;3[A- M&BU9MOV>6X>U49^;>]]QX],./UKT?0=?LWU.SOK6Y2PM8O$=I#;[G"-':I \ M:Y] 1C<>F6.:Q;O6/$'A_P
'",:@UMK1UF:2>5)EDGQY$)'S@DX)ZX/,,'IB ML/:RYP_;C/3WY'O7=;;-OC1"+98#:OK<3 1@&,AG4G '&,D\"IKZ M35%\-:O_,);>0W=J\L1TM5FCD)<2CF-^,=?
>@:;J3:8V]+I]T;!6VFZ$+>4#TQOQCK[UZ'),<8X*EO>BW>7^W;#Q%]NB'A2'2T M@E3[0NU4%OLDMC%G)=I,\8Y+!O>L_;2_K\O4KV:_K\SS3RY/)68QN(F8]LFT M[21U /0D9%6;G3-
3LHEFO=-N[6-CA7G@>-6/7) KMUAUB[\,^%YM866]MK/ M5=_D121O(+8I"%"1@Y^8AAC&2'?^PE;_/HQ:SJ_PY CI:HH MHKY@ZSQ'X]9MOBI\-M4N-
0US2+&VBU(3ZGHELTT]ONCC"@ (_P!X\'CH36!X MLTG0/'FC?#-H+KQ)XI@M?%BZ?=WFK0SVUP89%+N&"K'A1\@#@#&,9ZU]6T5Y MA[9\P?\
"!:79_&#XM:E:Z/>HUCH$3:=+YL[*9)+25) ,MB0X(&#NP>F#7+Q MZ?H\,'@.3XM:+K%_X-7P=;PV,<5O<2Q0:AG]Z)$B^82E,?3(^QZ* /D? MQQ'H.I76AZ#_,(;/9Z?_P
[[C2)_$&EW^I7EQ(SN!;1HD@$,HX.]B6 *]% MK+LY(M2TGX;:I\7K#6=5\$P:#-9RH\%Q[(=42=DS<1H-Y_=J%4D'GGU-?9E% M 'ROXJO+?X=^&O!OQ:\$Z)K-
KIEM9W.AS6&IB3[4T,N]K4L\&+;5G (R?NN M.,5[C\,?"S^#/ACH?AVX8O>06PDO'8[B]Q(3)*2>_P [-^&*;XH\ Z+XTU?1 M-2UVXU&2'1YAER4M99004>6,??*D<<]SU!KN:
,#5M+O=28-;Z]=V*C& M8HPOEO\ 4@!^?]EQ2:'(L=O)IK6]6=Q9X#Q1)/^P;CR:L^]2QW]G:"QMFNF6Z MF\LS ?P1_P!YO:]FC1I/XATN&10T3X6@DGFNHD./*EBDV-
:*>Q=RFS_8DS_" M:@\4:'HEGK^MZEJ,DUG8-JG0HS?*%9S\Q"]B[U '4D]L9IJO%M+^O0 MMTVCA,#.<<^M(55OO 'ZUUMWX5T_2].U&_U'5Y7AMYH8[;[-!DW:S0&:-OF(MV<
9SG'(&35^Y^'ES;?:%UU=0MX&F>=KE=19LZIO:/G=TR Y&"PQC!S6_M M(O[QHYVNH/LOV>2-5.S<[#]3D9(M /M6SKV@Z+=-:U?V\I0Z5%?.+:JMN-EK&
[QELYWD;FR!C/'/6LG52E9 M_P!;!R75S@=RJG&3!QZTN!G..:ZQ_"2MX9O-3A74HI].S%Z_VN!(XI4RH(7#% MU/S @L,, >G%3:IX3T>RNM>TRUUFZN=2TBW-TQ:W58)%!3 X.<8)!'
MO6GM8[?U_6H@VFGWUQ]EFTO5=6OI7"P6FG,J MDKCYFR58D^@QCJ2:Z6#P7:*-7DM[#4/$<5MJ9T^V-C,D.]53QP44DD$T+$ M2461N%)ZG
XR>YZFMO3VTN[TVYTD:?);2(LWFM+"KF+,@V2M)PX9!\@C ^=B M!:$;P];1HM1:<9SJ-),2)%2.&9"LA4=&:5CR2>G8<"MTU)ZK4&K*<9IVJ76E MO<267EK--"\'FL@9XU888H?
X202,]<$U1*]1M('!I7JWB'39+77]?M]5TG2+ M/PY'.+>5(]>.9&$>8?+*?O"Q?:,'.03GUK)NH5U&RDA\)6^@W^G_9 ?L+0J MNH1$1@R.2P#NX8,V49ACMCBL/;+>V_\ 6Y;@UH>?E5.
0#BEP!VKU:#2;S[5 MHA;0](;PP=,M)]0GFA@4K$T:F:4N/WH;DD$?Q8QUKB=#LK%&O/$&H1&;2-.D MQ'#)P;R8Y,4)]B!N?T4'U%.9-/^OZ9+@T<\0K?> /UH(7() R.E>B6EKK,O
M@[0]0T71M'N'N9;MKM[NWM@K,)AM!\S!" $CY> *<_\ PCJ3WJKX3NM"AN1J M$O\ R%HU=)H,+L6&252@4-Y@YVL1M.:7MO+^O/L/D/.>!Z"EP.>.O6NXN?M> M@>&Z>;1-
/L]3.MF"6*6SCF6)(#A$WAL+DY&#R#UQ6(XA@M)--T37+6SBL6 MU*&7SK>$$1B2*0H70'[JL,"0$-CCBM8U+LEQL_@<<=*3:N<[1GUQ2T5T$A M@9)QR>M(%4'(4_^N*6B@!-
][MVT9]:7 QTHHH 3:N[=M&?6EP/3WHHH 0 G M S2X'/'6BB@ Q2 = !]*6B@"SI]Y<:7]5K]$FRI<6LJS1$KD!E.1QWYJMQ MO9L%CDD#K111Y@%%(4#%%4# 4 >E+10
FU=V[;,^M&U=V[:,^M+10)F.59HR8Y M%(977AE(Z$$=#6EJ6O:UK"1QZKJEQ>)&Q95D;@,>K8[M[GFLVBE9-W"X4444 MP"BBB@ HHHH **** "BBB@ HHHH ****
"M[P7_R4#P[_P:A*W_]&+6#6]X+ M_P"2@??:^?PE;_HQ:SJ_P .0^VJ***^8.LZ"BBBO,/;"BBB@ HHHH **** M "LBW_Y__^O.W_P#P^O.W_P#P^
/0Y]:ZDOH:O>N7^('_) M-O$&G8_8N-I9K.#Z0/V:E5:Y[[B]9758IB IB I9"K!@" 1D@X'I5?3O#&HZDLS1M%":X:W MNA*2#;;8W\BSJ/B+4=5M;RWO?*9;NZCNGV)MV%(S&B*!PJ!3@#V%/$#7\4LEW
MI-A+J,T0ADU!HV,K@ #=C=LWX &_;G\>:KV>BWMU?7-E)&UG/;VLMVR7$;(V MV-"Y&",Y('%1ZAILNFBQ,LB/]MM([Q-N?E5\X!]^*NT+V07EN2Z;J[Z=9:C8 MM96UY;:A&B2QW
;"E&W(RE6!!]]CGD5+XBOI-7N-4:.'S[BS-BXVG;Y9@$ M)(YZ[1GZUEQV]S,DKV]K-.(5WR>5&7V+ZG X'N:T-0T.^L=>N-&CC:7>S 1 M[-&SY!4-D #./F%)J-]0O*Q>N/%EQG%5I_$=]
<:MK&IO*"))M6@>WG 4[55MN=O/!^4>M&E^'[C4=*U'59) M6M;*PVH\GV>27=(V<(HXX4DD*.O6]R&W+IV-RKAHKBP57^7'*X+*0V>0P/X5K:AJWAS
M7]6O:_4_[5T[S;LW$<=KLF5E(4="5"2G;DN,@D].*YN"UNKJ1H[6UGN)%\&62 M*-G*CU(XI(;>YN=XM;6;X,:EW$49XDW:QNZAXMOKKQ!<: MM:PQ6;2ZA_:P#<6<'Y
Y/W@O/IRS'J:RI2U0)M2^SQ_9XI:WMHS%##&68("Q M<\L23EF)Y-.U'2;C3M773&9;B9DA=?*!.[S(U=0!USAP/K3J[0=6T_7KO19+ M&>:]M9&9!1TAB=MVTXW 8R5XX.*WBH*U@?,
[W(-6U"76-0-7NHXTN+N0RR>6, M $^E:\/BR2VD?Y:Z%\I-M]80HM_"ZNF5*EE0-Y8?!/(7OGK6 EO<2L5BMY&& M!*D*A)!
R1QWP#^1IPM+MK9+E;20R\'Z]]WFJ3WFGV.G^7'!:6*OY446 M<%F.6=LDDL>!GT51VJ]MM=-:/>+S-;=K3L8L;T[;4-)@L)KV!D MCO]=;]%%BK
%6)&"2!SQG'H1ZUE:*:#4ANM0EO-+T[3IHX_*T_P WRB%^8^8V MYL_B,*MV.L06UD+.\T'3=3C5BR-<(ZR+G]"\;*67V..V*H+H9+9WC6EPMG.T, M8#/*(F*(#T).,
&DCM;J:"6>&UFEAAYDD2-F6/\ WB!@?C6]HVL%V>(!)XQN; MN*ZBU;2-.U:]EJ[H+*LB+$RQB)501NN%"* <]*R-4U:[UBYCFNA%&D,8A@@
M@39%!&,D(B]ADD]R222235>&SO+A6:WL[B=54NQCB9@%4G Z>]0]6[\L2;3L M8X#8X)^OXBH4(K8;DWN)15]]*N(]"_M:0A$^V&R,+*0X<('SCTP<>M26&@ZK
MJ&NV.BI9S07=ZZI$L\3)G/\ %TSMJ\5OS+>XK,S**M363P6HDF9HY_/:%K9X MG5UP MY^QS^0A :7RFV+GIEL8&?8^E1'3=0^WRV*V-Q)'[D^(M,T/[1 M%YVH"V*2<[4\]59<]^-
PSI*S=1+<<=FS%HJO)8WD1CWV<1+ND,4:.$'J<@#?6KS: M,T=G874MY&D=]:S74?R,Q C9UVG /)*<'H,C)%2VD%B@O"%H1?'[P%J: R-'='R8 MR%>3RVVJ3T!., G(Z^M3R:<&_-
G8K)]$FQ9/]'A?39;?!=/U5I4:*^>9$09W+Y9 M4'/UW#%%T%BC14\I=7(9H+>62..@22)&S+'GNQ P/QJW?Z+?V.JZEIRP279 MTZ9X9I8(F9!M)!8G' X[T75[!9F;16A-HVH0Z!9ZX\#?
8KN62*-PK=4VYR<8 MP=PQSS@^E5;BUNK1U2[M9[9F7HR.10FGL%F0T5,MK=/:O=I:SM;(M]U:_M+6W MB=8[FYCM?27)M8C8Q1N[!1N8# ZCCK5*1#'-
)&3DHQ4D>OQ2NKV"PRBBBF 4444 M %;W@O\ Y*!X\ \OQ\ <^C%^%_%(]N[82M_ T8M9U?X<@1M4445 M\P=9T*T%%%%%>8>V%%%%> !1110 4444 %9%O R-_]\
]>=O_P"AS5KUD6 "-J M_P#>=O_.AS4UU)?0>UN>7>)0>NN)LN7^(2-NWB]_W'&>G!-..%(E-VTG_^_HG"M[@N3W\.._\(_%2FXKKNWRAE.EPTJ7N%@TK7:%5<=I]K6N
2GF.9#QC(XBYLKBTF*31,J8>8T:RE'$W5M8KAU;9F#Y"2+P*(>D5<+YI9PJYBV<#'HU.*YL% G\@)W#-4_M`=!BJ@ZN_~ZMWTZ(*U<@;H#KZVR;U`@U^*$/@8(5]&2V+#S
O+JWMM8MTTJ.S>WBO?+M>*:FW;M-F6-!$VX-:+*J:W;U']2P-;&!/>JR*]>X-M)S(2ZS+L[K%XL-:X0CB#B];ZQ@$@H+UL[(Q#U*T9DW3I$(@3Z"'!Y=1]QFK2VL2P,I:%
]>@JS?:-I@&GS2R4QI[S_0LS.'A>($+9AJ:W\$+3[ND%'VR^2YDKVUPZC\&1[3!1W:1H&:8GI1L*L9W_@$R/GG((A&DD]J)<(VD57&O]&3^YE^EOBX[Z3H)3=4U%P%^JR.'O:
```


J:Y#:Z;J%SI^]PI MJ,NAVEL[PW?GR>:MT0ZB3JSB,#YNNWH2.:X_A"_%O\ T*^K?^ ,O_Q-'_"% M^+?^A7U;_P 9?\ XFC]W?X@][L=&BB6;5+:34)-&L(G>ZDW[Y8]
M,Y+;4"DYR=HK2BU**#Q!9U?ZLMI=&XNI?L;;HM];$M;2XF3D^6"Y50K$$YR, M=*X?^A"_%O\ T*^K??^ ,O_Q-'_"%^+?^A7U;_P 9?\ XF]_=C2\%Y+C-X2
MK6%\$:2JZ_<_VC'JDTCR>>?2/?6]R8R#R@M:MC[LW[SSC'A:JQX]>@9^_G5D%G+&A!0BLP]S3.C@+#K]F6^ZL<@+J1H_Y^;F^3NU+I+IGV+D_L.EEGPR.D^4VB#2D#
76FQZ'XD\00WMZ=;M+FV=+X7+6Z*Q\ M^4R G8C@J,9&<9P,5S,$T- \0%FU+5Y8+=[YB:[S"6C7>2K!CG Z8/0SVI/M^$+$Q\ 0KZM_P" ,O\ \32_\(9XN_Z%%_^5
!E_P#B:W=4F)Y^Q2B-B!G[H.!QG-T2YUK3/$F MD?V]XNMY5>2Y5!_;8G,;/ RB1I 2$1F*CEAR,D#&:YK_(0OQ;_T*^K?^ ,O M_P 31 PA?BW_ *%?5?5/_L6U K=I9ZD1.9UN/(1X,
M0PM)DAVW[F"Y.W\A>>\NA]NJ2:EX2T5;W4'O+Z"\N!P3-*9)4,BMRHPWXO+MW\RP:3JKN+=%0BLJTH4.\':G%KG/ C75GO>\Y]A<7CKCS,*L63JE\MQRB>C4N:0DI8YUWZ
M0PM)DAVW[F"Y.W\A>>\NA]NJ2:EX2T5;W4'O+Z"\NP3-*9)4C98N8G6:6WD>^:YVM MX0SQ;_T*^K^_O,_31 PA5ZC%/(9XN_Z%%?5 P P!E_^)K)C%CVaTo6PTHEG
.)H]K#N'++L8%%;_P#PAGBW_Z[H5+_(.R5L\K6~CZ?,_ZQL_7P[@ S6U"?8T=P(7_V_H#L.P.(^T<9$L1S\SOP!E%M#YQ\%%X&7_S8!(#)X4%HGB(VEE
P PIH[(1_Z\8F[M?0K80RS_7_/O_0W?^S1U$C5%#*PTXFRY$&UVFEG[J+8J\=)QQ8_1FH%MLB/9,K;+.K:K1PQ1XQ)K2MSH%7ZX/%OF!P
_PAGBW_Z[MPV5I^ODF/;K>%@U%Q^;SG\9AD@9+N\.1&R?B`X@Y=J9W3<Q#PB_2Y,@/
`OK M8G2AZ+2'Y^`/XT>BMUQIZ@`
```

Cover - shares	9 Months Ended	
	Jun. 30, 2024	Aug. 08, 2024

Cover [Abstract]	
Entity Registrant Name	CEL-SCI CORPORATION
Entity Central Index Key	0000725363
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Jun. 30, 2024
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Entity Common Stock Shares Outstanding	61,493,229
Entity File Number	001-11889
Entity Incorporation State Country Code	CO
Entity Tax Identification Number	84-0916344
Entity Address Address Line 1	8229 Boone Boulevard
Entity Address Address Line 2	Suite 802
Entity Address City Or Town	Vienna
Entity Address State Or Province	VA
Entity Address Postal Zip Code	22182
City Area Code	703
Local Phone Number	506-9460
Security 12b Title	Common Stock
Trading Symbol	CVM
Security Exchange Name	NYSE
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes

~~XML 19 R2.htm IDEA: XBRL DOCUMENT~~

CONDENSED BALANCE SHEETS - USD ($)	Jun. 30, 2024	Sep. 30, 2023
Current assets:		
Cash and cash equivalents	$ 384,652	$ 4,145,735
Prepaid expenses	551,337	520,368
Supplie used for R&D and manufacturing	2,555,249	2,248,072
Deposits current	51,129	4,245
Total current assets	3,542,367	6,918,420
Finance lease right of use assets	7,800,909	9,131,987
Operating lease right of use assets	1,548,010	1,698,243
Property and equipment, net	8,613,316	10,188,126
Patent costs, net	173,028	197,704
Deposits	2,319,101	2,319,101
Supplies used for R&D and manufacturing	71,589	74,669
Total assets	24,068,320	30,528,250
Current liabilities:		
Accounts payable	1,369,441	2,009,786
Accrued expenses	1,272,149	1,049,581
Due to employees	696,487	557,244
Finance lease obligation, current portion	1,949,245	1,771,804
Operating lease obligation, current portion	219,019	197,431
Total current liabilities	5,506,341	5,585,846
Finance lease obligations, net of current portion	8,477,784	9,949,565
Operating lease obligations, net of current portion	1,486,138	1,652,949
Other liabilities	125,000	125,000
Total liabilities	15,595,263	17,313,360
STOCKHOLDERS' EQUITY		
Preferred stock, $.01 par value; 200,000 shares authorized; 0 shares issued and outstanding	0	0
Common stock, $.01 par value; 600,000,000 shares authorized; 54,257,884 and 47,422,304 shares issued and outstanding at June 30, 2024 and September 30, 2023, respectively	542,578	474,223
Additional paid-in capital	515,832,848	499,832,063
Accumulated deficit	(507,902,369)	(487,091,396)
Total stockholders' equity	8,473,057	13,214,890
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 24,068,320	$ 30,528,250

~~XML 20 R3.htm IDEA: XBRL DOCUMENT~~

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2024	Sep. 30, 2023
CONDENSED BALANCE SHEETS		
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	200,000	200,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	600,000,000	600,000,000
Common stock, shares issued	54,257,884	47,422,304
Common stock, shares outstanding	54,257,884	47,422,304

~~XML 21 R4.htm IDEA: XBRL DOCUMENT~~

CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Operating expenses:				
Research and development	$ 4,703,160	$ 5,727,789	$ 13,684,204	$ 17,203,823
General and administrative	1,967,075	2,453,968	6,547,866	6,804,729
Total operating expenses	6,670,235	8,181,757	20,232,070	24,008,552
Operating loss	(6,670,235)	(8,181,757)	(20,232,070)	(24,008,552)
Interest expense, net	(190,705)	(181,670)	(571,102)	(493,522)
Other expense	(4,382)	(3,854)	(7,801)	(61,525)
Net loss	(6,856,558)	(8,367,281)	(20,810,973)	(24,563,599)
Modification of warrants	(659,456)	0	(659,456)	(171,552)
Net loss available to common shareholders	$ (7,516,014)	$ (8,367,281)	$ (21,470,429)	$ (24,735,151)
Net loss per common share - basic and diluted	$ (0.14)	$ (0.19)	$ (0.42)	$ (0.57)
Weighted average common shares outstanding - basic and diluted	53,994,384	44,254,363	51,479,454	43,761,395

~~XML 22 R5.htm IDEA: XBRL DOCUMENT~~

STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED) - USD ($)	Total	Common Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)
Balance, shares at Sep. 30, 2022		43,448,317		
Balance, amount at Sep. 30, 2022	$ 32,163,207	$ 434,484	$ 486,625,816	$ (454,897,093)
Warrant exercises shares		217,752		
Warrant exercises amount	447,291	$ 2,177	445,114	0
Equity based compensation - employees	1,703,931	$ 0	1,703,931	0
401(k) contributions paid in common stock shares		21,331		
401(k) contributions paid in common stock amount	50,178	$ 213	49,965	0
Stock issued to nonemployees for service shares		40,236		
Stock issued to nonemployees for service amount	91,623	$ 402	91,221	0
2014 incentive stock forfeited shares		(2,000)		
2014 incentive stock forfeited amount	(11,100)	$ (20)	(11,080)	0
Net Income (Loss)	(7,853,509)	$ 0	0	(7,853,509)
Balance, shares at Dec. 31, 2022		43,725,636		
Balance, amount at Dec. 31, 2022	26,591,621	$ 437,256	488,904,967	(462,750,602)
Balance, shares at Sep. 30, 2022		43,448,317		
Balance, amount at Sep. 30, 2022	32,163,207	$ 434,484	486,625,816	(454,897,093)
Net Income (Loss)	(24,563,599)			
Balance, shares at Jun. 30, 2023		44,748,437		
Balance, amount at Jun. 30, 2023	14,789,399	$ 447,484	493,802,607	(479,460,692)
Balance, shares at Dec. 31, 2022		43,725,636		
Balance, amount at Dec. 31, 2022	26,591,621	$ 437,256	488,904,967	(462,750,602)
Equity based compensation - employees	1,743,288	$ 0	1,743,288	0
401(k) contributions paid in common stock shares		23,627		
401(k) contributions paid in common stock amount	54,865	$ 236	54,629	0
Stock issued to nonemployees for service shares		38,562		
Stock issued to nonemployees for service amount	100,635	$ 386	100,249	0
Net Income (Loss)	(8,342,809)	$ 0	0	(8,342,809)
Balance, shares at Mar. 31, 2023		43,787,825		
Balance, amount at Mar. 31, 2023	20,147,600	$ 437,878	490,803,133	(471,093,411)
Equity based compensation - employees	1,551,319	$ 0	1,551,319	0
401(k) contributions paid in common stock shares		12,855		
401(k) contributions paid in common stock amount	52,663	$ 129	52,534	0
Stock issued to nonemployees for service shares		36,523		
Stock issued to nonemployees for service amount	135,669	$ 365	135,304	0
2014 incentive stock forfeited shares		(2,000)		
2014 incentive stock forfeited amount	(11,100)	$ (20)	(11,080)	0
Net Income (Loss)	(8,367,281)	$ 0	0	(8,367,281)
Proceeds from the sale of common stock shares		913,234		
Proceeds from the sale of common stock amount	1,552,497	$ 9,132	1,543,365	0
Share issuance costs	(271,968)	$ 0	(271,968)	0
Balance, shares at Jun. 30, 2023		44,748,437		
Balance, amount at Jun. 30, 2023	14,789,399	$ 447,484	493,802,607	(479,460,692)
Balance, shares at Sep. 30, 2023		47,422,304		
Balance, amount at Sep. 30, 2023	13,214,890	$ 474,223	499,832,063	(487,091,396)
Equity based compensation - employees	1,383,909	$ 0	1,383,909	0
401(k) contributions paid in common stock shares		17,724		
401(k) contributions paid in common stock amount	48,907	$ 177	48,730	0
Stock issued to nonemployees for service shares		88,573		
Stock issued to nonemployees for service amount	202,307	$ 886	201,421	0
Net Income (Loss)	(6,709,524)	$ 0	0	(6,709,524)
Proceeds from the sale of common stock shares		2,490,000		
Proceeds from the sale of common stock amount	4,980,000	$ 24,900	4,955,100	0
Share issuance costs	(470,229)	$ 0	(470,229)	0
Balance, shares at Dec. 31, 2023		50,018,601		
Balance, amount at Dec. 31, 2023	12,650,260	$ 500,186	505,950,994	(493,800,920)
Balance, shares at Sep. 30, 2023		47,422,304		
Balance, amount at Sep. 30, 2023	13,214,890	$ 474,223	499,832,063	(487,091,396)
Net Income (Loss)	(20,810,973)			
Balance, shares at Jun. 30, 2024		54,257,884		
Balance, amount at Jun. 30, 2024	8,473,057	$ 542,578	515,832,848	(507,902,369)
Balance, shares at Dec. 31, 2023		50,018,601		
Balance, amount at Dec. 31, 2023	12,650,260	$ 500,186	505,950,994	(493,800,920)
Equity based compensation - employees	1,432,540	$ 0	1,432,540	0
401(k) contributions paid in common stock shares		27,373		
401(k) contributions paid in common stock amount	53,485	$ 274	53,211	0
Stock issued to nonemployees for service shares		162,744		
Stock issued to nonemployees for service amount	380,870	$ 1,627	379,243	0
Net Income (Loss)	(7,244,891)	$ 0	0	(7,244,891)
Proceeds from the sale of common stock shares		3,875,000		
Proceeds from the sale of common stock amount	7,750,000	$ 38,750	7,711,250	0
Share issuance costs	(717,621)	$ 0	(717,621)	0
Balance, shares at Mar. 31, 2024		54,083,718		
Balance, amount at Mar. 31, 2024	14,304,643	$ 540,837	514,809,617	(501,045,811)
Equity based compensation - employees	728,120	$ 0	728,120	0
401(k) contributions paid in common stock shares		45,722		
401(k) contributions paid in common stock amount	60,577	$ 457	60,120	0
Stock issued to nonemployees for service shares		70,444		
Stock issued to nonemployees for service amount	155,655	$ 704	154,951	0
Net Income (Loss)	(6,856,558)	$ 0	0	(6,856,558)
Purchase of stock by officers and directors sahres		58,000		
Purchase of stock by officers and directors amount	80,620	$ 580	80,040	0
Balance, shares at Jun. 30, 2024		54,257,884		
Balance, amount at Jun. 30, 2024	$ 8,473,057	$ 542,578	$ 515,832,848	$ (507,902,369)

~~XML 23 R6.htm IDEA: XBRL DOCUMENT~~

CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023
CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)		
Net loss	$ (20,810,973)	$ (24,563,599)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	2,977,603	2,959,681

Non-cash lease expense	5,008	12,788
Share-based payments for services	778,571	473,723
Equity-based compensation	3,544,569	4,976,338
Common stock contributed to 401(k) plan (Increase)/decrease in assets:	162,969	157,706
Prepaid expenses	(15,708)	208,419
Supplies used for R&D and manufacturing	(304,097)	(24,491)
Deposits	(46,884)	(2,342,951)
Increase/(decrease) in liabilities:		
Accounts payable	(592,370)	66,616
Accrued expenses	167,568	243,800
Due to employees	139,243	28,173
Net cash used in operating activities	(13,994,502)	(17,803,797)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchases of property and equipment	(75,122)	(361,892)
Expenditures for patent costs	(13,211)	0
Net cash used in investing activities	(88,333)	(361,892)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from issuance of common stock	12,730,000	1,552,497
Payments of stock issuance costs	(1,173,577)	(213,796)
Proceeds from the purchase of stock by officers and directors	80,620	0
Proceeds from the exercise of warrants	0	447,291
Payments on obligations under finance leases	(1,315,291)	(1,157,371)
Net cash provided by financing activities	10,321,752	628,621
NET DECREASE IN CASH AND CASH EQUIVALENTS	(3,761,083)	(17,537,068)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	4,145,735	22,672,138
CASH AND CASH EQUIVALENTS, END OF PERIOD	384,652	5,135,070
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:		
Assets purchased under finance leases	20,797	0
Finance lease obligation included in accounts payable	1,296	927
Property and equipment included in current liabilities	2,770	0
Consulting services paid with issuance of common stock	738,832	327,927
Accrued consulting services to be paid with common stock	110,000	110,000
Financing costs included in current liabilities	91,975	58,172
Cash paid for interest	$ 706,517	$ 809,495

~~***XML 24 R7.htm IDEA: XBRL DOCUMENT***~~

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	**9 Months Ended**
	Jun. 30, 2024
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed financial statements of CEL-SCI Corporation (the "Company") are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company's annual report on Form 10-K for the year ended September 30, 2023.

In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments (all of which are of a normal recurring nature) and disclosures necessary for a fair presentation of the Company's financial position as of June 30, 2024 and the results of its operations for the nine months then ended. The condensed balance sheet as of September 30, 2023 is derived from the September 30, 2023 audited financial statements.

Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.

Summary of Significant Accounting Policies:

Cash and Cash Equivalents – Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.

Property and Equipment – Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.

Supplies used for R&D and manufacturing – Supplies are consumable items kept on hand to support the Company's R&D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.

Patents – Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

Leases – The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.
Share-Based Compensation – Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, *Compensation – Stock Compensation* ("ASC 718"). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.

The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company's stockholders.

The Company's stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company's stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.

Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.

Research and Development Costs – Research and development costs are expensed as incurred. Management accrues Clinical Research Organization ("CRO") expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known.

Net Loss Per Common Share – The Company calculates net loss per common share in accordance with ASC 260, *Earnings Per Share*. Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company's potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.

Income Taxes – The Company accounts for income taxes in accordance with the provisions of ASC 740, *Income Taxes*, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of June 30, 2024 and September 30, 2023.

Impairment of long-lived assets – CEL-SCI's fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI's recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.

Use of Estimates – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management's best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant.

Recently Adopted Accounting Standards

In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2016-13, *Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13")*. ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no impact on the Company's financial position, results of operations, or cash flows.

New Accounting Pronouncements

In November 2023, the FASB issued Accounting Standards Update No. 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures* (*"ASU 2023-07"*), which expands disclosures about a public entity's reportable segments and requires more enhanced information about a reportable segment's expenses, interim segment profit or loss, and how a public entity's chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is assessing the effect of this update on the condensed financial statement disclosures.

In December 2023, the FASB issued Accounting Standards Update No. 2023-09, *Improvements to Income Tax Disclosures*, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.

~~***XML 25 R8.htm IDEA: XBRL DOCUMENT***~~

LIQUIDITY	**9 Months Ended Jun. 30, 2024**

LIQUIDITY

LIQUIDITY

B. LIQUIDITY

The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and conducting clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine, the Company's lead investigational therapy, to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from any regulatory agency for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.
To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.

Due to the Company's recurring losses from operations and future liquidity needs, there is substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

~~***XML 26 R9.htm IDEA: XBRL DOCUMENT***~~

STOCKHOLDERS EQUITY	**9 Months Ended Jun. 30, 2024**

STOCKHOLDERS EQUITY

STOCKHOLDERS' EQUITY

C. STOCKHOLDERS' EQUITY

Proceeds from the Sale of Common Stock

In February 2024, the Company sold 3,875,000 shares of common stock at a public offering price of $2.00 per share and received proceeds of approximately $7.0 million, net of issuance costs of approximately $0.7 million.

In November 2023, the Company sold 2,490,000 shares of common stock at a public offering price of $2.00 per share and received proceeds of approximately $4.5 million, net of issuance costs of approximately $0.5 million.

In April 2023, the Company sold 794,117 shares of common stock at a public offering price of $1.70 per share and received proceeds of approximately $1.4 million. The Company granted the underwriters a 30-day option to purchase up to 119,117 additional shares of common stock to cover over-allotments. The underwriter fully exercised this option in May 2023, resulting in additional proceeds to the Company of approximately $200,000. The Company incurred issuance costs of approximately $0.2 million related to this offering.

Equity Compensation

Underlying share information for equity compensation plans as of June 30, 2024 is as follows:

Name of Plan	Total Shares Reserved Under Plans
Incentive Stock Option Plans	138,400
Non-Qualified Stock Option Plans	17,787,200
Stock Bonus Plans	1,283,760
Stock Compensation Plans	634,000
Incentive Stock Bonus Plan	640,000

Stock option activity:

	Nine months ended June 30,	
	2024	2023
Options granted	1,967,500	6,500
Options exercised	-	-
Options forfeited	293,000	179,832
Options expired	27,075	58,787

	Three Months Ended June 30,	
	2024	2023
Options granted	1,964,500	2,000
Options exercised	-	-
Options forfeited	240,000	57,500
Options expired	40	13,383

On March 1, 2024, the Company accelerated the vesting of 234,332 stock options issued to directors to vest on April 19, 2024. The Company concluded that the change in vesting of the options should be treated as a modification in accordance with ASC 718. As such, the Company revalued the options as of March 1, 2024 (the modification date) and subtracted any compensation cost already recognized prior to the modification date. This resulted in remaining compensation cost of approximately $260,000 that was amortized on a straight-line basis over the remaining service period. The remaining compensation cost of approximately $101,000 as of March 31, 2024 was expensed during the three months ended June 30, 2024.

Share-Based Compensation Expense:

	Nine months ended June 30,	
	2024	2023
Employees	$ 3,544,569	$ 4,976,338
Non-employees	$ 600,841	$ 473,723

	Three Months Ended June 30,	
	2024	2023
Employees	$ 728,120	$ 1,540,219
Non-employees	$ 230,678	$ 188,001

Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods. Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts.
Warrants and Non-Employee Options

The following chart represents the warrants and non-employee options outstanding at June 30, 2024:

Warrant/ Options	Issue Date	Shares Issuable upon Exercise of Warrants/ Options	Exercise Price	Expiration Date
Series N	8/18/2008	85,339	$ 3.00	8/18/2026
Series UU	6/11/2018	93,603	$ 2.80	6/30/2026
Series X	1/13/2016	120,000	$ 9.25	7/13/2026

Series Y	2/15/2016	26,000	$ 12.00	8/15/2026
Series MM	6/22/2017	333,432	$ 1.86	6/22/2026
Series NN	7/24/2017	200,087	$ 2.52	7/24/2026
Series RR	10/30/2017	234,009	$ 1.65	10/30/2026
Consultant Options	7/28/2017 – 9/2/2023	110,000	$1.39- $2.18	7/27/2027 - 9/1/2028

1. Equity Warrants

Changes in Equity Warrants

No warrants recorded as equity were exercised during the nine months ended June 30, 2024. The following warrants recorded as equity were exercised during the nine months ended June 30, 2023.

Warrants	Warrants Exercised	Exercise Price	Proceeds
Series RR	17,752	$ 1.65	$ 29,291
Series SS	200,000	$ 2.09	418,000
	217,752		$ 447,291

No warrants recorded as equity expired during the nine and three months ended June 30,2024. On February 5, 2023, 600 Series TT warrants, with an exercise price of $2.24, expired.

On May 4, 2024, the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $659,455, which was recorded as a deemed dividend in the financial statements for the nine and three months ended June 30, 2024. The Series N, X, MM, NN, RR and UU warrants are held by current Officers of the Company.

On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024. The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend. The Series RR warrants are held by current Officers of the Company.

2. Options and Shares Issued to Consultants

During the nine months ended June 30, 2024 and 2023, the Company issued 321,761 and 115,321 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $1.84 and $2.45 during the nine months ended June 30, 2024 and 2023, respectively. During the three months ended June 30, 2024 and 2023, the Company issued 70,444 and 36,523 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $1.33 and $2.41 during the three months ended June 30, 2024 and 2023, respectively.

No options were issued to a consultant during the nine months ended June 30, 2024. During the nine months ended June 30, 2023, 5,000 options with an exercise price of $11.61 issued to a consultant expired.
During the nine months ended June 30, 2024 and 2023, the Company recorded total expense of approximately $601,000 and $474,000, respectively, relating to the share-based compensation under various consulting agreements. During the three months ended June 30, 2024 and 2023, the Company recorded total expense of approximately $231,000 and $188,000, respectively, relating to the share-based compensation under these consulting agreements. On June 30, 2024 and September 30, 2023, consulting fees of approximately $221,000 and $205,000, respectively, are included in current assets as prepaid expenses and will be amortized over the remaining service periods.

~~***XML 27 R10.htm IDEA: XBRL DOCUMENT***~~

RELATED PARTY TRANSACTIONS	9 Months Ended Jun. 30, 2024
RELATED PARTY TRANSACTIONS	
RELATED PARTY TRANSACTIONS	D. RELATED PARTY TRANSACTIONS

D. RELATED PARTY TRANSACTIONS

During the nine and three months ended June 30, 2024, certain officers and directors purchased 58,000 shares of restricted common stock at an aggregated fair market value of approximately $80,620. No restricted shares of the Company's common stock were purchased by related parties during the nine and three months ended June 30, 2023.

On May 4, 2024, the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $659,455, which was recorded as a deemed dividend in the financial statements for the three months ended June 30, 2024. The Series N, X, MM, NN, RR and UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company's CEO, Geert Kersten, is a beneficiary.

On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024 (Note C). The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend.

~~***XML 28 R11.htm IDEA: XBRL DOCUMENT***~~

COMMITMENTS AND CONTINGENCIES	9 Months Ended Jun. 30, 2024
COMMITMENTS AND CONTINGENCIES	
COMMITMENTS AND CONTINGENCIES	E. COMMITMENTS AND CONTINGENCIES

E. COMMITMENTS AND CONTINGENCIES

Clinical Research Agreement

Under co-development and revenue sharing agreements with Ergomed, Ergomed agreed to contribute up to $12 million towards the Company's Phase 3 Clinical Trial in the form of discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreements in accordance with ASC 808, *Collaborative Arrangements*. The Company determined the payments to Ergomed are within the scope of ASC 730, *Research and Development*. Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its statements of operations. Since the inception of the agreement with Ergomed, the Company has incurred research and development expenses of approximately $35.8 million for Ergomed's services. This amount is net of Ergomed's discount of approximately $11.9 million. During the nine months ended June 30, 2024 and 2023, the Company recorded, net of Ergomed's discount, approximately $0.1 million for each period as research and development expense related to Ergomed's services. During the three months ended June 30, 2024 the Company did not record any research and development expense related to Egromed's services and during three months ended June 30, 2023, the Company recorded, net of Ergomed's discount, less than $0.1 million as research and development expense related to Ergomed's services.

Lease Agreements

The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company's specifications so that it can be used by the Company to manufacture Multikine for the Company's Phase 3 clinical trial and sales of the drug if approved by any regulatory agency. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain.

The San Tomas lease is classified as a finance lease on the Company's balance sheet, as well as several other smaller finance leases for office equipment. The finance right of use assets are being depreciated using the straight-line method over the underlying lease terms. Total cash paid related to finance leases during the nine months ended June 30, 2024 and 2023 was approximately $2.0 and $1.9 million, respectively, of which approximately $0.7 and $0.8 million was for interest, respectively, in each nine-month period. As of June 30, 2024, the weighted average discount rate of the Company's finance leases is 8.46% and the weighted average time to maturity is 4.34 years.
On January 11, 2023, the Company was required to deposit approximately $2.3 million to its landlord, equivalent to one year's rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned.

Approximate future minimum lease payments under finance leases as of June 30, 2024 are as follows:

Three months ending September 30, 2024	$ 666,000
Year ending September 30,	
2025	2,747,000
2026	2,838,000
2027	2,929,000
2028	3,021,000
2029	255,000
Total future minimum lease obligation	12,456,000
Less imputed interest on finance lease obligations	(2,029,000)
Net present value of financing lease obligations	10,427,000
Less net present value of financing lease obligations – current portion	(1,949,000)
Net present value of financing lease obligations - non-current portion	$ 8,478,000

The Company leases two facilities under operating leases. The lease for the Company's office headquarters will expire on November 30, 2025. The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on February 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. The Company incurred lease expense for operating leases of approximately $0.3 million for both the nine months ended June 30, 2024 and 2023. Total cash paid related to operating leases during the nine months ended June 30, 2024 and 2023 was approximately $0.3 million for each period. The weighted average discount rate of the Company's operating leases is 10.19% and the weighted average time to maturity is 7.16 years.

As of June 30, 2024, approximate future minimum lease payments under operating leases are as follows:

Three months ending September 30, 2024	$ 90,000
Year ending September 30,	
2025	366,000
2026	287,000
2027	277,000
2028	285,000
2029	294,000
Thereafter	746,000
Total future minimum lease obligation	2,345,000
Less imputed interest on operating lease obligation	(640,000)
Net present value of operating lease obligations	1,705,000
Less net present value of operating lease obligations - current portion	(219,000)
Net present value of operating lease obligations - non-current portion	$ 1,486,000

~~***XML 29 R12.htm IDEA: XBRL DOCUMENT***~~

PATENTS	9 Months Ended Jun. 30, 2024
PATENTS	
PATENTS	G. PATENTS During the nine and three months ended June 30, 2024 and 2023, there was no impairment of patent costs. The weighted average amortization period for patents is approximately 8 years. For the nine months ended June 30, 2024 and 2023, amortization of patent costs totaled approximately $25,000 and $29,000, respectively. For the three months ended June 30, 2024 and 2023, amortization of patent costs totaled approximately $7,000 and $9,000, respectively. The total estimated future amortization is as follows:

Three months ending September 30, 2024	$ 8,000
Year ending September 30,	
2025	29,000
2026	25,000
2027	22,000
2028	19,000
2029	16,000
Thereafter	54,000
Total	$ 173,000

~~XML 30 R13.htm IDEA: XBRL DOCUMENT~~

LOSS PER COMMON SHARE	9 Months Ended Jun. 30, 2024
LOSS PER COMMON SHARE	
LOSS PER COMMON SHARE	H. LOSS PER COMMON SHARE Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. The Company's potentially dilutive shares, which include outstanding common stock options, common stock warrants and unvested restricted stock are not included in the computation of diluted net loss per share if their effect would be anti-dilutive. The following table provides a reconciliation of the numerators and denominators of the basic and diluted loss per-share computations:

	Nine Months Ended June 30,		Three Months Ended June 30,	
Loss per share – basic and diluted	**2024**	**2023**	**2024**	**2023**
Net loss available to common – basic and diluted	$ (21,470,429)	$ (24,735,151)	$ (7,516,014)	$ (8,367,281)
Weighted average shares outstanding – basic and diluted	51,479,454	43,761,395	53,994,384	44,254,363
Basic and diluted loss per common share	$ (0.42)	$ (0.57)	$ (0.14)	$ (0.19)

In accordance with the contingently issuable shares guidance of ASC 260, *Earnings Per Share*, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of June 30 :

	2024	2023
Options and Warrants	17,497,453	13,824,365
Unvested Restricted Stock	147,250	147,250
Total	17,644,703	13,971,615

~~XML 31 R14.htm IDEA: XBRL DOCUMENT~~

SUBSEQUENT EVENTS	9 Months Ended Jun. 30, 2024
SUBSEQUENT EVENTS	
SUBSEQUENT EVENTS	J. SUBSEQUENT EVENTS On July 11, 2024, Geert Kersten, the Company's Chief Executive Officer and a director, loaned the Company $200,000. On July 18, 2024, Mr. Kersten loaned the Company an additional $250,000. These amounts were repaid on July 30, 2024. On July 29, 2024, the Company sold 3,715,000 shares of common stock at an offering price of $1.00 per share, and pre-funded warrants to purchase up to 7,130,000 shares of common stock, at an offering price of $0.99 per pre-funded warrant, for gross proceeds of approximately $10.8 million.

~~XML 32 R15.htm IDEA: XBRL DOCUMENT~~

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended Jun. 30, 2024
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	
Cash and Cash Equivalents	*Cash and Cash Equivalents* – Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.
Property and Equipment	*Property and Equipment* – Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.
Supplies used for R&D and manufacturing	*Supplies used for R&D and manufacturing* – Supplies are consumable items kept on hand to support the Company's R&D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.
Patents	*Patents* – Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.
Leases	*Leases* – The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.
Stock-Based Compensation	*Share-Based Compensation* – Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, *Compensation – Stock Compensation* ("ASC 718"). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period. The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company's stockholders. The Company's stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company's stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period. Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.
Research and Development Costs	*Research and Development Costs* – Research and development costs are expensed as incurred. Management accrues Clinical Research Organization ("CRO") expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known.
Net Loss Per Common Share	*Net Loss Per Common Share* – The Company calculates net loss per common share in accordance with ASC 260, *Earnings Per Share*. Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company's potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.
Income Taxes	*Income Taxes* – The Company accounts for income taxes in accordance with the provisions of ASC 740, *Income Taxes*, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of June 30, 2024 and September 30, 2023.
Impairment of long-lived assets	*Impairment of long-lived assets* – CEL-SCI's fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI's recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.
Use of Estimates	*Use of Estimates* – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management's best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial

statements in any given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant.

Recently Adopted Accounting Standards

In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2016-13, *Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13")*. ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no impact on the Company's financial position, results of operations, or cash flows.

New Accounting Pronouncements

In November 2023, the FASB issued Accounting Standards Update No. 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures* (*"ASU 2023-07"*), which expands disclosures about a public entity's reportable segments and requires more enhanced information about a reportable segment's expenses, interim segment profit or loss, and how a public entity's chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is assessing the effect of this update on the condensed financial statement disclosures.

In December 2023, the FASB issued Accounting Standards Update No. 2023-09, *Improvements to Income Tax Disclosures*, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.

~~***XML 33 R16.htm IDEA: XBRL DOCUMENT***~~

COMMITMENTS AND CONTINGENCIES (Tables)

9 Months Ended Jun. 30, 2024

COMMITMENTS AND CONTINGENCIES

Schedule of future minimum payments under finance leases

Three months ending September 30, 2024	$ 666,000
Year ending September 30,	
2025	2,747,000
2026	2,838,000
2027	2,929,000
2028	3,021,000
2029	255,000
Total future minimum lease obligation	12,456,000
Less imputed interest on finance lease obligations	(2,029,000)
Net present value of financing lease obligations	10,427,000
Less net present value of financing lease obligations – current portion	(1,949,000)
Net present value of financing lease obligations - non-current portion	$ 8,478,000

Schedule of future minimum payments under operating leases

Three months ending September 30, 2024	$ 90,000
Year ending September 30,	
2025	366,000
2026	287,000
2027	277,000
2028	285,000
2029	294,000
Thereafter	746,000
Total future minimum lease obligation	2,345,000
Less imputed interest on operating lease obligation	(640,000)
Net present value of operating lease obligations	1,705,000
Less net present value of operating lease obligations - current portion	(219,000)
Net present value of operating lease obligations - non-current portion	$1,486,000

~~***XML 34 R17.htm IDEA: XBRL DOCUMENT***~~

STOCKHOLDERS EQUITY (Tables)

9 Months Ended Jun. 30, 2024

STOCKHOLDERS EQUITY

Schedule of equity compensation plans

Name of Plan	Total Shares Reserved Under Plans
Incentive Stock Option Plans	138,400
Non-Qualified Stock Option Plans	17,787,200
Stock Bonus Plans	1,283,760
Stock Compensation Plans	634,000
Incentive Stock Bonus Plan	640,000

Schedule of Stock option activity

	Nine months ended June 30,	
	2024	2023
Options granted	1,967,500	6,500
Options exercised	-	-
Options forfeited	293,000	179,832
Options expired	27,075	58,787

	Three Months Ended June 30,	
	2024	2023
Options granted	1,964,500	2,000
Options exercised	-	-
Options forfeited	240,000	57,500
Options expired	40	13,383

Schedule of Stock-Based Compensation Expense

	Nine months ended June 30,	
	2024	2023
Employees	$3,544,569	$4,976,338
Non-employees	$ 600,841	$ 473,723

	Three Months Ended June 30,	
	2024	2023
Employees	$ 728,120	$1,540,219
Non-employees	$ 230,678	$ 188,001

Schedule of warrants and non-employee options outstanding

Warrant/ Options	Issue Date	Shares Issuable upon Exercise of Warrants/ Options	Exercise Price	Expiration Date
Series N	8/18/2008	85,339	$ 3.00	8/18/2026
Series UU	6/11/2018	93,603	$ 2.80	6/30/2026
Series X	1/13/2016	120,000	$ 9.25	7/13/2026
Series Y	2/15/2016	26,000	$ 12.00	8/15/2026
Series MM	6/22/2017	333,432	$ 1.86	6/22/2026
Series NN	7/24/2017	200,087	$ 2.52	7/24/2026
Series RR	10/30/2017	234,009	$ 1.65	10/30/2026
Consultant Options	7/28/2017 – 9/2/2023	110,000	$1.39-$2.18	7/27/2027 - 9/1/2028

Schedule of derivative liabilities

Warrants	Warrants Exercised	Exercise Price	Proceeds
Series RR	17,752	$ 1.65	$ 29,291
Series SS	200,000	$ 2.09	418,000
	217,752		$ 447,291

~~***XML 35 R18.htm IDEA: XBRL DOCUMENT***~~

PATENTS (Tables)

9 Months Ended Jun. 30, 2024

PATENTS

Schedule of total estimated future amortization

Three months ending September 30, 2024	$ 8,000
Year ending September 30,	
2025	29,000
2026	25,000
2027	22,000
2028	19,000
2029	16,000
Thereafter	54,000
Total	$173,000

~~***XML 36 R19.htm IDEA: XBRL DOCUMENT***~~

LOSS PER COMMON SHARE (Tables)	9 Months Ended Jun. 30, 2024
LOSS PER COMMON SHARE	
Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations	
Schedule of anti-dilutive securities	

	Nine Months Ended June 30,		Three Months Ended June 30,	
Loss per share – basic and diluted	**2024**	**2023**	**2024**	**2023**
Net loss available to common – basic and diluted	$(21,470,429)	$(24,735,151)	$ (7,516,014)	$ (8,367,281)
Weighted average shares outstanding – basic and diluted	51,479,454	43,761,395	53,994,384	44,254,363
Basic and diluted loss per common share	$ (0.42)	$ (0.57)	$ (0.14)	$ (0.19)

	2024	2023
Options and Warrants	17,497,453	13,824,365
Unvested Restricted Stock	147,250	147,250
Total	17,644,703	13,971,615

~~***XML 37 R20.htm IDEA: XBRL DOCUMENT***~~

STOCKHOLDERS EQUITY (Details)	Jun. 30, 2024 shares
Incentive Stock Bonus Plan [Member]	
Remaining Options/shares Under Plans	640,000
Non-Qualified Stock Option Plans [Member]	
Remaining Options/shares Under Plans	17,787,200
Stock Bonus Plans [Member]	
Remaining Options/shares Under Plans	1,283,760
Stock Compensation Plan [Member]	
Remaining Options/shares Under Plans	634,000
Incentive Stock Bonus Plan [Member]	
Remaining Options/shares Under Plans	138,400

~~***XML 38 R21.htm IDEA: XBRL DOCUMENT***~~

STOCKHOLDERS EQUITY (Details 1) - shares	3 Months Ended		9 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
STOCKHOLDERS EQUITY				
Options Granted	1,964,500	2,000	1,967,500	6,500
Options Forfeited	240,000	57,500	293,000	179,832
Option Exercised	0	0	0	0
Options Expired	40	13,383,000	27,075	58,787

~~***XML 39 R22.htm IDEA: XBRL DOCUMENT***~~

STOCKHOLDERS EQUITY (Details 2) - USD ($)	3 Months Ended		9 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Employees				
Stock Based Compensation Expense	$ 728,120	$ 1,540,219	$ 3,544,569	$ 4,976,338
Non-employees				
Stock Based Compensation Expense	$ 230,678	$ 188,001	$ 600,841	$ 473,723

~~***XML 40 R23.htm IDEA: XBRL DOCUMENT***~~

STOCKHOLDERS EQUITY (Details 3)	9 Months Ended Jun. 30, 2024 $ / shares shares
Consultants Options [Member]	
Shares Issuable Upon Exercise Of Warrant/options | shares	110,000
Exercise Price	$ 2.18
Minimum [Member] | Consultants [Member]	
Issue Date	7/28/2017
Exercise Price	$ 1.39
Expiration Date	7/27/2027
Maximum [Member] | Consultants [Member]	
Issue Date	9/2/2023
Expiration Date	9/1/2028
Series N [Member]	
Issue Date	8/18/2008
Shares Issuable Upon Exercise Of Warrant/options | shares	85,339
Exercise Price	$ 3.00
Expiration Date	8/18/2026
Series UU [Member]	
Issue Date	6/11/2018
Shares Issuable Upon Exercise Of Warrant/options | shares	93,603
Exercise Price	$ 2.80
Expiration Date	6/30/2026
Series X [Member]	
Issue Date	1/13/2016
Shares Issuable Upon Exercise Of Warrant/options | shares	120,000
Exercise Price	$ 9.25
Expiration Date	7/13/2026
Series Y [Member]	
Issue Date	2/15/2016
Shares Issuable Upon Exercise Of Warrant/options | shares	26,000
Exercise Price	$ 12.00
Expiration Date	8/15/2026
Series MM [Member]	
Issue Date	6/22/2017
Shares Issuable Upon Exercise Of Warrant/options | shares	333,432
Exercise Price	$ 1.86
Expiration Date	6/22/2026
Series NN [Member]	
Issue Date	7/24/2017
Shares Issuable Upon Exercise Of Warrant/options | shares	200,087
Exercise Price	$ 2.52
Expiration Date	7/24/2026
Series RR [Member]	
Issue Date	10/30/2017
Shares Issuable Upon Exercise Of Warrant/options | shares	234,009
Exercise Price	$ 1.65
Expiration Date	10/30/2026

~~***XML 41 R24.htm IDEA: XBRL DOCUMENT***~~

STOCKHOLDERS EQUITY (Details 4)	9 Months Ended Jun. 30, 2024 USD ($) $ / shares shares

Equity Warrants Exercised | shares	217,752
Proceeds From Equity Warrants Exercised | $	$ 447,291
Series RR [Member]	
Equity Warrants Exercised | shares	17,752
Equity Warrants Exercise Price | $ / shares	$ 1.65
Proceeds From Equity Warrants Exercised | $	$ 29,291
Series SS [Member]	
Equity Warrants Exercised | shares	200,000
Equity Warrants Exercise Price | $ / shares	$ 2.09
Proceeds From Equity Warrants Exercised | $	$ 418,000

~~XML 42 R25.htm IDEA: XBRL DOCUMENT~~

STOCKHOLDERS EQUITY (Details Narrative) - USD ($)	1 Months Ended				3 Months Ended		9 Months Ended		
	Feb. 29, 2024	Nov. 30, 2023	May 31, 2023	Oct. 28, 2022	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Sep. 30, 2023
Common stock shares issued	3,875,000	2,490,000			54,257,884		54,257,884		47,422,304
Public offering price	$ 2	$ 2.00							
Proceeds from issuance of common stock	$ 7,000,000	$ 4,500,000					$ 12,730,000	$ 1,552,497	
Amortization cost					$ 101,000		260,000		
Net of issuance costs	$ 700,000	$ 500,000							
Stock options							$ 234,332		
Consulting Agreements [Member]									
Weighted average grant date fair value							$ 1.84	$ 2.45	
Options issued								5,000	
Consulting fees inclued prepaid expenses					221,000		$ 221,000		$ 205,000
Total expense					$ 231,000	$ 188,000	$ 601,000	$ 474,000	
Consulting Agreements Other [Member]									
Weighted average grant date fair value							$ 11.61		
Restricted Stock [Member] | Consultants [Member]									
Weighted average grant date fair value					$ 1.33	$ 2.41	$ 2.24		
Common stock issued for service, shares					70,444	36,523	321,761	115,321	
Common Stock sale [Member]									
Public offering price					$ 1.70		$ 1.70		
Proceeds from issuance of common stock			$ 200,000				$ 1,400,000		
Issuance cost of common stock							$ 200,000		
Sale of common stock at a public offering price							794,117		
Additional purchase of common stock							119,117		
Series RR [Member]									
Incremental cost				$ 172,000			$ 659,455		

~~XML 43 R26.htm IDEA: XBRL DOCUMENT~~

RELATED PARTY TRANSACTIONS (Details Narrative) - Officer And Director [Member] - USD ($)	1 Months Ended		3 Months Ended	9 Months Ended
	May 04, 2024	Oct. 28, 2023	Jun. 30, 2024	Jun. 30, 2024
Incremental cost	$ 659,455	$ 172,000		
Purchase of newly issued shares by insiders			58,000	58,000
Purchase of restricted common stock fair value			$ 80,620	$ 80,620

~~XML 44 R27.htm IDEA: XBRL DOCUMENT~~

COMMITMENTS AND CONTINGENCIES (Details)	Jun. 30, 2024 USD ($)
COMMITMENTS AND CONTINGENCIES	
Three months ending September 30, 2024	$ 666,000
2025	2,747,000
2026	2,838,000
2027	2,929,000
2028	3,021,000
2029	255,000
Total future minimum lease obligation	12,456,000
Less imputed interest on finance lease obligations	(2,029,000)
Net present value of financing lease obligations	10,427,000
Less net present value of financing lease obligations - current portion	(1,949,000)
Net present value of financing lease obligations - non-current portion	$ 8,478,000

~~XML 45 R28.htm IDEA: XBRL DOCUMENT~~

COMMITMENTS AND CONTINGENCIES (Details 1)	Jun. 30, 2024 USD ($)
COMMITMENTS AND CONTINGENCIES	
Three months ending September 30, 2024	$ 90,000
2025	366,000
2026	287,000
2027	277,000
2028	285,000
2029	294,000
Thereafter	746,000
Total Future Minimum Lease Obligation	2,345,000
Less Imputed Interest On Operating Lease Obligation	(640,000)
Net Present Value Of Operating Lease Obligation	1,705,000
Net present value of lease finance lease obligations - current portion	(219,000)
Net present value of lease finance lease obligations - non-current portion	$ 1,486,000

~~XML 46 R29.htm IDEA: XBRL DOCUMENT~~

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended		
	Jan. 11, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Interest amount				$ 700,000	$ 800,000	
Lease expense for operating leases				300,000.0	300,000	
Total cash payment for oprating lease				$ 300,000	300,000.0	
Annual increase to interest payments		8.46%		8.46%		3.00%
Weighted average time of maturity of operating leases		4 years 4 months 2 days		7 years 1 month 28 days		
Research and development expenses		$ 35,800,000				
Weighted average discount rate operating lease		10.19%		10.19%		
Lease Agreements [Member]						
Total cash payment for oprating lease				$ 2,000,000	1,900,000	
Landlord [Member]						
Financing arrangement deposit base rent amount	$ 2,300,000					
Ergomed [Member]						
Net Of Discount				11,900,000		
Research and development expenses			$ 100,000	100,000	$ 100,000.0	
Clinical service trial				$ 12,000,000		

~~XML 47 R30.htm IDEA: XBRL DOCUMENT~~

PATENTS (Details)	Jun. 30, 2024 USD ($)
PATENTS	
Three months ending September 30, 2024	$ 8,000
2025	29,000
2026	25,000
2027	22,000
2028	19,000
2029	16,000
Thereafter	54,000
Total	$ 173,000

~~XML 48 R31.htm IDEA: XBRL DOCUMENT~~

PATENTS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
PATENTS				
Amortization expense	$ 7,000	$ 9,000	$ 25,000	$ 29,000
Weighted average amortization period for patents			8 years	

~~XML 49 R32.htm IDEA: XBRL DOCUMENT~~

LOSS PER COMMON SHARE (Details) - USD ($)	3 Months Ended		9 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
LOSS PER COMMON SHARE				
Net loss available to common shareholders - basic and diluted	$ (7,516,014)	$ (8,367,281)	$ (21,470,429)	$ (24,735,151)
Loss per share- basic and diluted				
Weighted average shares outstanding - basic and diluted	53,994,384	44,254,363	51,479,454	43,761,395
Basic and diluted loss per common share	$ (0.14)	$ (0.19)	$ (0.42)	$ (0.57)

~~XML 50 R33.htm IDEA: XBRL DOCUMENT~~

LOSS PER COMMON SHARE (Details 1) - shares	9 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023
Antidilutive Securities	17,644,703	13,971,615
Options and Warrants		
Antidilutive Securities	17,497,453	13,824,365
Unvested Restricted Stock [Member]		
Antidilutive Securities	147,250	147,250

~~XML 51 R34.htm IDEA: XBRL DOCUMENT~~

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended			
	Jul. 29, 2024	Jul. 18, 2024	Mar. 31, 2024	Dec. 31, 2023	Jun. 30, 2023	Jul. 11, 2024
Proceeds from newly issued shares			$ 7,750,000	$ 4,980,000	$ 1,552,497	
Subsequent Event [Member]						
Public offering price	$ 1.00					
Pre funded warrants offering price	$ 0.99					
Sale of common stock at a public offering price	3,715,000					
Proceeds from newly issued shares	$ 10,800,000					
Pre-funded warrants to purchase common stock	7,130,000					
Subsequent Event [Member] | Mr. Kersten [Member]						
Additional loan amount		$ 250,000				
Subsequent Event [Member] | Chief Executive Officer [Member]						
Amount of loan						$ 200,000

EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 (&Z##ED'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+
P04 M " !N@PY9B9IT8.\ K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R$G+.DSJRT9/'0Q6V-C-V&IK&B?&UDCZ]G.\-F5L#["CI=^? M/H$:[87N [Z$WF,@B_%N=&T7A?
9K=B3R B#J(SH5RY3H4G/?!Z?HB6GU,KC_\;L*N-W9O M_['Q55 V\.LNY!=02P,$% @ ;H,.69E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;;T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/
0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?
\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?
IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5
9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-*K^(+ M.7\N?
<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>
(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^N]]/^26<.
[1[\8$@F_S6VZ3VW>_,?-2K6J5D*Q$_M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q(]A[8N_5!+ P04
M" !N@PY9*4*8\@% " 'P & 'AL+W=O&&YH2><6W ME.DK*RY2HO2A6#MR*RB)\4PE,:-S@626ID2\ M36G"][<=KW,\|12O-\J<<,:C+5G3!55_;.="'SFE2Q2GE,F8,R3HZK8S\=X%
MOF\$^1TO,=W+D^_(H"PY_V(.9M%MQS4EH@D-E;$@^F-' YHDQDF7X]^#::?\ M32,_7YTO_A-^/Y7>@"Z-GXA3V3^'^V+
M>WMN!X695#P]B'4)TI@5G^3U\"!.!!C7"/!!@+\1>+T:@7\0Y$_.*4J68[TG MBHQ'@N^1,'=K-_,E?S:Y6M/$S%3C0@E]-=8Z-0[XC@K417)#!)4C1VE/<\4) M#_IHH<0)8
M/LG65\@=V.1?%<24ALR[!/< M?>@N@AD*'I_FCT^3Y]GC@PT5-&F)>EVB7C=!#2C3H F:Z=;[BGZG;S98V,G5 M?S?XVN_[-D90VY*Q7S+VP9*]YV&F1UR%GM^VUEJ$Y9[;_61#
E4MD6Y*I!NP M3!/-$^5,]PE9VYA@_8HDTO8H E#6$FI00@W@[I()D2/%,M1M\3,EP@RG2_H MUFJ#W;I==]CU71LD*&P).2PAATTZW"(E28*FF=27I76^@6V4R*SU!ZI:HGEN M-
8FZC> V.HZ@@*=;PJPCR1F;VM8)Z]KBG60$KPG>74K%.F9K](MV4!L0%#:L M!P5U;4%Q!8H;S0]'#OE$MUPH0[Q01&7V> 0[?K:&J@!6M>6L0HT'QHAJ9IA3 M$?,
('&W.6)5YK3:PP09M6:M,XS4*-?=QHH-%6P\.(^4=7N83@Y5?*]/VQLP;/?)&FM@45O&*MAX#9/-Z919 M3PB;U;;;2P0=KTHZ'AQ5CF,13U/]NKM0//RB)QCSEH8>,R4589$>F:R\WRG,
M'!Y#X7:=NYE5@=VX[_6&/L;#D;.S(5:YQX.CRDG71]9NK3VI^D9$]?UNIXW M& RMA;]$Y/&JS.,U"CTS%G*AIQ*2KUR8N83J>LWTJX>IW\@^[,+.P:,5]Q(Q M"%*0<_D%\9RT--
QUNO[/?M:P"5R$:YR$6Z4BR91 MI-UE^?E!WX8*RSL-]!]"DTYU_(ISQ*Z(R*R8E\B)>$J)>%&*8;UL [N]1$+"54+"<*C)&^I$4%(/!AO'DTI9=7>OX8:P-:U= M/#]C]/!Y<6?
=&;A$V/&KL./#X:1\Y_J4$:&H2-X.ZR-61-BK;A4/EK5%K(*- M#P>1:L%<$";C/+D"C+!9[1H7K&L+>;*AU2C1S)BNPV(3U2S]D..BEY44=JQ9 MXX)5_Y?
3.=GC-.N0^=:O1*%YC2JV.\NSY?;R)-]4=:K;B[WIC\0L8TJ4T)66 MNEJH6Q79O<:#X-M\Q77*E>)I_W5 246%NT-=7G*OC@?F!B)QGZI.5*%(FU6UQ/RKS@K-E/2A-1LCS_%'*XFPP/JZ?
71?C8U')),[X M=0'**DU9\73&$_%X,H"#YPC\7'.[OF^(0G MB8ZD>'S?!ATT[]0#=Z^?HW^JDU?)W+&23T3R=[R4ZY-!. !+OF)5(F_$XV>^ M38CJ> N1E/5?\+C%>@.PJ$HITNU@Q2"-
L\U_]F,[$3L#(.D9@+8#T&L'X.T M7">Z85:G-662C8\+\0@*C5;1]$4]-_5HE4VTC1XMMS+--3-03\TN5'0#L M#0'R$+$,G[B'SWG>#,?[PT M0*^DPS)G"WXR4$NEY,4#'XS?_P)]
[\B6W4*MIKD_C'%(?(J.1P^[^9@P @D-,&UP>U1)0Y4XJ5X7 M/&?Q$O ?JB65W,IP$X'NO)I2B''086B!(0_[H9T@;0A2)\%YE>=)S$%5\B50 M#1/1IT:G!"E%)&HP]V"0R3T F0G[S?D?2?
Y M*<]%&#>F M!&&_6P FSH]@2)!GIQDV-$,GS4]QQK(%!PE70@$*K0A K'1!.#B'!I<@]+S(MZ\ZKB8L@AE$8V#E'#>?(R?DJYP63JBC?QCHRV$"JRA!Z'=86G!^%B& [:^BU M.N2]T
Z4-2GD4[VZ=./*E5F00Y!Q:^UNH^T2"7W5&J#?(6P!0@^&(41^#^4= MZ81NRDSJ\EV(4I;]1*'Y_@![*.SRM."B(/!(#\M6_:!3<)I.8"6'S.ZC:E!- M4)?=R\!]>JU@0;=B;;ML^3_;
[#;ZWG*#-.PN-AN,^'[4P[[5,.@6L4TCZU]6 MT)0F1#P_Q*B[L"Q([%$4(MK3Q&"K8Y"^R@ E,;N+DUBJV;:Z(.C4P[?:H)\5 M;3_I5O^@6P!/%PM1*>,#B6C8MTI;
(81N)9Q6'$@!>)HGXHGWT#05S8]\ M$G;%VH*C-$"DK].UR@?=TK^9WBL.&Z>1BT(_L+*W*%M$HEVKLZ5O M 08!#/LZ-6HE$+DEL"O=;\P
F4J'8.3!;I58<$H".XI$M3J(7+KX;ZKV^DV M5K:FWE'J^=A8>U9@2-5.I8?OSK[0K8Q]];(1<^V97C/KIC*&) B"D'3S,(&1 M*C#J]WAIU$HHZ-X;;.7V)I;NP@I1%%/N[RM"
#K+RLW\>T%4'D M.Y5_?GLU^?WSU<5T=C/_&9_?CV__<=*UJFE;SX ^4G1]I-N)16Y)?6ZX"NN MJGT)2BD6WX;@W8$'E0THP -+*GX$E'0/51F 02:AW%9 M:EG6'E14LI3JHL>!(E-
TC4IT0?:S;!49N15Y(M)49'TI^IL4^]*D9(AH, Q# M4F=(@B%!:(@]XDX?, F^5!EO#O=JP)SGDJ=W:N$^']H-@8J1_J$-GFR3IK% M Q!%R6@U)HX$BFO/=A.U7@&YO<+I@06MX8
O\80U"6Z%LF2%^6'>FLOK36!3:%72JHV05T# M:0%"K.QP&/6L*MQ: NRV!+=7MZ<7X.+\].S\XOSV?#8'IY=3\-HVN@V^>U3: ML]NS('MV>Z.=LWW]P\H?K+B/LU))_4H-
]0X"-0W%YK>*S8T4>7WD%&E] MN>9,3;X&J,]70LCG&_T+0O.+T?@_4$L#!!0 (&Z##EDFF].7R@(,0) M 8 >&PO=V]R:W-H965T&ULK99K;YLP&(7_BL6F:9.Z M<
]H1Y!:FJJ;MBYJ=OGLPIM@%3"S3=+MU\\&RD)";M7X$+!YS_%SB,'V5Y0] M\@1 H*_:%77NHZ&HI(+FC5B29"1O#[CI^9!K G,70*K$5C'"NQ& M8%=!:[(JUC46./
972&FJJ6;NJB>3:66:4BN_L:98/(ND3H1A%_OKB=WL\DU MNKK\?'D73M#L=C+Y-D-OIYA!+A(0),+I._0>O48ZXHGLY;XNY-#*0(^:8:[J M8:P=PWPJ\P&RC3-D&9;3(P_WRV=0M'*
[*]=EX#:UU::V*C_[Q-1]P6HGI]]) MO647O, 1C#7Y&G%@2]""-Z_,H?&A+^9_,NN$MMO0]C[W8"I?$& ,8B1G5?1X MA@K,T!*G)?3%KKV\RDM]"Y:!,3!,7U^NQSE0U,%T6DSG-
;QZSB%6P 'RSK(+LMLOLB9,)YV8_K;G%LDNZKZ$ .6\CABR#EMYT+ MG,7-*19)K_PQ\Q2[YA9>J"HPSAJ&4KSEOK\=.K=L_1\B\-U+-<;C9P-
X.U"QW,LRS:41W#V5.\#UM256[6^^8+8@.4&PO=V]R:W-H965T&ULK9AA;Z,X$(;_BI4[MG7:E;<'&QM!+([6%W>M)3:NFO?WL)DZ"%G .G*3W[V^ A"3&0=7=?FF!O/.. MG\$,-
L.M*GZ42RDU>L_2O+P>++5>73E..5W*3)27:B5S^&6NBDQH."T63KDJ MI)C505GJ$-?UG4PD^6 TK*\]%:.A6NLTR>53@ZLA#P;R/O9)I63C".OW>F@S9G%7A\O'?_6L,#
MS)LHY9U*OR! ,TDW.Q3O6SVOXA=T"L\INJM*S_HFVC];T!FJY+K;)= M,(P@2_+FOWC?%>(H 'SL 6070,P >B; VP5X'\U =P"THQG8+J!&=QKVNG"1 MT&(T+-06%94:W*J#NOIU-
-0KR:N),M$%_)I G![=/8ZC>#R)(S1YN7F)'^+Q MRP0]?D6/3_'SS2A!Y7K98GB?"9GEOBH/S[LB7> ND4G>_1;TFOXYSJ_1)[[!1&74,MX M[CX>
[MEP_E_V^#]G/RF&U\X#K_;SSO@]KF0A=)(OD'R')E3*\LIVBQL3:C>I MFMI5N1)3>3V KE7*8B,'H]]^P;[[NZV^/],L^IEF\4\R.[D3M+T3M,]]] R. MHI@ND
M['@4H<]=S@S\KHY0YH5^8.!W=3ZC//!]@]ZB"US*26B']UMXOQ?^16E 5YTG MT8;N=X< Y,0ST;NZ >8,VZ@=W558R$N-Z92;!%2UPT8(W9XWL+S7OA# TI5 M:47FGHR=S
M$A@AH\6EK@7^T'-DGDR%?5^0,W15A2%R+6] M#-A2!A;"2,PJ=(7FQ/ZH5VP38H[//M*8'-#)A^XX$AN1I.(ME4@K-%59!J4H MEZ*02Y7.9&&O!>F\6R\X@W?U(.V%? ;B^9-
FN>)%UKZP[A=N?/CP?G7G8+8Y>9JQV[C)H= MT"X[>IF<5N.PSL/]"[WO]296PD)G Z^^A3RI2(E@5U]JJ$?U2OQH>6AG1L,R M)X2^V:E05TDI8=3S/;-(%D^8.? \F6M"FZ?'?
>R%9@MUCO:KF2P6]8>"$OC7 MN6ZV+.W5]F/$3;T%-Z[?XJL[;+D>51\OZOWQP;[Y\O$@BD62ERB5\E(=*R))+H4G8=O M?Z"D"B)V"9(N\B:Q[.5_C>6"V!\>Z.>?JOK#
[KXLF^SS9KW=O;BX;YJ'[Z^N M=HO[RJW[R5U5;XK&?:S?7^T>ZK)8[B_:K*\8(>IJ4ZRV%]?/]]]] M75_KQZ;]6I;OJZSW>-F4]1??BC7U:<7%_3BSV^\6;V_;]IO7%T_?RC>ES=E
M_;A=>T^79U4EJM-N=VMJFU6EWMTJN=_CCZ/HQ^'YUW^J_[AOO&O, MNV)7SJKU[ZME<__BPEQDR_*N>%PW;ZI/Y7'!LE6;U&M=_M_LT\'6ZDNLL7C MKJDVQXO=;
[!9;0__%Y^/@3B[@/*>"]CQ C;V GZ\@ <7,-US@3A>(((+!.FY M0!XOV#?]ZM#V?>#F15-VSW_\N>O?WUY=OYJUL[M_R:[S-[->S+-G?__F^57CG+<25XNCHQ\.CEB/H]NJ*=;(9;/X9;-
JLW'Y=--4 MBP_(U?/XU2^7RU6;C\4Z>UVLEI>OMMFL>%CAOXF-:[TI&]?ORF5FBWJ[VK[? M9<]>+A:/F\=UT;COSLN[U6+5!)&YZ^ MJ,M=5C393?
GP7<;)MQDCC&'!CRJV3YOO=P_%HGQQX1XGN[+^6%Y<_^-O5)%_M8K?D(";W8NV3YN.UX$(83O7SJX_GT4_IU282ZX20JTG!CH M0^9A@9:P.PK-@=:3H.DCE2RTZVF[/K5=
M1]LN"'WVX1O7ZFU3K]X]MJW>90]N/,I6VS86[0"W:P>X2&>+>IC:V332V7@8 MAWE*ES:16"?^YA1_DRC^_7W0@)!)0K4)DM @79 '885*(L^5#)(06O4D87X* M0AX-PKZ"RE:

[W:/K@$V5;:OM]=]E#CBR-NJK11G)P:B#]3F8PS 0QH.1;I[2 MI4TDU@D_);[0)FEN0'\2'CVU-H,1#Z2.I!)KBDE(;1FAWM5#>H84A1,6)(F'S0KB_Y?*%/XY7^KV63 MO=]ZIWZ9/?
NYVNUPE.7P%]1&MA6*@H2/\==OK"WH:K^@1F)R7 M"T%_@T7N$C2#D<>%AW,R7;9WQ8 M[E)8[1^"&H84*?B-R8G(E0Z3$)I>"L6T).IL].A&PY?_-%[_/V5.(RXY.0UA
M7=\SJY'4KTVEU@V\9P\;AX^GS&Q0" @]4QM'R\&Y#42Q;W(#,1V:W:">!&@< M!<8]_6'Q?U[)'#S^H^XFILH\]9I-I=8-M><-&@<.I,?_ZW%[2CR.1CXI M8E"$,81VR ;+?"]TR3G(>(;
Q3ZHX=0P M5!0Y-X2I\"%B$=-+H7.AB,H!A[F88/%8>,I]4]<\&(>1%@<1%+,@L9=3.Z8R*(#=S<\C%I2*DFEUKT+GDI8 MG$I2S(4R" JN/@NG,&<,69" CSQ,2[$\3,C1"Q+,(PF+
(TF"&=&XA\GY" F% M&ZG"F;ND3FT]M>Y-\C"XGB28%:406"@A+AJ/&OVUY/"&PR(?Q2U"<* 2]4DQ(" M0PB!:Z,-DV&DDA)"*K?N7@=/""PR(0P&GL,BO9U,U@I, 7.$$/9!#?<[8(1
M#.&4!RL;%C%UA$!)S@6E>!R3P@\3@A/+LTX+.RIE)33L"<>#6,]<:R610Q[M'CSYTF=VE1] MW9O@48"42%!:<9AV4ZY5 H\("$J\) GYK@8)R A1["JZS-XZSPY"7KN.[D M-
(2$@"U9)W5J4ZEU0^\)@<<)X%U7B[)$FS;3]B-ABTTN KL&WQ&-[2C2-%?A M7*T8!H*Q6A8Q[&NP!P(Q^03"X!)27'+R?G!DWAY?NTOJUZ92ZP;>,X"8? YA M./#
(K#Z"=B>0(P;8VAVBV+=VAY@.K=V)[\,(D_]=P*.1]E@"LG=)"\9 MU3E/ZM>F4NL&WI?"8O+>I>' 8^4YH\+D8<$ED+U+"Z"&(47V+N6YX8R$0&L1 MTTMA-'$C2:YZTM
7_^(KG5T0R)$#;G@.IFK%\.F%L5H6,>P;#WP-+K[^'8:X MB\D=$YFGUY]!7IGT$$,]M>Y=\!P@OOXY!H$#/,,(+_ZB0:)K2JXT37,1PDA MP8"U.U2,"G"F
;'K24CI$4'&$6$4HTNDIE=ND)+A%OPSI$BOT#0S;3$)R MV,(1U;I^-9&M$J/2T[N=LCN'4*H420\3)K4KTVEU@V\!P(Y\C #OK41#SQ2 MOS,E6Z8.TP["P"&H84BAHB0RER3/P7%N9-
U@3_0D9WUIZ.% CCQA,('2XY*3 MTQ Y78!3>E*_-I5:-_'>!V2,&$KRL%2?Q=U-/=]15,VF4NN^RL$7_FKD_B%\>EB@IW&(2DIM M\0J6\%(PJ0V8RTSJUZ92ZP;>4X8:>9@!GQ[& P\AP
A'Z3)D+ 69XQ#3,*)0 M4%+I.KP1X=H$8GHIB<[;D_X]VP>51Q U>9%B5/4K\VE5HW M\!X[U.1%BN' (XL4>/FC(&J@Y0^BV%?^(*9#Y8_RV*BV/'T-]M)*"",RE M1(8Y9*R610S[(N
Y1*4Z4]_'1!W,;EC0BYAFH/9N*1.;2]U[ETX>\%2'$I2 MS XK!"FX,.%.>@4)A6DP\&):C(*W+8U>KE">2%2B0P61?$P** I9K5 N9"!F M2?$DE5KW+G@\47$\23]K"
PN*>V(X8P(9'E"GB0"U/3.1,AIB!V?2GIZ40E MH!.%T(EFPL$9>-M9/CPD0#$P&(SPUWWCF4<$G63_4.2%9TEY04->X$9+.#^< MU*U-I=:]"1X7=!P7_O+\L(;UN]Y'+>R
&K+#/KYA=#$]2EEH:!'#OI?P>5]0 M<5X8.S"LD7/ FFIX!EG#.\B@P2.U+&+8U!'I^N1=3I^O@JEQ;CDY&Z'U.B" M&*YI")5)_=I4:MW
>R30(_>K\,"C%3P1*AR>9AKBP"&H84BAHJ3"D%R% M;[RQB*GC=J-'WGJ]3' QW'@R<#DH95?+N].-R;/=-P/Q'HA^.D+&+7UPU] M8:Y3%>:1T3#I,0*-O
I):A;NN4WJU*92Z]Z%LW>PIMK"%!D.81FOB SWQ[:U>F M;9?9$\+9C(M# <>,@"^](<8HHMZF%W/HAYBVKNH=W7VEVG:/SSD,.C]RA5> MZ_+.74R^:^OM^O"W? X?
FNIA_\=JWE5-4VWV7[Z?Q;*L6P/W\]N\O(\T/[] MF]-?5+K^/U\+ P04 " !N@PY9_EIW$CB4+9HM] X[3:O];#_UKR3E_R0OEY88QCGZD M259>C#:<;_&XS+5SR),[8]4%FE:5"\7K(D?
[D8X="^QFW\M.'BQGARO@V>V)KQ M^^VJ@$_C@Y8O92=:R1">?)G'/'- MQ<@=H8@]!E7";_7+VP7D"7\A7E2UG_12V/KV",45B7/TUUC4)#&6?,_^+'K MB$X#*-N0'8-2+^!.="
[AK0.M!&61W6/.#!Y+S(7U AK,&;N*C[IFX-T<29 M&,8U+^#;&-KQR>QF.?>7:W^.UG?3,_^KO[Q;HYLK-)NNOZ"KZYL_U^CD?CF] MGR_N_/DG=(KNUW-T\N]/YV,.3Q<^QN'N29?-
D\C DSST-<_XID1^%K'HN/T8 M5!^DD[WT2Z)U^$>5?4;4^41@Y@*/;W-Z<.:?30D[3V1S^D)U7]U_@WU?I%
M>CXKMT'(+D:P8$M6/+/1Y)=_8=OX317\!SD[Z@KST!6FSOMD">DGR.Y&H+(T+9M:GG>P/))G'>19VI&:1O^%A06YB)>(
MYY",PCP+XX2A;*=;W!7785!N4%6R",49@LQ9!#S.GIK4$_.8E6>]"*V/'.8/ MB4P=G@"=)H)8)B];K297M3,^Q*1WH76RT.#.T:F=YFL)L M!6Z&WT%MQHOXH>*@'):T:>"3[Y_0-
@DR=++(PD),DT_CB#578I$'9EGO M'GPT'VSB2:&I["S'.>R!T#]DQMK05@7;!G&TG]?*F;)ST7WX*3Q=FML*.\C" M)A[(K)BT(HE^?E?;;0*9L4F;8F+?_A*DV]_F=0))@ZQZA/19%9!'E?
J)K)\: M)M"A'X*"D/V>D)BF-Y!'<$MQK"6CP?1Y&7-U[U+VH;;MNF9?G,*.4!.2W)"EJS8 MU+)K/VW')_MI^TG,VR0.'N)DF$E8"^R?A=)'>3ON@Q;?6&N]R30,\TKD34B@ MP4.BS/
[%T=#8'F$.D9_K&1#V[;QT&IMV8GU\ 211<7>6*TR"+'M6+:T6A7 M-*EK&_B6V!B/3'G%1.)D:7;)'IE R(5"*0>/+\O4K8C+G8&Z(-;8&(],9?O M*
<24PF4>GH)RS[0,TM>N,G5<@SJ=Q'.LO\4GJO3[@K;^O[J]^8H6RV_^^FZQ M_!U-9W>+;XN[A;]6KUDMEW]ZS7Z0M^.M6LMEHN?RJBK"#62K$N6/:%N(,>2O M-
1,8U!=:4)0^I^H#(,#UU+$SZ ZBRHS9V/:(>/M)2E^BIZXOU&\6 +-84;MN M@UBH+4HU)@*P93@?K6FL!M8SZ2E+]'35UHKL%:+]>M2VE_D*CMM M/I?
<)6]LGWO+Y&JQG"YG[U@FY$.WS1_E[;@76KP3_0A8Q',M")/45R6 M59"%3*R9L%/8*KO!5&U7]&$8?>*I+"V+F$.ICK1@)GHPK_8;&M#;5."'"(:7 MBP+4&+ !)7-?M*28$C1
ZPF+:N)GM7'O4N,#<"&8TFLDRUMXMID M0#]M&4WUC%[Z=VCNSV[]Z=J',J4YN9PNY\V%_Y_[Q;?IM3C65!Y>]@CLV-AP M^PQ164*84)K;
]M_VM*:ZFD]*E7=.G_OE@N!5!NKM#*OUWX)@H?[NKURX2FKFE+LTAA9V%]&JHG M_;0^:3])GIWJ],ROHGA2 D P:%U=! MM(W"]G>LC(@(U54M?U^W-C5)\-OL1\IU-E(Y6)
[E"H_*5T(=M1X@P/1TM^JB?_M_IPD5(3$<_3 .H&]&8S,=HP5%?#;=L?!M!4 U5< 5P?8U_7NWYI4,MT]I#D2 M?60SR\7.P#;,;&L \XWS\]I^$3TN]KIQQADD/^76?.>H^WX."&[A?
B)2V+F& M9WI63^]X\Q([9<53_6Z_1'4R:5X*'^X>?C\PK=^;]^Y?XK-9\RN UDWSHX2O MO?$40U69L$=P:7QVH/N*YCU_\X'GV_I5^4/.>9[6EQL60%X6!O#]8Y[S_0?Q
M@,.O+2;_!U!+ P04 " !N@PY9%QO,V1P) !/%@ & 'AL+W=O9R9.3/2^=JZ![]2*HBG MLC#^HK,*H?K0Z_ELI4KIN[92!D\6UI4RX-(M>[YR2N9\]"QZ@W[_3:^4VG0N
MS_G>U%V>VSH4VJB\$[XN2^DV5ZJPZXO.2:>V<;N?]T W>I?GE5RJF0KWU=3A MJK?5DNM2&:^M$4XM+CK#DP]7KTF>!?ZNU=JW?@N*9&JM UV,\XM.GQQ2A=42N%K(N
MPJU=_ZY2/+^2OLP6GO\7ZRC[YGU'9+4/MDR'X4&I3?PKGQ(.K0/O^M\Y,$@' M!NQW-,1>7LL@+\^=70M'TM!&/SA4/@WGM*&DS(+#4XUSX?).!O/Q)>/8GJ[M,[N9W
WOQE\F8CBY%K/[SY^M_^@9[/Q;Y/QQ_%H.+D3PI'HR_WD;CSY34R_ M?!J/QC>S\UZ)Z2OER6K5]']X#M6WXO/UH25%S_T#?Z1:64]9W^G^&)5I]?=@J-> '7\E,773085ZY1]6Y
M?/'+R9O^V0]B>KV-Z?6/M/_8OJQU6%_#<,BROIM1=V(:$ F2F_INI=#8 MF2TK:3;:+$5F45'&JUPLM)$FT[0'L(*1!+X_.CFT_%L-!8CZRKKHJ]7 7I> M_/)N,.B?C:
(ROCHY>R6D4Z(VLLYU@%9IPR[(4GLLAHT -8<77M0D4 M;.6@5%<%S"R548[MX+FJPL[.O6"9Z2=_1B6RNE,BI5\5&*NE!&VU(%DJMKY
M6IH@@N6CKB;5%)I3R[K@2%D%/9RIK'8ZZ"1Q\Y2MI%DJX%]6VA-I=\4?*UTH MT)4!OU-DS=F$;:P76CU"0UC)P$_:T%4QTX0ZV+G*X)FC($8HX\+4V<8IP"LCRP;;$!%6 M?
Y;M5E6=O#WS3?:19^L BQ$T8\1)__BO*"/'1S9*.J&((($U,EK.E6LX[K0K MQE&QK;0AQX#L#N>C6&'MQMB5\$_BQV.N;A03,/^*$13OOZ0;L+)>Z6S%&<&% M3/6-0% -
C@P9&9"]5XS%7B.H3'F/P<\!2K&0VC4YBPG<+XXM5#LO*^MU[#:N M0I"^VI(^V^.B51X3F04T_:F42X7; &M 4:*, PC7)H+<93+9@3.7!3==W(VB MQ>=Y$"""E'&7U2'
Z6Z;6>";6@'\(]ZXKKFL=R "-_.6&,K F:9FO 5A?Y6 M.^C< %B5>\XX,L,=7\^A&PP!(JFMYW!^CG7LE=F!!)=0GBIF'6[7)O%]V'3%K5H M/7A%%50SFU G38A=K]IB%E=(3HE>&KT
GX%=ACMJG-I"9^"F#V(D_8]!XQ\W M0.U1%NS6(@ M3\]$%("0RD]*4MZ:V[,5^N08HPN*"'I45BSUO8NM=+#9P_ZCNQ99KI"8,4 R MM,:&.MI1!Z419HRYJU;#0_GFN8X"A
MR]JP&T4SC0($U/^$'KV@PC_"<$ HN0*V.5$Z]5%/Q'J-4A3M \@$ M.1(F[7& M[#CM'XX73]4IK#SX@.)N^:$;_Y+5^^X,9X$QQL'TF NSB7P"=N*VM)M<%3).YEZ"=@4=I<
M%2(MQ>5:NMQSE^1Z05R.)0VHI$TX;E!Q MD*6!(@E"T*:[\XN&(1%RA).&@@\(E8"+!=M@6F-FQY;Y/EDQLG].QN[@SZB3 M\X;)^A6)H[2EGCLBYW@%I?Z(\X%;O-6+?)=V"
(ZI0!88T6;E0<52KT7$&DI- M^*UI)?< E0Z(2Y-B:LB?9\CKT0;$#-[15!9GV('#A7347D+3KS05,5T-L$ M8L8]I[;4U4HQMMXL#NQKO!H4-@[E$71[,0&*G[:B2ETTHL&K/*,%3?28:U;
MQB?Q%FJ!]HL[^:3\GR[4]HU 1?6+(\+WN"0&P4S]Y[9XB8Y[.$6E15*=X. M?K=-;1HS:EW.%C9R7DD'_9,WD7P_;E>F@P>N+/Z(EVD]?AS.KK9OG8G?#QZ[MKHY@!)
[;+IHY/3H]:EL8&75+'1;O9+$8H'QVA0S0O[_#2D(G3P9M7'3G6%T- M&/N2]%YR4"C\W!VW_C0N-Y%EM9[]YBSQE+UQ*-C6N,>XWL]W%""L'_^T$/ M3H_[;[&S]"7I?
]V/?'B#7_*G3'I=@]WXO6]I=_NU=!@_$N]$ MXZ?6S](M-9BI4 L<[7??_MK!A.;/E_$BV(H_&LX OM];=^YXHB<^#-OY] MUHG+VZN>#];<.?BK;^X+?
@3"IK[_GEMKF:K1@0::H#>Y!X;.@M M:^]]U]3[LBEDI]>6OV7:D]_-7LY$PVU,NKPT6[?4\GG M&?NKK?;IK]CFO6?G,U%''^Q0C(%@4"8_Y;=2AP.#EZL?&*R+P3KASH$2RGI--
US\P_5E\L";T?OQB&F].[9>_,6%9[!'[\ MRNT\^3O_/[EETXO'35D*K_PH:[]:@>N>W(9FUT^?G#U?O3X!]&("=G'*^VE@ MITUO%F*R%H]&$F_M,$]S$[WT0IDZ,D>-*HSJE6U-
$'4U@>/+Z8FH4+:1&-2 M!"0M ES(^FM47]5OMA4UN0 UB]'9T2D*T*H(5/?&:MOMA#3P7RLR@2.(>V.W MFIJ.(%$M@S*="#:Y|>,@C5##$),ET&C6"P1-
PN]\H&$N1AG@2,AQU%AG!'XN MN.#2U7T*U=-&DV/$' AS(1M(0/G@)&LYIS;'P^!3+#*'#7U#27Q)!R!B"_%' MQ]AX6O)FJPT]E!: M(*0C79HP5$DZOL-J@"L)+38R7>^0)C4RPCN-M
ME=;BXE*C8]OHE-]A8+*IDD-!.!:CBK@B>ZV"@$.EK0UW4^!W, KTM2E6T@; M.4?*N!D M2 'GEBL4MT^8.]I>Y!QGO 70$^?O%R?O7CMA<9Y &9MR ?5R1(- M&YT<=W/V@L+
<4\C9R(IKOGL OT<\R!UGUQ".G(9Y$4?T.)NFWJ0\@*]7X(Q# MN6+PJ]$$B9-PF)\HX0"XXC':PS 5HGK(*"S&T!(O>(U1UW4F20XG$RIF^2R M;Q0LF"RY2+0G*IK"+
2<82!7@SM\;BCHSHMHBK86X@O*B3.%].ZHH&+ R&?; M45)/>1T(8$^/?>3Y'GY2\9@%RUPZ!%\RRJPK^WULH5W6,+9N"*U/6?@XCFA[MBL&4%EE6T1"*:
MGZ+B$O;.QZTN3ZDL)*P..\1LWT/T77D@:?,]4LFYDE4(K MT@5#SO=]1,9Y)E2!?RS1$58".COQ^3O%5*05,BR<46&2D*SOD) MM8R>QV92"&,-
NI_D@H;RX(+4"^Q1^@1ILID$(WQOMV!%ASL3*AK=1C'1*C+4 MPG&QOT,_$N>H>&R24YX5Z!JV&*ALG3@@W>-3%V6SX78T9>Y@*K$(&8.A^AYU M9;8MQ'M$WY!+[7"L-
:O&]C;@^W+G7XH%88@CX3 M'GP&FPO9DU2*T[QGJOM&*KTO_F',=$7CHRDO$]?)62)CK1?B]EBZC45/C0V% M3]R$K(&5"R$'&PTXS-,?=83$4&@>+KW:#/@(]HG,V
M@H_4P,+=XWT(-DU@S@Y%68AW|?N4]NGH>)RG,;]M]U1.A(/ W+0VLM"$5G#< M,*4-'Q[]M@&&$CY4/.-%YI#0VL@0]#,!'(QZ,V&FX(QLI.IL.-]O<,%DJA>_P
M"O*QN]/RX/**B=FE*SK/'W0CWV.GK]-_6_RY?=A>_X7XH-TG3)\&K4P72U> M/)L)EZ_E^278,5V%*QMPL4X_633D>/66VO#_H4#3A;?7\+4$L#!!0 (M &Z##EEE*G4]_PD .8=8
>&PO=V]R:W-H965T&UL MU5EM;]M&&OXK"S7HHM0!!-4TTBY=@#&8M7*#=F*H>&XQEK_CLB=G7G+7HTM@-;F8[50]A:?
ET59'8\6=;TZ'(^K=*&6 MLG+U2I58F6NSE#4>S?VX6ADE,]ZT+,:!YTW'2YF7HY,C?G=E3HYT4Q=YJ:Z, MJ)KE4IK-J2KT^GCDC[H7U_G]HJ87XY.CE;Q7-ZI^O[HR>!KW7+)\]N,?
GD9$SP3_RM6Z&OP6I,F=UA_IX6UV/((D"I46A,'B?\^J3-5%,0(M,/YJ>8YZD;1Q^+OC_BOK#EWN9*7.=/%'GM6+XURIF:RZ:HK_7Z-17]K?%^ MJ2X]_BO6EC: Q+2I:KUL-^YF9?V?
FYM<-@0^(IL2%H-P2,VPIBE+(6IX<_M;T6AJC!C7ZPJKP:X/*2G')3&ZSFV%?W-Q>GOWCM\M__G)^?2/?W__]O;#ô MT;@&8UH>!RV34\LD>(+)3+S39;VHO'F9J6QW_QB
>E!!A^HT>);AWYO2%:'G MB, +HF?XA;V6(?,+OT]+RR3;SX32X[!:R50=CQ#_E3*?U.CDQQ_\]??Z&8A1 M#S%ZCOL.Q+\]@_%Y+F>N&#+Z\8)XGJH6$,8A' M:GE4S$/6OHI5/N?
(/E5LO*O8]9 $18%\=D2)D@62O*H:8)O]]MZWR;/C;M-+NEVH3^I MY1UD0[=PCVZ!$\V_]UND3OY%MYE.T[]ê 8SB*<7B6>3X?OR-OEN_"U]^6ZT
M17@[@'1O9%EC+\%L4#?,VN2U,A5 A-Y!)C?="K[APUQ]H3+I [17-BAY]?\;* MR"S+B4063^D$XA3N-H+^',BBT#4Z"MH80F(%?.F %SU69DTKQA67G4(\E*\
MDYO6K!"#BD^VP>L!@MX&D#DT_6.3H&%2>.V:(R_3QA@(?H'/@\ZB %-(-]N M ;=^<\7Y7TU>;Y@]6]AD/=Z3OL6&L%LGY]5MZ[2(7T+93>EPTZ]0)9S"2%"7
M55^7@91>SS6LN]X.Q85<^-+/)YCNW["&,G3F(')FU73W795-VB$R2A$T^]M1UC M6))I&'&J/T2S92.FD:T&=J$-"9XFR%87],!B:=N?HO;WP$@4-"WD]HJYWYE-
M8V<"IE/^VZUOP^,_]]W\,Q!FE=EKS2]%%C"I@62_&UHI$C]0R4*+@#ITP@0"*9N0SY"TI[W(-,7[9F17 5R&TK@:J#A?; 9D$)36VG *TCZANX](@L&R=G,NU65:-!E+
M0O4C<2@SY3TEQE P+73BJH5N4$OOE*@Q!!-*225K]3/$;"]]>@$UM,DXC]=Y MO1!O;LY$[">N> .63;K85=]H3[)H6HT[23;E=DPE?B*""5D9,/S,U;A]IF]#
MN"1(Y8,DIEHB9$%C.TE+]7V9_YL+=XZT;RO6[IYD+22YK7A4FJC@T*1/=GG, M?T^EF]J88/.NR5!+;6J63#D$3QI)8_,!S3$T75,)HW)-<+:BJ'I0&T+WR75F M??
AU0'S/9R!#FX:=40D8PA0\@"MKN.\1@)KSY^G<=FU].SB5M'&GN)Q;=HCA*K8?MW+09/] M8YNG![@_YWAMFS5%23[P11*72[: $#W'N+\)N%6XK9VH!10D*,$[I-OY7:E
MH&/9A27VF-*NH[&%]H66=E*PTV"[NU^] MXEGPG IZ];KE"-N XX5(QGY"EP&)2"8(6@K@D$;A]GTP[4C?OQ?3L>_CG9\(M=+2I%U*HN0G:X3CT=FC_%/[8#XET*A"LG,2OQ,P-
)B*V"UO:#R(8^Q-+&TQ; M4C]H,4QV:-^]@ZP@(.)8A&'H1&@LH':3:;>P);ZX@+ @LL0\O:&[$N))T"UL MB:^OA>]9-8B:YXL9LYY.^A60G_41UUL:O!*[C0]N_FLQ&S.2$"-OJ[OOAK,#
M,F3 =J"'3!E.8?Z:!! CG=[-<'XQDWM8KJ]\.E"]T--^H+)K,=K9T$U\]H M0>0]8TDH]<' MM]>!,.<.&[+LS;ES+J59]X7BVC%L@QZS9PBSDT [C^!TM.2VV:>O(_YTQ =' M7#C(X?
2@Q2!07L;W)'.M;(5]BW'7=6@R8(IZC5*WN9@KALC?@]BGSLC=+<3 MN1%\)D*&/-QNPPL%'V. UG4Z!H_'X-8-M\!\M"Q.PM,)S,GFL"2ZT6.,8 H MABZ3(E-@"F=AP,^@ J4-
]3#/2\QS.1TV:[#B MGAV%:HN[7FNQ4=*T'NEXMYH$U#8?O(N^OR]^S->.%_MEQY#);[*(;EU\R M_J_VL'@;# 8_/+B\L>\'E_#M/-&&/@XE?L,Y/MHEH'??7F#P]<)*\55UL7$(
M[6!,>GRUL<5&@=@.)&UVK/E&FHR',4,B4,,G/!L!< M.YZTY\5VON6>NI4N!_*_JHN_..0!QEX(]PB>[D0^^]W_%+]^07UWMO75H^;+ MJ.Y$\/AT..U.A^2-*(YL&=H-
'1[Z&8_>.OC@CH(^.TY4?2:6>4@Z#'^A$+.[(.FP&^^*=*[;OI M#(!"[-NKS';:QOTZJ]@RZI2-5^BX&RUDGG6G'2),]B0^*
M0^7N^\PS'GQ[6RISSU\8R>]-6=O/Z[AY(0/]I^0_4$L#!!0 M (&Z##EG_7:8G\@, $X) 9 >&PO=V]R:W-H965T4BKKJD(1)>J3R[;1]%)MQ12!:.!GYO1:*#7MI *9P1F79:"-A=8 MZ'H8'
7;B;E#2]SP%NU=-2,>=7X_;]%_M\+US+TMA<**+WV5]\]V%P%D"*F5@7=]JKG]#MI^_P$ET8_PMU$QN?!I"LC=5E MF\P,2JF:?_'8ZK"7_"M^FPF]Y5; ME%M+_%9RGAW-
KWX=+ZNN83:>+J["8CZ>WHXGBR\WT]M!US"^B^HF+=9%@Q6_M@?4]KK6RN8&KE6+Z/+ +O';DXBVYB_A=P)_7]@/'40AQ%/?>P3O>-7OL\8[_MEV8&:K-[K6&ZSGM)*)#@,>#
<8I <.1A_')U$G]JAVMLO[;V'_HU,W>Z[,#; M<'""Y)FE68',$Q8D@5,H#0R2R64QTBPF%+A;BA 2),L['G2627XV/BV5Q'M- M\ZA:4Y+S7DFA?Q@&400F%RP2A_&-I9D8OE=HDNN
>SQY!Z$90P0]Q7A2KBW MF9#$3]=[/ID>1+%&ERV]BO2CY-V(Q0:^.XO"DSC]P%3OXSX5MD7"/[7+#.(4O7PFRDE'2;]?GN ,W"]]%!GI;O?:(<%X],XFI
MG]1(I:=ZB^3*W=V%\$<(7T.8AG!]S7]37W(^AUH0"66-8XF/ENMNB>%C4GX M4RYE\C[''UJCLYOM,KPD.XM[AEFY&NG1)+&ZR)N*@OZ5W8,&@4B6$?/O:4,!F
MQC9?ZM/4]H=R+P*30YC5PTGY@,ZKSR(%-N@D?_-@0;A6<>@$;Z4*GFY/O[NY)/C8'Y%CXU?X1 MVPIA)IR'I(9_^58P<%6HYNMT9^[ZK#U W)."D$"5@[]ABVLD
M>,V#DZN;\&5MZ=19HL+,:'"~-]$-[Z8"D\/_XHFCT]@= O_:$YW7#M#NWAU7[JW\ M3>YV\UK9YKK;S>X^%L;-'?D4WGOI7 M:266@*P(Q3H\YI/P!];N]F8'7E;\RE
MMGS_^L>&PO=V]R:W-H965TYLA>]I7/E^\'-IDM1<-O7I5!X].)>FX-ZW9C&P MI1\]!T)%*EZE^?^?^V1=S>:XKETLEOAAF]Z+@@TM5RA7@@I_RB\'=H-62R4(H*
[5B1LPO>E?#]]=C.N\/_$N*E>U< M.XID#04WNOF47?1B/?D[@]>4Z*X,;W6F>O-4F"W>M&^V\'^L0R MXU;I>_#0\C3\<<'<.CL^I/WMSAY4 MM]_9VSX[
(;=0(U,>STBIO,K<4I$87)5?K7WZ;)L/)!\N^+-&=:+1Q^-%(_)7*GR;^8GK.,FE3 M72D'8VESD%(A4V'IK'A.EUPMO #CS,+[7$!]'1TKA4D1 \B*,$G@?Y4(D2L
MUSQW:U;RM8\SJKV'BE*D@9%YM#'2=S>FE M16@%5]4=DX1T%]L 5>]08+4'/KR$1 MLTKF&6E9X841A<[W-F^N/;5OLDQ)ZK'K<8I[AAJEL+:#%"R4#9;=X6I.IL
M!+L#D9:LDG/&R-/HI&";#1BR]G#MM M<+L0*EV'T'T:F+0UY)P(2^H\K[-UDBFKAIFTC1,?:P KXWF.9U ',)60+0K59X!O]Q#2)=X3/#AW0OFGXAG;@]631I<$C=8%[RO'(%#"ML-
&L;U;IN= M(^;K9EDSN".?W3,L9/Y<$/0E6]",0AW]8.&FU& &>H[*H":SKDNM*"9[DE3 M7:DD#M):<162XGD(0B?9F#O<^KT#!2'Z3,-?B/?8H7;Z#) C0,Y2L-EE>95 M%A#KVY?
G*16;6*LV9FA#H)N*(K=6A*X. >62ST+WS$3*Z81X!MU(*X*XIHO: M)]I()E$U]M(L7[,414(9@HL[#4;'TQSVT"#$M-2X 7*B/],2@.:]1Q-B5 .<\KP<'FX,N$A'S.!%4K M$\!8*CF18D4\
I)VTSG 2.Z;IQ@]!S*":<,>_K6@@Y6LZ'$*C9B+$.0=W4VZ7 MP+RD5L]7D!EO^LL_0RW]<93T M8__^:-@_;Z87-041%=%P#] C\ "X'=FX/PFR/F,?,3CZR01FE7H,:MZN,1A=U M/CE]
[)VN6Z+/KCPQ;?D>^0!7?F_WFW,I[(:A3 MZ E^$?B5POO5B+6I:BK2Y,NS/VJ@!*%BDSPVK_P$;+2%UFDVF=!4NV7G+T'E M>]!?#U+/Z>X2-].'30936!U$Z41"GMFJ\]3T-
(KCF/V'N/BU@R+P-C#)]?!]_^ M$!8@+\K*>7(/W4>5VN'05MBR=PEL!U=^9?AZ+<3DKY%%$*P64-E:V%H+75]]ZD"P%S[Z#*5 %&UHI#&N]QSVFP!9>=O42 M(9CNPMO=K^L-
F7:S0#<8\V&;:X (I<.PI*%ALTQ2!F@+%*]SI>UX]9N8&4]M M 04C)+M-8)LX1>/E4@,=2RZ)6L7V6 K_#*@=&&K02,+VS;V:QM%NTNLH)6V M:>2@,H%LFAVUP_"U,\&SW>HT3-
5LF/2&($#;8W,,5"^4_&\S29MQZZ%3 M[XB4'+XSSK'10KJ=YGYX-TYVL=*4AZ/S0[5:/;:QVX8>OYRSF[F!8G,=,W? M#?XPF\PK7CCP-VT6NU[J]=^,^LO7&P3_K#TV:P[UT;!OG
MS@O'?GC*G,5_93^.3_#)M#!LOT'?<+/ C%Z[- M(8I-_*076+:Y<;KT7U-!%DX7_I*&\DC!T _G6KOFA@RTGI&ULG55M;]HP$/XKIPSM&R\AO)4F7T%F-ZD3*$S3I*J=W9*=W8*\SJ
M@[JB=5^2.^>>>>Q0\]=-7H=Y]Y^&^TPYQ<&\+4$:B^,ZU[1+Y.,&P9O,EX YE M4@_?Y&>2=V-4>1-BeO9+I1P$:=D^O2@TFG[S%P[-7Q5:L^2OW+J7]U3UA%AO@MN^J)ZWW
OQK:X0/[FROR]XPEKBSD*S:4 A9N)=<+I&U2V2^@;W"T^)UTVLCMJRL6J9MU/*^\!&,+3G0*Y4(ZLX*/ M-S/%[]&>&J0EGL&S]^%B;8&&[ÿJ_]8J2;*)88SC,9(0E+YÎ#? MB+(7$:"6[8CT8
MR.0GCTP\88>1+AA>6(>9/$9]WQZEF\M$^V>4)2Q[8X'ZUP;F59@4!R4;Z9 M 405H#0Z2XW/"_I2%4?25$\ MY]?+NV_+9@=@W1&:7_'4%Q)7 \!7@%=Q+86(-
=R+"Z!3ODXA;2;A7,@LO$G[-M10LZ01/"(.Q>X.O4F74<7^?MF97 [GF@;8.1SM@:)QZ='F%W#.UY4)#@AN"]U!SP-5CN72,3)SHW E#0U6 M9\9TDZ&R ?1]
[Z79.W:#^FZ<_@502P,$% @ ;H,.607;KRT2! 80D M D !X;"]W(W)K&ULI59M;]LV$/XK!W4H-D U MWBT]L0TD08!T:%X0M\[MG6]MHA2ID93=_/L=#*5FQ"]<8L_^VCN3=<+]=>4?
M=E+!T!G[67.BY5QG37 2!+BI:$SV2#16XLI:])@:':A/H1E%2.].:!W$8 MCH.;;.$M9FN22UFLC6<"?JD0+=U3=3K->5R-_E'1-
M6FZ>Y>Z.]O%D%[^07+M_V'6Z<>Q!T6HCZ]X8&=1,=%_RL_#@<$D?.<@[@UB MQ[MSY%C^2OQ9S)3<@;+:B&8%Z[S1G),V$U9@H6K#.W,XNOC<@E\M\]P\WA_M__@
R[NKY]M98!#:*@1%#W/=P<3OP$SA7@I3::@5)2V[0.D-/"*R]RNX[. M?[5B!$GH0OS\ZXS_VVSTE/P]@2N= -*>C6P.F@*[7V*>PA;4<
M,T[1L6&D%UX:EQQJ&SN,2WRB)(BLD')@G T+0U,-:9V(A ML8-T$[W*RFV^6+W:6]U^YG"!>&7^Z@&@=A*OX %VE&EVS%%\YG"T[6N%ZAZ'0;@@.C M:RO/;;;:^O^1 >CAWY-
Z'^@U^CR,_S4_C;?PAONG?IYD?H1%W3CWLVCLAU:M#2=^,L[]>&)77WX]M8=.Z?N^^MXZJ^ MXZJ"9FGBY"/3Z899(D_G:9^L'9U(\S M%,=)7WZG=N"H0"S!
<)3&'=5PE.5[:4]?)1OG%WO3%5*51!18?LQ4_9'$ R4V M6"]8+$$SKUB6RCVK3LDX=3]75\@;B,6[:+5$"+30\]96EX_"V*8]=V3C>+_MB MB7[_G>)O2R!*_$EL

|S@^[Y\GM_*9^G*)THQW5DX?+|)0[A%&6-^\M"A3//(M'T<9G.]NP<&UAR=]XRYWV[A:8;H;<)@=W@]7W;7YIMX|/NZ)VC",A],UFH:C M//- =1=Z-S"R<9?H2A]\DIU8X1N(*]N
ZVN)S:@?6 ?#]VKQ+U!+ P04 M" !N@PY9GCO^3O0" "\!@ &0 'AL+W=OAZ;1B,K?%(MXBQ)#N.:<1F,A_[L6H^]K6"2[S68-JZ9OIY@D(M1D$:K]N M^+RR[B

3DV=GNS@MXB$ M*4+I],L4X+VV;CMGD*,?@I(5=>/MS#%=[OOR2'>1ZNIN\K*6-Q,#1S3+$T], MMV5:S4][0'!7BPRPQ6^DGE7H7/2<8>.43U>P0P$X.^HV]>01NCG@ !F8N[M2W]B"N27*6&U/V"
M[S<11 AFPW\6)U'WS=ZWQ5&4GU:R\6*266V##KCZ}XYL?/$RQ? EE,$$ X?$S>"CQ0T#FBO@T3T MBW^+#/_+E27B>!,-UN$0)E,GO=8M4,$$H2UB0]]"(9/BU,',H&U364NUPBN;8KWF!0%1+%F\:+P+KL]1!T]>48Z?
3T2(Q%&4^L'U92]/U MR[>--5R"B&"8QF@WI8U%"]"(X2HSRVNE(G%-%U?G"].'09&MU.L(]]X5>_^ MKL;]*%H6%7('![DPHRVY#.O9 ?4K+CM>HR=/!366LS I3-84RGDL)98^PMZ:MWP/P7
M1U^Q>N*3S^"N0"R,N)*#_!#XE'!GDRB'68S2F.+;?M\YS.#;0*'1R;!UF9//:LL/YT:?=$__FU/#KL)@[I>+ 5]LP!)XX*S1FE_R+1;$4W M^B79 F_D:90Z47;-1?QT;_*]]DWAAM:CQ>H=YVS_^IFSK,QO8MPC'!C !M%?XXW5AQRT/
MWE=X.XAL^,>,H:=(#C:,L)QS5#49>4$'![<B1 //C)?9X;NWZM<9*B0BA5^ M)91IR#2A)OHBA6!Y-=<_GB-.OV^)K1@U)LYPPQ[ATHPQ0@9=A$=\NQN>1WXT MR&
<S7W\$Q#0+PD_2@F>P(2819M8#^MB)D#SXXC>5@;'/[K96&ZP]!X;@E]!*H M]5MO+1Z'+5^O^U?Z_>A_=+%^Z[=_SW?-6G#5T(6SF4HEN5G$_^"*JX@?CU]0&M*Z+A+%AM$>]-ZL
(Q""%1LKR*Q)"]S==1HNFI.%BC_2NO$=\M>;"4:%"$[-LC;CS['1A+W.CFF;2 +;F52)621HI*.-H4^].V?^/=RB792;I MY(,9XZ.) ?(O76% M][<37DP:Q%Z_V34!Y@XR[(.TH64BNP^/8&0QF#[AXE IG/#D_97YZ63T>7>&
M2V1@'L:'Q\B;T2AX4'.*U'3!D3'*5OAD*"EQ_&"KK]A9/PK/^MF=]1.U-!)7 MPK8O3-&].!D[_DD@EEY$]?BA7D\=%L!S/0HX[M-J:^@ZRC 2F:<^57Z@&1MQ#T:ZIDM2"ZL;P3%22_!]Q..&ESAB@H8;/#>%G M6!7]M@4L:0?
%2ZG]'"17:GZQN> W"TV"[7Z<8IDGR<<)/ M+XZ;*9YHG#]H'A]*32958D5;0:QUB0.#+8$9UD_F>O5O]-N:U-0AQ1*PK64DR M58/Y+@=;F"9X=; 1>;SCZ1?HWF0(\:+=?M'NA<%PALS@K:ZO&BE.$RJFT"(" M$Q<53]87KLN2-
HJC(>W^OG /E/8_?NT^@ 72\X$CM,]SK-S[!=#KE@&+(] M+;!;Z TU3/^4$QS2C%O>HX$SPY(?(W35\'!Q"N^V7]MJ+5+'B>X8V3!RS[W]Z7,+>-G O^%923>6MM@33!6W:>MSB2/*,=3Q1SB2UM34% MD]"(&
0X."0SOWZ_HQLW*5*( ]I2F*11*/[Z^\^QTP,]4KI=+4Q]I[Q::M] M0^UV6FJM5LO,6@WKYJ)".JY3B\4P*$RI"GM:X$_NOBDF>)IQ&;,9WT%I^7 M=9E;'_5;__PV>]S+ZR_O/MR M*&*,21AH^XI-"G_+.H?O]L:?
&M!4 .:V-/:LZ3$]2 D!U-6X M4*N["1<":RM/:PYEPO5U>9L2]H=?3)O-:G:V]S:Y4/T%7&@W)ZTM.>F1D*&U+@MJ-S,(&R/.M:ZKIAS]BK.C2OL<*EYG5;/A#T"(]@ B=,#OBI&"5?$13?@9YW3]IH.?)G MN]RLW=Q8I]H-
4)9P/JW.V2GG:SD7 RRA962&YD MCCY1KR,T3C1JE9$^CT7RY60A+#.$/ZUOQ?$$@F$M_FG::3W\Q MS^$"4B3W#G:IPO^I8.(1^V=$>D8$7"H*GX>MXT:LFI$Y#[9RI<\%$V1W#]>?
MQG<08G?:$,DZLK7;S\B\W[%B6,?:7!+W975S!7WW4]^1'U#Q'W:^;[KV ^?KW6./V#_R[]]$!]&H>UHBT\3 M$(X$1..C8CM/KC[;QCYBV"1?*%,%1@C/=\^"B"_@]*<%L,I) |#*(_3;_>[M+06Z$Y02)AM($-
]3$TW69Z@1HHL]2PZ<#/O/3 MO]!VT#<+BAR/$Q2Y.N$1N P4MI+)]"U3L:V6R F7*|R0\7]YWGTDUM]CA_U ML)M7T]70DTD!?QSW%SZFGK670T0@/*#6PH0$F]LNC:[:S-&)#WV_:]'CF/ZS
M!WI\KE5S02CCF&DRZX,Z%$T",H2X0*C F+ MPNRHG6YK;JVVMR;K,S,^R@(M21PS,6::'A^,&+-M%$VRB.F9)3,9<$-1)'A_46]UQ;9_E36*_]R::Q[KO4?=)#[](
M'/,B!'82T=984"$?:Z*]HN@?'Q$Y7%$#Z.#&;OTKZE9E:_N(ZW1OO\ M#9S(1^V.VB]@F)Q&W]Q[S,W6(N\)<^LQS&ULC+GM0F]M,4,?4CR$N=D%0?:7 M3V:5 ISE+;[Y-.ZOV/HD<.>Q898:Y3]D;T,Y_(4O#]N 2N&\!XVR?MHH
M9.CEC;YY]WB,+2#?S]YN5Y_4.J=]MY$M*SKT'19=HYQATZV"(/LQD]GV,KW% MW5W@U7%SL'V*AXY:ZV1; !3@"M_BFW>.MJ=;UVI61=0M2H=6%W.="X>V*^63 MJ"ORG9]34,-BQLH>O5QY_N):QC*%0>+|K V7W.
[@>=F(4-X;_3-NR\[V+|COXHU WC;U2CK!:WY>Z-OWCW>9EI] M[B]A8IOZ9*N8^;=%5RC+N/-^]&O[#536#.!M5SHTBT=A;_3-NT?9;!?5O:5* M;$TP5!IAO^,&E]ZKC6ZCRM,0\%6YC@E6E-SIEOAQ$0+A^Z)
M[O,TF=A^P&K_Q4W+$^,Y8C7AV MCNSDY.2W'&TVUD9/WIGBQDG]/6HUS3^T1 M"-ZA][C4IAV/AX,B><:%=LH@2;8KQTF_..%O%$V@%#/L33L.'YKL)U[G39S MPMF=/&<3GJ71@E-
G1./%94]Y@+;CC]@%.HV0[O7/E(]6K2H]CZ9&)N-&+1YU M*Q 7([_$?:$3-Z]\QQ\OOWC6"/9SP"/)@X"..<$MVJM,TS2[6+=CQ"-\V=!YL MH#&:!XKS-[FK769=A);IB:]XV 4=6YA/=r/F,8K]I5?O\M[,)HWUI@ZPU__0 MO>ZP[R
2U)"+!;"TL M<(E9H'$>)W?XNM-_8XT,J_ID^,WW8 WP*ED"0;G&Y9$"6[#X;[F/S:6$-M=5L MJ]WV>$=<0X5Z/]B=9/&MYB MN.O4<'ESR:13D82IF)P&[5$6IOS0-2S.%?>BC&I[A,G OFM2EC'G85..K!G+ MZ P3864&-
:>_>E4^N!*76B_: K\WRON&Z\$$96RYD+,+?KM,XY9+RM1D M3/F@K,(V7A+3.002E_2U141]5$^97@A/M^*K.AHW6D@!P@O6UDI\9;!>"Q_F MY^X'K?NA7]MU,^EW!03[4?5#:=2Z"1N4]">I/GT##48R_ |%>I#\KI[WLUX
MZ16_O#=/MZ4V&L6+1A;]S04-HFCM.&Y}3"+-81?H\ZU_?IM%HW@B%*&O56$C^DQH#R9 OBI-Y.BQ.1_5AZ!:OZX ^9=""TDF_?#]KJ MN'^$]=6VIGM\^R:QI?U!TP!;M-64CZ-/7$V)@RUH&*<[U3#"BWRYBG'4-NU
M%>I3CO?NEU[VR_2(+;@/G4W5A_5P8XG^4*]V5] ?CA8_#] :M+>]&L2Y?:.6 MJQN\]3L?$/]87M2TK6D_Y0HH7W0&]@ +$6)XR?RW?'QVDX5@'JN+/^U^HK- MX8_W[HNI '0W50#6PHTE\O^T6E]A+/'1HL5_FNAQA+I
MK]57"A\<+7X<0/QWMRK^_Q6+#+2.R/J_NGIC>%%K;$W^7UU%+]%Z'16 3JD M](;1UW>] (07^7(-H-%H],V<,1=OZ(+]0+4:YNJ .LAQS(=H-IMOV"\(* M<+15%2##
[H_%!7"=GYMX0(B1');Q60+B=>07]C=+'6"'.D!CMVF&F^<9UFLU MM=;MO&$>?U =0-LXB7!;683U:NLMZXC]9_6-VG83!-/L_EC\ '=W;PPQDI?3 M&^D =W=A'D"-),;*&-IE]KK5!M<+R77TPEH+ZI$K->
MN:9^4A7OL;&./^H_G]WCZ@?Q=C5*K MV8U6T]]15A.[2GYD\T1'K4QT7/+"#]O DX7SHAOUQLN4F%69T>:34Z=;67Q M .Q&O?ERK6PCY%[JH]%6Z+A:"0KONP]75/N-NI;4-76D;T=%&Q9V5M9*4;
MC6WM<#7)BY6%]:65A5GIA CB?;6Z$^K*JN.;;_X,S#]>=C**'=(^U'-!#I_MGDUT^P'6,6TE<^IC;/EX[40M'5U$)Q/I'N*P<=_EQL2\M"9]2_A?;F(C M2'OAK"]]%A5DLTD=_&21K4 [2035D_43O(L=
MN>NY9/+S@W277*F;Y&9]%^H0.R@"57A!QJ%+76EPCHJRGBC+78K*_%AC4YE M.VU15^+"*\%6]<9&L9H^]TQMV3@[3@*O76M97E\^M!=CXZJD5LSF2M!ZJP4 M=:&DVR1>LH';L:-V5LFc>4OXD'YS05NX-
1O/8U6.PV\'F+5Q2/;P=UQB5Q]] M$]$3*7P1>0[%OW*F>]VJ]=."#DK:721Z5YI OU\L"GE&52V BK %9?IY.M1V MHSOT^]M)RUXA9)FKE^>\98L/XU]S=TI%.NAV|(@XBHY@(>_XY)='H9=MG>O MMJR-
RRF^V=2ZKX9OOM2K\29HK $8/'*'@644EL@R6]P.E76VJ)1LHH&LZ+Y(M4U+CK6L@A\;2W"D9QW#<@[IY!1:U3?5S/^RFNR.A F()WNRLY'DH MJY@WE+ MSV2K&)A:EI-!@K-*_8EK+_@EX7R5&UOY8@S<0'?
G2HOS2U2E7:LIPHMR?Q^^ M6U6>3'\"RX99*]H,S2<;%\|SQ)0_&U+#]G^?13V[U.7[4@M7V,1%+$+[2;2YMGG?].*IPQZ@%=Z@?8DI=E]TT_V';@7K67=WX;SK/HZ= MJ]G::!5NOUIL9FE/E?>XQS6=OF
S8=]7/E29G2ZF$]X@$NCT')!V98O-G?,' MON%./42L]#C0 C MZ!?*$V#3@V0= E=Y7V^>2-H8PY'P(=-5AH'KPH\RCW-REVD/7<2)W0+$\GP> M-4X3T>'=O[Z"6A3G\UU]96]72ZV0W$L((Q@45$0%7^/8M-JQ9-
92)88WPVN6=WHS'P+%<3PZ(M%\AWI+1V,_0=N'VEWB7XU=4\LI"@" /H$03Q>IFDD"R"&5NZ*Z@%;FVN)NZ MXCOISY[JH]A&\W0SBJG'*(;^7>]ND6*T3CW7&;(RQ21P/X9!4?G%ZEWT4!0 MTO7]JR=H"UV B#XVBA?
QU%%BHCHWST$29^OG(A,<&%E+BYC30;18F6M MF5'64 UBR/+;6>N*:L^,T1?'!?1]!$3T#]QKY7?KCP@%V.!,P;57'E$W5SR+7Z_1,_4XL@R%X]# MYFGVG@IL7XC;!.3I/;@&ZT';QN8M28(R9<+TOO!0#>(BK9(?
#]U696RUVC M\"]&;^,T5%5B+=+LYF]?9E/+MYVMT!HP*<:1Z09W=]:K.Y }~L7 ^)T]\(K L0! M.":CK;;]V?EQKYAAMV]%= CM#*^&7ET7GW/52%MZ*QE05"9S[(YOE3#U'UQF]
MB",GN/H1>@NN'<41)A45)D:4K<=H>ZU2R)6M%0#O8O]8.XW>UXX]U+W)C7NK MN\[XHS?\S]$Q\5GWR1#]<;EX.JES9@7H"XCH@&IC;,E +G61CD=T39E3]2 MR_!.N=Z#Z&
[6]\"W6YUB0;P"%W6SO6]^89@POP/>&+QX?P)*8=Z!P? MVPL/6%[XNKC0543F:K67E;'*@]O98.*N.JEZ60'LP-)!#XFRI)3[BW_>5RZO MSR^N[QD2>>526FNE>\:N8@8%6!FXAOZ]HH]AD8^*;CWI<^_=YU72@,1]6/:N M*R>
)G^5K/LIRACHI%+G.[X'?LVUA/QU-J M6CY_?T;'R_@X-CCM#]WK=%I!]G %YXT6US#TGW"*"&I%/+_M@B$"4B?P))O&!_5PQ]NPN#=&SU8T/&8+%[;--G^A=4;+T//C!=I(V+,MQRV M?UJMFY^WNB%ZPD\
618@YXV=@X%J8^;326(*<>SYL6%X;'&1#9C!-_MO,:TPZ@>Z%T&!OP\T.[I+)(%<;CKR;0L96 H^M1Q?5 I1HKSR'@'ZT]UTT:D M$[B/(>>=F][0_<6YN!E?&T_6G_U_MA5_1B@;6BV.*(#SLZUQL:W,00+YDDF[7)7Y>W4?
W@/X K.P!28E]MV!3?#?]R(6[M:G92.U$U&SGOSNB5Y,]/F96_&@#\/50R3)]X2<>G9'=]F FS&V M:\HPAXR1CU?.%3UFG9ZNEM+X6)U2^LYNK]\0[JXO]^K_2NSY45>/7E]2\7 MUV>7%PNB;QG#4U>]&4#AE9IOU.
)!'T;>!MV?)7!=#*PC/A=#8A MO5RA?(MZNM)00G2BHX0*"FP+A<,(&(<3V&0VR1_*V/!C\K?%C2,V027G1%0^N MP0+MP'PP772E8%@Q#*]JX!EAB!@<%]@\V M&+7Q1K<.(#EEU23]:'E,/R>[)61<_Q/8+[\^2Y8
WT3(>BS;F%0N%N],R&\4]08WST@(3Z(:N?HV=VLXJ5MMC/9 M,105ET &"1D#]9KAA)>1;2M.MHU6-3L,(21;1ND MQZ5-'R'#&OZ+A"O\VO!OQN=BF7TSN02T-*V;[?HBH;5&YLQS$2SU.6"]JX,R
MDV;Z0OS;%XQKU9PTCSA"&C]0)OO'%5*8G^$=TO\3\<$<7%XG^AB_L9$Y4FS' M%S>G\"6NL:$'-W=#_*SC3R>3IOAB],F/#^X5?;:% M+D?H)$#)_]5-72P*IQWK&(FXUF3AF5$;@:6",2 ,$QW\"\<@S.$]NJO\#$JB
M.26=YTIWYQ;BSGMRE0@W,,N/%Y'N#<&@6F->[X$(MS4&1D6APK3VEZ>1BPU M3U9M%^CUSI(6%\9PML&8"D(OW:<[%;HP,8RA5&1K^C#)**Z2*].]3-?:*[M\60>T%+HD.FYZ\I#$2T =M5W3+@I\P-
84460($"#+/L>$S "_\&X#DZS^P1,"TO< E3]D!"IG!%#[#*+%O MV/2I5#8Q.CW#8!$ZTABX@2]&>,3O1,?A)@D;3%4(K4"H6 8=027@DYN/?L1AA)8%(]1H_38M*CQ?G:9(A%+HH M:_4N]QO0P7"R,@D6K1>4-
;&8^]D7NC6$'$QIO.3GP#_"/#D&)'96@&]3B;SXH9M8/N!9+?D<=<e=8 MT.'%2G_0 EM)4DZAK)^H6IM>;90NY/Q*;]W5+Q4R1T<,VD+K$,<^]JF/VM MZD1H99P[D50S=]MF*JU==];M5>UF*D&>W?O_6UE[TL\4B%R'-,L;?
TE:&/ M$941).L*D;40@U6F1[I2*OW%SRO-"UTA;BS:EF:<"98" :U$ZFM3L)O)6DD2?*E>YDRES].4]<.H;M^V6.LXIG##\"YT;MY-WG9K713$?86&\]8/#[M;$@%29M,M2DN6E)-N,?*Z<4O!W M,#>Q^YRFY,FAV/*-S!_0QQP/3-
A5)5XGD3 L]@+MAU@(Y)Q7Q"3U.ZQSFR[Q M#M>TF#C1*I&K]>OP+,L(*:MZ0#U:DX98L8"64U%)T$7H3QUKH8TAI]:Q)"]>]S$L. MS2I42&UA-0GM/]'-S3 P$SFBQFH?N,G4Y[+R_N2CX68$.7M,#]D0QRP3[. MOGFJ"-
N5<4"'>&OD?MC#"(!W7(*IDOY[5+,C$(5V%S/F/!9@IFBE396HU2##+ M>.+$*R^\W\Y4T:W,6WNAU+A/Q0R0?63*59K%:AE<\+D4S4:FFB\T!6ZS0HJ MX.7-^(N),N)?]%!NU<%?F.W<*)_4Q[_0/?
O7GS_TPEWB+>121$&)H6R1?G#< MW!O7YET"1V@5 49%1I8M]2;GX>&->P^OV383T.5R17=\'+ZVJGV2FY M^?H4TRX(WAXSQ62"#\]I#,K:^R=G-X32;:PVO]C0A+)_T=(I"+H>,Z%DPELGE?
W+E&Y!$/;82243'%R%5+XXP4XLZ89:6]#>XM!W47"A MK.!55I=;796LT5_.H(;\|B[2M61IC36>!3EBGG MT6 L-)7Z&!*%5Q!4SQVPA#5%D5:,U/WE4LZ M.Y%C-;59/P(G^"%DEKTF(2F4;]1]"OLLS; WH6,7!,U+
<9=@R7HV)RY%CV=\ MC;=\BSNA3O6T60]P30684H'CV9573G4[G:"]$R](,R>I-$5 ,(9BYS3459N= MU8)7A3'4WM,D[IP"8:R %$7!V!R-\S4=6:$@A6OMUQ4>"NJVB:&/OHST%T?
MV]M1"B[70]*5>>T)A+U6E4&0FIUTU]2SB[ZQF!]+N=B SRX9#+*>H*E-2[4 MM17,:D04Q$I@PXY5Z];V%DX=!S,&%FC4D[6:^*ZA&-2"^;ZBDR07,_.[N&<. M FT6N#-'MD=>5K89%FQ2=T_L[J9C$[&1R)"EC.)828W8#.\L?
4,W M+N+K>BD]FX.86\0^?!-O\CB_MD!:!L32E[U.A*LL)PH'OP=%A@&#;2#(MKTZ^2 M+6CXDN7*5 R9/L8Z/6@VK*;52W9DFQY/#)P^,E:M91+2S4S-XQYL68FPR@) M]36'/>P#XK'6*@NFRZU4PI8EN<5%;*W;,\B9]ON2?
8#NX/VWW-EK2X5M6JV] M96LXMU39ENQHM*7*MN?N,EG9UE]EI065;Z_'.*V]?M]E68YQ\#>7Y1B' M9MYE(<9>V'E&_U^)G>^](^1%M>M1S%E(<;N*2:3-+LJQ>RR(*;AFS7(I2R M&$&/WA)+)>EV+4'96D-$Y
E+9ITPI"$%V3RKK>9'V5)!1]ZZ6*%YH2MFG4"E8 M(=914DHFV7LM2ME52<5I_LSN0]](.64*S3"AUG %P=]WF.BVN-MI)FU[50KK MX97NDLPZS;+ 8D/26Z5F]5A461CBVR:-92*[5Z6QW51%-)!H.GM37XMK$]*
MQ:L+2U)O2M MSNAN95K*+:7"?18]M9NKA3$/FN6]-ZF5F]^]F-C*]?"!]G MLNMV6Z*D=FJEO%I37N76)BVA(:525B6]!AG67)S9N,>ZI+KV"]I2"BNO7F$] M4@.P>>0$ \O82T%2YG7;D6)+!E[LMR9)4YO=E_DV&D6M2?
J0&IA0#NO(?S(? MX5\XK*.STCO?Q+".O'1M+7<'+]4E;\! M5MOR!?2C$0Z?)5K[R,/43!MV<=N!YSI_^T#_O[SZRPU:"Q^8WK].]>+/#-# M.#'_&:>RZSAH$'TZNNE2 1^@[DQ'S.7!C@O]
M).N5%A6HU)NIVEC@XU_-1V.41L^P/*47>_4MO7D+12K=114]T0YY>]#M1.@ M24%3)=$-C7!&T.V3A3]?7?R'C\7X3!F2G>+R2Z36.GJ MD>G1=>';7+]DD0P>)>[8] HV%2>3)=?3HQ18!G.>_ES_4)'BU^.J!(MR[7* M-S]G#;:^
MEVDZY=B#LG:K8&23-T1G@;+99077$42TRP*NXZ*6O$DZZU++SLJXZ]^?7LH] MKN.BE]QQ.FO2RZYJN5;,SR@TN92ET,=%+GE3<=8EEQU5FFAEWXFRGNM5I0@N M)K-,;?&:'F#'LC#>O.OBKM9]91E;=?2VJY"4^!1)
UJF=CB#2:17-HC8[R8 ML'8BI#]-XTL9W'M;\X6I8AGUY$)W,?/&NS7<_D3?:H+8^Z'\Z^IH%]O^GWE M]N)..;NYNKJY5O]_]NXNCC4I[&z?=@[NT',_#K"S%P]O")(6A(ZKV!G-E9#Z: M%$'#R@CZJ]ZHFQ:%Z'T?
SIU$+!POO/'&F&C>'@]MQ4QD"P&X)QQ^!2^T%.<MP/>_@=+!;8OVNXRV>T\V;9PYFRIBZ9>$.K0 S,<1R]@*T.IR$'=3C]\=WJS@S MRBI7DY\^Z:ZK8U(;)]H$]]/A<0]USP>\QW_RSQ!2MN/+MU#/>MPT@R[Z*&] MP;R8CUM-
)4;!@^WPUW#]]5G'@S';D B^G4F9TS2+ ;%643!?0;8*8]7@]NO]3H/Z_LGAOE/9$747-[R4=QR86FYF$&JZV7.UB6*1X&C6]IG-_^E*-MTX2;#B[ITH8[,5 Q[.F+NG?.Z)KZ,9=XRBNWX[I;Q8/3_/>["O:;49L=G%2?
M'1FXZY8S)0;NI)%1K;$[#-Q>S70,YMJI]%2M9968N"18&![=QBXO?+$"_[M:@O3U+1FB8!'@H"=70KA;;4.B!"PJS;:'7>W3\'+&8>Y._IO("<-("C47'? M0.IDX]0>]C4H.4K20]X&5,8^B.Z8]]&;U=S\(9Z>MI4
M&]V2@Y<(OE8V>FUW*LH++89\#MY4ZRU \';C52!X,9WG/R],_DPD'A>:3E]3 M#<@2?WE"<8KL=*0=;'EKV@'0F>@H[=A8,]"RTB65;-EA?INEOLOK+S&CO59M MUC>K&#D.A]%1X&&SUMHA"F[B-
M^FMFKW^E^[!)@]|=XB'FSC/5]\##%SC02SPL M*'\YJVD[E\LM]Z*O\X$NS\]Q[$WQ<%S[$&S.]#+RT%7TX=R:\@\Y_TRIMVN]@C,/9#VH EBD]%GSAH]57E*W MAH&56R]GR.?>H_I^$LN\-7Y0T9U^T3E8YXU*
|\0%794I.?A M*[C(;I(_&O 3PT[6VF%S9MB#2'U6BE 6IN67A?5@V^=BU_WPU 4K[-IA^^6R M$*3(N7YE1N=QWV^9R[G6+F^XSIP<4K^+ZO)B^9X*XPK>9E Z.T4$A.8H(S0N M6)<8L>H;5DG?C--M+/*FV"Z6]G^
P/Y#W/P5-1!?P"NL==3F*?RWI;Q?7^$TA MT3&C;Z:MRN[0+]>!M5WT;:-C=.@8UG@]+<%$] L;<,]6^R[/-KX\+V-]YZ;/]^MY_[%__S M]>7+Z7KGX1VS8M9(=&U^W%OMEA0OOOM\8RM_#ZRYHFD\V%)5?C&.Z)7?#!<4
M/)O#B.G^H&<3TQ@K%$^>BFR=S.>FT/#)/^LKHQ.UQCZC]LJE]/;QBB^Q.+A MM%H].Q?!*SR/&;)?#=TSO#MC:%|QP]B/B-AWAH538&]U%UG'H]]G&8]F_2&6^B.% M6]RI_N&Y_A]TF/ LXBCK:+(Y8V%Q@MCY*
$/)=?DKMRKAG@=!VX+,X>>>S5LT#4)C:H1)7GKE&91S0N/2P!;/O*+/ '4Z)2C!#/]< M#*5$9IT_:US*YZ/E0,?'&LZJM;(9Q8+L$9] =IT:WD N1$K$)8<$"5JU=-L M&A>A1!8/5'R9\N!2#K_K#
UC1!#29_#7#Q]W;BT1V^U.5HM#H#(_;;=^X]?4 M:OP?NA48U\83?;.BB-D:I.(@]H!XQ"'2!C5]U&K5;A96P*M^$>5E;>%:O/F MRMSR=*#%Z3^;?T4.]R9F&QB;]6>=I#/,U2]B_^>5^YO#X'I9C-A+RL!ZV[M;D_;F?Y@5
:NH7^OT*R?CXIN/>ES[]WG51Q8C5C^OEONC)Q$3?*U__U,_L M*S=?E^7U[WKL\O>5^7LYOK\[^EF^YNZB_^WK/?WDYO;BKH=?],/1#O&,EEW M;>OVZZI6GU3$;AX-]]$TGGAS^*O76<4#'WE#,O=1L!&O='$=BSG84ZS
1!B((/@-QA\ M!G.P2:L22--AX.MK?N!"\;5R!CCU"GQPZHB MCXO3.P+7Y13=L3,;/(.,"UPHOFLQ)R%*GIT)9!B&R$![#<$"UM<>>$V*+,P$%;$/Z1M_O3IW8?]5[@;@.//%$(3%#04=U@^�P=F)0MIL_TB3.<
M!!0\5Q6XIZ\7O=N^RCG]GH$%T%8>[:]]R>[$"$#/=4RX8M>?H,__][P.P MZCO\?]]J@*QD6>3 !:W!IONYE^R/Q@+\\ &#U/!U=\Y'@\^\8(!'QQU^ M.>_!PJAZ"*S*<]$. Y!K/MH:.YTGKGT@4A#]P*]TU-
CRHX<%]D^3W]5E6Y M=FQ#RK+,C*@L5L<*/V@)<4X/3"U5&0#>XG@]%^M+)KJ->@%/LOKB.,RXSMW@_M0>F-I] \@+|(=/8>SG>"3R$06;3'=@[:A3V<\ZYM%/34R)4H1VH>(43H!T;_MT_]^AO>
+_7TL>'/:3OH\=5A%3ZH9\BC>7P6N!Z@)];B..(%[!'D+!QU!!Q] M@-.J #D\4!ZP1H=NWQD@6T;ACQAA8&E["%E*&X$\MON'HB<0<(S7U33 ME/C3B)6B5$P!QF/"M88LQ'FRDQHY$N\8U0Q)O$1D'@*#](-
FBGOP.2S";!,7 MVB<:&"2"MC*[*/]-13/G9K_HBLI(^AI8*I^+;P;6_<5%MO@/%'9WXBY1#1CR&$/7)$-/'_L07Q= M\B0@DEPA1,*/1/D(C$M#X0_.LDERDF_IY>0H]0B#%T2-'B<\-V+CPAZ M WR 6U'EL_C+N%034L)C9-0#?^*
Q]>[IAX31Z@:\KYM6"QC1GA"?#GVD.UN MW+GE.8E+ '%6&,?'IF??QPX>GIZ?]0)4%837AQD0 MG5=Q#8O,\0^*;Z#R!!<^J0!B59]MBD"IRF>0<2]R M;M55#E]4B*K@ D!1Z>544^HQ_90(&"$=],$3+6!(?
Y'E=$;>S$=0OL:F MZ_FA@%GC<>^)$C(2PSB1^P'<_T0 \UD!YCZF1D5/ZT4:IU#H#]W;EX\2M6 MH_+,*52!2;UN0S"MSG:'!GDZS)F4U"9NW%"+$!!'22ANA?P\V"_R<*2MC1IS M-
*CU&QC2*KH^]9&N*A:9>!203*K=82$5"?>G"U. M+"94>O$:[*$1X[P[#T"3W0"L*R<0.K.\J.Q2]$B4IB!?D; Q-TIH3 <2FC_M^^NI_K,(4-&#Y?S:%_.2WG"78AZ3*Q8DRW ?MI)@ON24<\'!C4#^8)9,O!,M= GX:Q]!97Y'F,.7
[,VQ];00$R?-\3R)[ZL21=/DWD]]5$VC1Z1_##,"W<<(M$B3/%Q1=*3$*,%BL^72&_Q@A2WETK$>#R.!]>#*]]DKMQ?W0-?Z Q#&"2U* MSP,\E-OSRE=-\8,I677$ZO2]H$_.Y]MG^@[N+(X3OM*2YF#//8$VPU9
M]RI2PW[5_X,W1^P:[]06;;24]Z>PVMFEI_Q?;#^BPH?M]O\[V>.MONT8[&D9 M@|V3,H>^(N-^>S">").LHKW0+^YX7>WQQNGTN^'>%,<]N$EXS<;)$7#UN]H" C M,RWI+&(_D=1SI=>*K_"]FUKRK]ETTVL3]4F78L]0U?-RTX!
[T?%?H$;F2+3 MCR\NF9B.?@//^$JF3Z$?[*\]\]RA+B;$(V_2"%-]#=-KZ0WXYAQBJQ!_M(GTE$?7#IS"Q'5 HW"G7FR+NEX*LHX@O.3CB &[5!.K_>"&9]4'&J9.!;M *0QW5BX*$+G($@L^*\"EDC\1&T/I E9 C&$4%7ZE]]
(FV;2UG"H050MOB M?RY#%HZ-XGV2N*(]>,9?:TR%]]5MFS0"1!(\S:IG&]<6QO39AS7&@$K-BC! M"<4/":TK?2]RLWHWSHY$R.%6K]TG_O.N]AQ]LSN9LA33:B)&M8Q6S]1HW MB#F:(75B2H6 (] OWYR=2&Y'
2,R:$5&@D&A!$U/,,-X-PZLG<'222*'R'W]/#G!R?,_%HSH.P3(Z"]E J\B9;Q\Z/C!"GW&,[$/X M?5TC<$S[]> MY)2(L+[M$MB7?-EZR!_E9#^NM!]$P/U_6W_ORS_DU8[8;_+1],[3%EQSR" M#TY:!4@'WP"6A>'_F4_QDIA8
K$YUF5 ?V)8,R_V)=A?AD4,P9,<,2&UJEF? M#?N\$GR8U]+<"527(Z:]](<&$"3@$R+O(OL1$=);V*R(6>T)/+V)\HTHGO@_M+R%YT^'8!9O"%*44A+6V#W AK.E%'V 3]).]2>$T4))0[(C7/LXY]1)YB18 M* W.K%,+*[_(0?
CQR_')1(Q5&]RA>B41T="'"]J-/O,)>DF,7$')@^7@+B MB/*,;??=8*23$+V9C-M,.ZLF^(6HH/H^$-VR9Y!?+K+P/GSN!5V.;+(M,&8E-$C)X2/\A]&H+],4L3%!*?OL[]"_E2)@OD0R^ JS/@-_,@8+ L=@ ML# QCX@Z:
<#W@1<0!@-K5/IKP?4K^&2)]6]:2]_+XQ+4P(^G.GOABB=AKE M#X>Q!\6F@5"+A?.N*@,&Q.PQ?"ITF8F$H=>8)U:'ARRA>0 (9D/ZQ=(U:"MA?MOC"B3R9]TR3FL&,P6,23_,DXQBH>1;0/^/T],P;]?=7"?*>#U;@@4-
M-W*ORSB,B$:95!B53:RF])VAB>NC MI79%2?>6R_:]5:36N=E&!?"^RU:J-Y"Q@?"[8^QL :C[=V1;Q557[70;P+ MB-=+B*'<53^&@=!6BENA4N4:%>ES=0W,C9%-JLDUZ3S95!H""N4,+6P NG8B M:G5*L*,]F5)*[>S*9!7=_
MX[8L-%"E,.7KEC@TL2R!RPG4B)(]6'E4S,_M%4&3-;,3S@\L>L&(<)@$DIL+%F]9%>E0%O4G&*BCQ@%A9E:8&4;*(-BMO1$R M=8,L%U]YW]O@%"+/X"PM/?EU'[_'& *%9#UY$C^5XA):T"(+,3\H3';,]?+"LT
M)D%"BP]C<(.5!D]=]*6ESTG7*HVPW-^1B4N;DB-=9@<[(=B8S<B0@$O24CD3>C?@50-_"!)"T'GB]CF6B% M4T2,_Z]%!]=$SN%X]&^7!: N8L6@<8DQT8#+.L&LRUIS.'DRF41^]L+_9"):!\.464KU04_5 "4*\7[L
M*^IXE/4C\BET&_B818D2S JCU";LSZCT]($*DC*T22#\I,B0/@F0$OVSFQ.5 M'\&W4!D:S-BS^;Y,Y3WZ/HXD>631NK17V7$\AHCEF*AD-+??_QZW9=_G"U_%2;/E4J/UGOU[?G"QX?WSK]^3<-0+0:I0[#+15$?3\Z28Q YS?R<6
MHX5"^.4>! '!SB1?E"Z/Y%D)D3= M+-:N,91"(E,KN.9"]"Q2)KN)"?3<*<+E"^\Z,_91^$G/%G#4SG]W I8F>[Y0@;'%*8%]9*D%11"E!EPUC21>S=/!W+5>6SKR=NG(@@O?:"-#*M 00Z% D[< M15?]MOY*+>+]
_TVGPU0M5@4G<"]@1+N6VW)'R4D>X:%E@/6["%C#4-O@/XC M4T,3*"CYY.$XDTH#"4+!F]5%IELFXL]1KZ_<&.\ M!$)7!K;)=T5Z9_V3'KD+>|>L&YDVXC"U_@C8*IY$!XWPHB$>3IX6/SPMG\G
M/Z1R@8GC^E6E,V#M7F+K$C[BN"+K,_=,\OU -7F'.LYE%@[5.S)D*"8]"B&BPP4&3?E MW$GVBW!/+X 7*T+IU1!,6:W"%9<\?WX4D?>N_CPMI\FCI7C1 %("5>=ASFZ M@.'=:NNG9#I\R.]XH0ESNG5"?)A/(95@]0/'>G3
2H*R$NZ_*EY#:G/U^J*[*\MC&B=UL'5T6D\X].QCUF M%2V\UB'?$"3UBSC/N1],ELBO,I>PBS&'IWQ$>(T)&-3*>*;%G)0H=*#1%/DM M\%;G29:@6A:L.["A(,53,& ?G M[K?MBC)?ZV/9!:Z8<=3&T3 R4X@
VQ2^XR@0Y'O&#%#,4V;%AHA4]),$O M,ED;EQ=3S+S6'T8)F<*OH]M$3#1+KF2U+1#;4>]W%F5(YT6E4BHHHNTC3XN2:5% M=4 PQ=L!P(XP=87]-%$6B\K!3-W+,#Y>AD00]TV3U=:$:1D(]L7V2Q]P9X) M^*"
[KRB2<9S9XT)&9?PFD?J(%S7_4H T[W4O'&=O>G:KR$,S^%.D=\Y$ X M57(%2@C CR@$\D2JNI$>XSTUCA&X?4*DS@65,(UP]"D%&$)(%5N21Q@D # M71!-#\R0:'PCW+IGD^)2DKYA+SA.''7;SM.
[QZDA\+3<%PABLT$;N)X($ FV MTL,\:Y.2-W7*]_7B*5!4#+:ASENV%+:SB3ED@4]T-DOAPJWR'F7_B9KYYEQY M#YH:P.@D$7A-0%P&]%P-.P,;Z?F=ZCG#\Y6F%]FBNL3WY=O,/%O#=<102;%]F MGL$.@TS]14]]"V2?
X]_TF:7;E2O#1%]:@.5$7+L4N.P4$YRWWA) DG6@>%$ M7$:ZVQ7]A^G)M4$9'.@#TQ+5*>%&I7,_6R'^IR 6:<"ZB^\GRJSRB -TN&L2)D7'JOOI57%G M-SF(8P%A!,1KN(8=Z5K+24G+)R5MWXK0VQ8CC5*,["=M*FJ0+EO;
(9DC8?/0 M-52_PBZ"TI8%O0US-J*&3F'A(.B0N9#X-.3\1=X5]L+IG>"HR&!$<"F1KR" M8#'1/ '@Q"9-Z$3&8)K=C;/XXA4"%('?A"%=%S@ M&#EC[BI8MM"D178_MN"EA&66$
!^U*_G)KGK1;.JUBE;YB+_K*N!3HV,U,CM M@V0D*SC05X+>]\B3?EPH^9L-2!K/B#*FX=+10*I%;PVN&7_1T*8PHNF12..]W M(-C![@SRCBWV:23V&M(-5IHD6FP!]Z'F@L94[;0*(_9\Z!:5\]]/AE7N+Y
ML+$8*@+Q#F"A$&68GH0M#H>Z9Z2*(E,Y43/@9G!';MD)(4?:XB1JYV.%^UF M3)V"Q#:P;H84$BR=03=A+ Y$L;AA8]6%3=UT@:O<6TWI=|>0AZ6%0=ES@E:9P M-D)0WGOS7_G 'O!X;'D:!F?Q@6 VHU2.]1G.(EIT%94P0S.^
Q!E_7 ^]:_ML"%&?TDSX:2#$^2D<2P$-TKWZU\ MJ;OUZBQ9D0=0LM9A0LH-,P[X'GDB@B5QJZ3)3E=-C,Q7SEL5^XV$]]#@!R7$@<&3]2#M1 Q,6.X!R5&,E2$Y+M2%(M+2R30)D$6815!]9!M@%0!T\ODS/IP)% 4-
Q@5C+*QM)/NDFAN0#L%RM4_4#. M"DDH5:ADS:&4%MD80#3OB]30PUQY<"CT)[I\<@=#SS"^1QM-N,6BAA8T9\RP ML06&G-"&O]^$I&5Y3]%:'#L"C,LSP9]M[B=+LFPD6S:2+2,P6W&=-4O7V0'$ M>B-?
K#>*Y38NZXV*TPQBQSUW\X2]Z(6F+Q!NG)C$?1*#]F/^85W\$"%:![M)=7(6&069!L<6PZF&84-&]D3FR<:P$W)SHCI)B__]=)DSYH/R/AOI]15/*M%O;6[_!9^KXRW:Z9F0E!KA+620P84MO2TB Q@$VL-
+;"@7Y0]'@Z^,:E^4 MC=\$74NLW';9;)^0]_,+\B)2L3,\X1E'(\UMF\(74U$PCRT;2]HN;;ND[,"[VL);RB3Q=+Z!^##3G;"1;3W-+UDSDDGM0XTH6<([1G HPIY/^ M/IDKYX[RNZ'\+|KVW@0N=1T)KZ-/U_$[
NYG0^DS]H#R]G\63*M^;49?,] H M:QZE+_=M>U5:I5=EY^DP,G& 53]4^1+E\6-]B!,/0M?H(I=N\LP1]AP;S"D$ M0+N6G=]W%X"X>S 5&"W\B>5P*BTBYP$QS\N6 M@FS]NV,MI%36]2V*-_=,SVJ]^&MS
M1.&*L.9)5U]U#ZU:)GF3_/B7]52Q4@!2M6/SO/68T*' -6C?-$,<:UT]H4(ATNA1M,BZ*N*N*LHH*08%^]^]^]HVY:1'.:<'X"BZ:3C0RQ'M;N !/Q!#CI*-4TX5>5ZPW"G>QR^6)LLK MISHITFSM!8.1>#9 5>F%&\Z?
+1"V$*5;YX$"M%:L 6G4FC0/!40?**HZ3"X1 MM3B-5DA4R&5S&W+SMJD0AW5%-5*_1.])0Y0')GX$]")+[PA1]]D]:/MVU8LZR$5?XR>]B&1^V.W#4^ZB[<@5KGZJZX6CN+[9]F4UP'Y& ML,/WWWXI('1'5"Q<+;ID@XCL4>F.Y.
]!0UL3S&=#$B2LCM\5*! MJ]AOG5 ,<]]4Q<^SFY2):+)A1#EQDS!M@VD0&_56E0N1TR\@CL>+=;W%MJ/&MS*#^**?#*X]-H7.]P-J_Z5$: =>Z@8 M[?K,IT+E"IE^B),?5^AZDLXF]Zn+C<[G9&.V/-:$/E,(R)>%9%G-X,8*-
#5/#H?3*LQ?/-R&I, M&)W<9TW-&[B0-TX85ILV'GFQ1Z)EL1S/E,;F H M7&'Y0F;@6LEX2L93,I[-&$^6AGG>I?(*C8QWI/)G\E)>D@R&V!3-.A#?]^
M,2R<'"K'=U(>'7O15&'E_0AK6Z9AQ,BR;G"GNPQHGPD"3\+]D1,ZFGQ7CA:GR!$+2&?'M#-/:> @_^6]!,YVS?U@A"7Z?1YA[@X7""'M]6"AUU1NA*2NB.C$@P$/ADT%'&"!F7VZ.Q@%[-#]"9C;+WW.1[@B'|CLS60\3
MF1NXEX$+3WMBN#5IYB!E1]BK@"K;,'4U/3GL&Y]T*1C:IXB:]5![EQ@<&$?VA MZ3 VB50PK$&AHD3A$D,9]_YH3,RA99!/@S823K4*X$V4NXOM(4&VBP'IXE71 M."R!K:*X>?
K:>|W&LIGDR733BRR^.+*2,0|9GST*E2|25QB]@L/8W MQ#IV5H>XH8:#N1"E* #A8811^+/@XR";K17,&='82)1^D+@=-'ZNP.7#6!0 M%XEN|SGX0OL(F2*P$D&O^A)'4,(MGN!0,RAB0?"N (@!<5?8YUUL)B+4)ZK
MTBB=@4<14(1#8M3]BSQHS$_WVWG]8(=Z;"W*:UFAHZ[M1+U:X*#][K%@6U]$]Z,]]V:@*@QB^_AT;75/E*P>Z:1Q0X&79#]TH1Q'PIH*9%+3]],RG:%AC+PH<_= 7$=3##"Q:@>M IGUP.SL(#23)"\|&D6Y89+^I@&V[XAO-
"4]XQ2NRGWB[VB?P'Z90V581.)< M7H!-#KCX4K*M5.4N827S7"0OA0G@5^<)68A,VA&SPVP2CH(&,])62QD!.G)!X M$-N"1(G4#B+%]ZJ+-"0\(S.$(=!=Z<7RS/R@&'&*4@? M'SG!PI:G8O@;HCSE["%,'P&5VKO4]_[>3=ID
MM1P@9>"SN'K(EC'88 ZYOX7Q0TSK85,>-2H+9)T*,)OSA4!NX%W@Z2TA%6 MANO,=0O(>%/IYRWQQO497H$O"]_S"GP10G!X/2555ZB:+POVI:I30\4RBN MIU/3Q^/$#QQ"0^\D$+%6B,7_#C?
P[@:XT:S;!L'D56QCDKVR1C1>BE]:IMI(ZM)>'8WM"L4Z$[&&B*K_'B]0]_KWRUWH,X4"CQDY(MP,Y&ABP*S%A?@#Z6XXKB0VYTA9O M%UN54C=B02;B(Z5,,UFHI:G#_K?/=R@
MQ_A<56ZX]\KS]]@^;RU"UQ"'4S19:>&)@"G07:P[B]P.;Z+0^"]]+1'0KD%N%\EK+3;*#+0HZ9).9:C+^/X=Y6=:G?B;:1 M]&I(WTA84%@.U,FMI'Y&'^S^ WW#K4SW'89V#*.5:C"U(D_\9ZA"#%7+6
MIZ(9CZ\@+DULQZX06R7']9?HT)C:4+.JQ=F4-]%=,&A(AB&?A:?#MKX&*-?. MW!!^37Q'^$DN!VoZ.:&E07*XF(<<.EE!$W9]\S_\@=AITKNT+G3;U4X&N#[8 M50>#KI8$P3:A]IT$NL=_?NN(E<6R6U]=N$TSPK
+7<37+4;>$=4 FJI**+)3$@F%9'!5:>930+#@"EE!1S]]H#474 M=CSF(94NU4-T'7_:_K1.Z4_:S=\3M)MR@YC$H?8H=;-88>+-[$5?EB+N4:V MS0]C>OR]_#"?>35?R+P2X;F[>'B.^T_R_@K16.P15#T'/;"$_K2<7Y5\+M6N3B M(-
QNODC2WR>QV(OE*XPX)Q2'T:UT MXRHGB_/S94?}+;HZ+*ZB=*_#9EV%C8Q5L1[MDN[B8AXI@DXDDPJ5(M65\+*>45'!M>/N]B,WQN X-K_A+]4=?Z&C/RR,=&;K
M^?:9;HX6.4(Y=&&9U'J7S1DR6XL,?;QC^*"[KEN%'LPX]#%U%O/JEV-9M9XR M>@X $1!?%:^3+6!^=USN6IX:@@X:>(Z#L/V!G JOF0K1, !XX_68G?$1A3 MK.<82&L+VBD4Y_'=.H+P6B.T_9GW&
[P*;@1"U9]Y)*S/UZT;O@M!I>/360. M"F%# C?ZSEE:?2QL@D:=90%9/PX/!*7?!$8.<)>Z$%@1/*7X.2_@)LBTE1]H1 @# X%A_]]KOTNV1>UN(N[^6T"D"N?+8
MT^Q;3;+.!@RPM<[0+O,T*N$#=NXM_L>% FW_\8>1[7QY\%NX!EZ1V5 0$ M*N-SN.ZS9 C;1:#Z/A (K:2ER'/.S^_O/XE?K9/]8-X3??;*_WJ.*WI-_C MOM_"TN]B@?]IH ^_8P,V>U0!>#GNQ[\AX8Q'B?"^+MIHW?
U|>O]Y6^7UQ>+ M6_AI/QV !.2;\S$M?S]_3->/U>S Z]71U\6]@16UAMK66NHO5Y T+S92VFK-MI]]VFTV"@B:MWHI3;7=U51-I@D5"C|O]4Y:KNM]76M>6C(K"7ZQO2?/8@^MBEI4"W&>T;SVNJ5]+-
R";BC11]U5ZJV.8,W5T Y/R24]]!(5ZMV&>MJME/AO MXL+G>EVM-3*]78D*,Q 5VFVUU6D5$16*:UK$NUU>?8Z/T7/9'!EM:'.?E8@F72.K{U'DXU'(A6L=FF MDYC]K|6FI5F$6;|]BB=Z=8CV(|+A7Y3-G6Z7*1ISCO*[[F&]
M=FZ'4=->U]G0Q@9_F0,[4;$NS;/@IKFB5$2A"M#8R9+SZ.265&[(-Z/&?\E_M?=1K2%R(3)272)&_=;R9Y!($H29=L+[8*3$+0"J H=1A>&%5^=WT)]B*+)4?'?"H*^[8L:48]4I(9=2AS/-F7-
OYBP&ML!PO@&YE# M.6D.)TZGFAR&79+Q&=%C,=LW-6^[6^Q@@6M8WA_7-W,*^>2L^(M6]QQ1FV_$:. MU1L.D=,B&[D0'6OS"RV*7+MJ[=LZ]VH.>7](B3_G@7@NZ-?=;Q%K&8>M=L*>MF*5RM8\LJ$XX(QB9 G
W+X^X+-2/!+KGX5;2BYP-0I]&\2ZY6YI"]> M]?SQ,\3]R%"9%C&4#ZG1S,8<\|+IK-X_X(X-I@H^K^K+$V)XI[0>8?F MKBW^D106QKOP# S-+ UN(0VPF""XTB'DAPCF,9AB#BV'H:BA)O+AVE2,7S- M'='HH47]AV2PUH\^4
M4 K*D ,3>'!02&? >J.VW_PPM>06W5ZH1A2WA,VF'=?EX>"H?D2M TDY]X1V M]R,D-ZP]C:@QV58S_(W11!XO?4C)TU?7C%+/"S)"N;^843D7AZQ<(=D]+(M1^2IW4]WL:ZZ2]@"

```
8ABG.QLC,+F2=@^C#@[A*!)S78GU%S]/2'$X=&/-"O M[8T<_F#]C PKR9T\>(EK.H$7 @"MA-B1HF92 %3=9R4>SQV.?Q$OL(& 0#W23-" MS(GCC.2].$,>K<>-^F,1%@E*F1[OZDIP/ 8.\@5ND/BR:1-(Z'1@Z^AN",V, MS2LY^
+Y.AC*K>]ZRN6EJER"]%,ZBU21GFT'-%&'.]S#BV$W4SA8Y;>P(MF MR7Q<=^8^=QO-]JQOL]] *QD+-UD;*8$ZTZR'!3?V$/]!K="?9075O/XV1%# M9<\!-X[K#Z$G#0 SL_3Y1\ +4[,5<_3?[\S&N\]T
MHP#Y__G6N[Z_O._=7_[C0NE=G^,'7^7?YY?]LZ\W_6]W%WVE]_/-MWL\WF\7 M]\K=9?^W?]AT[WT\]GZ4GW!"B]'"'Q$1WG] .?Q!74H&S."B_6>TD/N2:WO_T7=1@UKQ7=H+Y[K8LQ]]A:@<
M)RZ6G+9DX,#:MN&%QOG(0%X05]3Y 32#1A$V#./8,_NQ(;=Q?Z;ZE0W;72& MKK1:.-B&=\5;,FB=\5;DV>$UNR WJH#D4EK 7W5P_&LN$ M&[B0 Q1(Y+(?0ZBB+A95\PY11H-
N$4S1B4[Z*1F$PLC&M>7.>IR_QB_W8J,4 MQ+?]B[.H?T5@A5[D!Z%YBKZI=%H:YQ8_,HYR!#UR*O1Y&A,%>P[0[1[K'[<. M$K*%?X&%+:PF,1 /'">&>-'WD4GL2.1#61(-V%')X6YA/PR$ /9K@J-[I'=`MZEQX:1$V)/ EX5-
Z#O=2B("<9R&A-W;=<]A+[B%IAC9B^$T'OC#Q;8;$@BX M1G)+T?EP;^99%Z9@^1%''_O&E[ E4C)P^%>* / @/?MHG1M^XNGD?L2Z\AB. MC/:0AT?'$7.PF2=#_XY\CM]6>;".#R(;%@#OY7UOO_U\55FS8-.B,N^1UD;K$ M6(+-
K#=*94-!"CU"! 0H$]AK5A<7D =@H4%(91L#(0VY3 F@8!U#$1%T)(*8/ MX1T8Q=MQ/=O#BIZBF$DU0* KBB#OFAD-?RB4=?43EO#)/OFN3G MI; 10155?)VBIY]SH3!.)0>3LNUT0-.F2W"AHCFPR6&^5).$AL-[LRAR$[L
MI^.H=)FXZ>FB\RN6YP0FSE1&.LA2H,A-7[CVS??ZR?OZB;2+8SC<&U)<2SMM M--B&A'N94;B5=<[XV"V_?+=R9RFD0DO"S!7Z6GBR E-H\1/6:WPG-D$;$H8 M<_):^1+I!^&^OP$.-E[983[ : <;_0DSGS>(.HV.WL*P_ZO'$6Y?
F)S41M<6 M0 1-:# "01, G)-I.^(T(=36.7S\TZE4O$U8_LF6WG.Q'H[?(K^E3_'!&69? MV3(O*UIP@#]'[&+&&?R3!W35/OG MZ%#P%E_'0A0\!I^NAGTOI5WX[B9L[?P:Z"UNRYL)WAK(3OSN^H:#KXW$](@(":+L:
MHJTBO[CX,3$')]KH(4+OV?0N1D_9!9;87VKTGTR17CN3D+^E"K6PS6I ']/E MC?AH*_6?MOE>>3%+?OLLB'8+&8&Q.5O<<<= OD43LP?]CXT%!22[*$IY*]69 MH1MA^#C]P_C1T*H3?_KN7RMG-W>W-7>_^\N;Z4.I%@G7S
MM;1[6[';GBN>;^SG+:V]O$;;CJW[PGO;C89TKOO&1X6WU L>@.@5KUQUL=9P M.X:+V1+)W(99EYG$N_^]MTLZLMX>_UOI69[#A0^8]\DA:&.*E?4;R*"?*Q6 M&X.FF2S'0[F*QVS9:OLV*@^(E2?^U/K\_P%02P,$% @
;X,.616S-R"! M0@ ?TT ! !C=FU?,3!Q:6UG,3 N:G!GO;L%?!S+MCXZN$,@N#LD! CN M%H*%D('@GD'"'N[LD 8);@. $=T)@< L>W FF#N\/@ PPS;[+WD7WOW>?_W^>> MJWNO,XOIKJJNZ57K[J6^U55!_$2L .X]4U11'*"@H !>
(?\!$/, >0 &.O) M_^47$P,#$YL &QL+" L>'CX.P?UHJ/=)[I&0D+)049&2TY*3D%"S4-/2,S Q M,9%2L7*P,K+3,3(Q_NH$!0;3$QL+FP@;FXB1C(2,!=\*$'!T 8FP4-U16-!1F M "HQ"AHQ"[(P H&"@_"8
_G;@H**A8V!B8>/@X]B$;@:X!4%'0T%"1SX]4 M %GKCZP'H!-CD##QR6'>UWB-Q>Q;RA\<_P6;Y4GU=[*7XQ!6 3.7=SBXY!24 M5-1L[!R<#QX*"@F+B(J)RS]54%125ZFFL.6MHZNG;V#^Y[V%I96UC:N;NX>G ME[?/^P\AH6$?
PR,2$C\E):=\3DW+SWK M_S$P,3DU/3/[06]OOFE%PH #>7OQY_J18S4 M"Q5I%G2L7WJAH'K^:D",CL'$ATDBIX'UVOD^,W\P-NF3^"_5WW%8!%Y"R,Q< MQG')6057V4Y^]?:,9G]-L7?_*\W^H=@_]0(#\-%0D,9#(P;(
&YY(CAS4\A M9 -;ZUBAYFS$-C=D6^GE@YYY8/\VR/S/5!+\N?O\N(!CTP BL@]LF-K:\U5?H M:/K.6YUV#/#_E90&)]A3E2#M^N[G'4Z\3$L2P77 /83G;!5&3P3:+IARVGM
M/ANF/HLFTP\F;5FC!-5[6(T5OH;%CHPJ7^'L1%\A@_%C,;U!/.JU_'!?.]? MVRQ$]$=%+W[<76"JD%*O+CBQKV_XL6."UZ%EPLQ]5N%O_3@Q8JRT7/>(-:?; M-&.XE>G,(@-7SY&2"Q[?"SEOOB%C$;%WCO"HC MN]I8QV$;.?->
[^6FOK1-'&G5>A+7#\B*BHTROL-F/\A#(WX,$B2XQ' I/Z) MX7NCNZO(%IF"O?%=D,1\ZV*IEOK0Q1=7RN9&+5%YK)SK>T"]',*TB&U)WC5C MWAXXU;<3^H@)4/0>9%. HKF'6H^\Q620<_P>G Z2T,EEY J-
+5Z%PQ)^AFAQG/7O'W]MU,Z:SMW;9.#BD_F M%2E)2.5^YA/XSC-FIN(_5VO YEZ0A(>]Z^Q<\GDWPG3KUR .?TTKGM M6__^>-0C+3^/,0(66PL1TF5A9<79^Q+D/*PUPO%/U<") S$]F5M(; < V M27$.="^Y/I75?[3\@]
[$L]]U[WLM,)'K"V2V&X@'S3$13O=DC)D@:Q( $H>S MU9M]MWCBT_M,F @$\/BD8Y+N3U_TFNR<;R!>-2%7B]/'5YB(D3[OYRRQXXFM M?,N,4"MS7Q>%+--.YTT<)="_[U"9>^:9><-U&_KJ1]L,*K$ :)V = H SRE=JESH>M?-
M3+A_J1S;<+D.R2-/XL5.\R0\YB:_UA>;BR-_RFC(5L MNYD-\"L[GS',$+(1J*4) O ALDL\H 5LOY1X^,/E^)MI3HQ5]'.HT7)?25\SMP)MMH\34:VS'!&>89%65LVG?. M4Y:5$FM!4M(1X6^C,W+
["\+4B9C3MY_>:TP2#D[PQ$>1O3^NX1U_'6"Q6D-3 M;QGE,T/^92&7ZO%7X3$V$UUW_N8['':K#W1_0$+.,<0]!<7P7 34N7:EV& MWIH>4UQY^M!Q2QPT]@U$(@%WN)X_ZIM]M["^8^W'M3Z,UGO?YA)LEW+/9&?2
M/UN]HN5#EU#-/>6%HFK RCNY[SF$ Q&1P[&O$\P,P_(LWZMN>5!?&,?0X=PB.!M 0D1FRT%P6G=:OV2L$VW>OX]TO!]&YN50DHT&:FY2T-VM-\H+/]D5"'8,
MTP#)$2L71!_!CZC=#X\B*=W73+_N$5NG$.]RLEMMNC0>OR-]S!V3-/_+>9E< MG/%E-F[3-^3@6"'A3_:/%8E[I[H)]$6O-573S!B1/E7%>LPBM;'@+3<2RS MB3<4.NPTF%<<$AGE]IM^2]?R R8Q)547.<3W M8-
V9.C>#]%L=2U/!2:?]7OE1?GT8G+CJWCQHL;9>9\L7M8P_UY%%DOZI4P M_PNN7.A171LCI#>S4BAD)MGQE?YPP:FWZQ.:FBIS61HW+0OEZ6FJ#HO;G"PU MERSQD]((%08B E^3F(O:$^;>4[!A:LNW/KP&P]
$@'2^.I;I@HM/8&2%.R\Q M3R1]2NEW%WN2DXVLJ7+U,DQUULP,Y.L MBL8!<EX5Z4ART"U+VX;#I,OALZO 2;]GD(6O1)&P;=/A36[W;G))7GY#O%7 M,AZ,H+UY-9MK0^V?@0"0.;R9A(E4@G>H T,TGT^.9+[E?[4@/)O
V/&0,K>/ M5MCU>X\ L0+ +XGB@Y^^/Z1="6)<&;9AO$?/%#-\]32Y$8-7(3U$Q=R412_Y M;3A$HB[E(QQ&+#,%DYYHO31[O@ 9"Q^>JMW M(ESBB_=D(B.Z>N'KS3KV/S:+D%O+H06X:--0I6ID QHWJVTA&T[L;'1WNDW
M^;-K( ME2G "*@93(%ATWI@JLD5HE8%6GCYUC:IEM4BLP>I+BY4^&@N+(U@. MK/WYGB_US@'-\_KJVMI) W00,49=#*KPM0V 1O8 $XL4946:YH3M!]8(C5^W M@+1_Y %)K!.FY^AE\GL-=_;O=3FX:3^UE
@W>RQP7NDSVA$@"(F)7UD&[$T: MJ148=?F6V.B2^[BE0-)W#7$/,LD+;L1KU%*]+2Y6<%,13K?M5Y0 M(93GSCWPX%8-3WZNL.;QYKWP GW4E0U^N;<<>%0C@*I2SAPB%"AP5;** &9\ M0M#:$PUSLC;@R^H9
L,2:0TL\PA!B ML*P?IC!1R=[>T@Z]S23F:6DQ+!VZ;\68X$*(Z2UT]*:.%0I3GO1365W&AD?%$?S E:[_SW"1ZC(")ZFHKEO88C ERIM8"B2F\ M88TSWO-9K&A+VV<)A_!"M/\*&I,&5M>3G:9<78T^"I$37&A&_!/F-
FCT">IV=]IVD/LB MKCW]DO(C!IWZQTKH+H_1%;$'^UI<2_8DHWE@Q9 M;V8ZZB"]/^IS' E=RNN'6.A92=LR&'XLSF76DU[K1BE&DT]EK3[[FDV3/#]] M7G,QFQ\E'?)8F5YB]^\N.)^SD:*_%QI^LKW&T8-]JKM>9;
G(N#E"OS4 MGV7>A1,AEB8L(ZUB%CF9&-NJERQ.]%'PD.OEB4=]JCZ)TNO5!X_8DI795!== MM1H9F_E7E'5$&!U88CP@ J8ZX[(,9"8PD1/%^#POD&)VQ5)=[*JA% XYY=N> MN^$NK*1)Q^48YNM7C3]>N(X$I$3LR>#
:&L2;RFTIUZF,M58_+)57C*>K2]VAAH$ $ [^7_*X<]?;>DF\7'B..R MBV>F(&L:'[4*?$5@" GLJA !0D1B!0UOR]*) #8IF,;\2ZNI],$0?T=ROP1 M;W[@=N6>BE5YY 9)6Y\03TMBO2XRMAYVM7)/QY6.M15+Y_E? 'U2,>]^NNH
M@%V.;$>W=0;!W/RB5$Z%'P\H MP7]<&SFCSRX9/B,7)P?6.!056C5I+^6YN'T\>%5G;Y%LWO#(-TWR?A*6\TI\ MK,U%$R?:AN-]+Z67,> /XG55@7!;'PO(<%:&>;]9.&VEB8FXPYUO'NE>.NL M.42:AN"9L$I3$ZAF!P7?
WLP2(0C2)$]3F7;%8-8TGI:MRE@Z 8;_1+CV8=H$? MWLEHY&&MX<9)8;5[8*G0I\MOK#\$+ ?48W+J*-!1XEPC;O@C -=H3R8N[,5'-M>PT*LM^[7U=QMS!@9F,LU"4]L>?YBO$ZHP?.F7>$V!EVI!DPF;UZV)OJZT4,8!(QU9"
M0Z5\5*H.A 1!PF]NK]T@DG'DBYMUD^_07"2BL@T D/@\6[!EB!]!H37X;*^- M,K;R^"1F]#M9SM%:\U+7O;4AF' 5P!4A/L,T$E,\Q#*4*ZU_68=(8CF@7*N^ F#X+D7G[39A1EKG[ES&S_TT
M4&0.I>P;B)#020)XB71S5L'T3]8[P 3I>W7DU"Q&IL 2I4+)N()Q]:YGE&] M+T1H,X*S&LO;IT,9X/>6B:V2+R^;9NIS,2G]J8O"]\C9&QNFCIAC6VXR M\VLGVJ_;N-B]'HD&.FWW3\)"[ )(HO'[74TQ1W"/! M\Q\L1EU/@Q]?
2_"WKD9B_3YA$5S;[7;&ZI_E!-+WEUBH133QGXQ1%A7@BL M<)\".6U_=^A>;"=-L=M4%7;4HB1T\'$/T-2G?NXA0>"6+QBUS(>V09:T M2N-(8N(UV;7$=@N[7[&XJV2P!QXI<9*BHAVZ^C!:!\",#'3:"NZ-KQRL=T'
M(%AS,F(0YJS?NSMT2T<31R^@ MTHE%1074MONF-[&DK\*Z7@0\^K&]]#Y!3 "T_A[XGH4GW3 WBAK[TKK7TZ%Y[?A+;[LGSG,_2VN&8._K&]V"A!Z(L*X%B$G*2 M9N\"O ^UZ+O%>SG=
(H"OZQ.R"$]][&>+E,8L5'I,>]/D8&A+)OS@PSL*C*SG?.BO:"U1FP-C)XQL MZTQH(72@F!*ARI(R@Q]E1OIS:@\-Y_*.6)L> )+Q8F"Z31]R]%0G]IU7;;S? M_7T5)][,N#>WNMQ0#AU,+ =8OJCNHN&-%@T@Z-\WB?
]^X1U4;+KX&.,BUS MEV)Q]Y./"?MM MX]"IM:E:?Q?O@P/P\)]GCFF],P$Y9KR5Q<220!Y?;"*!/E2.] /?$[3UA%Q9Y-FI!>^6+I%$EL'H$#8$-_-%*N9 MERXIPIFGU3[,DC$NHT8;GJGWSMNMX@.9 AGHN*AD6V2)6XF6SU-
=UXQC]?]C: M=0EF_U+699<P0)Q@*F'WEW-3 M[5-;E6KCX^%ZZ\79X'A]L .759SHB4]__QI'_**?+Q*8V.H'W MS9O>1+RMC\$^>+09\G-XBX^DQ4Y4EQ85^/K8I$ E.,YW#"MBWKK.$UQ1E^*.
M/VXJ)YQSTST08C@@QJE?'8I^_59)BLNQLUY)[83?^M3;DT1H+3G4VLL]Y6I MA&P^MV!.7IP#-?DR>Q2"IK8L2P&[<._+V3XD]BO^1^SXCM)3'C7!(Z6(!M M(0"@@MPV$ &0+H+?D'I/(@#_+-
X:_M/B?]'ZG\5_VG7\-),C6Q[GO<+>:P] M+S>'S>"_D4,5)9L*HA?E.='K>W4R#Y,/*GN3!F5'R'0/5=N>GFX,X" =^M7;F3LI;^V?#PA\6?$+BZT] /(?2>L8YI;Z5POP'A7<+9O&P9:!!M(_4S]Z MOX2?%?4'F%85T XVZ*
P*6C>FATFM:0&>C@I=B6>7Q2(V&XI9AFE.L=YT!*5 M"'I)^H9Q<8]KM?W,TORQ,?Q!0OET!#CF64H=]K$VFGT-^T+BB\UDB=5@29=Y ME>AA_/7DR\AQ?I/T]-3\2EWX_66<:W;@H7:'?[?;<4TT>'%>
<&L0<'7%#S^NZ@]P+*]@/3DB?UNNH1TP MD]UT-]3>LGO*D+*_JW(Y-S,C.48.443/DO?#X@93,;/3C>L4CU\C\E'HWR3#.+PQ M&C3O<6WIN;FK)*BK.9B=B[:P=.<^3F0R.1I^7K^C^F8]T'"VQWUO=$U"]Z6 M3C ISJV(?
*W, VMMHDVN_AKE[=_US[;/G8@!LAN)]9!K]]_$S/EVM?@\NW0 MPB:M+3VOBQ2<>>!1(IBE]79TR>Y^\$0<%6G;:HYWY3'J?_1=?[\XM*O+6W MWV\]0BM90|G$D
D@&];C0F9G5CM#/=]>2 M]53IOZQ]EIA0!3N21'K+BANY!/E,?'I!4^0 /'9I5 (9H6@") : M761%??+WKV]7WGVKQBQ)>YEO="$.Q9U\I-Z_YAA2G]XITG0&MCR8/[$KNBJKCU*6"6F. M_ZDKA@#@=-UC>"C\_/+]M?;@
#6:NC6HCFB8='(Q_S3$\GYV2 M9L;;"MDKVHX<5Z7,*=NTNO 5AL?Y?(E.H-1.J>*I9W,MB?M$"8"+-*OI1A$ 'I? M [ MO/[=V\.WIRY1-WX?2BXEO'*PLAE, BT?E[2S\'?Y[,L+PLVHPDEMST',\YA
M)2DF[#,@=H8WOK9>P\/O#7,\"#O5R^6S]GJ@T7\:7[=ZDU3OQ7XN.()7F^8; M!#3KKMHW/A?6*7B=6OY%19O4Z?U&'R/;@16:@.IT_K2@_I(U$Z@EW1>E#!/*\F:Y,ZD M^;=\Q%]X6OF2#ZU!R2-. 62]+F(]X4+9HK
V827]C>ZSN,$_]YXP6=ZX+ MH]2Z%YORTG!48%PL?*'451_7+CR/4^S@X7^QD#@>>*\9Z6=(D4\F=]X^XV8,8 MRKDZ-O$*WE/NKSO!TE%I3 Q]V*^ Y]-K.N=C16C-*+L,\LEB'_)'D]%2]L*-R3UQFO
M;36C64!AEL[D37'+@S+$M$5/^7/-^(E4=:VI$4]]]#&,5'PT_L/1E4J%*?X% ME9XOM56B3P1G(8H"J?[_(NCFK:X^$((U.B8]5,D2[,SE2)/<$I+LP16Y&>"- M0-AZ:=$)Y314>FWYYV"[=@0"L,R<9'?XGFBAR/0HH]#
<]IY5'8&W4ZAR;M=S MXM#$V.:0O0Y/M#2'D++*QB($P%K>P0S)CQR&5F]KUYGZ&?RE&K?)6D>4R&Q_M3HZW;Y'"T_] /*H0;XS.M$( &,2 A O*.<+EMJS.X> ^>G'-4Z(C 2"_S(> M;_O(!L,H_B/^7:S[-
L=LHR3HA@89*\",!K<@1@PKL8+2\W(2(RIG-<18$"M#T^C>V](4(D@1WZVA/WP[$+$!)[(EIP^W32V9:< N[SHP.&I:D) K6DX$GT MAB0OR$FN:)T?83RM47!F';+\%'C_G$%N3'Q@V0,C#&2O/*BS(]N\T*L9FEGM
M)AGHG9O[B)=,IH2ZX[&-KA("P$R=W['+F1OOBE1#^?#O"%EX.?1=E[RM5LO] MEA2[EYPK(?D6C&\@4F4.#::T^DO&)P;I!,+P=8U(]]K&FE3S6\G\5Q0_;MM: MO?((;$?)K.I\A@S4AKN47#DUA^R_\2^[29CCOA#%]B"?
CCN_N">P8)$S1"3 M%M]7"U8'?*PK)X'F0]Y/;6,7NU6.@G/E?B=E0$MW[AOBS4XSG"U4(K$!O[RV M8YNX7?'+U*K"@IR=KUVDI[F5S#F?U-;Q$N*$W@=48=W&PY.#RR=K"$G'U.\EL? MPC ]2!O*%*7
[[Y=W1=I$'WNKNJNXHI87"7BC;7U#5#AH_L6+5>.2@.\1W M[R>.;QI&=;=. 0^?" 8.2_'5CN6O_>2]=47/-*?*_;K5G;!RZ@@2:4\M3+K MD\@'W-Q'N4FL9SQ?2!0'&]I/;X=G7<;.0.RNFYWA=1\),SSJUX.Z\O^,PL
MOO#V>S3^1ZS9E<35B0G2R'(-'S,LW0"%V3+BUJX9#GKN%E.J"4E.*.T Z MPF)/1!UMIQ!9B&+V?#PMUIUG#^U^/ 9(@)1##@!A$[]$RHB;83+]X@[Y7/T5 MAGL!K_7H<1\"^>*OZ]\HC(%S1IR)DYM4OTM90X$4\!
(H6KT5$C L!"'HL M&"%G)=A]W%-HQ/9OEAKYIVEH^[KQPBFMT_RB"_PSCTA,N=3;3LDW"EVI3-9I M;][@3D'L1[*%LITQL\V+]/VSUM]4[T[@L"QHT1ZAH:]$.$8=L+9,/&7 0'_J&E&UD@4+\]2D\+V+\[Y M4<]6.=-GUE80@
W+BH_S5Y$79)$KD@A )Y5MUID1-RSFPOF^> 1G;G'<7V&W MY<:&NI/G4LS;>M/'+#75(.S(=<K=3>X%^61K4U+[-HV.'=BW7"4SAL-W[$ M7A_.TO!5OT-$]>T#YAKEO$W[*"]17)42YPD5;FO&
M.$%>%4^OYT5E;TM99P!E]KZW:ODU4] XE@(*G@Y;?A#6L/SC:])WFN30.W 9< MENS.5IT_=;L1[89L^T,9N,(P'X& G#[HDEZZQ]Q810!J-WI\BLP!*QG0(+ MK9/!]]T%&.I3R,?@[+$\'59DK"2F7%&(-\@[. 8?
QW>4\:4BM9O"4W(I3- MEW0PE9.4!X-;,;O)KP%UANBQ?5CPK^4"-I?]MS,V,9 MK OG3&?P^ QW:376N0[1@O#"/H(=&UR1\YRZE-E258%4.^$OA85./^70:3\" MH>XFH="B1[KD:V133&=,P6 W#2Z4D:F1-
2SUAEWC11<3Z6S]>@C/%_;@R]@Z M(EYNVWO);S[VY^I$$^&O26T]%9.B;"T3NM^]E68S@EI]-$+.!]D7"Z8K$PO3 M]0_!5-KFW@'FI\H5C?[^^XME/=(47F'],^X-W >%,[P'AR\O)6X7=89S+35$
M;WF,QU5_U'BB!;5Z]_@:_^TQ]0T*2VSS=[^9FDA/O4"-;3GPPLUKY B6I:[5 MS51:KWAYIES=-'GN9;*E2B5$\]GRJH/^'&6']"7^(4W350_W;[^EN$C@FK8-BS*0N7/) M1O*,V?]>,"V_]K@,<&KP^$V-
/CPW[T)0PL\456I=IU,5_*EPWYK]P/H4_ MO8RQ8+BP,ZEBGV^P:\7!,E#WI+0/;8LQ>-C@A!#DG/L3/&]+SC_HZI(\,'O? M6T/14$:@7I36/"8_HK%@87G1H#8M]]??&)3![// YRM60O\RD\+[4-4T$=@[ MW;MKF7-
SG8]W5LNG.*97&PC >+0!*!*:.@E<-?GH3]]A/(5D!X_$ZZ4$TO8 M!TD1)(M!0P!RV2IS&QTI ONNPF0.& //G]9^ON_P&\:F4]_\W47=1Z)._E?4 M^:?S^ILW4T,6_;0^:8[ ]45QVMBMRJO< 2@+YK),;Y]468@?
6F\;O4@#A4@&$/Q7H1[K3]43F30,#)UMS#-D*M$$[=V,\) M K*T"$"P8[+C1PVD/Y6I\NHRGI"I63Z,KBPO(6MI3AFRH39FQ?]S^V*U_]\$P,VE A'9_HPUC\?BP[I.!?R MU(+8+!NRM>CVDM7%B-JKESR@M6EXZ"0G)L]*
'P#S6O(DMIQ&PRJU=58+ZUT M4?>^33R6QN3WW[OX&P&R'YL5]PSL[\E# &:17N4RT^U_E&A)L^"V$RU>IT]+ M15M"#M2!]'8F6WS>#SO9O9BW>CS@)O ]2.52'DE.N3/)^J=%)>6Y8=2Z1
MRGRZM"H<5;UB21!'@\:H)2U8WY+@+W%PXY'JB3'UPU%FWC)!V/S,3@OGR#6[ MRJ9F9=ZC%C3-;2#!Y4]V-&EK<;2&5NUE$: BY?_8U]20!*H_;=7^3V0FI>0B M20A;X'(B ] H9*/#(NV:I)A,J_7\!Z]>3,%@ U!'>R8$ /%4U-
G8)X!=MAFS? M?0#"/R8G A85]V+=WT#3]>W1OM^,--.:N.Y>NBR4^W\N3<#:5M>O$)H&M2W7 M+LIC'F79!0M] O=%K511129TK9PL?1+1-.?5E0NKB\T%]M M*.>\6="@&=OUD_]V9X+$0%\-) )''->\$-5!.1][']O9%UF]*
DYO)Q>A%0 M>X!5CIP"WCPI)^9Z]2>!83")]2HL!D*9CWF+A:-T8YGZ#=>L +^*?MA^AF,L M^ #L&>'.+;*ZD.(A3=EDY5BIMO*4N,R^?YVM>?UK;H?OY9Z([NB2"+1US6.F MC>;[2B;IL.6:<8B83U<;<
M.B.8C6/=3K092&4\WSH]D^[LQAPS(,2*.J+T$M-Y1ZG")9"XC04,O;UT.\D( MG#NSIAZ)=2CDLQHFCIAZ M%OTHQZWX2U-](ME\,M\=7 M,* C\?#^2^#L)],;[-(GEG+(0$7REP)5G]\3\3&(<,'=NUFSXRO?Z+CACK A M4]$>!$!-
LO76_R3&MKJEO(Y5H?_'XPT;NC%]#[%SPQPGSW&AE,WTX.8A&>F5%G.];)# ML£XKN/BXG\(:QX2?^(3-F#Q1NG.)(<%,7/5W/=A(U ;MH=&*>X^'X)\R8QHW M_^0XIB_-\+D,2X$TF, ]X"2?663:V)Z7BXP2$M@T+-
XMIN)6%B:VGIRLY3)^[:>03W@=3( M&A'ZQGF%SV?5%4OS_SH_32+_D"Z7Z+6'9PK"*6^8IC046-3_%>6L5.W-,/9R M_?MLM7>A%T8 8F,) W\^10!VP]U0Z:;INA\;@]6LW4F&'<4%7107Z92_8T$*
MD<%%3ND]&$8!#5G)5#P)((/)Q[X8K]SD]W\'EX)K2&?<\Q?X?E&Q/_K^ICU< MFG(OB^*D/KIPQMUVO] U @$8[#3HS\,M;5_70D>,=7?I2 '>$8=]S%* 58D()6 9%^"G & M)/63.L&"<7-*LWM1Z%;7SDH/7G*5V3\3]N*
(I<3BZA=%.R4;]N]HE6NC]&I6 M2#2M;SSAC7"8.+T\[WV)\7"SDW,_QC#;YXH.F=SA@MG2=P/H)MT:C=\DC,R( M4LWFD:GC,"19.12+O#S*P6CPTU]@4$:R%#DAT,KT_(HQ@?\CI'G',%QG*Z*% M=VZ>(
W.)4IG>\=WPMJ(P!%HNWG*&HXZ5H:"NKO_LO.T7\A+9-K'K&Y7?FC M:\/ 6VWPE#Q>166%LS6I<^T7 R7BQY3]F^'?10W.FU;]_5]A(-+]F?3+LM> MFWWM0L\V2Q:\Y3P+W9U]RI)U3*\::,$?P\*"]"XK34]:XOM@1DL5!I?(>
[(G M\EZ"AK;TUN/EAR#*'@_[#5T>;],%7/B"O+/?ZW9M=TO49D=22#_Z%S>>;GG M,0O@99#^.25"Z^M]DOJG')SX;_GH+L/O+P[\AUW3$ !8E(\2DLU=]VD#U_B0 M9*Y7-SI=_)"P=
8D%,UTBM?.\T+XE*2."KA@L5]2481_.++W;M!?_RZ_E"A M4+!3KG)0M#Q]WM&[.49Z[ZO2 "[(4DFIS:P(D]:$YM&"K6L^+@Y75[QYU.<# M38E3C*8?B>HVF(+9%U:8OOT":C]SF/G?(P?'4:,K]51"KX6=-M403_K((Y*0=M
@W^['E\Q9DF-X *BFT_:S2@I'HL98YOV]\^4X8:]E]]JK\ M&Y32_C*4&H]);-(48W/4_"L462>GUU7D%>ET?4M#7WGAX]&]K " -CNVD=!( M9XSZ(%[X>#YXKT2@RX[;T2LX3>6ED/5CHOZ"]_3BN("%ZLES/&_8(<\@,,*L M/0 L],-
UH3%1Q[6- (0<.I]?<-?.2?*M+/*?#;;6>XRMNC>&K"2IAZ,Q)-'> MZUC/XMK!_8UO/$PZ]SC5 ])-?@B.*X\R?87KHUHY=!]N9U M7-=8!.!4E5RQQIYD;_70+>4$I3Z5INLY@ M;_\E?'X1T-"9\]?_B6:T
M=+?"9]3H$V\3Q<7W]*97SKN'LE1+U$W536.OX:/6+9_#/X1?Q_%G"*\O;+47S^MR_;$$ZD0@+G AQ-)GT"/ M*X;6<\6#)SYYE!\*Z("F#KOC9*1PL["E/W@4F=C@X56T$-=>\5XQORA:N"'R M660?
$1N1K.,8MP@[>$"4EF69RCC78'E<;S.WP_5YHH7/TM+/W?8CL[W<-\^' MD-3]6,UC8]X37<'#H8.1 =QG&>9L%O'NG;.BAI*.7C!*I^LYG=NI*:'>T#MT4)B%G4_4BG4S=L0[4@.%8_,V?#> M]
RX>KV;8>D@859BU>10PA%I=T&SV2P\)N=*2R#A]QVO\#LC_%+$=P5_#*-$ MDL,>KSL!F]>OF%3':+M%$R,0#,7-AM]#QNG-(N^_7]C M;S'/FX3A6)A/?H <+O#6<%2LU&Y).%(ER' MY$5(#O%1+R77LW]#^"PG83*VMAC3?
3$@RI4&C-RX/0)0Q_[[M-HLAHE\;Q(9 MRKWR<3)"C-NWJF['2R76-VHS):N^W/QJ#PWE//TF]YC7&-,II,T?$CJ5.^7- M"[&7Y"WK08/VTGB2W^#P"$OK&\]O/:*0Y%F/NF3-FD))K[0^V_7),Y"OM#GZ
M(O^VRE1R5L)E%]W;A/Y,"&\^1,3Q%.@TP7N3LHW5ZK[T:,']U##T-)%E;*T1 M;_2:TD\" 3!U1*;%)GG%(^U(?R@YGH:I@DQRZ:V& ?_S.\5=(4U ]E?"+)]F M/(5B]&_G%?A2.OD;DO!@MC(H4$+@&3*[8)D[=-
U4V^A8@KTP>"8;,A(3^'C$ M\7VQ7I]80E9L_%?D&H\E_LK>;%16#?7HBH00E[@7M#7Y'[:U5!_*Q?*PAS. M1AQ(]?31K>]A95LCD$HHGYZX+>%6:Z]V@4SWCN.YCNTG^RZ'CM+N!">^]QEG MLO3.D*KNL?TVSMA;?
CBWSVNR Y_"DDO2"%VM##R=!&V%07[+C7.JCA[?)*_1 M4*%C)!FTL7 DR#3LZHA.H6Y/*=SCP=FXMM)_@27S."KMTN9W[]GH#1_3':#7 M60A;_"']N8P4G%PI]'56)5G@6,-^]Y-KRPFKTOG%&8_DK"FK'5Z2/:SZO,^F
M1@'(FTX'BPAPG_DY.I?H+"-^G>WF<[Z5N65T_,D;S28V[OBV[T:[E'/3_Z=I M?]G6DAGON?M@8/G=]N*-\S!ONOOM\@+O(+Q]^Q8!,!$M$WRYZ;^\0F$#"[?3\S3DDROQN2 2(P&_"V!X\*.E#OGUUZ8#[[#PVO9[T/=]
MA5)"Y>@&VFF'JG5.(L\->81C&M3:LROXYSOA,K6IEG7I3V*T=SI5O.ZX2D*! MO&OL=5)VC^81 (:,P&=SMW(7I1F+]++!PA 1.#Y_?' XXWV51T[>SB[X2*+ MT.*5:Z?R4L'FB%3#OC$03%3!8"5=>_!CZVFD^V9U M.^7B-
H\2LS30$O82R122D7@)1,(<=_>(%_>AD1I5##*!\-;5G/+U@9,Y&;U! M)93;H-8Q;^Q% 'Z_H1!Y@_\@G#3POUR2S?GGW(Q?OM]7^-P8(W(KLY9RAR%H M>GMD"LG[XT7EZ"']>;O55>Z06*QT$Z2]&^_'T*PN->TWXNA>E:8 [?
=E7H'= M:3HU]_L5QK5=CI=0**;4X2(4B3KF]V]?2IMKW%_MV3=K-^(K L3=OVON1,W_X MK\Y\/1]XH_E]*^:Z[A2Y3@1)*0GI,FOE$!DQ];N%!8!(TS!IP&L>")^$N-]E M7Z]-E \1)X-G5NVW%BJI3,0H@RKS,:FDM-
0Q&8+|%&R%6L3]NC1BCC4:VQMC M),Y1\AXX/8U+H K5=>K HJQ2]J* >A9!+8$GFO.CY5X)CB381E,".?78_.-)D)&;FCQ=MWXYOW\Y89AZK;OM.GQ(?$O#*+,7* M+-7X'?M('OL8!2,+I&.E_W8IA@:F-
@ELI0]LM,A>.O=>.G?!JA5L00!\))$R M?-:Z@_QL$%E9^^1ACB">_L4PDYU5BJ%1_&'?2-B@^8QH'E=E+5V7&B> M^HEQT4?8@S4N;O8M+]I"%H:#+*"Z547O7E.[?,?QOQC!-N]H);0RDSE,(5F,) MYO1'B1$ X.0%597#6S%*
M:/>(3M/29%)]XK#'C0^F]^'7WP*Q(;H6$* M!KAXGY?/0+8CA&PS_=TC?459I\@"1ET24_BP%P3Y#OL6^]EB76Q?$!'NZ\8O M+]A$VF(L53B%K@](]+1PILL^47KD[^MPF4.8]#;%,K6:L$8Y]X]$7X$) 4@N M%5V2"A^1E-
([5[W\X*A&K^UMD"<( MVT,B<>@LFMZYHI$PP!4X4G#6NL\[(N@]Y8(E5K+M.[[M.V.:Y6_M=R/UV34M MP+.5WMW"^]Q[*]:"?FSRK/BL3&!4T'LK1O8R-#O3Z#@\?]$SA^@F0.:&_5G[ M=EK7[.:B?
T[LC;_CW7VVMSKD[X7R)*840W]?*3*1._S#6M'_6#SZ;P6:1H[0 M>&/?$ 8HM,]3%L#5<8%TP>%TH],RYV.S;6/LI'\U;?LWA.CAR4:6:3<>\+*V M[HZ=8=W$^(1EC0/&M4C8IR7N>!G4U'0K!A2P6/Y4Y^.K6^"G;)\E.4E4F]-H
W^^^4KBU8?SQB&U$"#+"E55>(!!*""\.PE%+1] MRQ#&!YV1^.+L*'[X[J%:]V!(B1N^LR=S,]T/_L'6WM&. M8^S@M5)W@B8Y@2]K,*H9,^U97'#,\|ZIB/,VMNH\MM11B+2VNJEAH1+RY,S; MM]&^%'A>*=/5?
A]Y=58[O2;UHMV:-;F>F"^W)!/4HNRI')K8"K>:5_CY3!T) M5L@Y/NH+LU0[X>/44W2-Z:MPUM716 @8H:=OB6=];5VN_(W,'*3Q>2-..M-Z MX,5A7P$"@(#@<1"&B,'YXO/@#I">%L]]Y%0 ,JACX+A" M?6U>
N@^G(2("IK=5=AM&(VK$#MZ)K#!)C[#8]=$9@T34E$)6L'V(W)B4+,W MY_?6;'ZWT1>G(OUY[:NDG/\:C>E]&%#\Q49-\B7KE&78G9V3@]A#F'C-/]F#T!KI]KV6.E&X)5^A MU2:LO+KOM]T>G!VWA[E"(GCQ%P33-
"PXOX^\N4Y!T@/PB&O:=H4;G8S^I/2# M/8-$HT'GP@4@6\[];_DO\.+FY;Y+HIR7748+5P1";5-O62<\ZV%2L25IFQ]J MRGL1K?KI@ !![LYOH3KX17$#+D3KIMRV:86@8B_/U1:?@@F5O%&'@+'9A":Y
M1U\^:@CPBG:0[;3CKC9,.H+F26<%F^=1QTO)!#2:_N>S[]Q.]T M4_4&-+0-3) <1@!T]P^D UO?V)(<3=4B'0HP^E=24'!VMR^BGN)1\27VQM?Q MCN1"[Z-!1BMVUXN+O#TWL3PA\CT1W1&&YZII K^O]?
_W[W_L"B@>_FT]37M& M;(+-5/=CX(9"50[7]N+SHV]\N]U5AFLRVYV'Z)T1G*7W_L/=&?_CG?2Z*>FR M9?2YH[_X.@*@V&,D-27L65SB:TTPP>*@G8H6(ITGM?\-VK)D&GDN?%'=: H+
M)Z[$&ZT]ZI!/B[C.YOH,3*ZYIN;9954C_5A%0U!>SH]]W]-#[N-4;8M2-(\G MO.^XR9L=G.EEUO:'BR"OBV$?(1-9'VQ$9VF,MFHG ;1O5N^#G#W#E"_1[O]9!WW7F M*"XOT3KY[[U]]X-^=68$PS>+XS7E4/MQH.])):98_O3_]L
>1S6UBGWE!Y^O' MNW75GW&LZKKS!CA*3(&=675UV"G8R<)[]6("G%$HO+=+[=':R.?;N;3]Z]N[ M4'O9Y%>'V]F*9UE#B^<1_MQ\I_6!W6&Y&]0O4[H73S3\AS(+-@[L81&8\U:! M?A@+Y#\L(UZR\*/98!SK3DH$'N$3-
EJZ90R^C)#9W6P_UYP5YB'/XY4OPY*8 M"2N9^^5\TP1,6?WC?_EC_3Q!E/_;-]WJ(ET3DK[LH2 \3IM'ZJR"J\+JTT- MYYU_NP[)>6[ F1O\O]FWC1.?89G]S.'\NT0H17R5ILHK.S]I-WY[;P>?+"47];M\[&
[DME;31?.$^;M8]]&^>\KZECU&Y94 M5/L1!F=5Z#;$=VW&PL>'CL7E<@(R$N:Q X3[ 4WG?VE;H( 'U,R^AHE1+T8%[(D:"]W),+29=U$[SA%Y=B6HYA)N70%K!. MM\Q3&V2XO$CYC1G.EAR,Z_'?&2\SC87>2,DC3#9W=
[1GBB$"SE1C. M%Y$$55.77I@\3T:^'D5B-JQDY]>N'0U3?/_=7\;1^GW=6^/WB*KPVW0F(_W= M;@7# -ZE*4$0_#+/3N;TX>S8Q5F+$IS]AO?NPV'@N555[O]NESI24-L3&3*W MO6VW[.?;:=ETEEU.M86G3Q5S/)#7K89^M(-
Y3"-Y\[ MRHBRH8WRF3!5:F_ZS],)K \!8QQO^T(9IBLI$ Z@Q,9Z=:\RT@))D@- C#I M&XP Q/5X\6:?5S7],/?CO[#\;NE2QW3#HOIK7)=E=I60-;9QD+LO!;_&W3'[ M/&_T1].??FSBEU5$D.?;=YR_6/QCG7-K$6B-
$A62LE4A/2SX]]_-!.0@'?8VG^C&"@&XX2Y[_SCDZ]FY%'Z3 M9[?\U$4I9VZ[N(S*G[$VV"$ >AC^Q]>1<]!+3F.ZL9CT",%:V M8_.GB\S_CG#):+<92SQ/VUGY%L4H-0^RTL5.:U0::3&DG-\(2[ZR 83!20YU
M9V1NMV*AJB!3/03@.&V[.(?P_Y5BK/5DD'>) =3>P6.5AX/%9AVNKQM]#=HS MI0QV5%,CQ$KQKO4%TI'H\*EOC6U-N&J^030SIR?R7A"=D?]T$*H!>7U9D M(S/8_N/\WY8E(FW.:MC@HS+RDX,R2TQ[OE*D&]:?
LXO_;.L3V69CPJCF>"5S M[_G4:Q86EI(J=03@0[/6* R)L#;; (,_]!49I5GVM_\ M5XNLW/^D?!%RU,I3(%AW]?9ICL-S_#>>E9CE^L8]YOX$4Z8^PB-22LZR]/4* M\HZ"GL+C"XHN"9RO-?
_BGF:R;:ZUY7O2N>RA,TNV7+N5=@>O]$APS'284IM> MUXG0->00*>8V9!/NIXT4^=49?.";;VUTE&PZL.9'4G K='3&\WQC#$'VY?FN0A -(N M", R>^Q_=(Y)8'6 M/P-'^^"BRZM*EYEA,%C@>C2<['KWALHCHN"NZ#4"(,
70\,80![,)R=( Q M(E!U#/##E'^T)?UG![(45]6F_VRG\8?; <9__DND*/_Z9U \1T]0W#80>(=1 M5E/)_N#^RQ/R$$?SMC4Y[Y92%B=T^]$723NF&_^B./3^&8N_DXZ+^9<% ?LO)AL]FEM$7]=." M=T]H\FM2-AP4)_N/31*BZ-
!B4*BV@AC^THOTZ.P/KVIG0_/K$R7Y?CRZG(G" M2D'_YG^%53(JBE6HYCZECD79AE,=J_MM6GI. NCP-($3A]N<4"UN6)3Y-K>QN_%JS. ?3SO0H=B Z\M=5M>*#!:-BAQ[X#]SX9_LB M0Y($J5EDV$..ZL
FF8?"O%=*FR]Z*'-7!T(/_G@/9X/+EV:*V[S3/#,$P"U MZT C@H>VV*+GG"&)-_EOO<2Y?&DS"EPP'8CED3GBW03F!D>=KL/7X%K>2,+H M'/C0GQ0P^EN-4@K#%<5IT;@L_K];/U;:$@*XQ77_S_XSR/\?@H68^W\ 4$L# M!!0 (
&^##EDXX12.BVD .UV 0 8W9M7S$P<6EM9S$Q+FIP9^2Z M950;X_N655SOC:?^3ZS"CF)7 (GBF] M* )H:&C 2]0'0$X#\@ F!NI__6-A8F)A7,?!P<;&X< %^_N?6("$F(B B(B MDH 7<(T= )T9__#H 0,-$^_T_CC0[]!C8&)A
MX]R]AXNZ $8 W$%#1[^#TA]E .JL'^H\@$&(2<3 )X=%K&F&_65U;W]C<.CPZ/CD] M.[^XO/IE%Q] CO;WXU_:18BRZPX]+!C8O^Q"N"^/QZP)"#$P&/BPB.4UL,R?B M1_SO<$B>Q&26?[_+**!U0&KN/'2/C$EPD?
GPEVF_6_9?,RS@OV79/PS[TRXX M@(>.A@H>.B$@ USS1&APWWBR5C;G-P3I:)%*]%*M/F M7R!PP XL5,^L(O6E3$&CMC&8]M='[UBRU[_]62:'<$1*6N!A\4D846Q"'2<2 MH/6T4&V,'=_7\!L4GE])>A@KX;+)6;
(7ZBMO,>#DIU(\5P[A2TYW*@H<;2 MQ:8/' Q+%\1CRTJN!9Y[NV5@:QKUIR_MLKY(?AX\,/]ZHE+O!]\.-*AB?[Q%;5F1.[!/Q706,%.U5#UCHFFY3WY8)+#Q[.X%R M-]G8=I>G'1Q1^61(O"93%Q@?L%,3W.E(;
<^*$U+=_5]=\UHVKH_PLF[2W4+T M>E9@5[9W5!->(11,B$_S#KF6'.;!N#B3+A0?P30Z[HS.4,;*$]T.'NW?>X+ M@Y\2)EZ]:+[EGOMQM&ULH]8P(2W2+'2[LO(6'$4V;A M'B:AJP@KT;<1%QHO*U)?,8#G?
^%*5H%+!\:I<&Z\:Z"-G;:" M6BGT?%+PXOQEB&P=,*_8^D@ 3064O'@-PY52?)C0O\A#)$;)\DH,;70Q9,'N ME.IOIQ4L!]"&WY=PC4D;.QK]@M:-BS_AU&+$3<>RP=I]]$AT0.'%]A(]/*5Y
M^AE!]MV,U)CHA4+Z6^XM&R"*5=#\*2]E@I;P7C=C1]?+\Y\\MD,*),&LAN*Z MBM!BN$V2OZQLL]#H=I[Y=]!@3/631*"G-F&B09&]8?Z MH6)* M5]{:_.H9I=:JAWF!Q7:=SZIJOSCT?&%4V9WC%5+2"O*?
P8;=%2DBMG5P>Z'Y M@K$1Y]=H+.9 6)]E$+.$O:8C>>=MK2!>4QA;G^46O+TT&H/8^"[50)]$S;C0 M3/O,@M,3O4E%*(FF;&OC<6>">!ZLR(;2]I/G.)'@@.>Y.>_CIXSR-8$='H'\[ M[ $&/)]9<+EP4SZOYU;=6HE//TT+-
*QS,=^W'QSYX'/ M0AIG4O64Q:(M%^]>&<.(D)3;(U,.BDQV1Z+@F$_\QFB/FH/;K=3RIF;LW.M3 M!O?]]_3TC=97\!]/^"Q!7ZAFQN7,:W=3]1F4N"Z8<&/H],\')S[2'[QPO MA]L]QN\IU(Q(L29] YWK-
$:]\F:Q<*7E$".ZW)D8#/D[2>\.BX^..( ME;W-#B-5=<5^=]M..EK%/'K2I_I#2\X7#D-4?)W\FJ!P+<[UCO23W+=%_;@H M^T'>D ^"V\6[AF]&%*X%+[W(^KAE?#XV^E[7KV\P-29?QMRD#;>%]I".W#],N4L=7&;&UNEKF;
(XE6:,N(F5]"RUHB=.?2L3'((]F'Q MPMN7T3IGMF])2MV;]EO-]5)();6@#]RP:M_)R5"KWQ(*Q]\RMU9'1*C9@'= MK#^ZD%>]5]%,^ (FGN?Q;; ,9^=A_IK2UF=X3R>]T_>RWW*^%:Z-KSK[-.9_
MK*XKEN=]S^MK0/.#D*N&7S!FNI:?H,%L+CRUY%MO3QLL=/?]1)>:PDG>"EY>,_A([QRI]DDC.ML]YNX/H]RV)RR5^W,]#]+GQ$RGRK218@QQO* NA6*JEZP@TWB&*O_RX]GRS^_NF M 8)]9)]E:-
>U)UYE;CG9:3WCK%/;/BF\ M/\))QB6E;#.;&I[71]X0/#:Z*6YP(5*2\]2"((6@F^UI!W\E<^RL:'_N8^76\:XW*Z9UTE_Y80Q-G\_ASYUI)]J&E&0^^L@(=.DX.+INV_M\WL=J\"M6L"\4F\&P MIYA]ZKF@ %/DFY \UN$5I-
M5DS8E)'=4+"O<#DN(]:I@K_[PC(2@KC6R0&4Y M9:(*G)L[ /YXR5NW^/!,9([^,'=%O*/)*6\KO.!UY3O7R]3%(/W7-BNZ=ZNB M5!CK^MSI2!A&]KA.<-7,YU1F42&L8LGV]N]DU=L M2)>^:!7=*V4=/NG5MF!)&8)O'D";?
E;4UV$\HR;XP#_[7)UZPI0G3CBSX"+9 M,&%N[6I=-4H"+"W&]*;,2W./MX:>C\?[6]JP=ZW0=&IZR]#W3(3-A.)C=H%Y M3N">&.G;X;.GUU)3RY2OQ)]G+AEC+2N MIL<< W*]O/KCF/RXI7\(ZC0;RU< MT=%)Z=[O6#6.
[J]%1SIOK8-JHE3VP9#*M3 E<,CCKIUIOC0_6N[]WCX8BJC M[#&5>K5EK ;I2H+NI\D'@2Y$3KN@BVRXX=:C%]6OCTV#Q$U#P(T"-'N?[(:V M'C0X?AE7,&,P;U>&//'QUF-TA:M_V/>58[(M,/&,VKK-'!GF%=.=M6CERHB@
M!X*9)AIBOM,4R_PVLG/2)"U!1>Z;[%E9CL9*P936O#+*;K5%"WMX MEI9;HC_?66CD"655=LV-[GL:_/CAZYXV'#2)+Z%7.J#U85^Y0L_$?C5YC8F5 MVFNR9&HYR+R0;9XPO> ]!((W@2O%)P5[E6M '%+$^+=^[DHQYK
'+H^&O'ZT$%9-WKCAAP(R5;L^QN%X='!M)>EB_K MT.JX"%70-TW:PQZSN5%M,#^?5</8CUYKP MN#B[]H+.EO$3K-P+W4]_7?"SW>2TS,S4U\:OJ9-F!0:J(BWD!]\2Z1LW M!]L]]SX%O>U?_QF'S5GIX/4ZZG-)WX.!%V/-
```

Q)ON;TE&&2]_)(M$2FHII<0. M*SY&TXZ+"#M]]ORD[GP$VA;7L&G1>X-+GLPO(A,+V!!*2*)YR(*["'"A="PS&J"+%R,_)>IO:9D"^P=1>OK$]#?=Z;]7C>1@74)V*&YYXN,!MZ^6:T@28 M/C"E67&]6(B#U
M*O+>O+%:F0NYRZTM7IVBZ>Z43P3>=6%,;!¥'@74*$TREG56T<@?\Y^ MCB_&S9' 2'^;O8".!7-DS98^U'1EBAZ%T1]K$]8"0FM:$ MTLC**&]$\U//.?/0"KBB$4YT5+&UB,UZ,79L2$H/%)=-?A.=.*',$+YW52S MS1(Y5?
@_P]KF+>.R'@6_Z]Z6H]3@]+'BPOH0 2]HMY83AASI*LM8ZI{[-3Q MHUB91'?QA 7S8]FT>$FE92DUUX;@0^8@KU0?F* Y\? ,;\9KP M1C'AM/]@L1.^;]\"DUFN-M]DO]KJUA4!6F"9=/=S 7.D5="R[ZX;QYLW;_PV
MUG<"!JZM/U]PS&N/LX:-G_\TYFQ+C%.@-&@^_(IH,1P]C*}+/"**YOB*XH9A]]BR_/]).E^$*D^>.?! MQ"^HA0F(4Q/&8I,<9G6^0P+$]^61P!U#?R&;DI8=?22PP5 69#?O VGN\40 MPK_!L0-&LR]00+D%$L@(SD0"
[^XKG7%!3@A&90X8"M"UPGH1[=&(_,H0!(80 MW60Y$AB4UT "WX(S[C_CY+TFD]G"L..[(!B%F'&T M,BN_G] 5=%:2--1@$DD% E(MPY' [2T2V![$UE-P3OZ+2[/M(0/5+4@ KDZ01L,;LK[]T?_$@; S?5_.]3M
MRFT1#@MBJD:@^8<7LX2'A>C"M6YT"-SJ;RI+DDJ$'G\E-&R.GB!6);*55,! M(/EYTHNN>7;AYI18^;^<18PAB0,O]5%W M-(M#??\GC;[;8H-00M:P?(%)E:1 ? M^RQNT'5]GJ+3&ZA;4K\DVT,$(H$GI%_%=6F;N%PNS-
=L]%6HLBHJ4H(Q(@A! M@;G_>KC_1(00RWZ<:->7&:HU2N4C LOL.08_5<7Q*9]Q'OKEZ\0XD\-Y%AS[9T@3*-GR"]*(C7!4 \H]?5B>]4$='B.XJXE^]4<&."TL5Y M:VM\3'I<\M,[YFJU557ARWO!'3N8ER]ODDY,+Y0$TR_/(=\O-
]2P26)" !$E#F-0FG!K<]BIW+9'V_D;F^DR MR(]]S7*4N?I.1NS FG^G@]%T_WLSGAON5I\<*(MWCWR:?9YJT=CM4&*MX#4?B8:-1'7*-[HQEKV95"ST7[<_3NTLZS7[<_); MV=0VR8].98G1U5Z-PGJCLGE:)OSU[J;
[B%W;K(:SX"6LMIHNFW,L% $W@[V MQ>>SETY13]K.$3Z],F'C'NXM=77U9!,5/;_U-S[QIF=H=KA++^KL]9T\1V< MIFXW+,6NE/@Q>F'1-S3"_[>Z1$M>I]>5KR7-,MA\&BE7(:G&71[1]L 2KQ,TX3]H#0:-^A?
=O90>,YF7C$FQS+)'5V?2]_(O.% MV_WXXY&Y!GQ\>_=FIH/;/)A5;"=FS]Z+ +^[U"PL!TEG^HC)$MK0B:<,+=GI: M6V3KFOS3"KD=>]\D'A>RS96T28VNT]1AM]&+Y]5*(3-:P?^D.@UFDV>'=^W
MK[E]YA]YL4"3$;R2=';%ANX_M-M>)6Q/FUYH>[9;P!Y&)P3"AP3&4C]R/XLX M8U]'NB+HD$ T].7D]AF% MDHG(Y&>3Q=Z\B7GD3]"<$(>6 =@]@CQ]M[_L)L66' MOY*NB1//TUFL;=68'^9NWYS?55.OBPIUFOB*Q"YKV&\(#7
H,\7LM(&""'U" MSC,O+X_[Q2WFFAZ% 2M";E@= ZU\K9HK]N2,P2+6](O*\;*BI2TPBXLXA$)# M2P8*\H->/XA'Z[.CO-_02SH&+5;A36U6N);G.9QOYF OR:QYMQ8G__$1NU7[M%"OZ86E65]Q@@G"4
EX$SDMO0I5G]HM@XM]ONBGPZ\B7Y'M!]#CS[57(ONZ,MZ;$2L=$LI*$ [792<;@ MZ_;]C7S)QOOUL-Q1SZAAH^]L7B @3:=NN5]&<@(Q-@+98 2CU@==]#A3>/73 M!U(X77E^L1,(OV4DT*P@PLSI8K(Z&2E.]7,G&]-H!?
U7M^VV]WD?*]=RBZ@D-8UF6 MFH\]%%UX4D5C:DGN+U$(^_C_4[;]=Z1KM*2TU(%KCVLM3(P[-9DHT_*E'LT' M]#<,;F?Q(?;-S21D/A\)+!4V$$ &^D)NKR (MCFC>'W3'QV8H-$E'@2W4D V=)G/BE:)>NKJE64
>&7WT]5:%TGLS$(.58"0 M"I4<>C@9-8@$YC]\)XP5 &3!>?I?KDN_9U-FL^S+5* YM'4H9U*NCKR(D<8!P@4YZ:84'> MX7>7U!G>]UM9'37>5S7MR4BE);I@]4/KCP7M^4\M>FS8]5O7'(L]VIKHJ4GL M^Z'YU4]4D8)U+N\
"=QXH\!S8F7^BO2UKDA(R_+P/I*%!96>!>A686P9=_Z5 M-,;B1K&"@!>2=]$$MT57#2C,$]S,].UR5KIF"RR(=LL_+P.5V$&K*9';?9;/$ M6*T=!AHY!*DG*3V9<0@#.1>$:OZW&\HI3E0?_@9$5.0M/ =PH%270Y0G\
[DW%UEIRR&%C$-CM MOJH.=5R3C.ES(3OCT6&U-$IKU'1CWK>Y?@=5<#G2G].?G9[97%M:Q5]-97=X MCL,8>.Q-67?6IX?P1P?K#EFTM8\H[#P*YUY_[MMB]&M"DSV[=JAW'][7.*G:Y@\W/9" M:1Q0DZ=2?XX6!;^]?
V!MQOVD_S@=OXT+=5==6L_[A_9AJHG&T]S+:"20]TG MT7DNH--5.B*I'X9Y,.M%O_L\9#2*]@=UT,<"RL?Q8PL8I4D0%];%Y^Y$/Z9?!6]]E>"74^\)?8>&K=XPO]HW";3/_N(Q8)7+K"WZ.9,IQ?KK
M"3DY:>DH]M @7?(;"D!BX2Y70=7MB2KUM8^,(O:MXW!QB'8VWG3N;> YR)+ M6_A/Y:(>1:'!-N&%(F,C:+F@[B%WSXK<'XDF"4\]O) M)\)R"]0(F ?,8KJ;N;E&]B3YV7.\C>]URT ^VO%G_"L,/:$7S6F8*GB?2U$
MUS"*6M!AWUZ30I+8U*'?*7 7;PD=YG9=&\PD"A0A7*_>P6/GVZZXBP3=KXRK MJ'X:!44XJVL;GFBO)]SDD\D,4>,$RMAIA#Y=#T121"5BB:9E3$L3U8/VN/) M# #7>OX,Y%#"OM1=55AI2S-
IDE<3$VV.)$X+/9%+6F29/]]^+%HL%"D4 MM.,=/FM[//V#*5(S5CET0YT1PWLT3;<)!3+ND//5EHLB:NVQO]^(,R^]XDQO MD+D^FK_1T6X.:0?-%02=]]C7ONQ&)XPXOC&)'^4=0QNT"OO6D&Q4-1/14@'S M*\]Y*H.8K%.
:&=;/]A)176(C,FLNM%82U?R D5\D]].]Y?)2YGRWI;5HQK-8 MOKJV)L"^M>Q-.R.M]%3^K-/%-+1>^C>L14LAV1QCAAQ]JXZC%H_?:L7\%N+ MD$"KQ>)M=>39X&6-DA0A;9ON?BN?4XQK MQ?K-
:K.?,V^+P\@2UX6E;.8G.BN,PS^S:$XH*I6Y->+KIHG>(F^$H6F8$(UA MKWK,2O)O\6U.U#$[E]]C8K:X\84V31B1P$>NL0/%$+,E* ^$X&+ZNU/3>)90 M1+8YZ"D!.SLW]*Z,EVMM0IWZ;*#^0YNSA_2?*,W;M8"M()
MLO6/).F[.T@;%B;<_),"A2H=*U3]+0;]]=JNK$/R#T)N0%&E8YK8,RKBKR%\E MN%DTY3E^F:1M4BG-6VZ'&Z\B@>_;(!IOL;SC1R*A)).>,?$$_/DNI6@?VV61B MEWSZL)XTS+.-P!RP&WDKHF]T 3&>R+'-*A\]9:[N]WK4C9?
Z[%U*E-WN>KM* MT'CP1Y!Q'UE5[D(:^=THH>E:"OR#5]X3?01Y]7X'DONZ4+?KBU+RUS\9D0[(-B6L*+CVZ]M\DPE5[M;78<[E=2??[MK1G=C_0Y4^]+B<7=L9/>Q4C>'\'V=%C=Q<8XUL'&Q1X>+1QQ
M!,Z%DP_6DHOFMRHVO?\^WGZ8,)Q.G5NA1MWI]JP3_# M<"17(6/Y.I8]T:X.[QVK)GN8]2#4CU(B,);#CY^^]H M$.YAX+&80[&!\9]\&4L<_R&KL#&(V]W&,O;Z=@"]6G4U%>$>?*Y%LB)E4> M\
<*T@/VI:8]M&\]EZ]KS]6#TU,?%;O!LT]I=VGSEK,2)BU GVB(+]AQLX MT 2X(HCK#Z!S44P'\0D5^GN7D2W&\[O6*=>I,%U$)R.^8,(^R,2*]7VK>3OP%L^Q:M]+#KK.ZV:D/5]'F]/Y;.-;NT]RM%-/;:AKH#
M6L],:)$]K!.%VLP_^+8ZN W19_?Z&]Z?]=$CACYI$?BXGV7R72KYO"ZZT:R7V MB0F);Q\FV#@0+M:Q&FF@@T4(W&:\'#V"Y6]NS+N#(.VRN?;=_N?A,WW?RZX?U4FU5)+,\)OS*48_QY_G$[.$C3WT]ZU !PC3-
$CS+CMNK7\8>N5-!:X M6^9T# ET)"((_>@0?M,(1,O%F(EQQ*4M$A"X;EE(-C%' !Z:;]SG02A6V\]_M#1FHA,Q/(%*F<6?0WKK4RW]VT@@4]*Y%2:]OX<$ EY]A=\N*GUNF2.-1 (X MS:@O:2B6]#:]03'8]Z:**!S41='5,H2@B7' ;$-
+_^)NV1KOS0GHZ)=O8KZ MUC7.((RTQU2! \LJOVX/_\?M=NR2S!E]%%'V='SX.K\4@5>CS=8CAU21PLVL MY[S'(F3*TWNU,O))IGR01LY8Z?LC4$=#-0GU=^:N]]H&E!L#)P*U(:T"=+?H MT)8##D.QW,GHV7.
(T_!E^NZ]WV^)[^1^+S((FM/_$?H87]]($9VP,40=S'U M?H?6_)M38C$D,%58*#*84]A2A5A%6.V=(@YRCA@DP^B"<@-D?>QO;F"]8:3D M<FN^<4TLHYVI^NN?
QD(^^4]VE^U!6Y>70E@!\;@AMOYING|/LAUQ4.)XH>AJ>GGN>'WU"S;$HRO>/V[,]7)_8.@WCZI/ M.:9^Z1#]RP]5&\(^AMZ)\=9SM]A]N]A]B_8!E Q87D5X#TYP_"-UJ.M^;/ M3U'!C[Y0.#&]/W;2 KS9H;I'N>0[*^*"VR?
T;#RR&+Y*@N_S3RT97,GZK\ MZGK9WAGBJ:T>K\O]RYAY41+^>W]GCG]LH/S2',6^$+]\LGOQR>YOJH_4I#/ ML,NX=DZOB:<$S=:'\;3H_, I9O%G]BFA M,KK_GGU".7;/,;,5)TP'J6U1$46YQG)%6M3F)9EX=7PLSH?
X;G0"TR@E*?'Q M]P\I83G5?'8/R2]]ZE3PE+4QV,4HI3(:BI@%*P_&^]87:^%Z3Z\-/%P]&<M\8LI(R.UBY)D6NRS.5!XPN^N%"K-"M'X:M/X34NNC;VK5$_I@#8PNW%I',?E MPP=6,0P:R9.G+E'Y!N.C^1 1!RX/;]%TZ"XFS
MG8&D6X%TPX+1>)]LTS#G00C6UC!K^11=*K8X6^ G"""M!7<;OE,1(?#>KZ78:K@A\) M./ \W^X6>%8KIU/(;37+9PV+=TNVDQV8>G(ZY@]LA/4?O1YSTK_H>O"Z0/(M!S\]3M/W"-(11$^UH4.Z_9F'+?M)B KR:&[-SH$[
MD)%6I?O_*>+AD ,/]QYSY<<^$'4-^)K, 12F]V](6XA!43@B$3?;6+#FW'!3=MB+M&/T22XO3M,M\O4QSG&H,.CI?EZ@^Z??]8(WA@#S8Y8"[?=%,?]\%(/+B(K, MW/FVL4,TD;Q'@1PY)^5OP]4]Z*NTL![M;34)(]?E&X"-
+^3]T'>.K_28VW&,T+02<0S;9VZ02\0?7 M72E(5)%4*2X(N]YD>D)?=7\#\O/?Y1_HI/%5N6-4DB -A%R>BF""')*E$OP/ MNZ]D:TB F-EM9"%Z1\ OUL#BVGBKZP-#!"KOAM5I4F,B=FAG1_/NDKYT-Z1 M@V6M
6%8713I"@6=7TP8,.&EVE_2]L^F%)$3]MF__@WH$242M?D1EW#>_MKC-\S9X92[10;10s[Y0^/EZY#AMF9-NIU;#O4G13WTK8"]Q"99R*/O"91F? MQLA3\3X+/I$='RX5T^#;$9K('/Q]"N9*M=P*>0D\"-$*M:[(^QMB]?762+
[G MT7ZV1=50+]O\]]?!Y#";82E X5*-U4]#&Q(7E%9=PN>6=IW>/BL F8RMS M="B4VO[>3)BF."&I9)UG9|+6/'UB%"P"]ZV'1>*^CB$V8_IMQ>'U8W([V3[
M+U#!=S9[]X5,4HZU+9)GVW3,U77T>=%$8IMZI%7:'%D$O*]H1Y?5K=_;3=*] M.69W^_==@U]"NE83L/ADYDFLOS-Z@6A)564]K+$V3CU@4DYXI"HV69E<$@T4 MGZ)EMV2WYOBE!#)
97I],;_XPG567ND;7CWR ;AH%D"C0 <.9&%0U5/^/60P327?+ "L,_MHVU9A_RZN,S@D]L$VVIN3E"_K*[V*L/+>[6O;W=;]S>R4 N2QTT35W:'"";U4SRKIL1F&GJ^9O%^&-UP=IY-[JIN.
M2:]1E6='\]U$L26P\S+%T$]%[]WD#;X]6!C$5EB85BP_) M]&'#BTV$5(:QZ M76?NONL@2X/E@V;,K#D"ORRQ #\3-6[@/ 1']Y/U"P62FF0Q/:'KT8TZ#S^X MA;/S,'RMB=K,BE*L(>+.L1]*3UGM![GPLZ*2@=;I\^?YK\5>86?
3",@2]V< M6V"7:((?O&3,:UM$Z92R3+/'HH1F9_&F5E?5U>GG2T]RH C@,W>!?SM2",M7S]N$\%[V^Z9*^3>>"3>WH2!]%%GAWN$44#DWA/#=4V9UY--)34UP.6>HG
M!R>1P(N+;XP4HINR=,H&%^GRC>,P,"V-G/1L3B^)2$PM^ZID :U0-\#'(;>0 M5%CDN=PF+K4]-6>?L+0ET6!/0?_D52QI]56S&8SDW]6X8,@2(^*4./UA^$A(H-'5.]?AZ]5.Q6I3Z!TY+9OI4=A?6^E M6#IUZZ.D[-L$-OE-
X0UL4]26,5W40;X4^!9I\6@GX YH+GRKVE"M(Q-#/.BJ M:[QZ@)H.2-0I[/E'B 0]05]=_G%09I).'E13'I@R7%7U+6%@*=D@E"B8AY' MKP?^_0U!LR^TD3#".LDJ';LCDD]V"3$PY]M0LF68'\@PZC_&B&&PH1
OR636(/1*O% ;+G@^; I?N&&"!]>X.50HG-F<7HN9UX:&I0L0*1>O MLM8MN2)M\VG7]EX5 !U!\L3,^ABY-B8BW50]5#R$7EM;ADH9P(7H$]:<6E7:6 M4192]]OB%T@@PQ2A9]OO6N8?WL"'1R)
(X$@6TVEG[I^/^=A6^DGN$B@:QM! MXE?VCTNAE&PUGPW.!78=<]*V0%[0W_IB_T:O6FF]^?:C.%&"G>LF8K[O#FR M<-B3ZUQ\ 1Y6$S[;$GUMYQ_Q^[_IVS_LZ]1I>7\C"$L+PFE?U>Y MX)IP7/>'E;@] KX49V^KNE&)+
DZ1'KZ<58F6KB5N8760ZG1? M,/?G]96JC=W^)O[,;$ZS9[(($^<.]W M=M/((3.GUW:A%KPRZD !Y5X*$]XFTK!<^ZCH5=H+^V\]G]>H_UK38 ,W7LSN M'U:P&4/0^*4DNNS_UML*0C*/0S=1'$2!UQ;,Q-RL. ^IQIALK=&CF^N#
M.UW %'6D[\'YU+T]D'P>>ULO>W0A81%4Y<=$U!LRLCY47P\TL(^R?&N%Y<Y M;]%P]GM!=_4VN5]=;7!"H0W9]@%5$":R_-W>[+1?0ET6!/0?_D52QI]56S

(.5&WZ^\7QOG^|\X=XQ[M3QR+/?;:*VOON=:N2/N!^XG<.VALIHR0$! #S%_P-P,X B<.DB_D/X MZR_1I4M$)%=(2(B)2:Z1D9->N7Z-^CK5-2HJ:CIF!FK:&[145(R7.1G*!5SD*6"X-"G@KNY]JS.6+P]V.'$%*5Z8YBX7-M"<*.-
M149A<2%"CG#431+;!|\Z,G$T5 /XG)OCN3Y?Z.#L/R7H<34/ 2.KE1I'94!% M I%^166H")03-U]*U.,5G^ZU771!@2C!5HU!?YR/%2H@9Z/NY*YQYC75!4J; MX6NJE8))#I>WZS1UUU[$E+\BNKHTVDC!Y*,Z^<(-![S?R;?
88M2OR[5[[=%O M^[)V5.$95]8-]B?L55^*7+F54(OJ[&&LS8$65B*.(^UN= MC!XQ/C-EA:,J0 R-C=EL7).RYXX..).9#RWR\LP89=!IO#TISV")I'(6!APO,G;*:-]_L!3H@,R;:Y1]CWW9G9>5^GVP<_;_;)/ M#
(]2/CT>I1P5ZS=07%R@-7/()'!&>_UTM-OH*+--G+ 6"&6 \,?67URR MEUF:]Y>5#D.4,2UVE\!Q0/ \P;B,-K@0U62$?&=CIZM>$R:A+$1Z\9D$X)+N MM#2^6./H)VTGT4KS>:+,1[94HV23\5.C*"-5=^#RG$I_$7?@G4*V1)Z(8>(J
M;7.%8A^;-)66X<.TBA Y3D=7PZB-W#$.0W.KN]>NJOKF:;ZBIQ(R@M7M,/_T MY>P6L9.@/;G)J][UN;GI^A>9T#X@@#3FX>8G^,?' 6^GJ EVJ0UBP#C@AF@T M.?I^'2*J+&MN)KRDLS)XPVG'M+JAO=)???
4=%V8Q)V\4*V)WUM/9OT=D;\R_ MTV%H+ALT,69JTK72FRY"8JS JRQTTAX[Z2_K$(9D)CZ.0 B^;S:SS9HNZWQ] M%M0!FUYH'J;D"L]L(8GI9TQG+ETG6)K\;+)TLV)QB!4MC0/>@;7&#]O(P(P) M$PW-C:H^+?J2PQ'%RXW -
R]VU\S"+(K<6Q5746-+D=[M6#&0@^JG&HW=BI MY@3L6V0VTW7G/N<#*U SVU4U9I5YFG9(^P8J@:=]CLDXCB/1=?-$7R+C5M6H M\3*98>"I!ZES#,A3G3SSPPL9VS#@K"KLU-44U5)NC.8<@6*N+]I\+.9?"&4;
MXYF<4KL&S:ON5@_->B4?JSH7ZZ\L!UWPH4'6A39;@,+@$V+O9=1R[.NT._(] M \E 5>&+>BET3Y>6[RFKF.(W:L1<82DS$J;E[Z,I^M%;L=%$2U@2.\T\5V0S M3SSPF<%G];$F*>F/"1 -VF>TF7>1@LK>@(5R;J\,+<9?M2EQ[-
(]?#_^EO5S M]0O2 1&N@X"W&@ZW0/1YZ-.[J3,;$S]KS:SB[[\:#+ZDY>YF4/GW?N MWUGA;>&ID]EP+3H+$[1JW:28KX1"8ZOTD]6 8[*T>^_DGR3%52E?52#FP4?\ MX1'-@5\XDFR1)V0;R^@9WL7"7HUD"5^RYR^SKF-\,Z-
E*;K.<%GXAO3;F%<>;]3]7LV=]\]:+WD%U 0\.:(Y]?% M%3DNS[3'8S[.10YT:DL:A/=3N<;$TNYY;FMF/5S5ZZCJOD#5\%Q^\Y5GL?3: M#KU3*Q.JPQ 1%=Q?[OEB)G2Q/I6LQ'/4X$O\0+!.U542=A.VV'4[PO5&WHZC
MO6B8P;O2FG#(-4^_U;%.NEJ;,PUA]7[#YO>*-%>MO1Y8U9+JZ1A&M6<68D?, M:8(M*#IR-@P:2\]V_,>SE%/G!_A,IL63,I3TXU]]_O$IXQ;AC%TQK<<5=^M+ M_5\0#+D&^\O=*[W?KY(RL'1.G &W5H (.F]SI>^['73+
A>=X'E077-J[4)IZH3L9JTE<27+:] MF-'P_=X^&+:>1<'5A.*!GY<1ZXY.&4T\C3OHC%Q,+H=[=M;662V_^'9-[S4Y MA3G45A=U+W>+IXO*@7&U2+8GU*W?4>#8=86(E^1+S+.[S(T90D. 09&V/(L"
[illegible]

```
^$8*A<0(Z;_EEI9#/V#Z'0++C1TV$>W;4.:'>\5=/J5'?QN9:MN/S/ M=H='MA."&4X<,9G1BAN]["62,K/8LL?]9VZ-(?)A M:\?H]MMEB*F3_>W7S\ IF259^4N^1.SO&:]/R'ZQSZ:HOYLQ]]2TGU.V!,+T M59!=>]@9IEC TR3\3QO-
B;[^[*B^=9RKV MHORMY[.%7M.RU=(Z)AZWI9C/GX/JS"@MK96X:FS,2 )Q/KTQ!3HE) M":O6+]HX!$>38C06]"S.P].#V&E\R50?8?W_=9.WN+1V:#'<2>C24E+<+2*?
M5NKYUGO[]1952+4<7E]TZ*76]]CY!P27,@NMIQKLK/5E9;!RO?#'7:*G7^37 M*-2(A'?7CSKL.&*8QX,)^\^BJO7" PUI]QKB6!),JOQN54=MR%]FR3ZU[UI) M4@(!X-OG;2/PZ6$53"-XAGQ)]>AXIV+C&%
[5E?/+2X;OM$(%7]!)R%Q&SS? M9E3UQXK*1^.26$9.+FAV=!'UH:QS=%SOU#0DYC+?&2?=D).!"O6:0DC3]H>_MCTK(9(=R[I*HV-/,*)P_BW@\]RY*#B<-L"ZR$S]4BTD^F>1Q,S3MLPD]9&UE M3T#Z\U-X]KI]"*1.I.=[DZO-
?@ZR+/+Q678'GW:+)C[]9$"PR0L3,<) M/[G]ONM:VB$)-X+R.SQ]025LSO&,F]"!YO*.&6 Z=2Z^^Y$X&C/.CET0'#A/ M.T8ZS>[;'KMRUK*T&(G+!^+]68V>W<'RIV*B[V=;B4VL;%%[?O*,TR<42HOR?\"2W@;)NQ?
VR>853UJN&7QSJZD MJ'YU@C6;:XA\]Q3Q48]7VL-K;/0#,NE!"]DJK+ G[=PT(]$ 2PXG+ P0SXG M.""';=TU%L)#LP2[@W4]>&=>/\=''02.''O,*S&)F.& MAA#A-&\W+]#;]]>Q1"O)O=U]5HIM>+%PD%G$7N Y?
>\+5U0Y_Y.SSP^?R].X MRNF72%PU)P&>''V0H+0Q06LRM^61?9]4WV4&XO@+KM/Z/U3\'M0XA MF?2V:)Z94\;]\/&Q6H([K(7H(>=Y+^P^)3':Z-POAG;Q>HI/&LXCC>]7[+A MH(63(E:I@&2SW$T*(8!_)\^?]*=KH"^BW$
<.V'#]=HP*"'>)Q<]-WO+EK@ M>QK!'Z?"G:E)9T>M6ODK,JS\*JF.4//SEI.TKE&6/07RP>->%RLD.+'@@?Q: MY9+?F]5 A9>N:\G]'FVXI"IWZ K5N5]<)09Z-).VWR38ZWUS[ V 2 I4F(LM
M^(ZA[ADYF7WVE/.\0Q_++_'WA5UAC8'9510'Y2$;N?5)1%\-7?.@T'G:R^>5 MFZ[U[7=>&+R,?5T2J,"0\P8;!12WXY%Z4HE%&JA.>]E[:72$TYHU?DQ+]Q8] M\OB]1BGP()W6:V'C\%C<[4'[H-
!Z5\PNUYR9S6WN@_H$G&D-.6T8Z2+.#!XP+P MHCP*T V'ZT+N2&^XCDL?,*& 0]5+_F('ABDG]8V)>LX,>&1DA6S-P]#%-UBC M$8%O/;Q"6Q[,YF#>'>/<|T=2CM)H5I?$/BUU#2F950BB:E]) FP$&,B6B[ \ MT)+QE6#R?
T+*!2^9(YZC@+1U;130%(ZLP.'"O6FCBV[.R[UB M,_Z9X_ _%]3O3"[V0VV=#!L05 M>U+T<,.CJH]6A%;9H1Z$9?]/#+X$D8Q6[D1HJ!M78ND;8<'!N]8.E79X=./G0'3Z02=S=4",BVB M/-]_Y++T(&WE^ NS^ZG$1*OT_S4BY,\!-
F]FO4N)HVD0+981Y2?9 M+M-LZ6]E.[+!N826GH]6[C*& GX7C^!6"4P]D3!' 7 2%#">C^PK7#@&501M M>$*D?1"BMC?DSW14TS_-SL[;)X !M/&I@GZ*$M3-I.1(K&48 7#5#Q5Q]%+: MRI51&DS5D1K3[
219=Z33@2]=E/2?'T>BK^M#32--)_:AL\HL:U.E=[):QB\7G=?K#}_3;142I-+6+HD@1>X1L?C'DL#U3GHTGXB4"K?6*5 MA0+ H99T">6QH_$PES%[-P>3)35N0<"ZR*LM?ND&H]MH;"V'ZU>$":E72$'P M/W\7
D\ZHH!O7BR@F1-P;*K1MA1HY'0UU-H7VEE0X[>TQ!7RH-;L08AJ;U< MI<6Y6W+3W(;W:EGQR?]#"FE!J=#DYQK(*P(+A5Z M*#_XE0M>6%8OU7_JH&84F-A_<.1LZWP!>MEZ@ )4]L:>'A]*3;HRCA5T=KH
M]3**Z55A7\BVGZ_(.D@)%O'/&7H7ME]PIRWX?4ZQX3!,9*_P7?CA^T>T6B7 MX$:-3D3,C<[AP^"6MM\LB4=;HM;%QU]FI^L63?=,3#M-?"#57#"TLT,CS:.4 M*U$=PM1?$Z6?:SF]Q\]Z\)(/
(6\$;B1?/<+ET.&GO5B"83DMFLP<8,GNO;@> MR\S@>]M1#NWJP.6!7]05O)<(LX6#$HEKGG\W3_Y,F/%\S2@0/.BKA>+Q!X/ M7EP@*HB4<&+AHP[(8R[*DRCG*^Y)\NS@\)3"%B+PPC]8?L3=V#) TT.0O_9\ M3ZM+-
%"\&]9X6.],FYT^+%73D:AM*H*,D['4*@'2$HUMBURVUZU;\F1039$UZ M-P_4BCY?6 5CT[58;^WM1KU:^/CK&M])GIY?D7 6C4R/Q?\@-_YO.^Y,WX1"]>*7 M-.Y*1SU V5OXF4V%W(4IR721S!0[0WMRRHG.-W
+P=P"^C[1=ENV3O%[ <2 MMMW;U*] <2\&;9.1>=P.C5C0<=;ZESC[AW<$P<9OG=;_B"5/\\A3 CBP]DZ M\KOYA>&*@I)>CX8R6?&,M%"=E_F8$4YU1&*?^X1-^%.M#T6 1_GF(HR-);EVVD7Y\2$@702/^U,7 )[E 7PHP.H-]!*)
M/7,!FD6=4X+D9%PZ[VZ(VNIH>$B([F7&G8D_J&D@ M>'HA%.QNE+LK]"KKREK]UV/:!1HD05DH"RLF=XEN<7MNLV6_,4)W:[(KCNGF:_N@[VO)AYH#;8UWC.9.)>65M2DXR<),7RI3]GF_OOS, MU>VQ9AUA=1-H7856O
TRMEK_HF,*)F<>%:P+[G(,=L,?MJ"U?+S&6?VL*?)6 M9=TC,X*N8S"Y.T=:1#1O0M>H8W\G6,%X]]34P/)^;23-5!&L,<&G1Y_MV$/? MD5"HN5)WR,DZ2[$>GD+]/0PLTMLSL_J*\$1Y6"V2PS[!MG=Z2H23V_ANKH0) MS)
<4>S%:G,]C3@CUB0T/*%8/6S&^6@LLNMFI?P/[&YVXB]3<(IMNFI$]I_8@ MDMWP_GJR;9[!3$5OZ05%8,F)UEW3)G5VS)]@Q<(BN8F;#K-]C!!,+VY$>F) MI+OL""Q:Y6 AEI$Y>B=A,\NSBO$!T4B G)0'016Y/TPE<)YCV$.I]-
E8] #Y MM(IB:%*)RJB$\7Z-4BY(=/)YKZ(T#]#Q0/&D^,9VJ4MPLY-8YK B\TK7S5(! MID!#41IA1],F.3F.9Z7>.'>')L7*3)0I83N1.M05A:KW.=?Z2O5>W_2[4,^9 MNTR?L&6XZH+5AR^?
B.TVAB[^D)\G+C57!9MVO/L6FPR[XX//9XC+M\-ZNM;8 MM6_$B1PW.B(IB+^RJT':3CAA()&<$T=\/QK&72N##Y5S5QHT/VGO=HF3?%VGW MN"\MDQ$9F?]U4ITH625+?;B1S"+>SAQ3K;I]9+DB,*AG#9N0+8R=7(^> M++-
;R6E3)PY$6O\A6UM76\<\G[PP_7&D_,H]X*E^MLOZ+;GMB9-3LHM&5I=N M"U")5!H0WLTG<#_3? ^/\?U7@C++T%O+ ]V<\ZMM!EN%@^OG'\-]O BVAG7_M_29>?8)M->>\"LV_^8F]34WDIQY;']X)U;_T6V=.Q[GP^PT
D6K4#I&\7=&W,^EY&YA(XX7W1RW7\;=MQI< MN'_"6@VW@'E*MXN!_$Y]*T>*A'(]?K"X.G<4UEG<@MK8X)Q3Y5-_<.HMP(*V-MDS)O'-<>\]R&NOCSQ4^&R*LVE%)*VGAR$IUWI#!"#LG] XIXTFBR0CZ9%C%5
M/>6^:SDSB^'_5I]Y-!^,WL$USJ;*&D=.GX[GFAS0/NQE87Z[(5%OV5U&2]R: MD)T_I9.?O1>W(T4%_W0TQY-3,I)?$#(/L^6*Q_A4SG<1>@?KLK#]@&X]F_T8 M8K]RVL24U M'\]%S1.
<8IA"9R^R8!6P/5ZR9Z1YCDRB>OKIBDI<%[2WI=\X3^JA/\]{A*%+ M=8K+<_>'Q;CMG(.'[N*5F]>.\FO7-0!'STF3Q]")3D"X;&P_;]*(X/I=G%] M68<.\8>#@B?Q"IB&G^R9UB>DQE)90^IE6(HI"B8>7%6*W\F^2)_#,"4P8:3%
M7!/'-8"FI,0]OJ7?&U\(<,^1=SX(:VMI]>"P7Z9L+6#I4V1E"*3(11]]_MKX M**"ZBWI+TE9G!"$Y6FB%%$/A@F]>9+P5Q./M!;@F;BC-BB^=LIC]YY?@C$QX, MJRDNX.7AV M]];Z?!'G-6Y7R-
=C2*7M=%DQDMQE1+FLKK:NK$)AU]A5@=+44/VI#G6&8<$- ML=2!X0RC0*1@V/ZNYJ\8X6&-S)6BY#OP?.0UP!>ZUQ:VN)RE$0W##ESQ4\!] M+WC069861*NP_)(EU#@"P*965]V=:%#3]]U[7E]
M#>'X1S^EKVR#@I7A_K!"D$+I-MRCH,'+)WXCC\892[+Z%I/(UB7$A*YY&O'?:YAOR2\J77!PMMI7BE>!2PI.82 MM- T6N2H4W"R72<7^K8\:@F_IQ;,7&=_)%]-)]KYT5;#OR6<>B_V.8W'6].I M1KV-
(;WSQY:M$K$DR6W+/DDGZ#;Q9?YP/VD$!9CK?9N6N1M-<1!?+HI__1C/"M5;]#W"S^T0HX#TD[.6VM^)SADI?8 M2OZ?=N]/J_MZ&!<--XFR/;*QA+034TWK M&>I.&^CHZ1DD=1$(W^X(/O(5?_P#/^(66&R@\1 2<,K-?
_D"4NL'FS[;TZL1 MF4E[%R5'>"^T)(;@$3,1[_59\,G/JY%DS7]@8G'ENZ#1:8]H^N+_K@G2_82 WV_?!6;(*(EQ['U MA).[^;#W1&S[D*F MMM3\O/P" M,]L^M+<;=W"%2SXA06$Y08"N)#]MJX"?4$D6>&6A)%
<>G%(5T,/A:K5Z:]UH M+WK6_17,[^%;A319A4$L=570[PZ 4[[@RQO.Q4G29L38\/QV&G^_S(,U7^>\ MPG+G&\96WR_>Q738N2\B-4Y\AA"Z5P(43IBW(^2X8 MG1:KI]Z!;B/@72V;8S4^D4LR[O+
>G5^-^(E3^+->R4#-KS MORDQX(@IX+)6+ KPF$*;H&D4178Y^\7R%O"]&3VS(DAM-.[K?/>.LN=A' M 7C1Z,H5YU?.U:7180:2G+5MX!?]@B,E>*Y1HM^!]@ MKXM6D/H?8$ED07]*/?Q-JC-::O$ I,ZC1IK])O7[B>K_A@+0?
XM5#3F2C_AQ M38$'N"4#GHQF0#C_=P9 N%XLE+@H $5!DFX MU4ARC-CGLLQ(H0L97XOEA5_DO"A@?Q)M@ IZGA1ZGB8*0%Z%'Q97HH!%07"3 M.0]HX].!]#_#(E[]T)9Z4.CAB897B *N+D'+\@A.
(Q!X,!^,!@N%3\RX>_YH M!\W$HH!8KWO(XB5TR9%*"FZL#R_P]M" ><[UV7)WP086<)"5*]]C"ZT8* M M).CBVR'KWT0.H9F;@"Z<<"R@:2Y!"IW-L\WLRI^M@E>-L#Y<#':$@0M$1TY MC[
^EZCXKS,6EN01M_(OG4FFL'|!_)$F'O\R0O#O #W+*D,KT#9<\K9)_V1#_M 0)_+7_B]SZ#Z:DEW3AETA?/11P>2;=T3C33@:IW#Z3^6\-CK8$S3A>WD4! M6@T8KE P8^ZR*]F+-2,FU M,WAZ]YK5 4E%5\G49'R'5"T:^DT#.]5*
(L3_KCRVT7KKFN*?WHJB18[BC0@1Q@IX ZZU MQTNZ3/W(7>R]:YPBFE70]HE927848_ET]KH544.4^N(!EY M@=+EW"&L-@*X,1V^MA%]29C'Q/V9EGI*1_JN AO ZF^)?;KMJV2_4D#[A4-&A>/A5^/P^I(SY"'4W-
U#NN+RZ82BXVK_Y;O' M/T-+.@D^^++2"I BDFQ3W-[H2K:^X8 ;L1!@R GOW\),4=K)A5O39^ND_&:Z])V^00V\#*GX5!EP MRNJO/_RAIKXB7-5;Q:3=BND#WM#B#47LJE[1S3]&
[6F!!463A*SV/"64.X(MJT9W)9B@^T/8%;7E1-_T\.Y!>Z"�^B M/"1+XHA+*DX"[W#=^R3W/2I*7%B2?%SG=IB+54V.Z8S-Z/;MM-?#!4KN&%$] MU9\T>FQH?5)<[EJA9$N597X/7% KUXA%5$_V?Q?_0"LOD10),;"S10@-+Q^1
M%[-&9&M,>&<_VU)=B3#F%L#V48-MPS9$YV'_AU[IK-0AU(&VN?E]/K3T](GKA M'6"?LOZ]*?UHC_O%I^-V&L)01)RS6V&Y%HF8/*,#^O[T=(IY,8]%9;RX:-Y ML^EISH#,6#(!QFHNC V%$Z'/KDMZ[GV>IXH\+R9<5DR?<=
[8I(O\'#U#ZG!* MKM6*G"X]0&:<];@'LC#>N3V?X:3P""]56D>%276^C#=4N90[/21+?O_/?X#B MRK[?$LL]BB>S-Z#F8_[$K+UL1IVT#F#=/!.*F^<:!H]#;0.LOI?U,GGF24 $ MP]2,J^B(Y,!XYOSFF]
7R7:F_.:Y1K]#1HVZ%DS;"L.34M3NT'Z)7I=V9XZC MALYM]XG6V[H4"6|>UG;=M&.9(I*Q_&.22;MNO1^&;:1<<:@9S*CDEXI#M&IA MAL'\0.XESLJG1TR5LF+2Y*;\]]MVS[VTP0+=EE^/$$TBQM13T6$5I<>!_IDA
MSH>Q>P>0-S[.NM1#NLOYWBK,-I1A.9^WU51@FTO#7-9]\[<_A.G0]CH&%-C MJKP0=1KH%K-Q&T])@RE3JL2HZB=\S69'\@VM4I64)S\5X09[TJ/70,;0LE M.Q.8"OC)_C!7F]R?
_2E]&BL/W&:FUM0$UA1N0S:QI#'F$S"2C3$SXS)]_8 M6P88#[N:#1IK)&P5;9?QX7O#"SNV[%%FC+)$'<]Q&80^WL80?:Q O8@4JF,- M+'^8K;U6:QHL]^Z60K(Z[YD6&/^.D[(^ZQ+AGK8 M9L';$8VB79.C=0T[\D
M!_S8%3+]2U(L]=K#BO%))-3&&=RO'70/:Y,@E/&O)YE;@8]&K6R M'D;&$H77]SB_'DVF"1K]O[NF$ZQ3?;XC+]7/+4&JAT-\!XZ1Y:;;B&Y-4F4U>3^H&TG$S/R1'ET]WKA'4 WU%GTYZLVTFU
MUT@NWV=QP*ZDK#TW])\Q++8^"I8N9]C_H22XRW1B_V]J;Q+/\.&][(1P-V MXT?/FSU],MXY,K.OD#1=C*2D/LAB7CWH:,9E0ZC5C+S*IWT^7B!D+,"CIM#R MH,"YK2OVXY+?
(C\1L51'Q39+@I/IAK*0@U@0V_**HC]\1XK>8:T'T]P:EV?X+.?=!HS!I3ME#1]B%*29_.5C!VMR]YR/0K[M]X> MQ;H?n0N\)""7>-O0-8]^\K&JA*=$XTXH4**]T+;^L2W3O8E+X9F45]]$RS;" ME
I)@+A+9UMH%"!TT!GO:9*48\_S,H41G+4P\<\,M#VT@>)7=P98?<9]L.MF M9%F%?[V[;SQ^_PPLZJ4.5Z+KYUY>[V]"H<\XS@FG)BH$8DU802_"D,%5LKG M9:S.!:'3Z1[>B'D8I]T;J3SJM^)/YZ9T#W),^0[2S]4
M6TCUNFRK[J9&]TY!08_X.8?YE%22SQ[%ADN-.$ HS:HB#/4-#,WQ4K?O6L3< M:Z[2/VT:2*[#_GE6+"-8KEYE\ZP9'64/TH/8,&FUARFU_*8IJA-F9?C[:2BF
MV[SE,'_'RZP$C0@WS]@)1RVLK9D3*1T*,$S">SKLY]1^G1;E"X7GF[W<&I]& M"L]%O"B+>4< D(S0<6;6M1"[JV9V&7$NR=,+#M"ERXK-6*#%.X]];&\$Y\L M-"%*<<.0R_3X;*BS@^GD!W1G9_?8N6T,@YQI25:NB.7 MX?
2"S*^'P,[.I9]3]=TTL]]=L>%M:%VHB$QCTESOUH!--EWF)"FBH &C^:X ML75+?ON')>5G";\&I49VGB:*:J6,/6:PW%L>M+*WC1F+G;Q'F7DB'6#*@KXP]+(\DE1",?X M#43+D]S)Q2' MT\9WA"@ALT-/F)VVN>H2GMR[V0BSFR7
F&&EMY!P89$%\:3=CF9BJX1 \3TZ M"TVL^QKO++%R ONAO$3X6'Q*6)Y^5\$H)$,$9T_GBOT(7U3.WR5+B_#[ C>S5,PF-!^9H=[E25U>1"@XK$?\M[6+D[X1W-O>4
MX=$V<])M:+V<37GM9,8TQ^@;W4M+*\W.ZO=0E"$FIK!8H'I6]Y*M-('8;^]L M.7-2B?$E+7_7K#]"Z^WU('KV6:E9@R4>D\)&0,R+TCBG)CC)KUSL8M41>EQ M\I_'WC-0<&(G/^7(4'&6KK\L/6'PF33U?*TCN/I\P.NFEMF.Y>S?
+I MAEE2MK)_8 [E>$)8;6(FV\P@\YA^INPHV8^%^*S%*58W[,]Y? &Y_9K M&Q(;2]?!:ID.L>@!\SK*+[!0Q^J$S:=B29:@N,C7\G7.$M'1QPY4= YKP>W< MS->EM,@XATP<<,?82\;E]?$#ZS+29I4:.T%/C_<-
]&"KWQ$$GONEL71DJU M^X;93J3WQG?,NT?5H0_/"G(E*8Y%28&]]HB"\[L"L3)<: D3X&8X"7"IMZ M47,O-+LOE00+V%5@4K646T95U9&G-LA*HL&<&_UU4U1B0N92\ M9N/BSC4G]N+C+9C:+>Y@+)RB>TT-LC[7XMQ3
C!8R3#&5/5KX:TMV6::RFXM MK)[N5L>)?M">]Y]AU1D+X#R/_T$U*VE>#==]&N(&X5'M>$4]IUF_O@!&:R MY1Y+[3GG4O?;/Z+W)>^<@R^W.E61S+3F/O&TF8C0KA>.K@'K'JYUY63W0+3 Z
M&F_/[CC84SIR[,>17O!98@"W'GN:8\N^GGY_*0NV2AP?XFMJL\:UL@&UUK: M.;L-#U+*M%AU\M\YH+:CLX7\US2Y5]>Q^S$V-ZSX=T6N,]*I9&U_$1U?;=RXB MY1K=X.)8@F#G+7>:&?O([F;YQ>CR;QC?_206M-
$Z'&H>1#H9V!,G(I^! E]? M>_"A@-10%11P_9J%6;B?]/%A+@I8Q-=]|]].JN/HFW[MV-BPU@0+|OL*-48 T M32H2] =C( (P.O+KU! $T5Q$%O&)7_]5W57LGR M\ H4L)0%M184!!CIR4( WMSQ"$-H*NH"/HL%@Y<."V) ].?
|9'!GX_<@QL273 M+OBO:M )R'? 13I)22-P#"'IP<5[]1ZO=G-]"S^6X?TWP 8D:G*GQE((T#S M._9W?N]>94M1Q^.O;[T&P825?7Y-M#MH@-\/'5]>LQ+I)>V"%&OF4$DOK MJ*X(V B._3FXMX1*1U=1\,Q)]O2W^;P7F[_/OW[^=
[4H?;'|A[@5)!NL MF4 M,7>%IH58X-(+\OXZ$*KMTCLTD@L+: =*5^6?&=F> M^B-X%S#07%GL(["DEY70,R[_.F-6M1TT2>8.@2 !R#B!_)^@*/^$(?@WB+^! MDC\C9-C?1YL%FAF[Y*W^!4%2[GN#U[/.D3=2#S.0E.?
_:!3'/,P(DOYI>@X& M(] 8K+5V&I>W07"C%$P4D!*_,>[?];ZUU;C"U@8&[+Y=Y:PKB !?YTP\>>$ MQG^=\ >MF%>OVYS0)H?_8;+2;R9?OR=TW@0^GOX+27^:#"Z@"NO9DRKYS7?H M[:\(@C93LP@%*(X5"!7RT"LIUX?
MC3L2T@5,82.(?^P:81]QEAV PD^M,;?F MW]=8)/-K@LQ*N5O!Y9 Y:Z\K0EM8Z<,\CU&]-0/0]S+L MPT%-!PL!)Q"RC<&M:2&R"5"V_VC-5Y^>> M9*H*@W]NMYSAAZQ^1H:C#E=]K;HU0XY*-Q.H]KZ',DNHWFT:$-
Z,DVVRKY=@%_9@XXYEXZ[H,B3%9Z4L>P/5R MBDK/%?/G E9K*>WUOBZS,W%?&GY?>0?L;>\1_^AS8N"J&N-!D!=.;PA0"046 M9"N)DI^1?4W#<7:Z*.FS<4*2P+UKDV@=-]M]*[.'?U2/W>=7_/A4W]RE$@5\
M56HE\;8=#JZ*,OY*<9 MWR"B+>]N*L'^<1VIYT[-F4Z)SBD1Z;"9#P"WS3WZ%<=/$VRR?B MB%-:\X HC7Z^Q#8'[M6/[#"Z_22O*&$XKW#E[>#3B[FCO6,BA BVE1LLSX6R MB8'_!*ZPVMM)37RL?+VS-QLH]^#Z?
4$\6&KXC?'7;/RT^QK$PL7\KQ*V?$ M'G]1;QS,/^'?H@354]1IF1N?4Y3.\%IM\QGO89L?+$R+*P;+#"-!&S:]Q[(Y MDUVF45(B#V4#91XNLY*?[GH47N] .U5:C$Z[UR^@!M78;CWK%U2CBD]7$0+?
M7>100$LC3;S&R(FVI:Z%Z3Z#8G1?_8?8S^3?],4>4"W-Y"VU$AZRT%;I9Z?^\]0I]<0\]]W4.#_"BGD!3<=M9X*E&< MFE]:#3NL3].[X.V:_LS8HG!W_Z4!'VZ'.?7I.7F/"RP"MWUI=36&7HU<8O=MVN"-=5E53(4:22W!?/9/7M?
6@%M>;CX MG^_VN5C'?>MO'QCV#A!C#&^)_YEZ_'/-(%QWK)Y]]:XX8)R&R^E3RYP@SIZR M;\.*H67[=)M*A,EEBO&#YH].FVHND,<')K&9+O:MNN]'\>D[JB24G]="Y(X[&G$45?QLS!H[JDC$ARNKA M^^XN,?
JMK)RW'6/|;]TXB5+5"L+<9Z(=X3[E-+)P:CJ8M?.M\7_6:&3!,WJ.-'2.3.NX@?A%;8;Q( MC&E!PQ*=/FUX%;>L4ZT7;+:2(LI2Z51&2I7Y6O21QB4!*6=S=RYS++;4F'GK
MR\;A/>;J$:O,L@2%%,JH.O5!#UIY/'&VY4L2ZUZ=D$898&\%YQ15>"3(Q):O M)HI/9=^MDZ/RY9(39;J5.S3X6M4@4$<[CDQ5EN_?OHI@8;I@<1P>CP+0Z2RT M+F=I_^7F+XNY5/[GF4P0IU]:BG2V[:104E_9#2RGI326T92
BYV!.R\>.,!] M$A?09](G;C)5P[2CW[XNKN*#DE=7(0T;SU8]SM)Q3<]-!/C_O%I2BRE8'?N MZSGK>"T>8AT4&,92)6'\'@YY=1("P><28E!\MG]@^/E'>A!,\KJV!/Y^=XT* M<4KR]\X9S7*19&,XG;("&*-1+H"=*:9:/9]9?-(O)!M]*.
)MX;Z,0V6&!?KB0R&W'QE_<[ MLZ"N8&.L]M%5Q$RZB5>7F/(-3X9)%%C+(WKI,304.+7G^@'!CTZ1P!>[!>A4 MY34*@*'/>#\CN#4*D*P(1Q" $,INYO#\UF-::U9-W] 1RQ"",&?+5MNCY%G"
MR2Y8>6$%/FU/3X^X7N=:2E^;,TE:5V"0'_'+[C:89F*;7&OZG9U\R3+Z%.M! MISHH8+VR# 7X?$8!@1E(ZL]+$,39./C@ ?A0:(],]30!T@OM8H#ZH^'P(D30 MA^'T /(6,9(E'/X>#0D%',_HH,^Q9A30-
E&M*C]NC@($B!3.)*21U.!_2A*$ M_*8*_$]-Q=;I]>/Y8/'KL4^0U/Y+Q?\8"VY]@!#ZIZ*&QB CG4+$CBC3Y"'Q MORE%IR4$D(,%I+N%-)Q*&IYP]HO]RKSJ^.=*N'&;]%(\DA9]-EM^0 &8V"C@
MCOR_LFHQLY&QK0%)]F=V9[CW+Y+^;;;A@BQ(]W\!A.W7F/7Z&S1W >#_2%W5 MD/R?;/P+<_F7#Q BFH1K%H1A'0=HS,L56U4)>]]R%O2F# UEL=J;&70%[.QL M<$]N'N!VJ)#%B2&C7.P@7]]3E+OG=R
Z9C&WRJK6W*V'C M$AM> UY8+\G?CWK3 3S8(/@N+T)@WP<="+^ESY'7@.Q1 .X'?ZG>>,*"QR6* MO%%9I40[F)U,=U]_CN[ D21\WLAR<$E;8#Z( M*.15C#$ZU!\Q=^\P(#]!9& MA6^EDY,@:NG(EH<@^(1X%VF SS6]G^
M<2#D$_&*N;F101M8_+(+V=\*9I3P1U+O-UVSI/8']&N*SQ?1[LL%+RI<>V_B M1];IK/PQI%ZZ[&"A,QSM03_W VG$V2CD@/FW0)*$@Y#NYD9P4K1#3K?8?NTQ M72S,@Z;@UBOR$>A(^&NW]%(*@OAZ>?
$B<*^7URF9IS,)8G^?> =%>D*Q(_[T['/X!@GD=2M<\R%^' M4H,LZ#=36R^E"1$!1Z!_'8 F:N':(;\QQ73-E&%ZZD0)]!]Y@!SX;\G)V)X, M7P>[@#\L02(9GOQ+O^G?R1+:'E4]W?DGER!TM^>!* ][JTV1WEY!#]BH?1&<
M8^]F+V88;QY7&5$T^I0*]&I+Q4,MX>Z@GH.L-@NT_2@ MSLW_\7N%ZQ(R6;/F<7'9_0K+->4U2C^^>.\XZ2,*PQ[=39%_\KG/P>%EN3-F MGR6",D^_(?9T%::[T/Q#!GT69OB#&S%5.\:1?TQ>>$PF7.4+[Z)\*) M12[1LB/S6U-
I[Z]3]M]%EO'V,BMX5K"Y"6#;T?\1AO_+,B$3;,)3Y=:]7YG#1K2=5M/" M:H=YG=J8-4G>(GRLA79NO"V[;P=:W3P+U]NL[[0[DY>;W:VL#>^6Q\/ K^5W M"OO,FF5:W*K\1OL!/ LV>SF "_K%X]]3X!H_JY4?XXDGT?OEK)*[>#S
M(W21%8HN6/'VT3M&>A8,KT&"@!S MHP#XF.;U_^-A'U% E^&AR]HE>OB/E7!PKY9GN&)Z_3]2?"%(>]/()1YYA2Z> M#_.DEPS@&X?+I] M9';%1)D0/8HX"V]<;K,_+$XVOV-'G98#'(S3_M)<[H7"?8^B!W]7>.
[(S(7)PU&E.0EH(S/0PY-X6K5+O;WSV5-ZX5&$PNFJ4C M\+;7U10S+"3*S36GW#83ZFOY6CCWSK*D#7>*6]V>R*Z-5%'*VQB$O(T"_]1/ M-/8@!ZJ62/)>^$PSY$[V@7 )1>(AWKYZC84)OFGE[4PZ,6]&AL-
\3\2BQ$IDX)A9=5$\03#>1,]V@>>9S*?] RBOD>PI&V#-C/ ME_,B[N69@RVBX--*O*GX>L1"+51O/;OP@1K]H]ZF*#VZUQA&P@B2 Y4V+'CP M^N;!EB%-I1\[4WU]PHCY,IU\Z2/,],G3#MSB'!5?A"W:FRR+X%G^!01'GLQC M_?
J>0_ZS]$T*Y'+:X,>]\KD;_1UK2T79GQZ$LC/O28<_I!==#YHLPO+@/L32 M0SXS!AEGRB %T>Z6\[]+ H;0&U+W4^GEETL4R/O78=10" :%C7QA'PP M"@A";YU?K&&L5V3HK>Y A1(%D,LS_Q9UO!:\]Q_<96W
!Z$>3Z^%@Y"X,/26 MF$O;:D0]<(10"&;X)6&$T.#]\%L\$$\K78"6D!]Z(7< M+(:.R>[ V9%"6$XY0D3T^]8HR'N3[H:(I \7[62N5*VNMV/6/"5HZ'HIL: M%-'GE7>FOL6A ))Z 8W?_3H]+F[F2QP\*+0QY
M3$==A^(RBDSP09F$<-4-W,;)$)!QUYDBP;.GGUC%#T/S=O)4+A]'20<9DB2( MSL]OK:VT\P4P:_;OLI LN'F+ZLO>&[ADG2Y/;)]G-IT7'N[2.A8A%KU80%

+B'Z4_?/^1E)*4*$-JS! *R_:SW*745OW@ M:.M\/Z^P[AM,G/YE-\@\.3%9Z[Y,UV:8Q1L/RJ6AC"TQZ:GW>I(R3&$P$EL6 MHC9U-8A(MU/>2L@=;V7AA29#VH]$Z35:O? *O=Z1X+BZV.S81*M]OAZ31TZL M! H7LL\-
G9/U)OP@I]9#N1_>XS MC-5OSXK[>YA2,W?;_+.V\5)L:O77;<8/.1E)=J9V;.5:E\+"+<">4FD"\]W" M%/-32E#Z/$SV:8BH]-$4G(K!6[-M'N.@=T^BA_U9X-MO$2IWM4R'2/@%/ON0
M>AFN"^VYAL^+H].64K;_I]>^F@\9:BR6(,2&%O$E2EP40=11]'4SS, M&+:: M6 2G,(C&C#OK*N\P-*99H[&'N43QWJP^"\"3F>]&2]KN7SY-EUZ2$"]M&.Z MD<*VM0/Y._:0Q0*]'4+EU?Q@^-].-IBT8PL**01]$95V_K2* M5/S2

+)"K/J^Y 9(SAOIE5OM;U"I7.H=8F!W)#;S#KGD7^GU;.,YP- M0._BH10MU2H5J_:H6:-BS\:L38S4IHK&K)'2DAHU8D6IHG9][Q&U6R%&$T5+ M*VK%K!E:JD*O^_E][WWN?9_WP_E^/I[?_SG_(T>29(VJ,S?D8^0<;R9G)RM,
M?9IW!+^=FRW/R7YU'3L!.VX(YI)+UY$%NG_Z W&CJ$Y /[#/\1B?%-,>O!JU8Z:DZKFV)ASU65GBX1EL.=L\^VR-FS$;%C.1 M.GL?]UI>Y<8ZN+(<&V%2*YQ7](;6RG=9O:::17X[ES;ILA_&[?=EDW4^/<_)
M("&*4BU#EV_KJ5&SY@=:R7PX97."G(0L'EBY>Y1?B&0^G8>&4,;:+NMVTN%A M3,4DL\OR#A5DVFP_DK?KZ<)Q5G#[B;MOR-G&SSNL&@I[WU?1Y1N'*BC'T0]% M:H9H=L?QB@>T+RX%]"%_X=U-]NK[#WQ
[/B0X%5'^*K+Z/4=.;4Z>LG88EWY MA4J>YMS)ICV-0O<:HD_VT;2O&LMQGJ%.G<88-ZT!0,;U*+DK;-L)&M1H:,;J\M5/* MHJVB$,2_/])'3ZF ])2$K0<'_"805&6#:^QGO<6(#II*\ *W+*FL_8-Q;:G3 M.4JP%29%3;'^'&]])%H<=?
2VVWT?\,;1'Y_\0[. MZ=07:O64$#4OC1T/)X)]]OKRA3)4*R(H3WTJ'(%7A-*DFA]$H-7ISB6"'.D MZEGJ;BB=8%U(W-%1XM7P!1Z14R'[G3M,^V+VPM??[*B57J/)(*RH M_0481?QF!Z-
VC%]S+MF&I8PH%,H,YU,#UBHW,U.I]).MYBV,%S_AD7;J+7=OZ>4#J;DO!89- M7E';U&FIK#:9-IE0"-0T[ #"0BVD2%AVX@>=$WF2L% MCNYVCPM)K_S1E2B;1>!"\G8C4[]/^SQ?M*_U-/@=:LF.4:I:=6OL%TDFT3U<
MS(,XBRA>V67]F+2/Q!I=4;K@$0>&\,*_M"M,T6^OK;J0YC%DR=E%R<6]#$BOE0/Y0/YGA?K>Z/S/K$.F9=0W1M '#BCF? M:WA/[M6[T1^WHR'@H:&%Z$U<)">B2YE$/W]>AL$2I3,OQ:6!O+?7A%C*N=.U M24"
<$2<.EWTDV8:9\X!)[C@\T#^9+>)1+.*F&J8)8Y/,]4^YL=RBTD6XRI2 MOS'-IWO4"#\K/5OKG]V.8:? MXSS\J,F,337.GR6A9I)5WPT )C$ ;O< UR,R2A7Y&59.T8H?=Y@Z MOIL'44QH\;2A!A\I\2K[@U"!DS-
ES:WD^D/\P,IRK2#.73*0%]40/0*1RM%& M<04-H[YQ(P/!\X\%!@I>+'V=-#]YT",D;Y?C0A1TNV4DQC0T])XQS$LT3#"I M6C0NTD:D:9]7^*A!5RS" Q34-MGZ69:N[L(M\2!@O7JP1?_;\#\&:6_@0O)=
MCWI\1F\NL!/$RER0J'&/U#[DE_K&WS]4NY,CA!HD0*_XPWLV:# YBL@"K7L! ML@<651'%:1./>=D-<39[2#>!. M5$>_Q/K3=.X(@5":^4&O8>@ *JHST^3.&$B7O/?20QDGDE-[ 3C"$ZR7=4FB M)BVS59_1NEQ"X@/M6')-
"L2<@D/_VB4&W/]UFFX$"8P\'008]NU)R"49(& M(G:)Z,)C_<13FYT+0%:-+HI7B)B/!?C1/(E%W.9;G!4>$/9WO))'@ M@CN/MN^E,G-((C@7*OBI\NDQ )ULP-,YK@#NQ[\V'=\1)&)R#P:2 P,[).(O MJ\]5F:?44 4TQB"C]?
I[TQG6N*=:EE>>LG]1[E#T$WQ3M4$/ E'Z[X"[!/%1WAN*,6I!\'EO$&/GDEULO$ YK;:J/AXQ+,JA M\7)TV]\IS;X'T]@LC_-C"ZUM5IPM:=L^[N=NY-(B*%>-_W"2WB]P=QOCMPZ) MUK%QOZB9)ZHI^ST34V_FT FJ17U].3&QO:-
HV 7S262MYK=]G,C4H2_X%U#M MGM^(,P?=H##9$TG>(EG"*.!U0>9+Q;BA^;"P:AB=X,:]]AYR#+$F XKNG9UE M^3PT^J'Y]BCCVNI]=\T4E1-SLO63E;[6)KC4HAX#+RI4Z72.N^>9^\="OK65 MH_)Z#[UDZ%"\)[G?
3&$OGF7KL1"IW]?-2'.?8$Q8'(3XI*I\^C'=68C7RI)C8&=FN9TP"B= V8S"KI<)_/S!5)W-_N@OL7CWF]7;]0?B-SR.9 M5]$*.>YIKQKXM7E,=YA9A8A-U*W8 B70]62K99UZ/]U/-7N)!T-,!G"*.LAP8;Z&-\B1PKD=S4/IMBO
MMC9O)?+G;N*.KME+$(VO[V.UKU+?8Q_*2*15^H8,&2YRCM1%47*V9I3XH[(5 M4V1O[2]?JOE&P"\0L/.@S)M+?@_/&S@\:-'\*B$+SCNJY$9XB /KQH=YV)4W M"^@KIVW)MH55POC.")L/]
M:GLCX"LS90\T7\JKQ7P45&/CXGBA4_3'Y@W$C,LI'&7,I:DR9@)-Z)U@42#T M#9DRJ,5DCSV3Q<%=R70)0I,R,S!)H08G>ALL2Y.D?DW_OB\85WA;SPN1=8XSFZ/";E=,"$I$@A=;NK>AJ5SB9 :4*3=#2N"<^S:+3 MB;FA+;C
\XXC,PUL-9_WJCF\TVSZ#D=M:7MO6\=+?5_>;+3+!W#,43QKIJ+A M#EVK>>: DUCJZ@0!)D4[N[%:8^@O[4&C$YH:@(ZBCD)_JK\I.-0.CO@0133V#[O9UGR<-+S2@N5. MD])U23N,X<6I;U9O.\'^ AA 2&F^%LBX::$0YE(-N
N%4ALZ$BU)KQ6Q6^9Y M =R>?R]GXH?B[/>541LFLHQOE'S2W80=;Y^(CU3YH'$E6^57$O@"?2F M[F)$M]\].HU9<;8F<&BY\.5B0C(B-:Q>[7,Z!3(N3<,E6?<7$,&OMZKYTB]1 MFU?162.(6]I4?L,2&FD^X5=RP&[2U8?8R?
-..<0V,H "5O$6O?X%_Y26"1\XHB=Y'-L&-#VS$=]1_0*&X?#*>U0XFWIE!' M&03/BLA8PJ"$0_Q>2&7WK3,(U,A@\>RKJ;[&%6^M43KH4G&(^IP['5-+57I1 M^L../Y-;&@)VKNF_61$"V_;_ONU5.]AGDR\/\^CLI0+
M\H]H%)\]&%FA&M2G4^81M^L1U@TI_C$S4)VY)0KR)XKXDD>IK^3JW@ MBKC2F:">#"=ATP1U"[(4XBR5A1W7FZRSW@$^>I\:H/RS9*J;]/O%QT(3\L#R M8<:]!FP)\LQ2""[TO3BFSNRX0=F"^-C>SG,3J.G!F>?A<0K0
M;5$0R';?H<_5C4U"7-5O:(U^(": "[C4??&=S)7-7,TD_AA(_#>W;@L!OGR9 M_,1T8.5F2WZ0TAC;-"1X;JKADP683?#_8Q?P7\K,'<]]?M%R/5=G7O=Q1TC' MK%9-1CN2*3K=5%WYPGY9P\1/O.*4JBH7$+:0&"H@
!L4*)+DHI$;H0&8K.K M?2_A&DOI&Z.+(^K4F=&:)QIC(_MGP\S9MJXF,4!"(/+QF(*%UN7#"!LF3N+@ MQ7G)Z!C;J,Z?:VCYK= >O_GF@=2HZ#!"U&O*N0>:9,\' L8V;;'ZO-_-)&'. M1=M3I0R^7"D-8NH)%C@KRC!EO22=MK;
[S-.DNRLPP. K(H!AF#OBP('5PH Z M2:SHOQ'SWV__%!+ P04 " !O@PY9^GV$I*)^ !1C@ $ &-V;5\Q M,"%I;6/A62E8*@(*" GB/_,@9@"O >AHR WUU^=]=/3[F+B8F!@8 MF ^Q<1[@$CY\3$CPD(#@,0D5V6-B2F("
G)Z<_G'9F+22U2T$:F,'#!P?W#\] "+F(24C)R1B?DIRS,> M7CY^ 4&AUV\DI:1E9-^JJJEK:&HZQB;F)J96UA:.7UT=G%U<_<(" P*#OD< M&@:*^Q*?D/@U*3DK.R_<*% D!%^7W[E[@>(7'=0\]"AO$+%\H] MUU\_>
(2&_H3S/L$K90PC!T(Z+G_,QQ*QF15M#^BY50Z(/CB.8!$S\"PQ'OZ" M]C=D_QFP3_]'R/X.[ ]<. .*@I2/-1' '' -4?8TV_W_G&O>@[&UA=#8>R8 M-UC'S$9/FCI15^ZG,1]TA#Z(-#L,+&<>L"E9>;%Q@=T00C\;J'RA!)Y]UP#T
M.F^(GN(H5?.&IJF[WMZ7I?G\>$Y5&3)RXCFH9%X=\V[SU:?F#'O;JA7 MN.I=B@!@R[U& +ZY%"( /B0(0%CV'7%"" +P$JYZ=_,< 2 R).GC%7@HLN.* MQ8^2HZGD2ZAT6[0B"6 M)4L+WQ.\"?']'PC H9KOC]&?", F59'O0A
"L%R\O)/$86/R!G0AM@E]:9SA M1I$HP$!-:H[F(DC$-F+%=V6:GLNPRUZ.\XF) *28\-(Z:C96^39->G@?OTS] M2&P 0C*_88_!160P!:L!& 3I7? E#\/4 Y6 \ESHE)?($7*!^N/ %^RG-- M-KV1%E:V55/0R@"2;07_F+K.=U("
PY+.5K&/Q*- ]O&N%K$?$+-<"C#ZR/!'9[@W2GI_6DALZ M53=;&<,1S/VCL_V_.IOYCYU5_J7O&Z2^MOE(?361^I:'2Q,Z$K]F(]]W!U9KAWU5V M5KP^^D-EY(W7?]F0VP.-]4;H1Z"O:NGZ]5(F*1<#S=
MSU5$31R8(G"MEG0R;W$WA'10"'3;G0:( /S9,P7_Q*-FEWU[P:SE)"S0"3*] M^\;L@REM)!QL+WRL+C;)Q^]=>+BS3MZRVR?FZ^;M6!Y[EG_#CHOL#2SC#O4W M>?_QT)"\FSJ3*=:Y*&?
7QL8D2I!B4!!G*6S1]3I2@U>72DZJ5E>W?S-Y@PQ$ M:LO?B & Q^#73]%'^;XUG*ZV [8TBD$TG785+W2$\']1>8.!Q!N-)/:/H^9G MU_+#-S=R"(!WLM@8,G?$"1" !;/BZV<9&?,TO]*^^)D, M,C>J9Y&YV]%R/IT-
YQ<_/GQ^>V9QUY>/9'[RF3N-U=^8]_V52XM"OR?O'X?] MAYI_#_Q[^>+Q-54]OF[_6^;[(C-?_1W0OR "ND@\3\=(:O&[_'^8$.\LO#R MEZW3I6$MO]DZXP+O-R_^<>2E_O=HWGD;=SZ,R-HZ2#.M=O/+Q[]5]_\F^=&[
M13Z_S)$?>U:.M"H&,MGS_VZ.?SPT)/J'D'\(<*8N+HYTOFK/M2;2^0&_:H_L<-?^R1,JUA/CE"O.J M>%=8QV5!.?_VX?,=%:'ZIUFU^$I/L\( O^^L= MW4M<(P-4Q!*G2>]E'#_(] MMAD!N&N$(P G@H5E.(0_4]\95UQ5(^%E-
(NN!B_'(R'QZ(GLC$ MJ(8,!0U30YHSEI:UT*1KM6+YWMFWVG5_RZ5YW>DD)& M@&J8UU ZX!VT_+D7:W:W$*X*#Y*\STBB7$_O,_ZG -9"DZO8+:WDC,^\:1\> MAZBT6"Y+VD]>5W4ETUQW$"T M3B$%Z$;-!U-HDL(XI;\?
TU2+\G=J/MP\$SH_XX))V#I;2/222^U6I)]1=9B8 M/*LB!#6ZD)8YO6R)DSLP_VP+%PEL(IS.X6]TVG\HYK*<4A40Q3TC_G;M.\.K M,&%H&$AYSU1*_;GLD8X;)H1,0VH[0D%KS5TY M#N9/G6AGGC<]7* [MR-
QK!*B4#_U:4!^/6]:WP.W.VC%"D2ZBG4T6 R7\]_2 M]L07WVX_2Y>67WKC4+K]M/<1- %]^)T=.BHV6>OKN?8<,C"3SF_%V9/3>I+UL>X3 M]YI0-*;"N<[MVD#E:[X*]M3A]Y.Z+N#IKK%CKX:*%ENW.0BL_EIDXQ M@G4;
(OEFE,CCFXN804#=2$EVGY]]L9POLGR)SV /6_HHA)U&JTOR&J-5#^!] M.RG>9A_'=U?Y'27/$A :5PLL9^"; ISK=1SG ;"8.\"6.--=K)MT-4=]C]; M!V]S1;$%5 RWRCR,(K&I5O>0S6)O<;; 8K5'G 5MU1[/.YB+Q\WZ_45 D6Y'
M3=LRL&.,>,4R! [X'DBUP'(V3%&S7D<)$"#-1B7M)]K/B;_IW9@Z$?;T)310 M=#9>EC&V4=B7;0CK$NR0!2GUIS M5?V<7";]?6SV@$-+-F%UD,B16/R:I^9U5F1QA UIX4?;4M]6*Y?Q+1[2W&C] MB>6)A^Q]6Y"[#X,1H5XA-
_SFIV7IQVJ6C9+%%H:;A3EIF)"8V&^:2=8@R9A4 MD]Y&/*?T^8GU6M(N@6S4T2RUNK2I+[LESF+DXXQC7NS+Q2EFH;9>#:\(A8*? M>2$ C")(LU];3$RMDBK68?&19^+"NUL6=*+T:*'2!YO9G6<';AYA4T?
7ESML15(9;O%0IW# I5<0*LT2L[3$2'W__1/G]@>/,%'P\!F']]@ !(L;^GB,Y7_WFYGKW M0P-9,#F!Y"WM[Z-K"K+"+K-+-I"%]!C?^G^SM(:+XJM %!L94#M+3&ZO;9'7^U9&6U$U]H7X%20(L &8,[#XTR=
MI])!WU%4D"'YGK[9A&[9?IY-17B\NW"BG&!*++Z2)$*GDP(N)]OAXG">2M]9A M]IRYKZ]+0&,F:M6$T#\YH:BT,;R13/U$GO7N42&XP+GN4TXXCL.PZ5KH]@!; M0=N02^&LP@L!*BVLGV(8()E2TZK&.HO5)DAE;-G))7M-
TM;]K,>V[^5,5D'>13_<1MC7TN5$ MB8SY2.!7$7G 7B9C-A4R -J):@+5L*@"JS3B1KY/#,N,U M>F"X#7L'7\FZ7 +[=<&7V%I 8"*CE*C;@!AK1<680EC-\]78G-*^ZH74R6=LG-Q&2EQ"^4>EFKKFC.K<@XUP>#SP-U=
M$7FF3U>SB:XO[(Z#X@/CB.A)U0&1'0%Q/SDXXS1)?GCXI '+(G6VK;MSV[Q- MGT^3Z6&D$;(%^6M<][P:5GDE0#9H1U1]U=7@[9I?$@-\C_V9+BW+I/T^!>4] MZ6=&\2#K=UTD[(7=(37,R]P16N";(?
Y@L([6>O7[%U^%_Z:PLEA(M&Y0/- M[;@6XWB#I# &2E0$?H$%/YSVTFG(+BC5.*@M@Q#\B( MQ*,R1T]NK41I9**X<5.5"XVLZ&*GNB+DFI=-&$#N7=S^G9I-ASS\#ZWLS#-G MIJS(JVVHUL8=J^Z5O):ACSBD/A):89I3U57
```

= MS]I.U.?OP$VVP%.],6MV*I(-^6C,XN[^HLY"IH7!3 MXZP^$!*S]?V-/KU4G)O6V^_J\14:XUGHUCCQSE UQI-S5%S-]!U=R8MU1RC MKS'96ZD:7_3*+D/CZXDLLL(V:?^Q'/Y/=E;/-M\C)1%A!,"(U?>6%!R@.X]<
M@H/EQ:N^@B5^F=)=L(-[+_RK&_;R5D4%%IN'// M#%PS:CTX$$6'9;B&1HV*VN6&,5]@Y_5^U.:+!N/S7B/_L]Y+PWCBVZK1/9X5 M7/A<.\?. XH7Z#+# S(T+.4OSH85LQI'[<)@7C[T(>T)S22'5'M9/""?C=D:0

<;0,:G+E9.88+8'C!KD(R;UJX'&PB^#,.WAQ M<>?01#'^(WO7OOUAKF/X=;>MFTD'3]OQ+WGP*@^G5:1L[7'U)[7/,@P$WS,I M?]M>Y83[(BS6.%-C+&75T_'K]"+$KVV"G+9RZ5QQ]ZWW<1]/_>V6E!=K#KP$
MG>T+KK^VZW4!IZF#I7]|^W'5-Q:V%!S3"W4B%@FJUMVYY\0ZN1-8F%D:!@43 M)I*_3S9:RWN!>%1'MB.;\S%CMG.C$GLM:B(MU@;2Y$K6,#)_D]ZG^3EW6^.* M^+4>=[F5_-4'^:2*"9_;=-
PK2FMLK+A4U_!LQCUU>.6+G"!UB!-\F+GI=:6 MBE9+2OO(J6S4:3P122_?NO>*/CGL7=^(A9>_")-T!Z\-G'!-N/[B*F?0E*R7 MNM5#4]%Y>>Y'P#]/ #0OW\?$E2QU.+>R57W=D1CB*)MA"?%">B\IV3@9B#G
MJ3O+=$%7@^YT[UU*EQGE@M6!0CJ: O\F1?BJ=GLSJJ>K4S\!M/#XKH)<8),NCCR M6MLT&*Y=4\ |?O-+FZ N]N>;(U=P/ZB3]4@B7MD9]E'V:N @EI M(&&O3CH8OU18[J;Q5!;@[*.\ENH-QVP:A'XH
#.K#EN4H18,/<48R7O(CV$ M ?TESS3M10\'T,*T_0#I'Z01DY*6?INC[[_6FX16#R8W?2/5T'RYD<+4JOO6 M#$D2@Y&.MA1V5'U@"I@8,0L<9[.U>(E3^F]PMBV$+(\Q EV5;$@@ZGIB<.N M5_8K&M,$DW."_(:LV.!
(W'.48NG:1^8G%85M&F'<$CH>=1U3;U91(?#VY?BW M3A[-KR1-$.+')9V6&.7JJCJWJ!4S%IH^^/6-[DMQ3_(X[!R5Z=MZNM9 FLQ2 MH)@]IN:5)7A5,%:,K\)N>1R<;S2 '&2.A[N/D_J;BFQVST 7^Y015;U
MK@>^K,"LZ.BGK14X119C_;99*1!B#<\A4-):]/Z9+VV:2G1YA.F"$_!HN=DA:J4O:%RW&FP*T9W%U]PO?O]V"O@-&=T+"_6_>\K_*_$T4G:\CG9G'4Q7[DM@Q/_YC^WR]W\G|+\:_MTO_/3-3?VM!;_Q^TH2=,?:"A@>]GMFK
[>L]*)05RAOOL O_9^FG\'7!/\Z(M K[J=W1\4\W8J)UJ(I9B]K.=(K&LPN\L2#[C>F3KPXGZ9GFME2/84W"4.S;L M-)YI*2;SXFYTV32Z7U6U0E!6I25JK4'26O.*Y).90-]'Y#S7CL9XP58?$]NDLFYT$FW6.:U$.>]=JZ(!?K6WE\ M-
Y#?R FDSYXG 6.C]2U/.JC:3K9:46VFELI;E"Q:5_5>%AZN-(1_4)BO[AL8 MOGY+^\;VTXE-H9EGAHPKHP'<\E,/;#;\3V955(I%F]*@T MU*8.W:K);O37K,+#\SK,UX1K]1RC>44>UK ML.KHO".?O=OZF 1Q?=D3]? T,/+&2* M-
QDFDYVTC8L$%3K1M >DWU#;]YWO M3J1]O]%JDZ[(OGF,3+0VUVAU9Y1CM1S2HOE&SR*I>Q#6A%^WH\OED:/CI7,T MW1*8QRR2ZXCIO^H![6P_4C)1L^OWO2RX%+)9"M:H%CQ;6VB:7RC? XLBT1N M4-KL3M(T5&%
[K@Z9M'3(/G2KED[Q;>2XGEP^X^(\QN<:!6!OVO$G(!YN.)%_M@,G_8),J:;#X5R]Q7A"1FF9&?;OK:@_.M=9FSU'6LW5WZ7L"_0E7$D.1R-/ MYMT[0[WF3^ EUH],$$GXBN'C9*!N(E+X^GU>#KW>0VNM= G@%LM@/"B5-?!
M+[H=.]5Z7&N^/V>XB*&P)M#4;\[UW8)VK,EVV#"MPMMZ1SF3#TM=.OX/S4OS M>KO,KB8TT37=G?P_!.GG>2WN6AAE.WLX='<("-Z&%-1/? -2F$R2SP(_=%]* M9Y#Z#GTU8["S3T,@;:E6,=#O!']!BI&GZ@I&V_BUC-
,5)G#86E@Z8U]IS1&*WLW]MT?PJ9) =*"S M2N- V^*FNAY9D$RV@9L-7<8K&>C4I7H96&77ZY>XQOTN7P_%=.EU[(E7XM!" M.-(X^F+C=$,IE_MRHH-LP*CJUX(K_7V3FH!2-$4[;+L'^)FM#H4?_(7PO%O
,)#QO]2*_/#.C;_NPU09E*63-;XF<8:6)%+).94";GB]._:KOE M[B]_2_LTH8@KAQIF<<+=4N*>M*F=!%?1)C*;)^>0Q'[9A!E*W 9>+68FGNX_M7HQB3LFZ7+RA;6@\FS6@FOF\$K*2*+576XI!(Z@B+Y(@6-93.V9$XI'D?WMT.
MWEC47="9^SQ@TB@7[_\$4(E>?85_>#IE)ZRW%C\OB2)@6O*5*QPFZ'; 5&;Q MRCK2VN\"XS)U=FWAU/L/X%UCN&/_]%C/H9Z%72_,?P!XXO:"OYL@MVY%553 MN MSU>%]5$@W8H96?>;>33M>>$L6_6GXZP"
MDC&#H4:O@2ET^RAV# R+:;)1TXV+@6>TDLG\9(%H&! 8_X@*B]\K*U31(5##U^< MQR^*GK0UUGEHPCHV)22(0"1B<K<1$#@N+F@(7N18[DEC_(#^S M61,,%+*<;W+U^(P8Q0=4]R>6V$#VFFV7_[INFCD
M2J;*6]M9GN).XI YB5'S;,C'+/8\(:(E0ES]G!3G]0[)C]XYPWXA$1BSZE]G MKKRUOKV6\N';$>B:I@_89<(\6@^TYN>U0-MNKISMW@M,24&UZ7KU<=/RV7C/W]T>K\PZPC-J*_M4(6NRRAHWA)1>]CGE=?+ MTW"+$X=
[I4+CKC"/7A*&.F]W)[ED.Q<_5C/"P9YDA^D$"4"XIV511#90 M._?M**\Q7(5)+6; M@U8'#9 ;N6L=:G]/;KQO]P7T(&PT,[22^^!=6U'K[K#(GJ8L>GZ;&$V.H3" MWWSM=XV@_,\]38%_84P0KER?E$%[IK#=N=ETA2;!'I#1= M-
UI@R:4S/]ZW!2\22"?.FM)5^/VX_JQ.:GA1 K9WCS!C.DM9/V)G?#RJX^OI_A$_EN4)0T? MU)U%@]8ZMMQS*U(.!:K35O.PMPY%U0V+KS/;^4@U1=9^K,=T-9]ZHL 7I2:^ M1(OC?G[/,_F]5 4L$7IU%$]M?%)XB.+,G8:BF-
MGSMPY*!W6.*QL!#6=FF3 M#UZ5:/(D$]Z=&>$QS,PP@9JUFD+U<92,Q"ONY7-ZAFC*EF]WJMM^L^U (!MN: MUD(>TL9Z\7KP]3X.,_\]?%]BI@:OG O8T9&]Z2,ZAWW]^(C[#O8D:H\NQ=Z M>1F4N8N>I=O#O1./7W7R\
<_??=!K*S1G\!#"P.,QY/.E3+?EGC.?A$KXZ<V*A.T)M"\A)_M\$K=+K#AI,MO%M,C(QW*+0#BCI4RL.P21?GZOBC)@1&VC@:B,"=FQ@R@[?*%-=F+FH*E/VH' M6F"@N&:[6L(B=O"H,2%@D@P4.8KN!T6_%-'}1;RV$LN^-+A(5,YI_V9]DGC@L
M/7+N*#"^A#",H"0/LK+)9Q9T,2)%)X/6\/TT(QS1:W?.9_$;+.?%UV2_7K. MG.D!B?!VNQ%:+YC_N!)3?N)QP?/#3(G$!@ M7M3:7KP=I_2_TQ_M.K0(O!5AO)-$[7) MF=O"5./W@N[<+9.]P]Q/@+0Y(CW"V2_*
(.2&QQLRB"R(3E",UQ27BS\:+U,] MN9?@&Y9+FOYH6CWE,JT\:ORFS%5(H2_05(?=A5'8P^FZIDD-[C$R8@ 6,F^/1ZFMQ->(N!5U&!YX=.1.X76 MM(O6B4*:9DZZ@8)9H"IGNS-$=%.7M0WFF[08A#3!"ZN\K:AD)L7A?I[(#P6
M@KTN^QEH]96%7)2A-D]LU/UV134OTDD<:F'OF["9WY5Z5LRK?EM!9^.(^QR2]+R$XU^]]"12ZRSIY_5NO DF2VY M6*#?"G]<4F=;HJBQQNW$',6934?;SDDC?5'2]HI(5>G4))PS+2\,B#R)^FW M,8VJ^4E.EU*]:/1[M-
ZK_,93>KNY8<_>SYM,Q1Q#IX_\P30N'@"L-^)_[F0 M@V(/]\Q,*)R^%F^;9]5*<@KERAL"B3!4(/LO5R-YV/$?"]/.$B1#F"UP-*1V[XY M#@[MQD^;+_)]%T<)$_BB<;IG'2% M9,7]B2]<@YY!FO6Z?#-$P>L%-
(D_E&3>2:)\]:]TRO46@4KF+]W^,;SH(+4J ME\W@RORD6EQ=D)>5.,-_#5^L4>.I]&?MAB<)@/A9F='ZSBX%^_9CY8"= M[,F(523P)"-24O&"@P%1(9RHAWT/%XNL_%=[AQHG]=]>/<'&<< B?T\SD@!5 M9'-
#,25!W5LDOK1(6V3V">IW),R\V)Y5BNJ3!_N@S[8L"?B<\.U-03=QRCD[_M]KO]Q:8Y]ZT]-GJ)T#%.7N6C_E#ULQ%.XNSN#DF(IO'.;@\-!Z3H M(L,]T"[7LKSW4Z88!P\(&)FQ%QFUOCC)'>CLV+(5 HNM:2.NOAKVPU%6>=*D
M'_W^MPDC%OC>AC.3SLAF"!:[POK3/F=-MZ-#>.;")@4*G%+'@LPMNG[(QRN'\7'O>UFL'[U5_1%:SHWW/K^3T1=\)G4;V MZZU3M&97*]0!U3W6BGO;FHP?K-69'DSB>'PR>EG'[WTQ#Z-R2+05*BK"#2#A M\!9 27Y?
6DV\2Z:U;T.%P33!F/R"(#?"&*^]*A!#-F_H++ MPU:M2$->C_3PT.M8&RG-@%>]Q!O:?KG(,>]*?RM<_V=1;Q>45B:I1)G;P-1 M05:\YY[6A1S;P=:)6<][C/9%'=NH^,V/<6/VU<;#"XCO+C#[KX)+<;O). M^2= Z>*WRR"S-
=8#G'U6C"> =3>IYF^,*(&LHG);4']]9H##RV@^D+^DO'VU M(;9_\/9W=_70]<-#?&4)?_UXC(P+\B(HG.2)"^6Q1UOZ71:D[WG"W0R(/ M\ZG>#%L)"9+[IXGI_KL=N)'3 M,1!WR$[HOSR5?
W;/R(F(G]%3/2%:"G4/OU7+8'U$R!PG!^DGR7%42PY?;D[_ML(#&42IV6:1*;[60D,E-$3]U\76<6>M8I4KHK7Q#A)/(KIXXAE01?#Z'}W(G MGJT?2."?LI!!;2+"TSY\)HR3^3X_M-)Z>C!_6R=%LP?#J:&HJKHN?A7]J[%,
M'<51)D$IR.X,X*U_FTTC4C:C#C(T4/_;,H6-&4"/N[AO$:_[,.9/=@K+N'7 M@1/JDY*9]@3YW-_<%11#S0&5[[BD-#(C;$UU+]SP&T-FK%S&K06$8C4,A1-7 M9<@MIA-&5^+X56>I4>FLZNEBPB?V9-
@IJB'X]C*@IZ5^CY_*GPK6V>'F#QH ME9FQLVY<=T"V9[(.O&RW.ET1IL:3[23(M6/DFP72R=0D-^VNOY>SL11&N*R M"M,WAF%(F.,*45E+#GXT.VV@MERW0 H^/6*N",54^;70>C7HHQ ME[EHO70FYHA&>VA$@.+S=<-
H."QT]E;DD?R#[KSYP>(6I.94X]DLP_50"/@AY("M]]C'.94E)#-6)]Z+DP MA::NMXS7AZM*EKQ:N!?G4.)+8TTI:E-3 A!6SA:M+^/(WS42%HY.N9R&/JHS MNK#=Z]AP@KP1E_:3;\SI#LS5-%6:X3W6"XSJH?KF9-
E>KLZB%9.?!Q!R2'L9 M?@IAAWXI*5V.7CUFO4R%YFA:9UN2ZVW?EY@(5]*1IFR1VCW]"F_4C_#U=73L M"C$<-KC;*,(MN.)D.:3>K^Q0 \@I5S7[T]92]=>,G?2[!TN+@#H-_$7*AE] MPBZIMN-5"*^R/VQ\L;FU@3@VCP;/2\Y-
5-++1IWLY%N$(:/?Z1R2BU!5M_!K M(&M^6]3VN%C)8/9UZ'6OG#\,AE*+*QT_UF,4 MNB!)*]]$-;9_R"@.,]Q'2SH9@@S3NHYE:?'7@]A"\^FWOVZ\TNC)LS-9FV+B4HMAQ,O(,>B'O M"V->ZPM-
/E(QWM@YW+L&?"5]\G[0O#O?S@VG0-,?;K8DWGZ4G;;CTY;D9+2GC M-VF$Y3YAH.F%H@.0O 8G+:A!:&9W73NV!+&8FC_%VL#\#']]3=8V+IV6B M0VA6^D8-N:[R019]-EW^#40]?M+3,B!06?$4'L%57^ M%S
Y_)U1K.I],?:@M5 U8NQ_@EA\-_7#45X^[\8>EK^B^$SC8'XN\O"CU" M>0+T/0'^*W>LR%QLV[%7\G;4>29/G8MG3;_,NR;/60@4\(P&5%E7DAA[2X9 MG#P4\NA!^W!.5X;Z"]8K)H&O^&_7K-\-%2'8%AYI ME"/QKY/W!-
.A\CZ0/+I%W*VK/@&>IT-0[\.I759=$]Y.X%<6S_[U$%3'O,\K^ M!/*ILNUUT:]%;D_H[CIRWZ)@>'1_QE&6>/OJZ-SG9EWD*$K[=[I\[VLX)_YX4??.8TI^5>QLN]F"]*WGP#_D.DOEA+XAZ+_FST+HL_8$^ OJO]$":9? MB*;X[_B;?\?
7]UV:?P*X/@'(\+]NW;5=;S^C]U T/!X]"M]C%[YG(S]#>;H M+WBIOQ[_&:CK/Q+SR7X6_,_:$OF7"/C*+@C_21\2,_]!FX:\5R(+3X!>B;]D MR]I"#KT:7H"A >+.#XLW3O]#4;PG_#_(OL,]I^(_?\L(^NA3_T_B(9^9?;9
M^O$W2H*0NON3SW^#DY]MB6*9?#S 5Y:>9K]?P!02P,$% @ ;X..64=R M5/P\EP ^+0 ! !C=FU?,3!Q.6UG,34N:G!G'@F+L'6%3=EC9XD% H"))S M$@0DB.0<%)$D$B1GR:G(.0L2)]TCF[.-8)>">RG/EYP 6%A9@ M?O,!,+.,/("+
<:].P__C&P\7%P[^+CP\"X=\C(+O]E^P>.1GI/5)2DI24EI66GI\&)A86%G(-@XV9G8&#A:F/YA@X>+AX8/PPZ*QB9DI2"F8_R\W M3 = @H\UAW6*C74?N$6"A4V"A>$DAF "Q?K+PWXEX9U"QL"%P"_L.P
6UC8V+=NY+]1X.,7H)O? 1P27%(6_H&&N>X9]OO??=R 7>)!?@LSZM[J30 M&D.R"5[XA]V^OTE%34/[@)V#]K%J[1U=/7T#@PM MK:QM,:WL'SQ!O;Q]?W\P]I\$9%OXM)27V?
EI[Q(3/K4V%1\)>>2TB]EWVM[MZ^H;&IN:NZ<#=/;U]_0.#XQ.3OZ9@TS/P9@3*ZMKZQN;6-NKPZ/CD] 5]^_P/ MO;_;*Q_?^N7B0W>MVZV18,"$AQ<%GX\TB>:H-=N9/<%WN"3 M/TTN].Z\S2]HA:2P1"YA=M Z-B3/-
G^<3E\H6"S.8&_]%^% \"$P-*?3% QS4+ M.N*+OF-6@BH&N+LI\:QAS\/]B+P'8DND$"'=A=?UM*]RPA6?]50GF4GDL M_71Z9LMLYJN;Y:D"E^D2MX0R]S<+UT6^="+)GZ);;U1&!.9E'7)I7VB\N0)
M@=*EN$Z8#KWD"0I0GDT1^]K)8__$Y$>YH.L6@I<)'WI_;7((:MB M*O*TT;=+IXK($:O8[^W[UXU^*'*4H!^ ;"#T[+47,4D?E.[K-(&H MRL8 =IR!DFZ.=*3R%3P0CO'CS3FX\;8+^!1?5##H$YR_5IF?E7I4#'MZ^]*X
MI@;%$?:E4L7N>'9S?&?C>.8@ (..!58#T]Y%HB;1C^M"T]Q]VZ_0U2U=U.*Q@@"O0#*%9Y]P%&?9R)A$ T&4!?&%G$O%6@G'UK$.N)?,?TM,=;?=%2V_#22/#:[[C.S^T@^Q%A&R?Z5^/V@I@#H]@A2ZN$8T^0HY2@^JM'(H@KZ/EB%9-S4_TP^"
[5<=/P$=8B MBV+)?L2R>FIUD*&U3PY'>Z[(MH-YKO/)>(F5D;N&:T?HIX).$V9!F9Y;:D.E M3: OW)OBPHX:* R0&"CX==^T+=LP3Z0UZMPBT,EP-->N%V,E)_$",Z>4KY3L$_!T,RE4Y0HOO&(5"-YV.HOEABQ1:?
(#'UW/E9@4*7',GNX;48JG$A\R8X<1.MUISZX M_KC,66>0'[-P^WX@A=SXT$.VN$@S7KS=G(TZ/91-3:7A3*!S:PL*:"=1*%(G M^NA#Z$)Z6PMOKC0DP@>\$N8G[@"<(V)^P[IE2:5>6Z*P#0),O.$+,&74W7/0,[ISS7&\]5
MF]RK(K[T12W8W7CVIR]BK(D"" M**'!J.;S%^,K#4T37NV[%X]*Y]]#%,&7^62IX1(!>L>Y37ZA\W%-X67PNOE,&-V-V8)CD@'MC_(PR;\!&,=[MV$=BJAIA!Z&8=I#!;FB8XH-3X_G/]MX$^,.4]-!T]_;O06
MQ!Z=M/,E>.1_Z_M'8]N<\]Z#=:.655LV2(>%>LBN&OGBQ[]]YC^(NR.Q(K*@ MQ"$K)V16X]BG1!^-9Z*]Z%OUPNYL>QMB06' .^04V&@GQSHIIAA!RVQHM"] E MWOB5[5\$3MU3=FNI^F")6W.0M5D*?(KA_$]1>>-
QFPR#RHIVK'I#S/6#GN3 MTGM5K]IYPND!['I_W6(_V>A @Z^\(P$KVRFIWY["FB73AH9S@O@^+ !+]=]ER M!A[L2?ATR? P3YN2WOXIT;:3^W'U$IQEOT6K/FQP-R#=0("#C*HF=HZ,ZBH.6
MN="_@E!5B9[^:R5FWI.;;,LFC4WL>9W]!6["Z"/>P&#?8]YG_!GRQ-WRK MVY*?L"P_19SE" L>RQW)($UL*[$C2^-HROX+0K#@FP#3RH V>$<4)?-H0E4H MY6[M9PE[@2#D9-_0?
DA71S+]0@2!&O^5OLL]K499##7YX5ML&".6YZ*OA3' M3H'NOMO[RQZ*; 0&R8\Y-N'8'L5]#CF.2_9D]YL'9E6^<0RR/D1Q8.V MM,Z%\MO][["\YJ0FGY0F<,"*:*^SSV.S>_8;:C"A;+67/Y(6%.8(N*P\Q*C4W5Z,U$5^':'()G@.
MO;N?+@(?!!)X FH0'I^;U4NA:07[N@9"OF,S1C,SYCP"%*/YK$]K F]SEQU M[?]?>XVYGC5@E7RSS%=0&2HE(27Z.<02NV67R2]Q?\3ZXX9G MM*E,"9"!
MR%5!T++)->V]9$0!86NZ]IW>7P/&2^:6$[=;+ZXI.>*,Y$6K[7]^MC6TY6;^MN+"?4/K&HT(KZN@5PH_M#&48;]#1'-_\60*?@AE\+$TN[36X'!YBINM(P]B M[67_9L'WIV8L]7X01\L>*CDT"(>6EWK5]$O82;"+;V,0ZZOW*^3-
M.,_^R>*..F<6;8XGCI+=M&A"C@);$ MG]@Q>8VL!'/H0=C2!:5&:PF;>?X/Z8N>2;*<VN(K<7H2(HF[&'4:5 M;&\0RPBM:KKYJY>]]FEU#]1>SM#Y>;LR#&6-3OG-
HP(QOU2S;N+#CXR:8!5UDK+K&C74T>>JEK9%S+4-]$PJ-?>?#&J! M'DU57!(@I$.Z:;6]!S[=7I4_M:VCJNZER31NY8IF%*=0CY6ZM:F>\A'U;Q MWM[^^P8]]BSC]K7ZSW?KRH?8MP/WPW7W%E=>58(\
<:]S5;SHN\Y"Q;IFT5 M<9W?SL@X6B38B;XW3)SE/E:XPA+2/36<]S:0NV014!ZN8UK"C4S7\E2$\]F M@0$"I[%E14,,$1[N?2U^81B8]NX>!UF]8/$V1(&[2,F+4@>63;HS>GC 6M=
MH;='GVCZ^B]$VJV:U2GGRVGV*:EH6?'Y7"M"2CCO-F18_MQ49*(:$XN41C5I'SC&*%CO@QO97N@WAS@#]:SNR-.W<^-%AK1>YG>K A*V]'M'Q0Y6[U3X]:S\WA&TGMPK/:\+VY)9U7>O>1]I2C'8')RY]Q M41:CM&ESU.
YL8X*L)$&ZB3O72N+I4AU4;>SL/ARL\CI=_*F"/-'35[_GR^A MTC?L1\3RB>!F=WV]7>]5\W9@09FM;(Z^50Y15HCCL8EE+3]:P4S_'SM:RA-_MU"72T!A0FLF;1+WN*M_?ZKI*EDZ? \NV#R&7T@PJ6$""7Q![?X!;KUT2.:V]
MX\WB^3"Y9M/=TB%5:DR2X#^! 99Y4_U7@T398)+'=4*C,S**3 IQC_+H#:O MSO@]R,(17QS=1XZU5?5I2\]X85ZM&"[4@.]W>+K+3KNLVOT]Q8U_6I\Y\;$18%KN*0!A1(M4(EP"AI 7
M(C!1G_KSMVI3/R+5'X]"K7SNDKWY]7*7T5V1 A01^]HQ[#]T4G6Q=.!2]F M=FH<48'2PFTGY^!;Y,<2'_#DH6_4S2E(N8^B9-T%1>7 MNK/:OLR%PC$CZ0TOD[?_0%4SNCKC-W68&@AY>34V=^M5\]YTT!KDD)HZ7A\(
M1A-<$&TF]15#<3+.&NI/*??<4LE=>-Y@-^*0XBEWL$H+<&*[:(]Y?G3OWF]>M2K/]8D!*/3O?\:U?:=[&VO,IUP29+D$?19.,TX3#%I/P"W)DZN3WP@D4ZY MG^'KC]>HDIA:$S/]\4KVA.#-=A29@2*/;L[<HZR-
7E1$1;4XVH>C?MA=26S MLC5HY7/M,!)\@6966N]_PK&E+LOO:X0$WL/+]"GT-)>JFRT ?[$E]P8X!8& ML*Q,PP#XIE%7.=\S>TI-TTUDN*H9AKHJGO=LJ8G/.=EE2<&O\CO!'%P R]04 Y[(Z=A\AR\8;KF;FL[.PRC9'R1;O]EAS
MMZ79?-/1=!M")X]9R]@3W,)LO^235.G7]-R>]%6!;\7K7.V+_60+IHA"!?P MEZE>G@=UZWYQ0=PEA>]^8?]A5 4>M];M%<'^)9AP\M+E)E0BNKIZ5]J:GZ5G M>?Q.=Q7.L>;-%G]
16WJAVBL(.A=X$K1230"RPP2R!+WE&^3+CX?ZT]1LKY: M'.JZOTN?9,3P;OT+1W/[GQ/$<2NZ?R&%.!%:3ME 3.S7 MA>)EJ$N-7ZS?99A;)LP#IFN55^T060H1):HKSC):2OA*\[GZ1)ORC!L*?KEU M%8'/?
A[KI#@&R6ID[#G4F&R=OE([=?2@>0"?_;'0+39[V"[?0F\1+]M-I9?+ MAP0?^[\7U;UF'M^G?&WW_PCVFLISH_MK?8*_I1XC V6_1Y[U-%MZ@$%Z?:WKKU9L%DS1RK%3'H]TIB?CK D9
MVX^]2#"F3)"X3A\U"%:LF[B\^+:PMKG.1,2D04"!507F(51](1YK%7&6+W_V M-DDMF-21X[5(PIMOWT5#>\K&:4^*FJTO]^6*VZRBF7LPP56>[(B8LZOB]ML M4@MR].ZRCZA(H9X2LTT1^@;V@S"IM7U=
[@RA@FG+T]6A0EX>Q\9Q:$5Y M>I.?H%"V9V]^$YUN/%HT!CA./MS88:%/3=\2O4\W1!2$A'YW Y<=VA5&['&K] MZ3:OG/2K$W%R!88/AKW>:X#(B*"M("CN?,GIJQ\-WBCXCXEY->Y:S6J[24%Q M@[MH4[3#\Q?
&2Q(YKNLA>^)CG;Z7ZUNN?"38MF9@OGC^V$DA?Z$X@4L9Q]:V$ MQ "K+$CB"!;'3L:L:Y-5O:/6NQX/W[&<7]>))P GNNU\NY.UTPFAFP2=/_. M@??8,+ GTUC$-_12I+W!-4]"YOEOV^43/67"1MO,&91+!.9:I\V:*2PGUN-4 M2
4[?/SJODUT5VHP*]_;[6A3BA>/~/"/*#B1;;KPO4KUE_GR*^.(M3>O\ZI! MSY09<:A@O".BC\6F=KJ9UPX8F0*"V*S#_HX-^7O19DJ7X&9AD!2%LSS1DPWA M'X!YFA'O.O+6K/Y?K:XUL&$453%IEJ=^97>H_1U%+ MTC)\
<@$.X(0:/R_K4X+9=S.SHU$>R4P[+\W=46.?5<=E%9<+\B*O3E.<=BU3 M;G.T?,_:#XA]5Y+B6[%&5&J2\VV%^9[OL+\T..=; U@(!M[;>A8[2VLXZ:>D M^/74?BX7".I]C#1 -TXV5$TM!M3ZWI6G2/>CJ:-"/ZX-
AOIXD_M@??"FR!@"= MY5VZ-V]S8B=C@(B08@SPTZ,; Z!E6S' RON0KO9Q#+ IC@BY9%H(00W^MVS_M+=L_(IO*30U@MF7N4>G[(62N]XL]!:3'_6^P_V!V:T?F R%(6CQ]4@#=V23&.MQMHN<5IIH:(V[AL]+2K3LYW1#B*"-
$37&!Q5[]5],8BJ"7X>:'G#,]/SHU!V MATC3;=8FX">T0-T816C;G*$43(/#/*]X*Z2_Y0K@;#)&W_G<+D%=U>Q-]CB(Y:A %<*C]@@V 3E9\,;S/DW7]M/..!PDC: M2ZWJT>M4X6Q>HV]F23%X4]%"@-
PB&'F+>SP,/X43NPYV66L<23QZ<&[;R'; MYG]9T_.B5>>-L-87P;G,?U$-D6+B*]*G@RQN"#L9@DHDEE^Y59HZ-#$7SG>L M**"(G==V;_6$F1[Q":T%5_NU&-M]C5Q08W;0ZYBUER!O3DWD&A2%]M^_W&7S MI@OM
SA7V$.EN]'8]JHE>@/Q"W3&]VC3A4]{Y^!/+.9/:7+M*,5]+0!+E5> M>/,9 >+]YA1M]-&#Q)>_]BM9Z]= R4<$[RBTY06NUNCC?K]%%=9 A[^K4]X1T M!;GY%?ORM]/;'US@*?M7:B,Z#X7M
X]Z='@]62QL:N3]+T!]H5/]XRT+.*OX%()PU]'Y_)@""UL*I5U$"!HZ##-ZC[M85MW@?8H[+T4,L>KN3?A'>5\3"9V-8ZR% =2.E^[5?N]b)N#,50MDY*]Q>B M\D'F1VC]%]_$W9]DAWVINR?3.]OE M@?X=
[OW![$NC7:SVHT#B2VT16?RS M5ZX@NPLV?A0Q&%_O9E/7"@#]R[F_@T(M@N7+K]&]NOEC$ /&U<+N';\^#Z_UE MV#+<C2NIB?X-1]&6ZM]G;.7_R/G]G%LQ6I;AA>_+)O7;8.R]#U^3K9U_MLTM'A+US?%E-
E@I'T8?^L1VS/@='5H?P>*EQZIS=*A<3NP9 MIQ,U/HUTW^,KE:E[5>]9@2<2"37'GCT'A)Q5Q&_WKZT9DT MN>V77)929H&]VSX+(3Z=+X9*A\AWL;MWFH(@U:&UCY+;ROF+65^]XWRW::>+F M%&Z+6>-U[2CI2<-
'U:4.6>D%/.TDC#^,1N_Y[NU9!H1^$IY-6R+.E@D7PC]N MHT!55B/XR-3T 7QB;V#DRVG?2E)MU*"AS8":A3=/N;XT_B3S[UM^2N#C3UR M'2M;4(JQ5 B;C!)[&>[F<%7]X_9=#V]KMR]=*V=KR?=E;G2>%1V.Z0T0!/O M-14
]G\AF\5MN&EZ,]2X%#Y=7E%]MWN(VON8+GJ@XMX3(S&Q(O "A=O*_G2 M!C(X;!GQP#0!D8FRG/E+'*^P,AU;G'_/S/AG1U+,_$*=&HW7*]>TI"A M#B+[[6N,;>T)M^2SY1>3O!9,!15>5^EVHY?:X2?FC(+-$H8Y*ZY]GT-C1T1G;E
"O]HY*4]_8T*D8:\X48R(BA'8;)D+\P\@Y1.+;> MB-*I*EE+C#,69_24^1%)F3NB"DUR>YP"53QVCUP]S>B_H1?H8 MM%<*<&-.\(6HP*9W57.^Z/+%>S*E"%:KZGZU!$6)'&P*%M?URBMYI3% M.3.O9[FI:I&\L\O0]3VT0:?
ED/N3ERS%\UTMZNDSB*TQ$9+FQZI8DY0WQ?9@=5 M.#+5!4GUNV$$"(\))>'EUF8B>K=/+2]!6?CCQ%$(F-;6/GZ]2C4Q<")9$X>MBX1M""[N>LX]6M3 ^"ILZD9H^8>:18?3H<B;?[,(-1U1#N]WIH=#+QV/[6E1C=
(.#RMX;7P7"WG/^&P6.'DLX(8,^EU M;A(N$6F9+]](?*E^"5Y^A?)G/Q@MK_V84^_HKN0U?V>PG[(5V'\856^_ID% MT9WD]4$!?5292%_D]GZRY&DEN<@[SMNY ?64&P:+T;[PH%2S2X#$+1]6CB# M^F=E6[!'GA8[/W^<)]Z
0D]&4]5K5 (TG;TEH>_^$]WTV8KM':O'NM49U:B><_M_\WD<=FIA$OD[LEMO1?5$^_]2V,EWD_Q,#HR+<_E9$Y6#6DO]6',R,HVAO52 MI\KC"YI]]T5#*]WXNQ=ONW]2T8CWSQ_W^)ZF@=XA@CQ>5[\CVE!!]>F-#2D*
MUD*BISSZ:?8<(S/I3T]C$\1F1^RP=PD^(T\K[-]YPX.N"G^P/A$9T"S>)+=E M;F@PS-U1'*^][6*F'3/ ZY\?BB:U*F+QB>?$496RNS*QC/9/7O51>EAL/E8 MH: MX;5OZ&2A77?X- D:?0'R34=PC?
@<[1EZ'IU$B35Y%0ER]4*]XQ*8 M5Y_Y_>%,B]L,SVS@_MO4X%[$-RK,X6M-,Q-AO+EX98]B&Z847T%^.9%6:&;$&8$;$F3!L@ON&2\ MQ'P5#5%&\+>\%0G-FF #N')>ZTE&U0OT]ZE36>G*TC9EAU4),^@Z5LBL
M/!>!8V>8U80W9GB]UTK "?1CBT;\FF[_M@(T^EYUY)/4/LW#O8/HAA</3=.O@<)-M-RT-9_"Y&O#;3RLNTX:X,Q)\29CY%IW:8KR,;?YW_5G>C M>PU5*Y'8S+,KY4T-
CPK80F#;HD]*L.$^3PP8(!!]O M"X:BF*XC78A#EM)=KE4JZV*23EWIT1--?MH=K=PEFG^M+)00_97@?_W7P)LBWC)D]WEFDAMQ70UYH M-J="8T+!^V]9G6-34LR_$ELW!R^4^67EO1)^UO2]DL\U0VG8(%?+,U85YY-
6ACD2C_M1\4.#;?$L<)4GUDP*L]R83P=:KE"2K'AFU4951"1P*>3,O3;_F]% %^F!K@MFZ&5RIW! M0X/F.CG/M@>?PKKI$Z 01T@^AUBASCZG" B4M'R,US?M,^%W#\TP>71M6UT
M#7[.K=+.2!R7,"@;XWNL7<[_Q[0AS/2="XW;&;7C0;3E"Y9V19,=[H^JZM?C3^MG]\'5^"_WY>5T4+TO M4.NR6I0@]8#^*8,I[#O"[X/ZH\$YIX9R#TXL_4@BV##FL;^&5[+N1_R
ML[@@9.G0]%@\$(5P7%W0QO#]FOC!C;D;MB\/[=QD4W#3@C)Y#W9_!DBF;(-02Y#VAECZU[J]0 T=/DL,R9)%&!!N M&&7Z(+=2MDY*]Q>B M\D'F1VC]%]_$W9]DAWVINR?3 M^#*1HAG-
BI_RORVBT]D*RM[G(.TT;RFS$V&ANVX,@=H#*%M0B9S3\CH69H>-M+,=%$KY][/7KDA?%>:J<2]Y;)%G5]FWI_^]5]C;PI[8Z-Q9U 9-QJ9@]Q/G/K!&72QWMA/9:X"=)M$K?630:4M R:(CT]U
03^W$[JB MEHS*M4.N)!WU5BS-#@3*^U0Q1P_[[LF6&9 M/76Z-=1I+]H7_(E4#L%OW9(DD%>.:!I=[VUL2G3F?>[3K?$#YY?T7.(_>MHE M#%YU+_F&TI3<1.&X<&!^O,M?#WM[GQ:+8]>/,0^N9A)
[)3'0V1T2V4]8Y(A>A;@X: M &O>A;\W_*G3?#@X?O:Y]*6W),QH*8\<W2]6[AR^NWWW/^_#USC*V(7G% MR26^Y2LAR4F/U_^#[F5C]C[WT7>8UUUW6>$,59S,EVHN='$W60"OQ.?^?)S/
M7,WB1A:]H*L6O\]0KAIDW^P!I4Z6V=[MP6+O:2]"Y&?^JY*0.YZFW.3"ZTC M+^^V2Y9I9,=[H^JZM?C3 H&8"5'\U]\%!!O,;I:,?0W*0$KN4:_Q"0E%"P]E'KI$YM)(=Z(8AM_L-]=
M:7&9]+^S)=SO=5LHVVXG>U2+ 8BW]-Z5V]WMKS?%! Q8-B]9VV7XO+=D_4&D M6$K=*=WK,Z+:D_56!F=,^*L1]+$D=P=<;DJLK"U M6MO0[3]9AG[ZFARL^"!PV6!3:30KRWVUE[EIPU]4(VY"0DNW,L:GC8,^OHN?
M>2Q?Z2=O0Z-JO^T<>U-Z*3\GZ]O^O%>N]]E]VX_H]UUPEVN0<UK>(M=75IQEFY,[F]N46X2W91V1W.!V#'XNX1:S>3(G_YRR M25N2O2M4]=4VW(PDVCLCL]AYR<[P?ZY^OP"W/Y.MA0K[5D\HIAUT%OO9*?.%5
M<,6_F,U&=O1X9)@1.%EE[H05@Q#[OH."TU]F[-^Q'Z4^;0YZ4Z]2.9\7H!^LV*W1'G'7H9!!?MPNA_Q$\V&MN-9*SS4-@]@5$D<((][.((J>]J1.9?2S
M6C24QG5]/A]NU;L7RL_BCVUXSA2VYTG7)K*]<[.J7U:=B\O#9&]=->I&C-V--MYWI"P3Q"<"N]+)=(9S[EZF;(1X5)N_N]?G%:@/H"VQ?NA,+Q$@BZ !=2^]WS M<^DW9?S&IBQS-FTCL]H:'CE*5EL@A_!"_1YS%@T[
+-9>6V<]5*M4@5(;_Q M0^5T*[M5D,N/5A#U6H";R;=]K[_HKP*N@S9+K[%ZCI!SVA'V)>FX;;.MN^&X2/+[Z_Z_43A^23?N"K=S[S34U@#4]LE>>@48[S>L:H5 M@QB$^?ZV7V%Q2]?
+.$$U29&WRU$9^R%#*D?V+Z^V]4>3]I+-]B)SDKD]O5ND[6^1F MN((!2"(N,U*Z_LFBDJH7=>>:-;F[#ON)+A-OI%C ME:E@%S/3J"]6#?3.78+J+3_#X,J*7&_9ED.]PUNGGG5A-%F?H+5 -
WI$9K6Z0-KE:,U*S4;<,N]W=.6L3N(K^F+*1H.] M,>]LX#GH0]'7E5GW' V0]K][FWOK^Z]EN7^CWK[(K+T.U]),?W_[K:S-GS]9 M-R6K^]ZZA)MAC/4-Z:MKBC.A)NV^;#A:-R]7_>>R#O0;:GH]\TS1OE$VHY7?RR'M!#P8_
[.TJ&FA(%,6:B(-M;V[M8++R:SLYZ"'"KPY(B:?K6]43-Q TNM8 U_22#/57.+'6B>'\$C0E[EKX0]W5^.=24 @"=@]VB]ZK'+1S*.B;.C78=='M4!Z8-OZTK%4*6-*I^>YMO%]\/+/;![W*T,ZMNI%Z96_5BK]WI+FI=YY.(
M>XNT3^X@*9R:67-Y M4NZO1=+$_L_]!E@VM[NI<6^C.*[)SMHO'1+1^K2R5[<"E3' VZL##$!;]0IM M>Q^.K+(1,2CV#F^;96SOR]NRET)">J5DYX:3'_[^N(V:!/?)D"#"< MM&J9N%3QG-3HZ1R4]Q?9%UCXXD&3RV
6T^/!"]9(SO5#V]$,E#[#@.T,+5 M11:?M6E5887P=CQ.SE96]6]A]>]MM;T/A!LHB-B.:*]X63QIK58T:]7X]Q6RE M&B%(,32D%9'WQ7?<+IC2@9%K_'H@H"I-FD-DAX6?!K48@EKW$#1:^#A%K>'M.>TN3$G5]1)!-Y@W$%0N-
!,4,%:Q3DI=O=K[X1]@U/:WX?8R>%5!F;V"]^MUNCQR4PTSXJ%&XWNG/RS5 D8V-E,Q11*O58+F"0WW\B%7D$$G)^64K.A% MUQS6U!W"W_S,PK_%820@'1=74*V&,[,9'G%(JZ#PL,%I4]Z(X?;U0"M/@:
(@C;WAB_WTU*SHBH0[Y623#8;*EF>4>MHL #$'BD!]2;$?P:>M@130BVO MAP&M249NY19;^]'2AX0MU"]$L9Q@K#X-.>8$[IK_SV/AOPR&[BB]Z-I$$K0A MIE TD>U.4G5CVB^^]2'-U-Z-UD)2N7$Y,[=WJ;OIF&K];
[T7&C*1H7T,@R= M#*7/9M@;XQ!N%Z/XI0W2/Z]51E4?]1[,)_'P-T1S1E'K@B3G(4&]KG<=9# MI6:5S6YO2.!1BNHA0LT/MI#IZ[IL> \NHXI=-V6 Z/,6$>4'4NZG2B2]!.2> M>]YO:D/(ZN8H^SO?,0[&X]G?7.6RTC,_Y[
[BS7&O]I:[W3DXWE"^#S)M*3 M8]9]4]65.V,G[-ID#*<]NOCF%O]U\81BLV.1$9;+\'U2R/>XKCF3U:[WQRZR M+&T CDK,GCZ^'RJFWQ=17F>V9R(SVHNGZL!?7%V=_;Q-)+V!-'+^?DE]2B82FP$'OSX$[[20.OITG*]_0
MD2]W2*[_74?[H4*0P*^6-0-6]>RW0=6)BTU0:5]SV7]YBLA$>,-7E-HME%^&$.JO_U8+0P<*%:O)6&&#KSEHL/?3^K'%[ZPK]7ISF.;[KDF;IY8CT[@(R63?!_# M?,A%0Q_Z\M=\N\Y(M@RP
C;]\H8PQ^K;2=E[F[<8@;.G@$SS'5^]O2??HNO M4M*GAK[DWT.Z,7;KR/T=LJX,0&/#NW@8'X>;&!M#K53^4U"]RRHBWSOP522K M-W1GJ_3@9#>P<4LR:L;]UMK342\0=#9R*X^QY^8]@G2\D!9L!?\Y<@HU#QQ
M>2?!I9ZBDQ]?I'C:UNY*L!N]:M:^U#QM(Z+K\Q,))=AQ/T]?C]B0)2KK->W/L5-R%@$9S=R\B4^UA>X_K'-LD#E5IX(-F(K=IY%@Q*Y\6SH6 MIYC^7?7 0BP%3% OOH]661+9S?+4?]G\H7]G"H$DS,PVV%_A9EHE4R%7-$90 YQ-
9AD4S(@.4(,]XU-ZC M&M&^1?,X2CP^3$I7B/KW+;U(9CF)5F:HSXC;;2VD%:P31E^XU_/YAFT M$X=I=>HVU(_EE>Q/_KO>OQP'_YV$B!35&4(9->"#UKM"_UTUS*3G2U_O/U" MD#XBI^Q6^;544F<^.W6=;
(EPV96,3&8CR,@IV2]TX2W''YY^'S^]65=A_<5H?O/G=@PC@;W% M451.RYW/@BF2,L. 7V1=62#OKT>\SKR7;D5;WY]=#:'.S#U+%$KI>"T@2.0# M/!DUQ24X#T]$9E-XF\48BC4?>?ZV3&&ZS_:\UI9+!>]WPVTBA'];?T;4I=?R
MO$%?70T3T]2SI#:>1G0Z(OE-!'<!MI>0P4 &%V#@#&*%[M#]<[@/ DB>?3\3#]V\K M]2.]=KIZ7_^<;]R89 Y.]VBY*L1]%0]LU"@1?^C,HOOE$APE9$\QX$WYV"D.6+$*<]$&\=IJ5*Y3YKJH6?0:CP,-U$
<*8KR(R=H&.9,]&E@YDG.Y M[_\XZDGI ET\9 !TN2141Q7^7>]?CI7^9C_@_2_GAC]GY0X2KUY"TV9.V M\2?TN^*# M Q\R*>=/E2M\U,ZWC7.:1XB=ZS8]-4"Q#O HZ Q1AFB4#*O=^8.1
M;!NX[\NZ@H1P#2[=G6KZ^/SP/,.83_DM E)>CO;<4UESURR\?V:AQ#?#11" MDO!L2,3]1>C*5>ZO30@0K\O:SDV7^M SQDV@4(*3Z_=C<!,,I9!!742%)S-OZ^E,/#F=U M]ZQW*
>;4)!,FNW_>RNVW]]#]C]"L(VE=-<^^?7Z'(G@,F0W^C*'EMQH/?=V M.8,UR1_V94R.D3!VZ<,CUE\5P8_L278B[5>SU]9 ;[K+8@:47.9/ O O%'I MT3B5XI +D.]V!C+\0U=\[K-V>-0;DD^D0BGD8Q]TSX%ZL?U?[17K\0[OH]Q!
M!/#B'3R9 K-#,I<;LAS-]R=]2N=@2:3&V6!,"^AFY!F]%/%8]MQ.E1CINO @ MK55SVZFM!9]2,Q>X]; M!U/,C+O'83:UT@+U:R:0[W#>>Y 'Y.^M>--G8W$5D$ M!CC6@8 1!UZ]C?!2'3YX]HC?0:CP,-U$
W&7_WJJP$;;0*?.Q0"YU1U, MCG]=1+])?0'H=0XEO.B6V5?%?YW(KSF6/-V,)-B(MB\#A'W'3-$"#$GXZ,U.V-?#2#N,;-V/<#L@L?6H#S2&/Z;+[M<>834\
(@3#OPNDN]Q$)X1=O"'YY'0CN2RSBZ42-\20L&/$6BDK=R]AA\3UT? MY[N][;S/W]B)G76LPF]0%%6N'@1R]@.Y-6L;3S&X1(HV>_#3=@K;GX[]QDS MT(#,BY5=-MC)9=!-&#G23C,W.RYD#]-46LF5ZPY:
[-Z.NVM\9 =]U'AC&.> M!='RJK+WOM]@\+;((5PN;OY#D?.BO0&DE&;)%H0@NR<5ZNYDT7#QLI/JP(#X MQ4/IEPJ *Y4LT.[34$?6:[*]>*IM(G1[F_L3FGY:#ROF387Y M/Y ~=:#>*+LA*ACAOY=2EIK9<\^+4A4CXYE?
A79?"'"6:E(R'2AAR1ZLZ&>R6W0_V]M) RT@>ZX^$'4_M.00TQE<,'FNI]]_<5I2.N>@U4EVH$]8E4SM=>.&FDZAM!Z0&Q-G<[0^K.=+[*F_OXRFRWD_51HVD%NXHJKQ?G9+S$XE]:3]$^;$IH_IFI/FI*[D\8@-]%<]A7D-$1-
MD3IDA2NOLG]O/8M84+2Y4UHFSJ.?BBN_O'A/QW3 MI3HDMAZ1G]E7$?H:03NGD6$7.4*W\<7POIY>D)4J_D/Y3_66,0AQ@0Q&\ M-@N(>4.]#%F'I%'S(AZG+Q?54[]%V@8K!LF8KIN:0K:'B@G_4GUY(]4\Z#%*
MN"+WP#]HK;BR?!HK)"C+$G(ZSG5^R_)/ 8M9;1M+97K\Q(M MHO<2%80R%C@G/#$ H1$9LTVH=?]++XAP%IU'>;Y-YZ_ZMZN5\MV*JX;L^>V@H(FF \E;\Q~&\8[IRU!;JE;]IOQ[D(\I\@UF/KSJ?KR$$MM#H:1"^^PS/^0?/.$]H*H%6]
3Q6E;]U!KBIXF_V6"%>?LR_JS!7 M<7*L+G1V!X0-%0'))=L\#XDDI'JESD]RDLT@*J7L]TF@/5MK@KKGXS&*=R60K M$R+>0W]]5\7>X"]:"4-]"]RBUD41]*UC_TI%?7OG9HZ5$CD_NKD2J)^MO=YXIM:QU)O@$?
U;V&1]KC*MVF<+K.-.5"^3*]/U3V@"6[PCPKF!N-W?R(1 MNFP7]Z0YUC?Z#F%[*]=E5_E8D>S M:<4!@ 9VDET?_+S7^PLR6]G85KN<9_$PR&0.F2SWSF.PEVO;>]3\]_=
MYAK77YB;=0K;TG9^\%+9N.]':$3_]IZ"8_GFV=CM@!A-5U6BX.IO4*^Y;&&"^ M75]H%/ME3$\C3"A #!%0H3N"DRY/"&;;+IBCIZ"12O)EK5.[]BB^B4 BV5<% MX-,UDSV7]:H/5)4]&T)87Q3,]Z*%,B$_ID23S=C.F&R)P?
Z/L,LGMLOS$I*S!*7,^,+^,R;#6#BUXDBEI^EUA" M6#T]A;YP=<8^A&.]T0AW"X]1[9,OG=16[^NBTD%\SB2BC\[<]8I3<,0*A=#X2>[#]]L1B@A+.X>(#];$L?;-W]B80*W>0U*IKS]WGSN:]AM9.U;4@A^]Y MO6Z;]?@:-
[OMQW,>OY:5[18?/IAKKSNWX5$WY2E/^!]ZI]"TY!@]*\OM)/KH;#6P]GKD-G6*!^,HP)^,4]P^>,@?%:DUN5/MKG)=5Y5%;->!%)#Z&-,GORK,-]SM5[]E !*-~";=[^]/N)*MHI MYX."^"^
45D&Q_#%RLP3>_3BV,)%G"W:]#RBNB\[NBBXZ0YMZ])PN;M?V+PW MFT-$%[BL]*]U86V.HKJ]1&G=>2H3F-SBL%K1WRGCY6O[3H$7-27.Y@WI;I M1QR?KO3 I=LC>*5>U$CW1"'ZP:W1,ZN-DO/2\-3?B@A0B6RN

D4IO)A/+3[M"W1?+5*$!.1]L.79G-N>O+KL?;+KZ/WO!.[*EV<=S7@%0<(G?:=Y'P6I0OCT M6N+=@RBL[X"^ 1H@ P6_CPE1R%'MEO31ES!GY_W[NK8)3"0+_!HE.#E]TU-O M3;&1<3"/6:A("5O]*D]!\F6W0 -
D"@9%W87\FO1^RVQ->"&RE[>;%_(21Y MZ)-\,ONS#*2E_E%+%'IP6Y'@Q7!9N4-++(/!&> U>KX-['%6TC(!Z*?K0BD+ M)EK/K(F*A6_,M3,,P)A/ M!(E9E5TV]C6[_H0!T%(0#+ R^3[(D$IDZ4/K0I?.[V<&,G8@V%\N9V/[^7
M[)]32@[N[T:T*6B/!])6&->*PBXER_M6AP++Z\?:^CZNB::$!^_/9!K*23I? M34:UX9BI!0XE=M7#)?'-3%*L.+LS^';#A)E6[IE&3*_P(]A= M!$$G;>F^T4CO3?$\<2M]+]@@ 6K.-!]-M/MA3U]3C.C#E$;\]:P@N$A'$T6'!MKD+*4?
M7ZAA53X"K]]8&;7^[BJ!>_/J,#EA6X]+<[[CM QFVK&&!Q&T ()V*A8U2_GE5/ M(&Y?E5&K6E]22ID4]/]P'OEG^_#^Y,1.132'D*%Q>ABG[N%[H=LC3W@P[,%ISVG-FWW1U.\XG_-_8>^NH.+]F M3;0)'BRX0X(G6 CN$(*%$
CN[DTCP9U-<(<-8(%EX8@30.-NP2'QMV]T30^ M?-^<==>?[?N?<<^;NN?.G37S1_^Q>ZVWNG;5WD_5[^[:U3"A%B;64-"M*Y8 MH1Y_;-;ED)>S4#H[5*=.=C-G4]]>;$F(DF9:$+@R0]Z[I%3&$IGX/CTVTXLV MR: CCBV4)?
8#B6:,PF+;.>G.]C][_: K!F4;[H[[(I>%L"-O(?\%7_*$4#!-_M%#:];<,TL&%-W'PW"2(WBSRL/'-=SO-]2]'<>GZ7^C/^R M %?/Z=&0A5/G.7.^ N]>[@5X?'<6ADAJY*GFQ:Q=$XK/2'C9#&Z1PRKO?P<-M!K(H[NS?
4[4PC3/.VAT'!DZL6/EOL1+C1@I,*BHC&60B+G]$[P M.F0L&L.4(R;VD:X72BC9>**]ND!0.#[DOH(6+Q>*NP1OP .B;1.$.=F7/ M1.&?L0IE>P&;*H)!%+<G&/WJ5UR%,2/W@6%A;4:$6;IYH2 U^2]U[LJEA)C M-IT"-
K;,4_*)/IG[^!*T5X1!9Z:U1G$FHFEZZVY/?;P%/;6ZB%*]3]K23E. MV&T.6$QTM>T-=^R41GG;HIG/%/_Z;7(#;/P0[VGX>,^XDG/4D"-:L3CK9%&?O?'1C]XAV MYM]'Q^(C-W8]1*(1WG1X@O^IM\4NN?%OI<;/E09!W(I95B?
XN9SP M;+?)''' M+68]#9!'X0'P,]'C<^??;4HA\ BAI[467(R]T%;GU*?VI#RH)+S8%H5R^KT M#T?*?:%K1]HB D^+UU*XO-^)^:>1PF@]R0=9B&C4<0+CX=0G Z?9(CS2:^GW> $+%)_TTV3OS]M&,)IGU M-
'%Z,T]P1RKCQ\]'^Z,7?SCPP,]>1F&%5>R-Y]#VFQ8@WZ(E'|/$6ZJ%N[&265^6=;A]/.)$6W':4^7 MXH]7W^)?G0>3__2H*Y8 LY\TR1T M;>6U;]0T71?E6\?]]S1E>M7*O5 ;#ZW@<^80*ZY8Y%$KO@&X>S/8]LE*4;-
M"\X)$1150;@$URC__AW!!\@DDR%CYVE%6HE1R[W&WX^.C_W M[/W\FCB]]GZ,PW:G2$ XPPW>;]"3H>@?+>P1M+V-ZK;Y&H,X33\IC*3K],IM[AB8D!+Q@2Y6?_H%5Y@N5
M<14VW,J,^4K:X8TX)MBYD<_[KC(0O7RZ,32!A,HAZ2Q#MRZIT?B-P&G/N=:5 M#.GF9_9Y;G'9G-W&KWK^>6!=/4,%% 66S$\SQ(%2K.*>X$; U:#]](5H^#LU M8\\XE4<0^.J]5*C;R3%>LX2].&
[U0AHT\$KT%*%$0PRV#=BS%XCN.;P+B@? M%%^$3(INN!'5]?T1,FS1>Y&L48%MYG,6>:DY<3"MY?<)-&K4]!8C QGY1,&X M4)'_<8<34=P:FIL#]9- VG)G*E,5%7@3BB_),[Y,RCI68_Z%_)R*-=)O4>T M)\%\=U96]2?
H(]&4#FOI(X/X#RK; LT2W>VIZHEZ@-'K,T^[ZI;0[5PBW)I M@E55G!T=:PZ)F8S,PR=4!KB9"GW5 H-7BJA1WRMJ+?OIOBH6VO?5>]>&X(S MP/GE2=4)]\A*6,I9?GZA00;9!
M]+6Z^R)!OWG;!9)/N7;"=X]';QM2T_%>;.J(!B3%/)K< 453T^FA:)+6B M^) ?H2R Q\>N@I&LUYH>_X/KQ0^TPDY$@9TB"'*\9HR3W7_'L3=HARG9 A\ M);#,8+KG_9_7%9T5)J:#@W,R\^M#FI-W7/,P>7'@/I)L:]*BK.!?5&
<5%\ON> + MEN(&\X8)]L"!E2X0Q5!9$UH/A=?%;LSMLB@Q-A(%<,O%I6GMIO[;45Z_YVR3 M__;S(>:31UY&B=\"+@E46D@AGKG]B0/L-5E^BL?+HI^)1^1AE0U+H!5A^[
M1$)IR^Q4VJKF^0A*#AD%1K;P=,'+T"2W54/\CC.=+|K=D7LL+YG2] 1F4/$U M%&!]HM5_B; T4,WD.0]"3S!?"T =Y FQ?W296&VT^08+T7Q=&-V4;68&6.M MR<+9*'3N,HPN]S%XGTS)ZK#* :\#:[89U9]RC-
P[)"8FI[&I.6@.-9 Y12]] MY*,*"4K'+7NH@B]W"2\CGYI=*K&LQZ6+/32RBY['3'\)O6IABQWV]V5M6M6;2 MWHWMPYS?.;DSQIP1-FJQ1!HFV/@OI/SOQ#RQ%?S642!7K(Z.I]H68LTB9*QP
M1L5_@..5YS']\%!DCGT(="0FZW:97>VK,YI MAQSG!<+6!!)_'H1 6>6-EXG>/'E,/;96K&,G478TM+$="Y%'>VCU$&I(P0A. M='G"3FYR6!7QF59 E<2+!\#H5=%CUA7W (".8EK*.K?.9#|] .SX3CP&M4_<=R'#'@
R6]D/@"#)^V4IVF32G@> F;_ R#W3.4QR:!_ #CFW1"OT=\1 MI ?<8ST ;OP [AK:U"<1)P3W84.2#P"T@+N6N .5\(!S"=O'#(3Q 7!XCC+[MR<#QDK5+\IJ>[P%P2_@ N+R6_)^JT !ROE.D=HDC3&WLB-?#*S-'ZD/\ 31%
M@.'#]FIY6.R1-B+GS!@#*L_'++#T#6(=6>0-1]B-WSB4/,\V[KBVC15K]?=],0POA+DSA9QU5]S1$XRER MXNL-+G]=#0NR0WV=BV;:S2W7E05P@]YPMCQ#@]^:%(#'Y3]>_J_61 X!>96? MHR)"/M05Y]?T:8+#I
86ZV4)C#^QPV'X*E.%(T!2I2GY4@("\Q(H]%I7HG ; M'-(RM"(@TOU^R!@I#;KDH4K@6@"A>GU6%,8,-DK]7VV!_ :C'X<9 MTE+? (7HUS.E>')T3W\C;5\XB9>6DAK!!'6RF_X/Q:09+,\L>K*\@X/7@PRG
MZQ]Y&K@BMF28A#]^>]03XK''\7Z$%LO3G]9$91-4*LLV$7%O*!2.#^;1N2C MW: L(A?Q54TQNP7%R'LEX8=;1=D_SY7^KP9#%5TU^"RSPA^3^\)_WK5?Z&M' MZOL)7NQ$QGLP-=/7
Q'MW.G_#]"(F9X0?'CD2RPF6&T@#;R,\DBTX90=B]&R M U1#F*Z/;ZVL6*Q,_H=RZ!SX:24"GE;O]_;2V#]\,/Y$!H$(?*FQ/M3,%P-X M+2=IQ@&:1Z+/(MQ?\(#@"FT26:!!-SH;ZG1AY?HS+QAQLA&BG--6!0AW1;)=Z!^PQ_Y&
(@^(*-MP7_V$L-.Z[-J0<]]%<;Z^]]!T!'.6K-/U;DYD%(5#$'1#A<%/,XM-9O/]YQ MDFM#ZFNC/GI;_-)F_J)P]+PR GJ5_59^1+^XU]53#Q$X4L3Y=5I%7$:H+)BT395YW;#CFG M[_T___6![3\=WCX
B#R!AE,M,XSMLFB;]!S*0'GSTK23*3TLH8H%Q*RT.H"+ MENBR+.P*%BQ('.Z.5B-^II_;3QO$4#F.3XIM0OJ.839;79?91HG54R=ZUDK2 M(IT'0!2?"AYXPLY% ;\@:?EWE9Q!^?MVER\+28&B*]<:(H)1M9FFQV.^-Y3G MAZ%
[.,AH@[?US!2ACYR]?<14W<6R?=N]S$5O;#SKG\4 Q] XR8HV6>W5B/L9L;KE+O=O%!^A17"KS M_%?,2"IOEP*=>?2K8I[D1"$&F]YW=PXTEP6-N; A0Z>//%KO%'Y:C"(BX[-M%8F"R5E+A-+&!*]MP41,+04+Q)7HM(
=7S797T>/N G]]"JB5:\34|F,CU6 M,C$.F:[71PH?UH(3'_N.:'AFN0!F6]>Y@=#*8_3 ;F(8^-]_F/<$9:";25G MRP!G"ZLL-@;%%,$.&"NB;OR=N/3N."R]<^P3U&!S71>U:%^T;Z5<:N"^"']FP2CF,/^# MN$TL?6?
_QPEKF&LVF4VBS767BY(Y>UFUC!,BY=5G"8OGZ\^=?U !5CC=""'CM MZ]YE]{8933})!@X!T'/P'H'6R<-0-"["7SD629DYO^8G^"'M]UN@)#?U91_G! M$NO#C\=L(66H,4("CG$&.-!-V>(P45E7 M-_U@9PHGU:>J_H=A-
EBB6F;Y/B=DI&M/WWSXZ M]B:*5Z'81\H ZUOAZ'3#%,B7V]'$<'2KS$DTGZ&O_&I>W/@C6^-M;_6OI4G?"69O[ML\G<%KKG/C'F6.G MG&DC#C[I^K;_4;->RHT#Q.PM(UZH&GN*=LTI?7],0QOQ(OTN^ZP[I-%QNTA;4
M)_9,?,WT"ER#-0@#./I:3%MN^W[DK-^E(V-R(I@->B-YBBYZ2$\BN4.\&G!+ M81!P$@DXR^ .O9Z<8YV] &%@9XG3;]1!%9=83PO3#S>^XM*6NI-N.#4+E7L] M;\SH$4S!^^Y(MZ&K;]!=5<'0Y"L\@A\;UZ"S%B%/0SVI?
THVQ:6.D%;.C(A8^A4G\>;V6\0*)%F(OK>!4Y#]/GF:O?#^]HL*X)#]6&]@^;$/ZS$,_)Z;UQ) MW]|TM"_LX,OO8'L?>]]VJUA%ALP54K^YHSJWYK?'LEG;!]=.K0V\#@K5E;^2 M]OXLQEFH+Y7.>RIUP=,OX,V@57K,
[E+#,HX_2GXN+5*+TA(]#!4!%LC17;B(MQRW#/0&9MT\OL"<1=N@3A07OZ'LGF^RDE'C1"*YPD[5+\6'OZ'N3(MTW,Q:_8B_MX2]?"QQ3%,\3FSSF1?\LMNBNZ"YXE/LN//I) '3!D3)YN ;F[95 R' 0>9I MP4WA_-
R82(%MU6"'_HWF>L[3'Q4!+L,$C,+= '5H4\O$/=M.*B$R\O)& B39EE,+ZP>AUS]F=.>@/N&"/!*.I6=O0\RIBP(LVV: |^:MC= MYW,93U/YT4Q5GK&,\&I)G1'1&OYSJN+"YI9\I;L9I]U;2)Y*Z70K>5O5MK@0 MV[PO?R/9*S?
0,WA/V(I%[2>>YZ,S=-&N\Q3WA?&"D]2N%%4+3DMC8U07&3FO MV/H'."LD4I':A6(@OY1WV3&CUH>MH]=I7G;BGLFF#LHC6X@TT^6]*("E:[76 MHR_)<01LQDF]SIN5!=[]\P;]6QY\S]_4&;)T0/W"-P3]24[50BS/>W9I729
M=XIS7%>^D>\FN$9#&C\ ,CI;\VJ+L""':P(0$(BDT3'T9R)C[W>00\F2$UA MYO4#($4LN(]Q-!V05V(,U".(:3)F/HZHH.J1)!#(?=+$O]GS[!2@6'9AY.H MPDI*WRDN8Q"FUS)^RM^6%M9I&!710K_L66LI,]1?KC1%=]) --
T@G"]XT]M^_WR"8$I+$5D;]DVO,:H4[<^U0$!6T#= W:O#=L;7\YT4 M%&?DC"$;*&>.XJ1^VI-V0KU)W11Y?:7+C/2)-4Z$60SN\6ZZ409#.+]CEAJW M8<7]L1_MX&DK0P&R<'QP-9*UO_IC#-P_/R5.=MV>9[MB1'V(ZN]A=
(55XHA:\%07PW?MTLO)/ 1 9=E053[AU#]6&U;R3V1]>B+;FFW M%3_WLQO>0R-LA$'KK)C]=#AR/6;V''^2+MT-SK*ED9'4]I6A72/+&K]FPR0 M?% WF8[F@!^]->IHY %P]#:3=TTNV:/4L")[-:V"GSW)A2\FP(E@\6G9?='/
MTD!V0P<)U@V'\2;N6.3D(QX-/0+;/UX%,-*9TZ'C3)BS4LN=+KV)K)(%>&&& M01:!\C XEQO([L8@DINP-Z>=(.(,*_VN8],?,?^#M9XV9DDB_41??7GT:I M+#R"RLNTV.3.UZYP?Y0TL<#%>+]880]ZE![]X]+XMODCNT@+U;-
#_I\U/2-M!].7 Q^1KIO@_0)%#EZB(A MQ@\LA.ZKV?KCCM;ZP/0'1,W2CV94HB*L,:ED>]G?#RM>??\G31!HXK.R=Y% M;HQ(]EP2?_L93B4C-5K\Z?MH>_-]T\:T)'TWSLXAI_)VF"87!.@#!+\B@2VP MZ&[IC%F 6AF?
F'Q\\JISU_#=$0;8Q@G_2#C9NEK0UFY"A6GHZ;N@=;-#ZC5, M(%X3G7"ITRT_HDG_@RQ+=]&$R;F36,F#$5+N7(<<)V/E"=;$GA!9B%@ T3LAC M(8XX2']VL+K"K]:IM-!.S?<-,9P:QY3)8'5/8REBXP" '9/LT!E>2\?3V=A
M>\FNU]6CPP.@F=UEDX@)]Y%&IOQ8WQ$'?EY?,0US^*EP)%F.V<4J/RC_LZ1/H!\'2B(^:R%JB?]KP^5N<=GMN+ MV$5FT#B6ME"<\SZ4%&;YH<:7^.NL5D3AJ0[^^2QYX,C=$;ZMZ\F M^6\$>.W<"7MQ0]?H.=^-
V\^SC/IO,6O3E4UCP&"'7(-J#,7I>_1"C-[W1BOA"2$.P^&J*/O$FQR>[T870T2CY]#BW+ MQ?7[50^64QXY,:>M0<7,Y\V^8]$(*JZ:L < RHY(R] K@M\>1O:)TDQ5O6X, MLNP=TA%I*.WL7ZY4,:CV[(Y"$#Z?
X.1Z68/]$+^WL@W0=_W/AM[\C&^+-B6A MX^U6A9RDU/Q$.G3PT+2\:%8F /"P6SZW/+9*Y,ZF14:%&C2D(>/^4$ MR-507C946*OG7G$CG2PYW%@HZ?E'?U4EGK85(F?=Z]1 7\E2?3W]$;RN3W-S M?H%>Y 24*?-
Q"WW25Z,K%O0!ZE(4[@\ HL+&J76=6HZ=4[NH O!,_=V^]#YG MQZ\XQP^T15O*=EFI)VK7]_?]K=6<+9W><+:L#UOR,146;D\/ W-'671%3H4K M6E30;$ T6S& ;;,F&9$&S(;98?#KY^A0(M(>ST]5@U2W%&5X/R89(2R
M!;EX,9,#_A/4&.3O>S%8UZFU&6D5UP*9HR0X.$)7P9RUIOQSR@'?L\P$>X&" MW\P/U5-=HE';CH#C'.Y-:RK0IEC!&.L82VR0TM M<<+GG9_E#VK!VF).YJ:LI$Q3*EZ6NC$S3/%<.'C&L_TGK<77^N,7UYN,38
MI58".\/2Z[]9QH9%"5KTY8X-ZD!8K)BED^L=EVBS=%>"D;%LL:YM!'/W5/GG M5V\/]>.+\97H0@("-"+;*2NMIEHK=O\M_%]1N1I,Z3= *#A3@3D?]F99W&.I
M>SR1L>NK2U%>MFB"5*%53)>'K*G>,I3^XZ4KF'&_AJUI\S9WN_4=49%^M5&9 M] =G,2);6)SI8PXT7?XSGM6*V-!*TGU-I8(2XDTRIEI)* 9P AQ_VX%-PY"7FZ*K%^/8]\?K$ M4>8H3@3#V?N*59C9-OK-I?
GL,BTO([W5D01,OC#_C!4O,#8WN8@&._V5UGQY25PE8%/%]B%V%;YJHMG]]T 7AP*GFE.U^\9+]^&K"M]*ZRUEX]6UM8Q5Y8"-K>,')]1NEP_M>:G5#]G(1-\]*:*$-?^HMQ-
TCE!TLM$=>]%A>%Z\.HL9Y\'_N+HVJ]\"^V^R].GATW!=%O]4.X&R[<8F$;> MZI5-?L[->HH'=<-WO>0R1?C1]P?5@VMO[U4(Z;)X5D)"@G*UXIWWRW/ZKS ,(_;;^#]>.S:XTY:.AYYN?3I74-R(V,--KE M0$&X.LT F2QCR]NX
L#GE < (3>Y>LVX6QQ!E-(\+.J=9N3.^Y_L7UY]#X\-M?]G7'AF%S/=A>=]IGLCD5$D#7KD9E]DBA9)KB6BR'EJA'H2"]XL],LS$VPI:>KMF*"M:Q9H^3V-&-M(Y)"!3]H.?>UD^ZX#>]F48^[^LQ4"PF,$?V<
HK*>A@F0VW!R\GC:@;DO[; MQ2[N#6O8\]S1BY-BA'D]>G]N81,M+!W9,J0+1K4@Z-Y&M]LN-MU\C>768TR,&B#L3]H\D M"]3AJOPD=Q#\DM;6P[^\#^>5C]#S M[&HF"-M3KK"S9H:TW+(+=AM;*Z*E?
M/QMS&NH3Y"8QA2CM[P"&S]Y_"B0VGS[XA2^WZ:52&FO"M-E<'[M8@UQ&H/L=8 M/Q0]K[&;!$+9/U6IRN]1M-5U)4R< ?@^UP<&$;[W-,BAL-6#=\8BDI/K%75 M)7K46T1(H2]L9.^(Q]9PO]P[TF4;;H7R"_<8;;+"]I M1-
SG&\@D_S0F)80BYU>!6]',3XS7M1CR$]!'\&B0XVI]B27\L)>.L*7DR9M M+;,12-\<:FA9&)VOX?F*$H&MEE/5XV^OB%E!:8*KK[H/Z888H+HD=>KNU_BE8 MO6.
(_3"FH]R6QL<]$$4SYK7WAE4@#P3LT=M"B+@L*'M,;_;B9>P3\U.]FD T MA;+]9!V]GB]B]9]O?&9_;QRA9\ CIFX+';,#^L+I9T^O;% ^XA7_XN'8C<&4A MX.'1]P<6[&RX8/T@ M^F^R/V\^/"FN4YRW]YG\9?89_VUP(':9!-
Y)VXG8M_G_LV\HK5^X9< -PZ3W'Z 0 ?8IE /VU3@-NQ9]U0M]B&1LPP]68>8V :*GRL F*S#O,! M&HK0*CX /$)-Q/6<:+O5L9^,=;QOUEN([^QUQ)W\&/Q([N\5)98FS7_)B:(M]D.D,>$TE/U"U38U&]OU)D:
<#\;IHUI5XR?!*;'+]+-8H2:LIVGV.[^,S&.8 M)WY!$]5^26RB9;KD> *"4K!;N,K%+\E&[>:)]82TX."4:C]>:2"KZT;5QQ7 MSA+YU IH[&NH:PQ.>?"K&R@(0-"<%._9 ;>2FR>0GC\"%]BW]_BG"]9L1<,@ M :]VHDSD,S]7I%L'Q
M78G2HH&,%"0HYIT2 BJDGB$_?RDWFN_^6NHQ=&9S3WEGZ:"P/GAX!?>XY02) M#_BE=]9/=0RGJCCTDYA\Y,Q R4/I#@#].3AQE]R3DMN M^%VR.C$!?]ZG6"H:N6D/[@&$K!7_?%[!]9$E=W9'ZWU5\#?^;MC?W+^.5%&9
MYD-A\'TW:EF=7I8(A5[$DV6_BN3;>9ZPS:'0]WM55!IAN?*"48N7B1G7*9]&25Q<48-1E[M0GS:.PI,VM+M6_9Z_0^M8U;3$,PQ+B++T';W5_-\B5X9P>@+W?K)"Q]%7*0(M%WT_3MB[SR_;BGRE*IKKSK
]]:);_6UDE[E99Y(C=-4@Y@:F/].1W;T>SBA: MM(56R?LCNE+Q2TDM4D6?51SV%F(# A7*895AW%ZFQ?)N:TH944/O-7WF(T F MK06R<8,ZOV6? O:(2OF0N3-FT$._^VB?S&-M+;=$1KLTO"VM#9<>Z/0T<&&QZ
MB9],2=E_+$5K'.(&B]'K^;8&>%EZB<>%':S_S0DEN@3"K^WUV3^/]3=\7>8N/ M@-C?*@_)*-;WY)"'WE&) L?1R"8ZCY7P.0^V.>?S]"?BO7>&5+^O1]SDS7 M]/P0 =<;<<*$0T?8E8XJF(?8)GAJ%'\EA$5GX()>
(5IOYY3]'LK'#M\20X]0;_6FP'W7AK^4C@I:FH+M00U^,%B1V,<$#8,>VY@'0V]H1]\ #0-%?[#&/R%*>-#ZC%E2X8;[L.MIY-#M\K]$A%U)\S=&E>SQZBIV=]DZ"?8Z3-"*/U M:^\:7"O)7U"WI9D:,QC7-"]]0N^)+QY"!I@QB8CR
MN3XNK'[6(3"@ZZBR=XL+NZ0CGW2UN6<24?'>>0 X!EZI=9@KC^]"M&DX%/#]M_PCO2U%]Q@CB+FAIK3G GEL"9X6,)B;H_>@P%3R2\B0[ZQ$]?C67;#<$E M.(SDG?GA8:LW4#P&(9#=Z M4>&&5e^"^F'=
AG)&GYP3]-.CP>7XLOJ(E_!A11XU3IBMFSTRN9]F3X73@ M-$Z9_T:1&Z>3C!4UYSP"]]])##)!Z;OF%8=-_-M-N0X6N$OK032TWZ\9IR M &6Z67OBGI7#'Z=J^@+,%P)!**U]9S:H\!-I-X9;;))4/]3P']E%QL!U:4PGS
M2$!:WRCUDOUQL5'WVG\1S5;O^'+XZAL7)D$63Q]I\MI-;^@]U^30QJ8Z)1% MC3YKS O=UU$OG%2KLSDCA)C< -Y/0=F)UVC,W;3]7H&?X"6I2H6/W_C,\(M6'X .*9-* *QDW?YXFIJ-RJ%UK)9NR'+HZ@.2&+Y>0H(>-(HW*M?
U'8E89DX8?F?1 MVB^+L\$IT\Y4^>"B57;,$4C$B2GPU1Y7_';/5FHHZ%-0%4NH9]IWQ@AOERG*38)W(Y !=MT1+T-;!JZROY_,@M"D T#T GOZ]UN6>++7S 7!-9?' .#E&Y/WS, =(!] MN"^/2?Y/%%/E-
@C^")77S_=S]3>A"0-2!0]),TMNY1"*I\G.0//U*"6<"&VI!:S;3OH6.(68]RBZZ#&=9RA]2!;= M27)*%% L_;M C1%F-4O:XF\YHG*"PH,K! Y R/3'.@Y4F\]SW2)U%L"5]B?F
MV;"EIB#].$Q%Q%)GV^)I=K2R*"TRZ70]S@:RP\VE)/0:VQ M"TZN!\"B:&<;CB=X>5#V;:#%>VV3B*T=X9M?^N80?>W MCAG_.?:MAD3%O%U6>+3O@=;U!3F/?M-/9I>CWIQCI!;Y+2=WV /@G&-V ;"^ MO*H!H8^@PX9-
<'&6^X\LS9T92>4"LTRCKP]-@Y&C&*ZMA-RY2/DB5Q+7>@?^ M.[FA NC$3Y?-VLBO["VQ\F73-<^"I?IT#">62W&(M?FNL4X'EC1.I;;NI@QG M=H;:F+COI4?
#F*RDV\IT;IF3.L@:\:O634N4+8\R077I'DEW#"@.B!^DU_;ZS'^$#RWA!4=^R\%*&9'0.@GG*LB=! MC%I2'\3&XEXKMV:!0"-4%0;VTG\;4*N2V6&*.GG6[%V_249Y8/IH#?W8Q/TLH M^.LN<$'5I9&;G5%@=)=1NBH'H"
=_^CGB'%75'YO>VVAN M%0G^SSV-#]X8^E6;;*V"_(=!^<1HE(*EX9='PBK?GLQHS5W]IGV@.:E5S6VY+QVY)G%"R1 M[K&27)QINKA9=BW^)]LU\]T MK-U1SR9 &OKNWS?P=]0T?!C.^R/#$O.7[D\ M47XIEO=),-
E:]]R/3D;K@4IE,0*Y;GZX@TXF'^1QRL1.">TERL%A$Q?7G<7 M7/24@,IX.RU2Q_<(^TYYY]=43H2Y?]T/L2FW#P)]TC%]#68C6 ZJ0OG.A6:IQN:O<6S%UKD6;]]Y M>-G;0WSQ-I51HAY /.1'@IPOC&0%P;X<]KE'T'B*
[Q!RV3TS!I.0G#9MIZ M+]I9SY$>];J7-5)"%YDV80:-THTGHJ@7A^D$'AS>;\P!C3@S5N%"6I7H6!M"E$\]"UA,&[C;+(%$@]WQ#P^]6STR2]"I^OQ2HRY/?$6-
[].;]LUX0-B2!A!G!B/>#X4Q^_5]U88ISYOA]R M>(=HK($CT3#X%',\K]BT.?^]]*LWDG[N-FY#D-N@DY\9K ->I>.RY][LT#]\@ M09S-SSQ9R2-[RP2WB@75?HVB>9Q#4Q=)_0*9)!.*-K]ZG[_Q'1X7-L,2$]:&
M18]B^@/]&#NFM>#]U/TF2E/;ARX HP*YG+Q@>],9Y!]]M*/V+M] T;8S:T MO+_^6<8E8]VIPMW6A&ZH18W;/?&; V'.Y,K'8F_E3"?I7Q?SX]%HGFQ5Q M:V'CE9Q/Y]
[F*"'ML"23*X":]^KHGK?/=>O*+VIX13Y0*TMEE[:*&-\K3=QH2 MJODY)OYI#3]&PNWR8OMYP0EWL+VO8O'L@C)>(P44N_!4.EUVSIW-88#BB+$% ML*-L:=-" *]UQ+)+!V75H+>4>#HXG61S49R)O12#/"(0K&];T\-
JZ0(Y4^> MS+[0AGYA9V>?WJEM:]4XC8V3!1T9]N4PPU&TTTE'K#^[;'L? M=&69QOE&&QF9[,G>1LO1 Y_A+YS*\1ID9G=F6BT!8U2-;07THALS*WYRVA\- MENE[O>R]\'U*U16F QCN(F#[&]R=CA=-%G^$2Z*FVUN/E"P.-
MPTPT+]QY%\4XD-$5.6 N2O,H)>91<7G6'N-LN0KTY,JH4\90>5WN=*B(.;O$ MP38R\;]N*T;0/?LI!I9NL:F_5&@Q2KD)MM2B':;WJYI)1:!,GRV8]\HM^4I& MW%-#&;ZY1,/PP/Z-LE M&_1DZ!S-\L?0
*)O0M+]XL,VCA*AGO$96OJ-]WSEE^A! $VL)$&M1O61KTH MO=765]\^;J].GH#)-"Y&)F]UEC36!7;]=-8!VOR BD9=B&2'P#]SQFI@]@V M>)L2X)6[2SCPO).L[+*]]-A,YKIOTYQV([[;M**S>@8S_(G @*^X\=@Y!._^
M$4C+P7KK&!]^JUL6/^TM&A^/54.6U8=_Y8C T+TF']?CCG!0Z8]'3^?9.'Z*RI1>C] MZ*^(\#;[)RQM2C= 1V_]B_7#@2V.7C)BB9N_%G-AF2" M?.S-QONC8KQ6$4&>HP"8S>V30:.P MLDDAM=#X*G,V--$^C>@2BC8*1EIE -
#36,^8"*G^83IE"BQ]CB.9^)NB-WN5 MRDYNK.SYCH+91S^OBHI_UX?_;MMQ MT1&R73(ZIOON1F+&5UM*;:T-,4W0;XST:@DPU\/CQ_W--N&:C:T5M9W9/Y+ M0OB/])\<0R+NR0
MPSI]R6<$REN.8X=*SHXSV"L^A2_>5\E3@[U]+&MICVSZ%5T?;.+Z"#<2O3Q%U'OPBE;ET.U;REY$S M]+-"*-B\&&Z^::?GLQ>T^]N]W2'7WPM;DDLI4/Q._]]]I&@/_O9, MJ3GT=''&QQ8*+PL*-QI5QO*E2&4$061M#WY4P;Z
K/DRL,H9B?^6.S9-D3]9& MVO=H3M?.Z+M@-'&!"INB&]UZI2S-[V%)+DYX7!*K_RAM7%=/E MW^O31%[].:@R]K9>N+#;F/2N1M]1_U0_NZ:3Z3<9/X>*,$?.(1N]-0B0;LLRL*NZ4NF[F5@DRU5O&!R:CE&@4%O?U-
MZVL29<>+$";/;?6Z"/X6:N-#V9O\]P;P%?N].R)*=L3S"PNTNR1.>EV6B=KN M3TMSO!.%A5!+P'M;OJKW+"KX"P$=]$"@1'47A]'|MUZ]J-[6PQ.)F,_-T=;Y M4&;B?AFS:#Z?N1.6??Z)>5+W<^-12@9#
(2Z,1_XB.C'@SGK(9M5+3MR!7Z=KTRI'\/2O*+E57_(C367N) MG9RN5:(I=L.9[R]81!\]5M,OCFIMR,N,N/'&:=DIX>6"W53HP&9(^W$4C_:MQ,=LW]POWV>E]'6VQ8(=DTGS?;/U&@XV-V>UI(."] G"OCU)1-1I:8I,CBA
M'8UJ^PK@B"4NTFT<^@F"WR6*.E\5(AI-/ 2_AI::'T_J^"5@Y"GCF/*1P)#+]W[Y:?O(&"5] "#>]-QSP43^CTK_HE*<(>6 .]#W MUX?<754Q*?^B0MY?IF&828+2]Q<5=OXRC6EK68!S]E\U^,L]W&:'I&BL_V*4 M-Z/2_Z(JA2
-5]Q,N5]@Q/NT_]EY_YS_\/N_^%'^ZNA#-CW'7)UG1YGP1.F MC3A*6X7]JU3/VZI'>7$QI>&D+?Y20A=#&6]>]C%-E&O+]HKG"R'.X =*C;@5M_F M]9]>*=9D9D0I]*L1PO6X>+2651Q'5(D%9O=MM!]NPA+G*-MZ 3V.
MQ)X_ESO=6_0X.BYG](["8@;Z=UN))NYHE@>U6OU%&M,M!64Z"EQF36!UCSD MWM@>Z:+6GP&Z*7DR:W$A]YA91SC9!UCK M?F-H,T\W>]I9]) M?^O#AZ.R4]]%(]7%@=R_J+=)#6-V]#D++$79_;
<>L3=2GKKAACL^X\ M*[C6U\ERU]C#H-/36KO6?].EMG7'=!D>G$VE+&G2ND3O=(DQGV^?)V(* M;BF1/GE1$,A8D8N'F>MLNL_NIC6T[\6;885V5#23:&=U4I].X^.\6Q_T:)A M1O]A!1<75V5AB!?
>0C#@#;_#W%>GOV7WO8:^%G#P1=F=TCTA3 L1FKGV8K4L M*LG5?\9ZH=A2Y_)PAC*,M" ML%,%HXE8ORYEZR7D2T?]S;L22ZC9O,?>#P'%3M T-V384(N,4W^B]; MWVT>1XUBP"8ZDMNS;$A 6 !_@S!/VW<,Y1V5$
M0_AC(X!3N:-ZEN8B:<12W.HNO\#XBT3&DB7QN^&K+.4)"4""^LR+/Z?1*+N:M^0CK_*MQ?L-72F0"WN!Y8\.B] = T_?]*OMMQFI&F(^&$;4]P.W_V4VE/QZ_D*A_S*B=BP\>3F9Q=1I--++Z M?AM=$(%;SV_^#K&5D3,S
K2^C)#]':H?4;'MM9D6CLIQI"@&$'_-ACIRR[Y>M264\DP?#FHU-@ZS6'5VMA)&9+\JE6*CZ'IH](3HB2E#].C\,8]"[MQ1)*M_KX96E\?)+TE!^]RT_7=I7WGZ212TI%M%G8N<= '(6)?YOS*]^Y)!S"]TQS
M80K"VK2TEL7MQ?EF@#*S3O]>/M2?.%0W;*:""9(HG*O_TF'3QT;-X"[* JD M/["N.22G4#7#2"'MV)%%>#7@&#FG]P"]#Y156 ETHDG,UW]A;B+8MR5L9?]O1 M&@:OCU#8)B[/S>]<@WY?:T?0U?
@P&HBP;_OOK%.P,K&B(=CS(]$C'57W/([B2 M?ME64Y6(_8B/%\#21]VM.V94-@.XI739/.+GFR M=HH$-2[:!MDLJQB^@DVHNG0@@#31[^Z'@32^5S-U^(C;KV9D\H..02<$89R\O MCM/;^= Z6 -<<@V:A%+H-
"A4B^=4.)6[]>:NG&0&W4 46^^,^(^'PB3)UYU;) MQS=-=^"Y]C+&04<-]?O(E\L:Z*FAHMP-K37T3'7+?(#%%T/WFV^A4LP4?5^B=MHR->ZI""4>WE9Z;4U*H](F6(KH0^*&&Q9@*EPBLIBG7:.R!!+QWZI]CL&BVO M-
N2&N!:\DCAKTEB?OI#'^_).2Z&ZZS8').1QX<2OTS,?R@PKU]?.F.2,B\[M#N(^IFF(M&6NEWOYM#>(']? E(5AUU-R0FR$^*W7G!U>FX$Q>9^].!7$O MKM>>=U*ZCC\-4M>U64FE =(X2:P>]]P;&EZA!]F_G?XOW4U%9D
<@3B-JB" MW9+/^/$P_G21N>N):5?O?MH=>MK4+;;56'_]!&?9YI?7O5D.I+O8MKU)@9_MSL]<*7$L2I8]Q M/:P9EN+%$KOD%O_D=U=P8!MA;-XX1'MU.4RKYVB9_%39S9EV,G7<^,.TG$(/ MHRD/]--F!7<=[3H=4-ZP29?
=&TD3.NO.MFS MO+4Y2SS7N_V)3^3 Q9ZE\(6"U##SAMB!#FN;.0C=]PC2ESLIRK"-'OSWWH(1UL [AA9:3&WWS2<-RC$Q-QM3R/2#60WV?LPV5M]MQ
M=7F.F!Q[!M$0#1GNWK7,$]'5=5?3[[H(P@EX#KQ]^DJ4KH2]FY==_\7SMCYBLA\@=E!E-[DVA]5+1?D]:'_1[X M\'6C4;]I'2AY(YT[_)A)P,##6#7%>!<EI44MH:]F,I0E@/O@&<2];OB MY3.ZR'2+KQLJYQ2 ']]!+6N;4-
]F8IRI'GU"(.3S]L*OZQ=A;]]5?U%7RO M32&]/-1GA$"#ML&G]4",B F/OF4T"&T!7<)28%7A*KYV9I+M KN5W(]44#=: MTLB1!VAF(];PYCQTP-A$ M^2VX$;P-V55> MU,+T,5]X]B(T\4M-2F(0&;_M1R"Z;YG+Z5.WXB9
%Q MKG$%![C@)TZ%\4 B3:UX^O0F]N\!C2+^ @M2:LVIH&45S^B;#!+]3H9+$#&V MS70]C._ULWVZ\HSY>L<3YTW^?QYH6M^U",AY)T^.LC3$E/&2TYM16&?S * M\W7W?V(_U>B00_*A#R2/ZZJUF]1U-6B-(=
['VS\/%9U]0('NLRFZG$9FEMK MD46.^1Q]\;?5%&=.!_]=?*8012KC*Z?6^P,097.IKB<1XY1/KV;P@L7)Y>^M2>F-H8?XEA-,UE/^<"6M9,;F&,SPN^'(R)5=M6E%]<5L.;@">!N[EC_;Y0 M#A%>)+(AR ?>
VPK_^E!Y%V2,$&8OK?6*K@#0Z0/ZNK;$!GR6^O"]*8$X1Y4 M^IX13C:JN@0A/)S#'3X*T)K:%O,"Y_L_CL50/L=VOD=YV]$N,4PY=@[8PA M,S*.:]B;CIL1929),:65EKE3:5B,:M-4=W!29KKA,?S0M\NGP
MV%261/<=]'>)_M9A^2B"MDD#;7>ZMM&=,9]Y!PYRS6P,TO8(?:4AWV9 TIL.K MJ]-;^;MMD.8]4(BA[B4Q9[EJV*?YVW%9%C1>3VN',#*/M(^: QW:V"#X*XTV\]RD MFH.NTR/$6^;%%+=6/4]]!9113R'1_K X)M7Z]Y*
(#YDOH(KC6!>?XRWQ@QE";893@8,N(A.F;G(-%2P9S M>V%3]4>]--&6>YYB+!]A6DH(/(%5E9VBP(E*3RIZ_+V@1Q-\BR$:$@$#3=SXGK3%"P;:Q QPTN0XD]DP M61A(2LI@;])MJ#@,IYJJX,0,&B;,;:):-F-9_=U-5D]:YR%:
N9O5>KRZ35_G M]K@)6:KZ.CL^<8[8/D%L_>>6_*-0"9/>"M<'G3N>KD/>!:5X9\%??*1'8@ MW7ZA@5]#\DGU 4_*Q:G_D%8@DE(HV'A:;]:X"3&+.Z3*Z6IVU(.R90EIN(M-LB9:]+E'D
MN4]C[C*+8IH0G#)"UC>CFBVV\NT2W^1U-GI)4X^6,?9.H"6G MAY;8*-J2E M&,S"+YZ"[^H$&8'U7?S%-=:OQ 0\^8=]E'G>R;8FLT**_^M$?[5O^94OK@6 M,%,,@:? 0KF>MK;Y]X_)]_:KT$ M&CBMU+^1/D
&A:XE3&"MN@))+*0Q^Z79]3O>0T_H]%XK Y;TB6C/84C58BPD M]HZKW7/FC]\.8PYF%]?QAO7M]V?\6?.[_;8:;GGQ+0%/8]'3G"E]"083]Q=MV\S&%;^2;'<^*E"9GQ^?<+X?1+"_X4.K8 H]ZH(3NH?- M1V8%3TM
E'1/D]BG,]"RAMQED]2*)VY#('!78X_/>U1O/O;^"\VIA<\8 M>Q=%XP'K$M@&G[B8F7[LHMKIX';5S->E[+1B0;Z'QGBR]G"O(_#"Q]O(L7T M\6W69]_X.2;F/6*XAXW9V3$;X,$RX=T(PY@P6;_Y7<^A>]WXW-VEL]C/#GB
M".V!UT]RY#QZZ-]DY)&DF.F.V.=POH,OPD0]OM<;]/ &^8N'Z2L?G:5%CI.MR#".\D>W=RF1=+D'VLV>9]AZ'K(.M%5Z1)@6I]\FL5NBB6.=K^B%[5OYRL MVG>;[I:N.&^]N,S"*YC9.I.V]9R"UQ*]0]XTX:8W0ZF-E
<]K00,HOD(@3 M:VOXO.$EFV/ZG[U5A'A7WJ?'IVS=M4"";X8X5-_>,)@%R4_^DIW^9G,KP7 M=/]]Z78]Y:F>C4@2"EV#=Z0+04X+(,"+BG29]_-1/ZZ6'XA]78 MGT%A]:ZXAW!NK:RR!CT)9<>]0&7K]95MEKK?Z*97O 5&1*G?
S=UUWLPUW MTSMG>K(AB]G7+6.Z8>E&-V;++GL%DW]/7*N ;G\F&B>)]?%2:L&!M7*LI(=\ MTQ2P6]A;6T7N)_MG]X"'"W*B7;X1"L'.X]:6Q'M;]GHY;-.0FJ!A=,L X8 M5Y5HOI]?H$TQ1?MV95W&;^6&#W^"K<>:
(5D[JM^T;CI21R_&+WGSP@;/;G?+ M@"NH9VAKOH.%I&QPQ.)AK[H0GAY.K'M?]>J@"W.L"''V<(G'4O^B_E:5#_"%K6VE1_+67":&WBPTQN4D8T#2'@SMHW#)2X\.L$<-M8#%0#6E]"G74*XR7:($2/"!40;U/CKSTDF^
?/\I*,*7%'9E\E2Z M0OC^RKCO[_YVB]B-O86[WE8D8AV.T=ZQ<]'_)N!8;\E8@OBDO;T9*;0&F/ MXL$^;;HKVY:$W-KZ^#*;]>16KAH!("S-D=RNS,X]\?X:]Y6..[[9AIWQ1<:&\44VTK$O?0\L MU7Z>F=! MCTUOOQYM0H]UT?
SW 'E;5DX T1\;$L#)M=VCU#)W?8D(W(S+;'>X!3CG;RDV/ MV7N7]H-V>5T5O/OL7[N'"==-G+HT9/V1,#_0/%@^<,\H+/1UE"0K;NOQ'+)5 MT"'H)<->]O&E]G47E-N%"E0C^D]Y_ZGFT&5]%@*CIT73**5.O 2U)OI
M7N]F,V27Z"N)RR5%A4Q>((-0[A4UN CNP=A;/"M?GV2^6E/]OKH*]B M1U4>%X@X^X[%90=35_KTD]]Q.RTBHE)5A+61BE=8=&1N&$O.V <#$D!5- MQ"'SE=S?&X!)U: 9L&,O/WF/GOU7F=V M"Q%DU=TGSDR%$'YG?
E1*?B!3!E1P4WP,H5R9PR]-X[9]L&+O MT]<2C@NF\69T#DG58PT*%CS\GU7O[O4D7'TR[H';Y7UL)74&B@**2HOI5@) MY]Q6> 340A\P25!;$GVDY 9QB8?[V3Y.VW2/FA1$>BQ_:CE83/N*63#7]-#R MIX K_+ST[A3L-
:&D4\EDRE:347HV9]J'N$UG47]N7H77=KKS7S5D;=:X.F] M%M-8K^*[X[D^7+FN9],$['X?TD5[5X4[=%:;#91[8,\GT1LEMCDRUP M^SZ#K3ON]G&_0K+%'8Z<8W5@YD^Z411KKG'HZJ/CE\YQ11B?
+PM;]LCD811TNT4P'%]W>"9J9A M2ZU6KCKU-9D5&!M2IM:'7H'$:1SQ>UWD+7LD.8!-X1MOKIPNET6F@X4S1#!A M@XF)&XM0QHP#06^2 ^=YU(,_^_=H6OH;P1'A%=4I8;\VJ:MKH^D]Q_I(#9*Z MT3350ED'P8#/VB$CJ;
(,HZIV6W^]24#Z*BNWUZX5N+Z9/W#%^<.%;F0%E.R.M%5BBK9@BWBD!*X5;?F%$B-E+*X5;*+GZ3!.NHV,'T4]GT]%2PLK=766A2OQUC"? MR]DI0QZSE"""92.6]+M4]+9NH]]!19M!Q "-WGY-P>7TB&K-NG32\GZZNPF
MLKS=ZT_\T1^$>;D0]K"*&H^H:_A_D%9-@*OBD?RB)/M-5RH>^Y/-$'EIF#%3 M7/X.R?DB5'NGZ313D>STA=XDT=R-RUV:C3. /_U9]U0XCZ,I'O/,,;M*S+Z MYQ^*9N8]R0$PFH CN]X!>]OP9;?%M@X?X*3F
DSC@Z^6L&H]=QT/"*-]YFD>O MSDE8AMX9 O*_N%$2]Z!Y@M!\Z<*#A9_#F7DDYDVH@8&C X]D:=A >'U0%%? M#E"W?DH,OS!;9]]'H*SY1+G:I2]$+-&I-[&7==N=+5/#F]]B+$(UNVE[DGCPD]+?9V16;_VVV9TSU
MW.Z(:&XM^0RV[+WM.GD!4VUL.YP\)3<8'3-LT1]P%MSFXCK#*Q[WM7F'3T8 MS]'L%+ 26S!?/LD6 M] A*<+ _GAFMSG33N(7X3HGS>$7&QZRZ*$V_F- M,DEK)5](I_MZ':R;CMI*YK"AY(,L]A6P[R33CK'"L5&
($C:7&]](:)\+K=;JD" MSE"]QGN @O008WKQ[^_]EU'2&;Y'2ZS!1KN\RW=E]0;+8AC'3R8!K]QMTV K MQD &1VD9^;IC.NYDSK[^HGHRC'VB9'YPV]3B7&L&(XUU64DU>P5UW&[FK9'M M*W'G_=
@*YDY83\KB#54G9^%B66_Z W;\YW*.68COR V;[(A--W&*.587'A> M79;Z/@5]K^K&/4OW1@L347+2F%WP=W$E_]@"[IDMG[EXYU M,%2@I99+0D+!70<%,#^&[%'38K4@HLAQ12UGA7\5:NA"
[MR9*O!5R;E6_1/ M2F8SP=[5KEME-G-K[@Y9VG7,Q2 A4M]HK;_Y^NH_X <4QS#3BW'ING_?W=$ M_E=H.QBSUT"]\N^I<5S;QXN&T;W\1 P,SB?G_+KPFID0MLZEKM/_/UYL]W/_M!5!+ P04^!O@PY9E#+]S2Q,!:5@ #P
&-V;5\&,^%Q\6F;&PPPB*B8N(2DXFI*CY15 M5-6>2.Z'.T5@ TH]UFD&,)!S>T?&VQV@.N^"-)U@EX][Y6I]DEH8C\"Z_P=PJK3S+,]I 8UK MUL.:D3UWF= DN^A%;R@;P1N:=TPK==
OKW[]A05@8_UU_$NY;F/DNH$Q*T>P[+FP;GC\&Y;^8 5QR M>1V\9\X4+(^!^O^<5GE;02L0KI'5,_?C!)2LPDOL\^B?:?Q@Y/\$P8+*7TGV MMV#_D&L6.;PA;@^S8 4*?-[8W-BK+W!]U/FE/7ZY.QN<)@ J79RX/Q,CA ME;HF/V@N@!4YZ!!S;MOEUR*??
#49.9=PFW((&/2=U7F06)73/)*K;@GWUOP\ &X[X"2_-BQ@VU#>!#_M_]@*9]KETFMNAUU/+7WE88[U!3.>"5I-YD?)\O-!P5W8Y01 MTD]XOAT2)9S:*_URTF75?IY@&Q<=A/WZI?R0E6$6&NT<+26_M%!H-J\OM[]G@D7Y8
M\;-U4H;:<2&2+]'GC&-&^S^Q\$1TC10,T_E=F*W$*A3CJ5K M,YO!YY16XFO/MIX+,-6-$XPTRX+SJE2X46;6 &5.5EA(8_]&R@)@]!W MW.GN,EE]OU]'GB\R1UK'0C)6I'%,%/ MUL.:D3UWF='^ DN"A%;RQ:P1N:=TPK==
[VSGU.3K-G44-6@PH><)OI]^] MX9YA'][P_@2&#?30R.);,:;$@'964]QRX:T3]Z4;W]N?!1C$'-DEC8_O+.MC] B5L!!YHP$>: MW_(C7>&J5F2Z(SOG8@P#?AN]H@Z^4'_]/($T?C6C9"^/2]O(@)6I$?]*E8]
M=QGH@*LW$4?.S."&]00$;5N974/S>GI1"E_*K@_E8"6N%;Y5]T0?SMKFYZ?-M5\AG,*OO%DPP2"1OR=GN."F!)]9PB6MVL;R9KR2ZD?RQY',0]VK4:O8!9ED MA9%O=*0^+>)%.12IBO?6H8GF6:%6EGX8MT7KOGN[*#HTB-
]X]S5T"U>K:82H>M M592A"W/LF;GBX]"H_3B/*+FAQ8D%+FH]>]HM2:(UX9S4YB7GI.'JZG*><+8VV] M&O8O$,"4(Z7%5IH%QWOB/9-1Y/2[W'.H@FE/7ZY.QN<)@ J_]79RX>+/Q.CA ME;HF/V@N@!4YZ!!S;MOEUR*?Q@A$-!0Z.BI-9NR$U O@%A*
F#2]YU@^U;E ;'=?4Z65V"P%_(B4?!$O M8> 5D874)15ZI/YFN+5]J!V!Q<4]Z\8_OWPJ\D[6B;B]:(UV;9*18Z=H, MXV^A@T>:C#XUC82?327O&7I@/>.\%3I>/?A]^6E+:ED&2?V-BFWV^EA9#I/MPG)3ZVV1CF4-,L7&K]]

[8UWY]'6&?Z5"=#/=U.8>\] M'_"M'S'/G(6=*5?6+3]\;BO/%S9W,NY6&/\1H5BRCWF(HJ-3N=I 8/@2M,= M-%]K@_-A#-,)U?T*],?[%#U,%;]CB*% M\K26T0 Q7[*S]^-FO%1-Q+&P0U$FU0+1*EN
P&C!KY=W0%L>@]\@W91'+5E? MC.PDB9-A1B8+|TK.#R;NA+)(6.$*)TC<$-N,42E9#&UED#9 /60^][7< M9HAC;7ATTA>VQO^U3()DO\SVEPIZ_"E\-::E'8IV3)S"2_;JAG2G_H'ZN# M/_+Q3GZ,S1BB?V'QT55<-
HW[1P&0'<'Y+UL)-XAX2]+O2R'8)G=.'K=4.)FF M-SS0A>TMN=15$B/8/0)8XVNAA^/IC%?-RZ*!=CK]^2])(5*<7ZH-3=UD].49 MR.PK[99B"7Y]ZN'%1P-/TR?'=>080E*/#K_-LAJ) M)B_[20YN[TN9?,PB6KOS@:?

cvm_10q_htm.xml IDEA: XBRL DOCUMENT 0000725363 2023-10-012024-06-30 0000725363 cvm:MrKerstenMemberus-gaap:SubsequentEventMember 2024-07-012024-07-18 0000725363 srt:ChiefExecutiveOfficerMemberus-gaap:SubsequentEventMember 2024-07-11 0000725363 us-gaap:SubsequentEventMember 2024-07-012024-07-29 0000725363 us-gaap:SubsequentEventMember 2024-07-29 0000725363 cvm:UnvestedRestrictedStockMember 2022-10-012023-06-30 0000725363 cvm:UnvestedRestrictedStockMember 2023-10-012024-06-30 0000725363 cvm:OptionsMember 2022-10-012023-06-30 0000725363 cvm:OptionsMember 2023-10-012024-06-30 0000725363 cvm:LandlordMember 2023-01-012023-01-11 0000725363 cvm:ErgomedMember 2023-04-012023-06-30 0000725363 cvm:ErgomedMember 2022-10-012023-06-30 0000725363 us-gaap:LeaseAgreementsMember 2022-10-012023-06-30 0000725363 us-gaap:LeaseAgreementsMember 2023-10-012024-06-30 0000725363 cvm:ErgomedMember 2023-10-012024-06-30 0000725363 cvm:OfficerandDirectorMember 2023-10-012023-10-28 0000725363 cvm:OfficerandDirectorMember 2024-04-012024-06-30 0000725363 cvm:OfficerandDirectorMember 2023-10-012024-06-30 0000725363 cvm:OfficerandDirectorMember 2024-05-012024-05-04 0000725363 cvm:ConsultingAgreementsMember 2023-04-012023-06-30 0000725363 cvm:ConsultingAgreementsMember 2024-04-012024-06-30 0000725363 2024-02-012024-02-29 0000725363 2023-11-012023-11-30 0000725363 cvm:EquityProceedsFromSaleCommonStockMember 2023-05-012023-05-31 0000725363 cvm:EquityProceedsFromSaleCommonStockMember 2023-10-012024-06-30 0000725363 cvm:EquityProceedsFromSaleCommonStockMember 2024-06-30 0000725363 2023-11-30 0000725363 2024-02-29 0000725363 cvm:RestrictedStocksMembercvm:ConsultantsMember 2022-10-012023-06-30 0000725363 cvm:ConsultingAgreementsMember 2023-09-30 0000725363 cvm:ConsultingAgreementsMember 2024-06-30 0000725363 cvm:RestrictedStocksMembercvm:ConsultantsMember 2023-04-012023-06-30 0000725363 cvm:RestrictedStocksMembercvm:ConsultantsMember 2024-04-012024-06-30 0000725363 cvm:ConsultingAgreementsMember 2023-10-012024-06-30 0000725363 cvm:RestrictedStocksMembercvm:ConsultantsMember 2023-10-012024-06-30 0000725363 cvm:ConsultingAgreementsMember 2022-10-012023-06-30 0000725363 cvm:ConsultingAgreementsOtherMember 2023-10-012024-06-30 0000725363 cvm:SeriesRRMember 2022-10-012022-10-28 0000725363 cvm:SeriesSSMember 2023-10-012024-06-30 0000725363 srt:MinimumMembercvm:ConsultantsMember 2024-06-30 0000725363 cvm:ConsultantsOptionMember 2024-06-30 0000725363 cvm:SeriesRRMember 2024-06-30 0000725363 cvm:SeriesNNMember 2024-06-30 0000725363 cvm:SeriesMMMember 2024-06-30 0000725363 cvm:SeriesYMember 2024-06-30 0000725363 cvm:SeriesXMember 2024-06-30 0000725363 cvm:SeriesUUMember 2024-06-30 0000725363 cvm:SeriesNMember 2024-06-30 0000725363 srt:MaximumMembercvm:ConsultantsMember 2023-10-012024-06-30 0000725363 srt:MinimumMembercvm:ConsultantsMember 2023-10-012024-06-30 0000725363 cvm:SeriesRRMember 2023-10-012024-06-30 0000725363 cvm:SeriesNNMember 2023-10-012024-06-30 0000725363 cvm:SeriesMMMember 2023-10-012024-06-30 0000725363 cvm:SeriesYMember 2023-10-012024-06-30 0000725363 cvm:SeriesXMember 2023-10-012024-06-30 0000725363 cvm:SeriesUUMember 2023-10-012024-06-30 0000725363 cvm:SeriesNMember 2023-10-012024-06-30 0000725363 cvm:NonEmployeesMember 2023-04-012023-06-30 0000725363 cvm:NonEmployeesMember 2024-04-012024-06-30 0000725363 cvm:NonEmployeesMember 2022-10-012023-06-30 0000725363 cvm:NonEmployeesMember 2023-10-012024-06-30 0000725363 us-gaap:EmployeeStockMember 2023-10-012024-06-30 0000725363 us-gaap:EmployeeStockMember 2022-10-012023-06-30 0000725363 us-gaap:EmployeeStockMember 2023-04-012023-06-30 0000725363 us-gaap:EmployeeStockMember 2024-04-012024-06-30 0000725363 cvm:IncentiveStockBonusPlansMember 2024-06-30 0000725363 us-gaap:StockCompensationPlanMember 2024-06-30 0000725363 cvm:StockBonusPlansMember 2024-06-30 0000725363 cvm:NonQualifiedStockOptionsPlansMember 2024-06-30 0000725363 cvm:IncentiveStockBonusPlanMember 2024-06-30 0000725363 us-gaap:RetainedEarningsMember 2024-06-30 0000725363 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000725363 us-gaap:CommonStockMember 2024-06-30 0000725363 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0000725363 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0000725363 us-gaap:CommonStockMember 2024-04-012024-06-30 0000725363 2024-03-31 0000725363 us-gaap:RetainedEarningsMember 2024-03-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000725363 us-gaap:CommonStockMember 2024-03-31 0000725363 2024-01-012024-03-31 0000725363 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0000725363 us-gaap:CommonStockMember 2024-01-012024-03-31 0000725363 2023-12-31 0000725363 us-gaap:RetainedEarningsMember 2023-12-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000725363 us-gaap:CommonStockMember 2023-12-31 0000725363 2023-10-012023-12-31 0000725363 us-gaap:RetainedEarningsMember 2023-10-012023-12-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2023-10-012023-12-31 0000725363 us-gaap:CommonStockMember 2023-10-012023-12-31 0000725363 us-gaap:RetainedEarningsMember 2023-09-30 0000725363 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000725363 us-gaap:CommonStockMember 2023-09-30 0000725363 2023-06-30 0000725363 us-gaap:RetainedEarningsMember 2023-06-30 0000725363 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000725363 us-gaap:CommonStockMember 2023-06-30 0000725363 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0000725363 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0000725363 us-gaap:CommonStockMember 2023-04-012023-06-30 0000725363 2023-03-31 0000725363 us-gaap:RetainedEarningsMember 2023-03-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000725363 us-gaap:CommonStockMember 2023-03-31 0000725363 2023-01-012023-03-31 0000725363 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0000725363 us-gaap:CommonStockMember 2023-01-012023-03-31 0000725363 2022-12-31 0000725363 us-gaap:RetainedEarningsMember 2022-12-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000725363 us-gaap:CommonStockMember 2022-12-31 0000725363 2022-10-012022-12-31 0000725363 us-gaap:RetainedEarningsMember 2022-10-012022-12-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2022-10-012022-12-31 0000725363 us-gaap:CommonStockMember 2022-10-012022-12-31 0000725363 2022-09-30 0000725363 us-gaap:RetainedEarningsMember 2022-09-30 0000725363 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000725363 us-gaap:CommonStockMember 2022-09-30

0000725363 2022-10-012023-06-30 0000725363 2024-04-012024-06-30 0000725363 2023-04-012023-06-30 0000725363 2023-09-30 0000725363 2024-06-30 0000725363 2024-08-08 iso4217:USD shares
iso4217:USD shares pure0000725363false--09-30Q320240.012000000000.0160000000005425788447422304000058000806203000000.0300000.0100000.010-Qtrue2024-06-30false001-11889CEL-SCI
CORPORATIONCO84-09163448229 Boone BoulevardSuite 802ViennaVA22182703506-9460Common StockCVMNYSEYesYesNon-accelerated
Filertruefalsefalse61493229384652414573555133752036825552492248072511294245354236769184207800909913198715480101698243861331610188126173028197704231910123191017158974669240683203052
507902369-4870913968473057132148902406832030528250136842041720382365478666804729202320702400855 2-20232070-24008552-571102-493522780161525-20810973-24563599-659456-171552-21470429-
24735151-0.42-0.57514794544376139547031605727789196707524539686670235818175 7-6670235-8181757-190705-18167043823854-6856558-8367281-6594560-7516014-8367281-0.14-
0.19539943844425436347422304474223499832063-48709139613214890177241774873004890788573886201421020230724900002490049551000049800000138390901383909 0-4702290-47022900-6709524-
6709524500186015001865059509 94-49380092012650260273732745321105348516274416273792430380870387500038750771125007750000014325400143254 00-7176210-71762100-7244891-
7244891540837185408375148096 17-50104581114304643457224576012006057770444704154951015565558000058080040080620072812007281200 0-6856558-68565585425788454257851583 2848-
5079023698473057434483174344844866258 16-454897093321632072177522177445114044729101703931017039312133121349965050178402364029122109162 3-2000-20-110800-1110000-7853509-
785350943725636437256488904967-462750602265916210174328801743288236272365462905486538562386100249010063500-8342809-834280943787825437878490803133-
471093411201476000155131901551319128551295253405266336523365135304013566991323491321543365015 52497-2000-20-110800-111000-2719680-27196800-8367281-836728144748437447484493802607-
4794606921478939920810973245635992977603295968150081278877857147372335445694976338162969157 706615708-20841930409724491-46884-2342951-5923706661616756824380013924328173-13994502-
17803797751223618921321 10-88333-3618921273000015524971173577213796-80620004472911315291115737110321752628621-3761083-
17537068414573522672138384652513507020797012969272770073883232792711000011000091975581727065178 09495<p style="font-size:10pt;font-family:times new roman;margin:0px">A. <span style="text-
decoration:underline">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-
align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.25in; text-align:justify;">Basis of Presentation
</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-
align:justify;">The accompanying condensed financial statements of CEL-SCI Corporation (the “Company”) are unaudited and certain information and footnote disclosures normally included in the annual financial
statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission.
While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in
conjunction with the financial statements and notes included in the Company’s annual report on Form 10-K for the year ended September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman;
MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In the opinion of management, the accompanying unaudited
condensed financial statements contain all adjustments (all of which are of a normal recurring nature) and disclosures necessary for a fair presentation of the Company’s financial position as of June 30, 2024 and the
results of its operations for the nine months then ended. The condensed balance sheet as of September 30, 2023 is derived from the September 30, 2023 audited financial statements.</p><p style="FONT-SIZE: 10pt;
FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Due to recurring losses from
operations and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the
outcome of this uncertainty. Refer to discussion in Note B.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY:
times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Summary of Significant Accounting Policies:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY:
times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Cash and Cash Equivalents -
Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than
three months to be cash equivalents.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman;
MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Property and Equipment - Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five
to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are
expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-
align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Supplies used for R&D and manufacturing - Supplies are
consumable items kept on hand to support the Company’s R&D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.</p><p style="FONT-
SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">
Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in
technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future
undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the
estimated fair value of the asset and its carrying value.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times
new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Leases - The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period
of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an
option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The
incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term
leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times
new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Share-Based Compensation - Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with
the provisions of ASC 718, Compensation - Stock Compensation (“ASC 718”). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires
five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method
as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times
new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock
Bonus Plan. These Plans are collectively referred to as the “Plans”. All Plans have been approved by the Company’s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px;
text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The Company’s stock options are not transferable, and the actual value of the
stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based
its assumption for stock price volatility on the variance of daily closing prices of the Company’s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal
to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined
based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the
future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new
roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service,
performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of
performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-
align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Research and Development Costs - Research and development costs
are expensed as incurred. Management accrues Clinical Research Organization (“CRO”) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those
costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in
which the facts that give rise to the revision become known. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY:
times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Net Loss Per Common Share - The Company calculates net loss per common share in accordance with ASC 260, Earnings Per
Share. Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period.
The Company’s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per
share for all periods as the result would be anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times
new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Income Taxes - The Company accounts for income taxes in accordance with the provisions of ASC 740, Income Taxes, on a tax
jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their
respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company
records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of June 30, 2024
and September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Impairment of long-lived assets - CEL-SCI’s fixed assets are
made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying
amount of the long-lived asset (group) might not be recoverable. CEL-SCI’s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these
assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the
impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman;
MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Use of Estimates - The preparation of financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates
are based on management’s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock
options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates,
although management does not generally believe such differences would materially affect the financial statements in any given year. Additionally, in calculating the right of use assets and lease liabilities, estimates
and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to
be significant. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in;
text-align:justify;">Recently Adopted Accounting Standards</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-
FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2016-13, Financial
Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires a financial asset (or a group of financial assets) measured at
amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that
reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal
years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after
December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13
had no impact on the Company’s financial position, results of operations, or cash flows. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-
SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">New Accounting Pronouncements</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman;
MARGIN: 0px 0px 0px 0.25in; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In November 2023, the FASB
issued Accounting Standards Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which expands disclosures about a
public entity’s reportable segments and requires more enhanced information about a reportable segment’s expenses, interim segment profit or loss, and how a public entity’s chief operating decision maker uses
reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods
beginning after December 15, 2024. The Company is assessing the effect of this update on the condensed financial statement disclosures. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN:
0px 0px 0px 0.25in; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In December 2023, the FASB issued Accounting
Standards Update No. 2023-09, Improvements to Income Tax Disclosures, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes
paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is
permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in;
text-align:justify;">Cash and Cash Equivalents - Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly
liquid investments with a maturity when purchased of less than three months to be cash equivalents.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-
align:justify;">Property and Equipment - Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold
improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred.
Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-
align:justify;">Supplies used for R&D and manufacturing - Supplies are consumable items kept on hand to support the Company’s R&D and manufacturing operations. Supplies are recorded at
cost and are charged to expense as they are used in operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Patents - Patent
expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other
circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows
expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the
asset and its carrying value.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Leases - The Company accounts for contracts that convey
the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory
equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the
lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the
commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense
for such short-term leases is not material.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Share-Based Compensation - Compensation
cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, Compensation - Stock Compensation (“ASC 718”). The fair value of stock
options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free
rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times
new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The Company has Incentive Stock Option Plans,
Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the “Plans”. All Plans have been approved by the
Company’s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px
0px 0.25in; text-align:justify;">The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the
date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s stock.
The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term
of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes
model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new
roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Restricted stock granted under the Incentive Stock
Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at

fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Research and Development Costs – Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (“CRO”) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Net Loss Per Common Share – The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share. Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Income Taxes – The Company accounts for income taxes in accordance with the provisions of ASC 740, Income Taxes, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of June 30, 2024 and September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Impairment of long-lived assets – CEL-SCI’s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI’s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Use of Estimates – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no impact on the Company’s financial position, results of operations, or cash flows. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In November 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which expands disclosures about a public entity’s reportable segments and requires more enhanced information about a reportable segment’s expenses, interim segment profit or loss, and how a public entity’s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is assessing the effect of this update on the condensed financial statement disclosures. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Improvements to Income Tax Disclosures, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">B. LIQUIDITY</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and conducting clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine, the Company’s lead investigational therapy, to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from any regulatory agency for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Due to the Company’s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">C. STOCKHOLDERS’ EQUITY</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Proceeds from the Sale of Common Stock</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In February 2024, the Company sold 3,875,000 shares of common stock at a public offering price of $2.00 per share and received proceeds of approximately $7.0 million, net of issuance costs of approximately $0.7 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In November 2023, the Company sold 2,490,000 shares of common stock at a public offering price of $2.00 per share and received proceeds of approximately $4.5 million, net of issuance costs of approximately $0.5 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">In April 2023, the Company sold 794,117 shares of common stock at a public offering price of $1.70 per share and received proceeds of approximately $1.4 million. The Company granted the underwriters a 30-day option to purchase up to 119,117 additional shares of common stock to cover over-allotments. The underwriter fully exercised this option in May 2023, resulting in additional proceeds to the Company of approximately $200,000. The Company incurred issuance costs of approximately $0.2 million related to this offering.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Equity Compensation</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Underlying share information for equity compensation plans as of June 30, 2024 is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Name of Plan</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total Shares Reserved </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Under Plans</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,787,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,283,760</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"> Stock option activity:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;">Nine months ended June 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> 2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"> 2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,967,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">293,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">179,832</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,075</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">58,787</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;">Three Months Ended June 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> 2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"> 2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,964,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space:

nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">240,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,383</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">On March 1, 2024, the Company accelerated the vesting of 234,332 stock options issued to directors to vest on April 19, 2024. The Company concluded that the change in vesting of the options should be treated as a modification in accordance with ASC 718. As such, the Company revalued the options as of March 1, 2024 (the modification date) and subtracted any compensation cost already recognized prior to the modification date. This resulted in remaining compensation cost of approximately $260,000 that was amortized on a straight-line basis over the remaining service period. The remaining compensation cost of approximately $101,000 as of March 31, 2024 was expensed during the three months ended June 30, 2024.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Share-Based Compensation Expense:</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Nine months ended June 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,544,569</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,976,338</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">600,841</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">473,723</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three Months Ended June 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">728,120</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,540,219</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">230,678</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">188,001</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods. Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts. </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.25in">Warrants and Non-Employee Options</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The following chart represents the warrants and non-employee options outstanding at June 30, 2024:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Warrant/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Options</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">Shares Issuable</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">of Warrants/ Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:15%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2026 </p></td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/11/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">93,603</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.80</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/30/2026</p></td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">120,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9.25</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/13/2026</p></td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">26,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">12.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/15/2026</p></td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">333,432</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.86</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2026</p></td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">200,087</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.52</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2026</p></td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">234,009</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.65</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2026</p></td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">7/28/2017 – 9/2/2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">110,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">$1.39- $2.18</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">7/27/2027 -

9/1/2028</p></td><td> </td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">1. Equity Warrants</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Changes in Equity Warrants</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">No warrants recorded as equity were exercised during the nine months ended June 30, 2024. The following warrants recorded as equity were exercised during the nine months ended June 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Proceeds</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,752</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,291</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">418,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">217,752</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">447,291</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">No warrants recorded as equity expired during the nine and three months ended June 30,2024. On February 5, 2023, 600 Series TT warrants, with an exercise price of $2.24, expired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">On May 4, 2024, the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $659,455, which was recorded as a deemed dividend in the financial statements for the nine and three months ended June 30, 2024. The Series N, X, MM, NN, RR and UU warrants are held by current Officers of the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024. The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend. The Series RR warrants are held by current Officers of the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">2. Options and Shares Issued to Consultants</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">During the nine months ended June 30, 2024 and 2023, the Company issued 321,761 and 115,321 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $1.84 and $2.45 during the nine months ended June 30, 2024 and 2023, respectively. During the three months ended June 30, 2024 and 2023, the Company issued 70,444 and 36,523 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $1.33 and $2.41 during the three months ended June 30, 2024 and 2023, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">No options were issued to a consultant during the nine months ended June 30, 2024. During the nine months ended June 30, 2023, 5,000 options with an exercise price of $11.61 issued to a consultant expired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">During the nine months ended June 30, 2024 and 2023, the Company recorded total expense of approximately $601,000 and $474,000, respectively, relating to the share-based compensation under various consulting agreements. During the three months ended June 30, 2024 and 2023, the Company recorded total expense of approximately $231,000 and $188,000, respectively, relating to the share-based compensation under these consulting agreements. On June 30, 2024 and September 30, 2023, consulting fees of approximately $221,000 and $205,000, respectively, are included in current assets as prepaid expenses and will be amortized over the remaining service periods.</p>38750002700000070000024900002.00450000050000007941171.70140000011911720000200000<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Name of Plan</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total Shares Reserved </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Under Plans</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,787,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,283,760</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>138400177872001283760634000640000<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;">Nine months ended June 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> 2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"> 2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,967,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">293,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">179,832</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,075</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">58,787</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;">Three Months Ended June 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> 2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"> 2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,964,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">240,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr

style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,383</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>1967500650029300017983227075587871964500200024000057500401338300023433226000010100<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Nine months ended June 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,544,569</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,976,338</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">600,841</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">473,723</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three Months Ended June 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">728,120</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,540,219</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">230,678</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">188,001</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>354456949763386008414737237281201540219230678188001<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Warrant/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Options</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">Shares Issuable</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">of Warrants/ Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:15%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2026 </p></td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/11/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">93,603</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.80</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/30/2026</p></td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">120,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9.25</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/13/2026</p></td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">26,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">12.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/15/2026</p></td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">333,432</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.86</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2026</p></td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">200,087</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.52</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2026</p></td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">234,009</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.65</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2026</p></td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">7/28/2017 - 9/2/2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">110,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">$1.39- $2.18</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">7/27/2027 - 9/1/2028</p></td><td> </td></tr></tbody>
</table>8/18/2008853393.008/18/20266/11/2018936032.806/30/20261/13/20161200009.257/13/20262/15/20162600012.008/15/20266/22/20173334321.866/22/20267/24/20172000872.527/24/202610/30/20172340091.6
cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Proceeds</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,752</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,291</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series SS</p></td><td

style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">418,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">217,752</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">447,291</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody>
</table>177521.65292912000002.094180002177524472912.246594551720003217611153211.842.4570444365231.332.41500011.616010004740002310001880002210002050000<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">D. RELATED PARTY TRANSACTIONS</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">During the nine and three months ended June 30, 2024, certain officers and directors purchased 58,000 shares of restricted common stock at an aggregated fair market value of approximately $80,620. No restricted shares of the Company's common stock were purchased by related parties during the nine and three months ended June 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">On May 4, 2024, the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $659,455, which was recorded as a deemed dividend in the financial statements for the three months ended June 30, 2024. The Series N, X, MM, NN, RR and UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company's CEO, Geert Kersten, is a beneficiary.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024 (Note C). The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend.</p>5800080620659455172000<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E. COMMITMENTS AND CONTINGENCIES</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.25in">Clinical Research Agreement</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Under co-development and revenue sharing agreements with Ergomed, Ergomed agreed to contribute up to $12 million towards the Company's Phase 3 Clinical Trial in the form of discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreements in accordance with ASC 808, Collaborative Arrangements. The Company determined the payments to Ergomed are within the scope of ASC 730, Research and Development. Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its statements of operations. Since the inception of the agreement with Ergomed, the Company has incurred research and development expenses of approximately $35.8 million for Ergomed's services. This amount is net of Ergomed's discount of approximately $11.9 million. During the nine months ended June 30, 2024 and 2023, the Company recorded, net of Ergomed's discount, approximately $0.1 million for each period as research and development expense related to Ergomed's services. During the three months ended June 30, 2024 the Company did not record any research and development expense related to Ergomed's services and during three months ended June 30, 2023, the Company recorded, net of Ergomed's discount, less than $0.1 million as research and development expense related to Ergomed's services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Lease Agreements</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company's specifications so that it can be used by the Company to manufacture Multikine for the Company's Phase 3 clinical trial and sales of the drug if approved by any regulatory agency. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The San Tomas lease is classified as a finance lease on the Company's balance sheet, as well as several other smaller finance leases for office equipment. The finance right of use assets are being depreciated using the straight-line method over the underlying lease terms. Total cash paid related to finance leases during the nine months ended June 30, 2024 and 2023 was approximately $2.0 and $1.9 million, respectively, of which approximately $0.7 and $0.8 million was for interest, respectively, in each nine-month period. As of June 30, 2024, the weighted average discount rate of the Company's finance leases is 8.46% and the weighted average time to maturity is 4.34 years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">On January 11, 2023, the Company was required to deposit approximately $2.3 million to its landlord, equivalent to one year's rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">Approximate future minimum lease payments under finance leases as of June 30, 2024 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">666,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,747,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> 2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,838,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> 2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,929,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> 2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,021,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> 2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">255,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> Total future minimum lease obligation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,456,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,029,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> Net present value of financing lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,427,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> Less net present value of financing lease obligations - current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,949,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> Net present value of financing lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,478,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">The Company leases two facilities under operating leases. The lease for the Company's office headquarters will expire on November 30, 2025. The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on February 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. The Company incurred lease expense for operating leases of approximately $0.3 million for both the nine months ended June 30, 2024 and 2023. Total cash paid related to operating leases during the nine months ended June 30, 2024 and 2023 was approximately $0.3 million for each period. The weighted average discount rate of the Company's operating leases is 10.19% and the weighted average time to maturity is 7.16 years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">As of June 30, 2024, approximate future minimum lease payments under operating leases are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">366,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">277,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">746,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,345,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(640,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-

align:bottom;text-align:right;">1,705,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of operating lease obligations - current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(219,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,486,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>12000000358000001190000010000010000000.03200000019000007000008000000.0846P4Y4M2D2300000<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">666,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,747,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> 2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,838,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> 2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,929,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> 2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,021,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> 2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">255,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> Total future minimum lease obligation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,456,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,029,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> Net present value of financing lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,427,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> Less net present value of financing lease obligations - current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,949,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> Net present value of financing lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,478,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>6660002747000283800029290003021000255000124560002029000104270001949000847800030000003000000.1019P7Y1M28D<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">366,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">277,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">746,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,345,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(640,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,705,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of operating lease obligations - current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(219,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,486,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>900003660002870002770002850002940007460002345000640000170500021900001486000<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">G. PATENTS</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-align:justify;">During the nine and three months ended June 30, 2024 and 2023, there was no impairment of patent costs. The weighted average amortization period for patents is approximately 8 years. For the nine months ended June 30, 2024 and 2023, amortization of patent costs totaled approximately $25,000 and $29,000, respectively. For the three months ended June 30, 2024 and 2023, amortization of patent costs totaled approximately $7,000 and $9,000, respectively. The total estimated future amortization is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">54,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">173,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>P8Y25000029000070009000<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new

roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new
roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td
style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new
roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new
roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td
style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new
roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new
roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td
style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new
roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new
roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td
style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new
roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new
roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td
style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-
size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">54,000</td><td style="PADDING-BOTTOM:
1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p
style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td
style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-
align:right;">173,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody>
</table>8000290002500022000190001600054000173000<p style="font-size:10pt;font-family:times new roman;margin:0px">H. LOSS PER COMMON SHARE</p><p
style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-align:justify;">Basic
loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which
include outstanding common stock options, common stock warrants and unvested restricted stock are not included in the computation of diluted net loss per share if their effect would be anti-dilutive.</p><p
style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-
align:justify;">The following table provides a reconciliation of the numerators and denominators of the basic and diluted loss per-share computations:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new
roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-
size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6"
style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Nine Months Ended</p></td><td
style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new
roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-
align:center;">Three Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td>
<p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell"
colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">June
30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times
new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new
roman; MARGIN: 0px; text-align:center;">June 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr
style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Loss per share - basic and diluted</p></td><td style="white-space:
nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-
size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2"
style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">
2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p
style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p
style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-
size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2"
style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">
2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-
color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common - basic and diluted</p></td><td style="width:1%;white-space:
nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell"
style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(21,470,429</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td
style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space:
nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(24,735,151</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-
space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-
align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,516,014</td><td style="PADDING-BOTTOM:
1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-
BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,367,281</td><td
style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-
family:times new roman;margin:0px">Weighted average shares outstanding - basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new
roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell"
style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">51,479,454</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times
new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px
solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-
align:right;">43,761,395</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space:
nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new
roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">53,994,384</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space:
nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td>
<td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px
solid;width:9%;vertical-align:bottom;text-align:right;">44,254,363</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p>
</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Basic and diluted loss per common share</p></td>
<td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space:
nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.42</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space:
nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-
align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.57</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-
align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px
double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.14</td><td style="PADDING-
BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td
style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">
(0.19</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-
align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-align:justify;">In accordance with the contingently issuable shares guidance of ASC 260,
Earnings Per Share, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of June 30 :</p><p style="FONT-
SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-
right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-
family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY:
times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new
roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px
solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-
BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p
style="font-size:10pt;font-family:times new roman;margin:0px">Options and Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p>
</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-
align:right;">17,497,453</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-
size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell"
style="width:9%;vertical-align:bottom;text-align:right;">13,824,365</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr
style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested Restricted Stock</p></td><td style="width:1%;white-
space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times
new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space:
nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td>
<td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px
solid;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p>
</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space:
nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new
roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">17,644,703</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space:
nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td>
<td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px
double;width:9%;vertical-align:bottom;text-align:right;">13,971,615</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new
roman;margin:0px"> </p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-
size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6"
style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Nine Months Ended</p></td><td
style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new
roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-
align:center;">Three Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td>
<p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell"
colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">June
30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times
new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new
roman; MARGIN: 0px; text-align:center;">June 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr
style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Loss per share - basic and diluted</p></td><td style="white-space:
nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-
size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2"
style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">
2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p
style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p
style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-
size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2"
style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">
2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-
color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common - basic and diluted</p></td><td style="width:1%;white-space:
nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell"
style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(21,470,429</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td
style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space:
nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(24,735,151</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-
space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-
align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,516,014</td><td style="PADDING-BOTTOM:

1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,367,281</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average shares outstanding – basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">51,479,454</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,761,395</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">53,994,384</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">44,254,363</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.42</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.57</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.14</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.19</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table>-21470429-24735151-7516014-836728151479454437613955399438444254363-0.42-0.57-0.14-0.19<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,497,453</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,824,365</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">17,644,703</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">13,971,615</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>17497453138243651472501472501764470313971615<p style="font-size:10pt;font-family:times new roman;margin:0px">J. SUBSEQUENT EVENTS </p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">On July 11, 2024, Geert Kersten, the Company's Chief Executive Officer and a director, loaned the Company $200,000. On July 18, 2024, Mr. Kersten loaned the Company an additional $250,000. These amounts were repaid on July 30, 2024.</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">On July 29, 2024, the Company sold 3,715,000 shares of common stock at an offering price of $1.00 per share, and pre-funded warrants to purchase up to 7,130,000 shares of common stock, at an offering price of $0.99 per pre-funded warrant, for gross proceeds of approximately $10.8 million. </p>20000025000037150001.0071300000.9910800000

76[?]_?:N=7=OXI MNZ#)S]_;#9Q!JUU0V06G[/I-=D'-KF4V MZ%ZY3.(819G,..BZ0Y(L03&H^H?8*B9;K&M]$\Z@AF,[KM>^=&WKN5)9G4C? M0 A$DC23L$&$2E#[52)5V2-",5U##4\T5BVK!GBN4]L.>%1*[4[N3I$\R)" M)=KC.%,L40FG-_[+\.QZ_BS7:=^+]G/AM#M+79$_^DI&=*Y.(<[U\)3QMH]> M.O^55'O@=B3UN8+:W27TM4E5P)31\Y=
UVMLWPT:RI!Y=+SJ7Y49YENBG&*(M5*1U$:AY\^+T+SJ2I?F)NV)2G=]YI]Q)A\ZNA#O/H'"_\ 4$L# M!!0 (&Z##EFZ"F@*)P, (* 9 >&PO=V]R:W-H965TV4B,7IBE66XBQN&()
M4/4F9#S&4G7YQA0)!]S.@N+(="S+,V-.J"TLF/9+.5^H$9]!*\@3G(IV3&5<L5-8D!BH(HXA#V#=N[.M;V]4! MV8AG
GMQTD9Z*DO&7G1GM.X;EB:""%922V#ULX,!1)%64AR_#]$3]MO MZO?9Y-5DEEC @$4_R5IN^T;'0&L(<1K)1[;_#H<)M;7>BD4B^T;[?*S?-M]
M%9+%AV!%$!.;_^+7PT*9WO$]6BEIAO95+-H M!4>H_E?FD]NW1,7)8# =CT>+\=UD,4+T>3;W60PNINCBR%(3"*!
M[,\]4RH['62N#M*WN;13(_TCI5>H97U!CN6XZ&D^1!F9NPH55N[9*;T_%KW;S"S3OGYE>Y>64WO][-+]S_M8F[M6K=.X=8YY];MV;2@,GPH@5=Y=DN>OEN_5VSKF(FL
M9EAY=8ONGV2'.U&I <0 M HWB))6P1B.J%@2$1%.*I@EPQ:..\[L [1+@1>?6GV;[F KMQN053-2]/=-9 MBTKTC*4D83_"N>4X&S?:FB!8^JSFW.?ADL.<+L,CH4HRI!"0C%=P:'""D"!
M+M6MQ[D.21BO96Z5%]2QN_7,Q_QH-R?(_V2FC%Z^A]LM)77;[50<'O/D1M?5 MT1CS#S%.$80]TKK2Y03/"XZ\(UF27?)+E7)D#6WJD@#K>)H]R%C\]VCZX:B M[O^ %!+ P04 "
!N@PY9N/IZO5@% !6) &0 'AL+W=O! MMYQ?>K?H@TL%B9,+0GG1"7-1_0;^GSKH@\ ?YQ80@:@,%98.9N7SIP#SKIH
MP3*QR9&71332V'MF^['WI(=KWOOO/3^DV,$_DFR,X3QK\BQG:ZN/^^8[Z1Y MUR[,>QIS]WASG7?OQ[S[/^8],)N[-)3FVEO7DJ);)V*WX/4.\"XS03G-!2(I MVV5"$] G(T"-V>?
YEH1TVI&#Y3A&5UDVI=4H[;L_\V3]E6Z?YS20*&UE![42@^,2E]DV4Y* M'61Q-6Y7TFL?:2/U5*%+V*AQG^PS>]3KCYM_[9OF0@;@?4<-/F0 M00D;MP/HUAY;T@YK:8=&:;\4BW8:(?
(@A^BUU%;N.!!;R<6FV/%8/*OC8X9O MHYM3M3;'WS//E/ <]5!:K@L=%)%G750N9%2>..IA%14NHT+.Z%!4/F14 1"L ME3VC.GM&QC[?2"+AX0:1+)(]P0>YQ=T6TU^6LSQ8@\-5-
&;P?9OFY!Y$)Z M]2!A/B0L (*ULF%<9\/XM+$DBO-0K>]1'#WHZU%$EQI&_]FL=,.U]C&K^<(M2)_><3Y]2)\!$*PE.;;WA03[B,7^Q9I36]P#T#\+FMY3_]].7S/K5(%!:2XH MS0.E^;"T
(K6SIA&Z0G_/ L&;'D[(&DN: TKZ(UIS7'UFT>]H;-W0,>Z[8/ M4/&U-7?VFCOF44(N$!+&(_/H8&2: T'Y060-':F;*O!V)S0*"/ M,Y*%:AQ0M>=L7QN4"Y MI)=K9!;[4*T>0):BP2EN; T#
[^M,V+M4L$'J1M T=HYL*]<8G/I\KLJ%&;F MR5D!27,K6G-VPQH5O.I=_YUV-I&\ *H7;1WW94ILK]I-Y84XE/L&A8Y#B@2/ M2:(5#[02"4IS06E>16M)=V";%IQA**5]6 UWF)
(*5\7+ZCDJ!BRR]^1ZZOU M2S 7Q:L?KZ[/\;F+-=<]?.Z7K[CL\>4;-PO"UW&6RQWG2KJRSX;R:>'E2RSE MB6#;XAV*>R8$2XO##241Y;J!_'[%F'@Y40[J5XEF_P%02P,$% @ ;H,.
M67&-$5QB @ @< !D !X;"]W;W)K&ULA95M M,]HP%(7_BI5-4R=-Q DDO"O$*NVF;=(F5.CVV<"%6'7LS#;0 ?O9#GAH2> + M\=LYS[%)KK.CD"^J -#HM61<38-
"ZVH2AFI=0$E43U3 SB;UFE,-<(K4O2R+_S(")XS2(@O/ $]T5V@Z$ M>5:1'2Q /U=S:7]A=]G0$KBB@B,)VVEP'TUF$;8"M^(GA:.Z:".[E940+[;S M=3,-LT#-;:6A#S.,_#,&:=3([?)]/
,ZWPLGUV_^PV;S:S(@H>]/M%-[J8 M!],_;6!+]DP_B>,7.&THL7YKP93[1<=Z;7\:5&>Q"9!27G])*^G@[@0 MQ'&'(#X)8I>[!KF4CT23/)/BB*1=;=QLPVW5]4TXRNV_LM#2S%*CT_G\?
OGI MQW*'[AY!$\K4*RA$OM9.ANN3Q:RVB#LLONUY*7Q!Q3C>(">%X_H[NU_-J%) MY:/%/EKL?O7H[4%]H6#=J%]D2)[FN#8:N9-52 /$.3OWD0I_G@E5M_'ZE]S
MSY>%!$*"EX+I0"/B&\AU:0*6A7(']'Y1]"6NO9-G;_]6@[Y"&.6-.?9G U MC6$E;:Q:E5RPXG$G+/&PY!8L;8,E35C2"4L]++T%&[;!TB8L[H0-/6QX"S9] M@PT;L*C[&$<>-KH%&
[?!1DU8V@D,>]CXQNL*IEIO-<@VY+B!3 :=R C_*RKX M.E1HPEHK"6Y\ ]&PWR2&%Q7-W@[?B=Q1KA"#K1'BWM!$EG7!K3M:5*[(K80V M)=,U"W-)@;0+S/Q6"WNV+KIK[W\+U!+
P04 " !N@PY9'QYA':L" L M"0 &0 'AL+W=O,("6!:9O4*FK:];,+EV 5;&8[+]VOGVT(2QI*NBU?P#[N>>Z>,[IS ML&;\]260 $FV*G(JAE4E9#FQ;)!D46)RQ$]CZ,F>\P%)M^<(6)0>
<&E"1VZ[C MG-L%)M0* V.,\C!@2YD3"E..Q+(H,'\>0\[60ZMG;0VW9)%);;##H,0+F(&\ M+Z=<+]R&)24%4$#811SF0VO4&\1]{6&7O2FV_IT'}T0I!# M(C4#5]\53"#/-9%*XV?-;34A-
1'WO67_8K0K+8]8P(3E#R25V="ZM% *<[S, MY2U;?X5:CTDP8;DP3[2N?/TK"R5+(5E1@U4&!-'5&V_J.NP %$\[P*T![DN M_PK-JP>6R/X-F^@:MZD6H_D]F
MDJNO1.%D.!W=Q3=W,W02@<0D%^@&!+54H#;"3FG9< MT;JOT'KHFE&9"133%-(6?-2-O^K VTIBH]/=ZAR[G83?E_0,>Y7X87C.(&]VBWQH=/5@5-TZ.3V#
[SB%]\]KCVQ-49LOU/L@^G4D"*\ ]X& M#*\[ZDO@A*5(C34M@E4BK9"=;XVW_RF&11M_9+] R8MTF*CY1%=23V3OLO
M@"_W!4H84L]]Z;06)O1/C(3[85]W!M,>BWV2%T%]LG]A[ZZ1UQCOB!4H!SF M*I1S=J&$\6HV5QO)2C-\'IE4H\PL,W6= :X=U/S\# "<"P &0 'AL+W=O%?|\Y MR;
(V\ZH"_=+:SCW/^9X[VS?:,?Y#9 "2_"]+2HR-3,KUI6F*108E%1=L#15^ M63)>4HE3OC+%F@--:U!9F(YE!69)\]{1O7:C$IS,;&P" I+.FFD+=L[Q'->'S%MV"%]'_)KK$-'(,L-D*R
ML@7C#L]\:O[HKU:'/0#RZ %."W#Z.]9@-L"W%,]>"W_]6#WP+[T,TF]EJX MF$H:C3C,$:ZLD4T-O5K-.J55ZI,YI+CUQQQ,OIR,Y^367)+IC?7US=?R?SC MU6U"7L<@:5Z(-
^0=N9O'Y/7+-R-3HCL%,AQ#"[6)V'6"?.4<+/F^]"N-9;XEB.I]G/]'2X]POG_[PG_^S]0 RW M2]Q;\[E_DWA=DAL:3T^CKK%+L:8+&!MX3PG@6S"B5R_LP'JO4_B<9/$YR9(S
MD1WDPNMRX1UCC[B>U P(0C=X]FC]P40RI2*C'#)6L_%'D>\%?,% MH55*TKS82.W!FC3N@MJ=>BFVT;O0Q\W:6'C;_7QH# =N$#H#^] PUA@ZMA=:
MGC,\M$QTEE[H^K;_R'F@DM^IY!^O6*70&GBCR(E*^.>LWG.2Q>/;:18O<"QMVCR(PAV)4)B>O)]=6K=-Hf\O=KQW>'0XR)AM$-]L=^O]]#3MUPJ/J3/IQ-R==U?'^ =>]
MT1""^R?)NGARA/56O5,9:ZT\IR>"ULH/>PJ8>^U&"7Q5]WD"P]E4LGF NM6N ME;RJ.ZC>^L2^G-J:]1A;SZ93?*1O^M9KRE=Y)4@!2W1E7828,-[T@LU$KG7= M[-
PSB:U3/&ULK55=;]HP%/TK M5B9-F[0UWTG;021@G;H# 3]^C#MP2078C6Q,]N![M_/=B #%M@F\8(_1 TCT7!94]*U]R6!:$PY4C498GYSR$4;-.W7&NW,2.K7.H-.^E5 M>-5SD
-5E*N5W;)DI 0]"*.(P]O#=S;4:SC3B<#+Y M/)G/T?1NAD:3\7CR!8@>K94YVF4G6ZYAPVW M=X+[!HT9E;E =S2#[!!O*YVM6&\G=NB=)?Q4TROD.V^0YWA!AY[1O\/],W+\
M]NY\PQ>Q&;M@&'F@-6JW!6:V32K\;@3#-T"/F/%9*20LRRXIMZ+*?0M53,$]#58 MRMX?!2R0D[DA/,*EJO9GFJAL#UP]^Y(QN5OH]K^GOP" M4$L#!!0 (&Z##EG!?M%BA 0 /4<
9 >&PO=V]R:W-H965T\#K9,?XHU@"2/*5))]:=M92; M:\,0P1I2*]{8!C+U3<1X2]5ZY"W=N>F_M\MSBM>TY$GJ:4?
[N%A.VF':OS_.)SO%I+_<*8339T!0N0#YM[KIZ,BA+&*60B M9AGA$$T[-]:U;W6UH"CQ)8:=.+@GNBE+QA[UPZ_AM&/]&D$"@=0(]CZV,
(*]86'J\]TKVB\:LR2"IBSY.\XE,MI9]0A(40T3^1GMOL(^P;U M-2]@B2BN9%>6':B(02XD2_=B]9S&6?E)G_8_Q(% <9H%]EY@OQ;T3@BZ>T'W MW B]O:!W;H3^7M
-5S#8"P;G"H9[P;!(5OGK%]EQ]*2S"6<[PG5I1=,W17X+_MM+A]N%^^>#^^DOXGY1UP5YYX"D<2+()\HYU49Y3SZ0 MAX5#WOWX?F)(%51+C6 ?X+8,8)\
(8)$]ELFU(&X60MB@=]KUW1.]H1I;M=A^ M;O&MW0K\+4^NB#W^F=BFW6NHS_P,N34Z*7?:Y7+47Y&N=5+NMLL=""IYMT'N MO57Y3,G-
DW+_G+8W5KZ6BFYEOF[!ZYW@W7,6 (2"1)RE)(-=\HW$0N00$K&F M'$23W5]1NN>^%AL:P+2CNF8!? N=V4_6 /SEZ9<8*<$C8H8'H(V,Z&P[ZI M_B;&]C#%Q^5ZX]%Q.>^XG-
7OV[WQL%[.1VI$+86]*H6]UA0N\]6 KSEDDKA; M*?WG#M(E\'^;4M>*NC1UF# '$^9BPCQ,F(\$]SFE7SFEW_[/GB^3." LBH#' MV8IL>!Q
DTOZQ[:O&W[>&NC2U&>?SSD6"UU_^]U_>Z.>!1+D>O\E. M3RHR*<[P0Y3Y.H:(N$\0Y'HOF%P116I>RMM[E]9P%]L%D^:@TEQ4FH=*\[%H=5.1[[&U: M[9N;-
T5OHMO;^UKN=6PWO'NO;*$[@7?'D@>$?Y*LX$22!2 MH$I:42S(>R65Y59HZF*FE-!DY[T*!NWW),Q(EYR1P M7A_&3!C@EH5=T\ S1LQZN:S%,.MF7
MW@P_MEH=]Q@C7WC(6Z:CA>VZC4>%DMOEBXD+6%U:LN">BHQ,J.!3S8%57]*+ MM0OW(3!30NG V'VSB2*(U \.CEP/MK35*E4NLGM,KB_TW;X ;#I@4$N1&>P
M3UQ@/*]H,4S+*5]*MI!C?!1U#0MF_7E74XUW0=]0=D2VAN-LE4Z9SI+DU$-]'Q M2+ "I@@^7'\#=]"H$T!A5VD;.Z5Q)VGC38,-]&E9TQ(6Z@WG\4]]K8F?'>K!?
MLFM:0VW3R;@.Z.^].>U=V=Z+=(.*WROS>6FG(YL^%"B[UJS@]Z;_*CH#F'J$ M]].J$NM/@L]ER=SDGYUP/*(;7K!0FC_8;% J,QM@'3W3!L^VXW\TK2Z92NS M*:=5@7ONOT'/?
W>=YTPR3<6N:5O[KWF57^PXOOA7EIO_*H>&O1[,0^RUFQR\ M!9/)6S#Y.FLR;(^=G-M[V3KH@&\063D.[R)B&W28+KDPG#9]A8\SYE\=,!9 M>4.G[C5Q3]^.SUE!E\+
<=F!&MNUO+.?+,NU&7<-"M*.V[:\]PO2CI7E]L+BYS MMF+YI.W]^:1!K9AL[87$ Z1]^;R(QC'87X$,"P/Y@#C.!:6YW^:SQ"=C\,P M;T,O,D0Y0Y3C6#YDTGRP/'Y.:B_3-
,TCI,$6]"]O.M@@[U;DL#7KX9Y P:6 M!S+]V5KCNXU7R--U@.WI4Q6"S12O1&RF^%H#XE\W8*2I?]>Q/,# =@&K'?$,>P]Y@U[@G$D33$$:M%?HTF"K$X"'__^8$]'"*>]'P',]R",02>
M1AS!'(-'#(GCYAP\.(_"S3D5;G\]&?\&4$L#!!0 (&Z##EF7BKI

-8?20$3;8T.P6BP^0"X99K>]9!:GO5^8:6I/[*M[12+6LN2B)543STZJV@9%5O M*)5ET7/Z_6&O)*RRK]\.[Y]+GE[@DN:2\4I5-A5WC#[7K^U-$3VQFBU9P>2O
MD=7^+]B%2E:QDKW0U\.<)%^R%5Y(4.!>*$:6O6*XHT*R_)]]W$!F M9%FW-9(L4Z) 1M:PKUZX9]*6[3_:]Q/%^$35G->EG>1C5D@] B+IK>"[+:L>
MFM>H7O2T:K1Q.#SW0;P4_Q-&OEZSG 8\WY6TDOLX"EHT@%6]8=O:0A4IZ(91$GB((QQ&* ;^K%?HCP) PSK-$Y M)WS.73H9XK31(%X!T/PH29UX6SL)8 29CE,S#U,LB#7(0
[,0G;1<);X MWR;)- A3C,+O"QWR%(_9Q(^AZ>H/%4@QP"D$.SD#<>CE]]>1IB1:B&.(F1 M%ROHQ6SF:9!G .296<S+<.V 4 =F$6+ VG:]{% M:.ZEV3W*4B_&GM\,J+X VGUH?
>Z;SHG9+,KV]=!.,I4C613?AK$?A1U(4"*& M+3)708P[TK A:]B&M3%-,$9]]45-\%1RXHF7ACH<9 O;L"[PX@:K%%#Q0N'= MVZA!AK!-*Z)9OM+]U@_1;1R-(]]3D)
[O)XNXXS$;6/'2B]](%&;HC) D;,.6^).V1]D@6]B&=7$T?X]20NJP?&OCZ @'5!)6 M=" =2!^.87U D,CN8$("<0P+!,1T.IC@<<2P6!,MX,)*<8QK1@(<]#!A(3C M&#^3
)@QT3$AX3B&A3B&A0-Z\8>C8T+.<0P[!\9T=4Q(08YA M!<&8 QT3P=]Z"]7P6@C3W<1U$R#FN8>>\I\LX%DG(
M.>YG'&9>XZIC@I=@'WVLZ0Z]C@DYQVV=TSO%86OZI)RLGJ<*5[N(Z^_@U02P,$% @ ;H,.68S?7ZUN M 0 W10 !H !X;"]2"+ MUIF_=]VKKKV+[DW=NE15WO'B=&9T?O?
W/Q*XHKKGJ[/+OQK,^C\'ZIQMNKK+6J^B<#:7UJ=+W M>K[M]*2AU3A91:=+]H;3A90.'<00Q.&## 29\$%K"%]'#]I T"9\4)!2?B@ M+01MPP?M(&@7/F@/0?OP012CC+&I 76
K0FY)H$>$T(-@D0FY!L$F V(=HD M0&U"MDF VX1PDP"Y">DF 783XDT"]&4FP7HS:@W"]";%S_; O1FU)L%Z,VH M-PO0FU%O%) WH]XL0&]&O5F WHQZLP"]&?5F 7H;U-L(T-
N@WD: W@;U-@+T M-HO#$@%Z&]3;O%-OYQ^U=7//&UL4$L! A0#% @ ;H,.62E"F/(!0 @!\ !@ M (<"!#@@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @
;H,.6=O=]&PO=V]R:W-H965T&UL4$L! A0#% @ ;H,.6?]=IB?R P 3@D !D M ("!GDP 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ ;H,.607;KRT2! 80D !D M ("!MUP 'AL+W=O

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end XML 53 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 56 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 128 232 1 false 35 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://cvm.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - CONDENSED BALANCE SHEETS Sheet http://cvm.com/role/CondensedBalanceSheets CONDENSED BALANCE SHEETS Statements 2 false false R3.htm 000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) Sheet http://cvm.com/role/CondensedBalanceSheetsParenthetical CONDENSED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://cvm.com/role/CondensedStatementsOfOperationsUnaudited CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 000005 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED) Sheet http://cvm.com/role/StatementsOfStockholdersEquityUnaudited STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED) Statements 5 false false R6.htm 000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 6 false false R7.htm 000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 000008 - Disclosure - LIQUIDITY Sheet http://cvm.com/role/LIQUIDITY LIQUIDITY Notes 8 false false R9.htm 000009 - Disclosure - STOCKHOLDERS EQUITY Sheet http://cvm.com/role/StockholdersEquity STOCKHOLDERS EQUITY Notes 9 false false R10.htm 000010 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://cvm.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 10 false false R11.htm 000011 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://cvm.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 11 false false R12.htm 000012 - Disclosure - PATENTS Sheet http://cvm.com/role/PATENTS PATENTS Notes 12 false false R13.htm 000013 - Disclosure - LOSS PER COMMON SHARE Sheet http://cvm.com/role/LossPerCommonShare LOSS PER COMMON SHARE Notes 13 false false R14.htm 000014 - Disclosure - SUBSEQUENT EVENTS Sheet http://cvm.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 14 false false R15.htm 000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 15 false false R16.htm 000016 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://cvm.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://cvm.com/role/CommitmentsAndContingencies 16 false false R17.htm 000017 - Disclosure - STOCKHOLDERS EQUITY (Tables) Sheet http://cvm.com/role/StockholdersEquityTables STOCKHOLDERS EQUITY (Tables) Tables http://cvm.com/role/StockholdersEquity 17 false false R18.htm 000018 - Disclosure - PATENTS (Tables) Sheet http://cvm.com/role/PatentsTables PATENTS (Tables) Tables http://cvm.com/role/PATENTS 18 false false R19.htm 000019 - Disclosure - LOSS PER COMMON SHARE (Tables) Sheet http://cvm.com/role/LossPerCommonShareTables LOSS PER COMMON SHARE (Tables) Tables http://cvm.com/role/LossPerCommonShare 19 false false R20.htm 000020 - Disclosure - STOCKHOLDERS EQUITY (Details) Sheet http://cvm.com/role/StockholdersEquityDetails STOCKHOLDERS EQUITY (Details) Details http://cvm.com/role/StockholdersEquityTables 20 false false R21.htm 000021 - Disclosure - STOCKHOLDERS EQUITY (Details 1) Sheet http://cvm.com/role/StockholdersEquityDetails1 STOCKHOLDERS EQUITY (Details 1) Details http://cvm.com/role/StockholdersEquityTables 21 false false R22.htm 000022 - Disclosure - STOCKHOLDERS EQUITY (Details 2) Sheet http://cvm.com/role/StockholdersEquityDetails2 STOCKHOLDERS EQUITY (Details 2) Details http://cvm.com/role/StockholdersEquityTables 22 false false R23.htm 000023 - Disclosure - STOCKHOLDERS EQUITY (Details 3) Sheet http://cvm.com/role/StockholdersEquityDetails3 STOCKHOLDERS EQUITY (Details 3) Details http://cvm.com/role/StockholdersEquityTables 23 false false R24.htm 000024 - Disclosure - STOCKHOLDERS EQUITY (Details 4) Sheet http://cvm.com/role/StockholdersEquityDetails4 STOCKHOLDERS EQUITY (Details 4) Details http://cvm.com/role/StockholdersEquityTables 24 false false R25.htm 000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative) Sheet http://cvm.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS EQUITY (Details Narrative) Details http://cvm.com/role/StockholdersEquityTables 25 false false R26.htm 000026 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://cvm.com/role/RelatedPartyTransactions 26 false false R27.htm 000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://cvm.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://cvm.com/role/CommitmentsAndContingenciesTables 27 false false R28.htm 000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1) Sheet http://cvm.com/role/CommitmentsAndContingenciesDetails1 COMMITMENTS AND CONTINGENCIES (Details 1) Details http://cvm.com/role/CommitmentsAndContingenciesTables 28 false false R29.htm 000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://cvm.com/role/CommitmentsAndContingenciesTables 29 false false R30.htm 000030 - Disclosure - PATENTS (Details) Sheet http://cvm.com/role/PatentsDetails PATENTS (Details) Details http://cvm.com/role/PatentsTables 30 false false R31.htm 000031 - Disclosure - PATENTS (Details Narrative) Sheet http://cvm.com/role/PatentsDetailsNarrative PATENTS (Details Narrative) Details http://cvm.com/role/PatentsTables 31 false false R32.htm 000032 - Disclosure - LOSS PER COMMON SHARE (Details) Sheet http://cvm.com/role/LossPerCommonShareDetails LOSS PER COMMON SHARE (Details) Details http://cvm.com/role/LossPerCommonShareTables 32 false false R33.htm 000033 - Disclosure - LOSS PER COMMON SHARE (Details 1) Sheet http://cvm.com/role/LossPerCommonShareDetails1 LOSS PER COMMON SHARE (Details 1) Details http://cvm.com/role/LossPerCommonShareTables 33 false false R34.htm 000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://cvm.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://cvm.com/role/SubsequentEvents 34 false false All Reports Book All Reports cvm-20240630.xsd cvm-20240630_cal.xml cvm-20240630_def.xml cvm-20240630_lab.xml cvm-20240630_pre.xml cvm_10q.htm cvm_10qimg10.jpg cvm_10qimg11.jpg cvm_10qimg12.jpg cvm_10qimg13.jpg cvm_10qimg14.jpg cvm_10qimg15.jpg cvm_10qimg8.jpg cvm_10qimg9.jpg http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 true true JSON 59 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "cvm_10q.htm": { "nsprefix": "cvm", "nsuri": "http://cvm.com/20240630", "dts": { "schema": { "local": ["cvm-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["cvm-20240630_cal.xml"] }, "definitionLink": { "local": ["cvm-20240630_def.xml"] }, "labelLink": { "local": ["cvm-20240630_lab.xml"] }, "presentationLink": { "local": ["cvm-20240630_pre.xml"] }, "inline": { "local": ["cvm_10q.htm"] } }, "keyStandard": 172, "keyCustom": 60, "axisStandard": 12, "axisCustom": 0, "memberStandard": 10, "memberCustom": 25, "hidden": { "total": 23, "http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 16, "http://cvm.com/20240630": 2 }, "contextCount": 128, "entityCount": 1, "segmentCount": 35, "elementCount": 319, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 443, "http://xbrl.sec.gov/dei/2024": 30 }, "report": { "R1": { "role": "http://cvm.com/role/Cover", "longName": "000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "strong", "p", "td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "strong", "p", "td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://cvm.com/role/CondensedBalanceSheets", "longName": "000002 - Statement - CONDENSED BALANCE SHEETS", "shortName": "CONDENSED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "unique": true } }, "R3": { "role": "http://cvm.com/role/CondensedBalanceSheetsParenthetical", "longName": "000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited", "longName": "000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)", "shortName": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited", "longName": "000005 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)", "shortName": "STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2022-09-30_us-gaap_CommonStockMember", "name": "us-gaap:SharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2022-12-31_us-gaap_CommonStockMember", "name": "cvm:WarrantExercisesShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "unique": true } }, "R6": { "role": "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited", "longName": "000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)", "shortName": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies", "longName": "000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://cvm.com/role/LIQUIDITY", "longName": "000008 - Disclosure - LIQUIDITY", "shortName": "LIQUIDITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "cvm:LiquidityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "cvm:LiquidityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://cvm.com/role/StockholdersEquity", "longName": "000009 - Disclosure - STOCKHOLDERS EQUITY", "shortName": "STOCKHOLDERS EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://cvm.com/role/RelatedPartyTransactions", "longName": "000010 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://cvm.com/role/CommitmentsAndContingencies", "longName": "000011 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://cvm.com/role/PATENTS", "longName": "000012 - Disclosure - PATENTS", "shortName": "PATENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://cvm.com/role/LossPerCommonShare", "longName": "000013 - Disclosure - LOSS PER COMMON SHARE", "shortName": "LOSS PER COMMON SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://cvm.com/role/SubsequentEvents", "longName": "000014 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "15", "firstAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://cvm.com/role/CommitmentsAndContingenciesTables", "longName": "000016 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "16", "firstAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://cvm.com/role/StockholdersEquityTables", "longName": "000017 - Disclosure - STOCKHOLDERS EQUITY (Tables)", "shortName": "STOCKHOLDERS EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://cvm.com/role/PatentsTables", "longName": "000018 - Disclosure - PATENTS (Tables)", "shortName": "PATENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://cvm.com/role/LossPerCommonShareTables", "longName": "000019 - Disclosure - LOSS PER COMMON SHARE (Tables)", "shortName": "LOSS PER COMMON SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://cvm.com/role/StockholdersEquityDetails", "longName": "000020 - Disclosure - STOCKHOLDERS EQUITY (Details)", "shortName": "STOCKHOLDERS EQUITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "20", "firstAnchor": { "contextRef": "AsOf2024-06-30_cvm_IncentiveStockBonusPlanMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30_cvm_IncentiveStockBonusPlanMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://cvm.com/role/StockholdersEquityDetails1", "longName": "000021 - Disclosure - STOCKHOLDERS EQUITY (Details 1)", "shortName": "STOCKHOLDERS EQUITY (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://cvm.com/role/StockholdersEquityDetails2", "longName": "000022 - Disclosure - STOCKHOLDERS EQUITY (Details 2)", "shortName": "STOCKHOLDERS EQUITY (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30_us-gaap_EmployeeStockMember", "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30_us-gaap_EmployeeStockMember", "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://cvm.com/role/StockholdersEquityDetails3", "longName": "000023 - Disclosure - STOCKHOLDERS EQUITY (Details 3)", "shortName": "STOCKHOLDERS EQUITY (Details 3)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "AsOf2024-06-30_cvm_ConsultantsOptionMember", "name": "cvm:SharesIssuableUponExerciseOfWarrantOptions", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30_cvm_ConsultantsOptionMember", "name": "cvm:SharesIssuableUponExerciseOfWarrantOptions", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://cvm.com/role/StockholdersEquityDetails4", "longName": "000024 - Disclosure - STOCKHOLDERS EQUITY (Details 4)", "shortName": "STOCKHOLDERS EQUITY (Details 4)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "cvm:EquityWarrantsExercised", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "cvm:ScheduleOfDerivativeLiabilitiesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "cvm:EquityWarrantsExercised", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "cvm:ScheduleOfDerivativeLiabilitiesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://cvm.com/role/StockholdersEquityDetailsNarrative", "longName": "000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)", "shortName": "STOCKHOLDERS EQUITY (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "AsOf2024-02-29", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-02-29", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "000026 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "From2024-05-01to2024-05-04_cvm_OfficerandDirectorMember", "name": "cvm:IncrementalCostDeemedDividend", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-05-04_cvm_OfficerandDirectorMember", "name": "cvm:IncrementalCostDeemedDividend", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails", "longName": "000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails1", "longName": "000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:InterestPaid", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:InterestPaid", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://cvm.com/role/PatentsDetails", "longName": "000030 - Disclosure - PATENTS (Details)", "shortName": "PATENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://cvm.com/role/PatentsDetailsNarrative", "longName": "000031 - Disclosure - PATENTS (Details Narrative)", "shortName": "PATENTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://cvm.com/role/LossPerCommonShareDetails", "longName": "000032 - Disclosure - LOSS PER COMMON SHARE (Details)", "shortName": "LOSS PER COMMON SHARE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://cvm.com/role/LossPerCommonShareDetails1", "longName": "000033 - Disclosure - LOSS PER COMMON SHARE (Details 1)", "shortName": "LOSS PER COMMON SHARE (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-06-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://cvm.com/role/SubsequentEventsDetailsNarrative", "longName": "000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-07-29_us-gaap_SubsequentEventMember", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cvm_10q.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 13.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r27", "r413"] }, "cvm_AccruedConsultingServicesToBePaidWithCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "AccruedConsultingServicesToBePaidWithCommonStock", "crdr": "credit", "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Accrued consulting services to be paid with common stock" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 14.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r29"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 25.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r37", "r413", "r515"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Additional Paid-In Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r323", "r440", "r441", "r442", "r443", "r497", "r516"] }, "cvm_AdditionalPurchaseOfCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://cvm.com/20240630", "localname": "AdditionalPurchaseOfCommonStock", "presentation": ["http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Additional purchase of common stock" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Total expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r212", "r218"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "presentation": ["http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Amortization cost", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": ["r44", "r163", "r437", "r500"] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": ["http://cvm.com/role/PatentsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Amortization expense", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r3", "r135", "r141", "r403"] }, "cvm_AnnualIncreaseToInterestPayments": { "xbrltype": "percentItemType", "nsuri": "http://cvm.com/20240630", "localname": "AnnualIncreaseToInterestPayments", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Annual increase to interest payments" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://cvm.com/role/LossPerCommonShareDetails1"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r115"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://cvm.com/role/LossPerCommonShareDetails1", "http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r16"] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://cvm.com/role/LossPerCommonShareDetails1", "http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r16"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "[Assets]", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r57", "r64", "r77", "r95", "r119", "r121", "r122", "r123", "r125", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r238", "r242", "r254", "r294", "r347", "r400", "r401", "r413", "r425", "r466", "r467", "r505"] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "[Assets, Current]", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r74", "r80", "r95", "r125", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r238", "r242", "r254", "r413", "r466", "r467", "r505"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "cvm_AssetsPurchasedUnderFinanceLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "AssetsPurchasedUnderFinanceLeases", "crdr": "credit", "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Assets purchased under finance leases" } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://cvm.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r183", "r184", "r185", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r207", "r208", "r209", "r210", "r211"] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": ["http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "verboseLabel": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r50"] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r12"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets", "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD", "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF PERIOD", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r10", "r47", "r93"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r47"] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": ["http://cvm.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "auth_ref": ["r450"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://cvm.com/role/StockholdersEquityDetails3", "http://cvm.com/role/StockholdersEquityDetails4", "http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Class Of Warrant Or Right Axis", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r22"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://cvm.com/role/StockholdersEquityDetails3", "http://cvm.com/role/StockholdersEquityDetails4", "http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://cvm.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "verboseLabel": "Public offering price", "label": "[Class of Warrant or Right, Exercise Price of Warrants or Rights]", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r177"] }, "cvm_ClinicalServiceTrial": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "ClinicalServiceTrial", "crdr": "debit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Clinical service trial" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 22.0 } }, "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r33", "r58", "r296", "r334"] }, "cvm_CommitmentsAndContingenciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://cvm.com/20240630", "localname": "CommitmentsAndContingenciesAbstract", "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://cvm.com/role/CommitmentsAndContingencies"], "lang": { "en-us": { "role": { "verboseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r52", "r148", "r149", "r390", "r463", "r465"] }, "cvm_CommonStockContributedToEmployeeBenefitPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "CommonStockContributedToEmployeeBenefitPlan", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Common stock contributed to 401(k) plan (Increase)/decrease in assets:" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r415", "r416", "r417", "r419", "r420", "r421", "r422", "r440", "r441", "r443", "r497", "r514", "r516"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://cvm.com/role/CondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r36"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://cvm.com/role/CondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r36", "r335"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://cvm.com/role/CondensedBalanceSheetsParenthetical", "http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "verboseLabel": "Common stock shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r36"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://cvm.com/role/CondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r5", "r36", "r335", "r353", "r516", "r517"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"CommonStockValue", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 24.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common stock, $.01 par value; 600,000,000 shares authorized; 54,257,884 and 47,422,304 shares issued and outstanding at June 30, 2024 and September 30, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r36", "r298", "r413"] }, "cvm_ConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "ConsultantsMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetails3", "http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Consultants [Member]", "verboseLabel": "Consultants [Member]" } } }, "auth_ref": [] }, "cvm_ConsultantsOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "ConsultantsOptionMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetails3"], "lang": { "en-us": { "role": { "label": "Consultants Options [Member]" } } }, "auth_ref": [] }, "cvm_ConsultingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "ConsultingAgreementsMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Consulting Agreements [Member]" } } }, "auth_ref": [] }, "cvm_ConsultingAgreementsOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "ConsultingAgreementsOtherMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Consulting Agreements Other [Member]" } } }, "auth_ref": [] }, "cvm_ConsultingFeesIncluedPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "ConsultingFeesIncluedPrepaidExpenses", "crdr": "debit", "presentation": ["http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Consulting fees inclued prepaid expenses" } } }, "auth_ref": [] }, "cvm_ConsultingServicesPaidWithIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "ConsultingServicesPaidWithIssuanceOfCommonStock", "crdr": "credit", "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Consulting services paid with issuance of common stock" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DepositsAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsCurrent", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Deposits current", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter." } } }, "auth_ref": ["r434"] }, "us-gaap_DepositsAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 11.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Deposits", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r433"] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r3", "r21"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r429"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r430"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "cvm_DueToEmployeeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "DueToEmployeeCurrent", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 15.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Due to employees" } } }, "auth_ref": [] }, "cvm_EarningPerShareBasicAndDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://cvm.com/20240630", "localname": "EarningPerShareBasicAndDiluted", "presentation": ["http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Net loss per common share - basic and diluted" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "LOSS PER COMMON SHARE" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAndDilutedAbstract", "presentation": ["http://cvm.com/role/LossPerCommonShareDetails"], "lang": { "en-us": { "role": { "label": "Loss per share-basic and diluted" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Net Loss Per Common Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r16", "r17", "r116"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://cvm.com/role/LossPerCommonShare"], "lang": { "en-us": { "role": { "verboseLabel": "LOSS PER COMMON SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r109", "r115", "r117", "r118"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "crdr": "debit", "presentation": ["http://cvm.com/role/StockholdersEquityDetails2"], "lang": { "en-us": { "role": { "label": "Stock Based Compensation Expense", "documentation": "Amount of cost capitalized for award under share-based payment arrangement." } } }, "auth_ref": ["r213"] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetails2"], "lang": { "en-us": { "role": { "label": "Employees", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 1", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 2", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r427"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Common Stock Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r427"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r427"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r431"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://cvm.com/role/Cover"], "lang": {

"en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r427"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r427"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r427"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r427"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "STOCKHOLDERS EQUITY" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r5", "r72", "r84", "r85", "r86", "r96", "r97", "r98", "r100", "r105", "r106", "r108", "r120", "r126", "r127", "r147", "r178", "r228", "r229", "r230", "r231", "r232", "r234", "r235", "r236", "r244", "r245", "r246", "r247", "r248", "r249", "r251", "r255", "r256", "r257", "r258", "r259", "r260", "r262", "r263", "r271", "r306", "r309", "r310", "r311", "r323", "r375"] }, "cvm_EquityProceedsFromSaleCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "EquityProceedsFromSaleCommonStockMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common Stock sale [Member]" } } }, "auth_ref": [] }, "cvm_EquityWarrantsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://cvm.com/20240630", "localname": "EquityWarrantsExercisePrice", "presentation": ["http://cvm.com/role/StockholdersEquityDetails4"], "lang": { "en-us": { "role": { "label": "Equity Warrants Exercise Price" } } }, "auth_ref": [] }, "cvm_EquityWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://cvm.com/20240630", "localname": "EquityWarrantsExercised", "presentation": ["http://cvm.com/role/StockholdersEquityDetails4"], "lang": { "en-us": { "role": { "label": "Equity Warrants Exercised" } } }, "auth_ref": [] }, "cvm_ErgomedMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "ErgomedMember", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Ergomed [Member]" } } }, "auth_ref": [] }, "cvm_ExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://cvm.com/20240630", "localname": "ExercisePrice", "presentation": ["http://cvm.com/role/StockholdersEquityDetails3"], "lang": { "en-us": { "role": { "label": "Exercise Price" } } }, "auth_ref": [] }, "cvm_ExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://cvm.com/20240630", "localname": "ExpirationDate", "presentation": ["http://cvm.com/role/StockholdersEquityDetails3"], "lang": { "en-us": { "role": { "label": "Expiration Date" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Net present value of financing lease obligations", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": ["r265", "r269"] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 16.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Finance lease obligation, current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": ["r265"] }, "cvm_FinanceLeaseLiabilityCurrentPortion": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "FinanceLeaseLiabilityCurrentPortion", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Less net present value of financing lease obligations - current portion", "label": "[Less net present value of financing lease obligations - current portion]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of future minimum payments under finance leases", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } } }, "auth_ref": ["r502"] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 19.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Finance lease obligations, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": ["r265"] }, "cvm_FinanceLeaseLiabilityNoncurrentPortion": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "FinanceLeaseLiabilityNoncurrentPortion", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Net present value of financing lease obligations - non-current portion" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Total future minimum lease obligation", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": ["r269"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r269"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "2029", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r269"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r269"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r269"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r269"] }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Three months ending September 30, 2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r502"] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Less imputed interest on finance lease obligations", "label": "[Finance Lease, Liability, Undiscounted Excess Amount]", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": ["r269"] }, "cvm_FinanceLeaseObligationIncludedInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "FinanceLeaseObligationIncludedInAccountsPayable", "crdr": "credit", "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Finance lease obligation included in accounts payable" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Finance lease right of use assets", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": ["r264"] }, "cvm_FinancingArrangementDepositBaseRentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "FinancingArrangementDepositBaseRentAmount", "crdr": "debit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Financing arrangement deposit base rent amount" } } }, "auth_ref": [] }, "cvm_FinancingCostsIncludedInCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "FinancingCostsIncludedInCurrentLiabilities", "crdr": "credit", "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Financing costs included in current liabilities" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": ["http://cvm.com/role/PatentsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year One]", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r142", "r394", "r403"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": ["http://cvm.com/role/PatentsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Three months ending September 30, 2024", "label": "[Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year]", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": ["r518"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive", "crdr": "debit", "presentation": ["http://cvm.com/role/PatentsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Thereafter", "label": "[Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five]", "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet date. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": ["http://cvm.com/role/PatentsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "2029", "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Five]", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r142", "r394", "r403"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": ["http://cvm.com/role/PatentsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "2028", "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Four]", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r142", "r394", "r403"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": ["http://cvm.com/role/PatentsDetails"], "lang": { "en-us": { "role": {

"verboseLabel": "2027", "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Three]", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r142", "r394", "r403"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": ["http://cvm.com/role/PatentsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Two]", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r142", "r394", "r403"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r134", "r136", "r137", "r138", "r139", "r140", "r143", "r144", "r289", "r290", "r394"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r134", "r136", "r137", "r138", "r139", "r140", "r143", "r144", "r394"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 10.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Patent costs, net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r289", "r458"] }, "cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://cvm.com/20240630", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod", "presentation": ["http://cvm.com/role/PatentsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Weighted average amortization period for patents" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r43", "r357"] }, "cvm_ImpairmentOfLongLivedAssetsPolicyTextblock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvm.com/20240630", "localname": "ImpairmentOfLongLivedAssetsPolicyTextblock", "presentation": ["http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Impairment of long-lived assets" } } }, "auth_ref": [] }, "cvm_IncentiveStockBonusPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "IncentiveStockBonusPlanMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Incentive Stock Bonus Plan [Member]", "label": "[Incentive Stock Bonus Plan [Member]]" } } }, "auth_ref": [] }, "cvm_IncentiveStockBonusPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "IncentiveStockBonusPlansMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Incentive Stock Bonus Plan [Member]" } } }, "auth_ref": [] }, "cvm_IncentiveStockForfeitedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "IncentiveStockForfeitedAmount", "crdr": "credit", "presentation": ["http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "2014 incentive stock forfeited amount" } } }, "auth_ref": [] }, "cvm_IncentiveStockForfeitedShares": { "xbrltype": "sharesItemType", "nsuri": "http://cvm.com/20240630", "localname": "IncentiveStockForfeitedShares", "presentation": ["http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "2014 incentive stock forfeited shares" } } }, "auth_ref": [] }, "cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares": { "xbrltype": "perShareItemType", "nsuri": "http://cvm.com/20240630", "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShares", "presentation": ["http://cvm.com/role/LossPerCommonShareDetails"], "lang": { "en-us": { "role": { "label": "Basic and diluted loss per common share" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": ["http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": ["r83", "r222", "r223", "r224", "r225", "r226", "r227", "r316"] }, "us-gaap_IncreaseDecreaseDueFromOfficersAndStockholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseDueFromOfficersAndStockholders", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Proceeds from the purchase of stock by officers and directors", "label": "[Increase (Decrease) Due from Officers and Stockholders]", "documentation": "The increase (decrease) during the reporting period in receivables to be collected from the reporting entity's executives and owners." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "[Increase (Decrease) in Accounts Payable]", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "label": "[Increase (Decrease) in Accrued Liabilities]", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeposits", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Deposits", "label": "[Increase (Decrease) in Deposits]", "documentation": "The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances." } } }, "auth_ref": ["r11", "r62"] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Due to employees", "label": "[Increase (Decrease) in Employee Related Liabilities]", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Supplies used for R&D and manufacturing", "label": "[Increase (Decrease) in Inventories]", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract", "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase/(decrease) in liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses", "label": "[Increase (Decrease) in Prepaid Expense]", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": ["r2"] }, "cvm_IncrementalCostDeemedDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "IncrementalCostDeemedDividend", "crdr": "debit", "presentation": ["http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative", "http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Incremental cost", "verboseLabel": "Incremental cost" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": ["http://cvm.com/role/PATENTS"], "lang": { "en-us": { "role": { "verboseLabel": "PATENTS", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": ["r133", "r145", "r146", "r393", "r394"] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": ["http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Patents", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } }, "auth_ref": ["r285", "r286", "r287", "r289", "r396", "r452"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "lang": { "en-us": { "role": { "label": "PATENTS" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Interest expense, net", "documentation": "Amount of interest income (expense) classified as operating." } } }, "auth_ref": ["r291", "r446"] }, "us-gaap_InterestPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaid", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Interest amount", "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities." } } }, "auth_ref": ["r438"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r88", "r91", "r92"] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": ["http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Supplies used for R&D and manufacturing", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": ["r65", "r76", "r78", "r128", "r129", "r130", "r284", "r397"] }, "cvm_IssuanceCostOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "IssuanceCostOfCommonStock", "crdr": "debit", "presentation": ["http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang":

{ "en-us": { "role": { "label": "Issuance cost of common stock" } } }, "auth_ref": [] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Share-based payments for services", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": ["r3"] }, "cvm_IssueDate1": { "xbrltype": "stringItemType", "nsuri": "http://cvm.com/20240630", "localname": "IssueDate1", "presentation": ["http://cvm.com/role/StockholdersEquityDetails3"], "lang": { "en-us": { "role": { "label": "Issue Date" } } }, "auth_ref": [] }, "cvm_LIQUIDITYAbstract": { "xbrltype": "stringItemType", "nsuri": "http://cvm.com/20240630", "localname": "LIQUIDITYAbstract", "lang": { "en-us": { "role": { "label": "LIQUIDITY" } } }, "auth_ref": [] }, "cvm_LandlordMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "LandlordMember", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Landlord [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseAgreementsMember", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Lease Agreements [Member]", "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset." } } }, "auth_ref": ["r25", "r453", "r454", "r455", "r456", "r457", "r458", "r461", "r462"] }, "cvm_LeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvm.com/20240630", "localname": "LeasesPolicyTextBlock", "presentation": ["http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Leases" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of future minimum payments under operating leases", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r502"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails1"], "lang": { "en-us": { "role": { "label": "Total Future Minimum Lease Obligation", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r269"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails1"], "lang": { "en-us": { "role": { "label": "Thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r269"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails1"], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year One]", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r269"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails1"], "lang": { "en-us": { "role": { "verboseLabel": "2029", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Five]", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r269"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails1"], "lang": { "en-us": { "role": { "verboseLabel": "2028", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Four]", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r269"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails1"], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Three]", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r269"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails1"], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Two]", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r269"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails1"], "lang": { "en-us": { "role": { "verboseLabel": "Three months ending September 30, 2024", "label": "[Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year]", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r502"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails1"], "lang": { "en-us": { "role": { "negatedLabel": "Less Imputed Interest On Operating Lease Obligation", "label": "[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r269"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 27.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "[Liabilities]", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r8", "r28", "r29", "r30", "r31", "r32", "r33", "r34", "r95", "r125", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r239", "r242", "r243", "r254", "r333", "r398", "r425", "r466", "r505", "r506"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY", "label": "[Liabilities and Equity]", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r41", "r59", "r300", "r413", "r439", "r451", "r499"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 18.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "[Liabilities, Current]", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r30", "r75", "r95", "r125", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r239", "r242", "r243", "r254", "r413", "r466", "r505", "r506"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "cvm_LiquidityDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvm.com/20240630", "localname": "LiquidityDisclosureTextBlock", "presentation": ["http://cvm.com/role/LIQUIDITY"], "lang": { "en-us": { "role": { "verboseLabel": "LIQUIDITY", "label": "[LIQUIDITY]" } } }, "auth_ref": [] }, "us-gaap_LoansAndLeasesReceivableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansAndLeasesReceivableRelatedParties", "crdr": "debit", "presentation": ["http://cvm.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Amount of loan", "documentation": "For an unclassified balance sheet, reflects the carrying amount of unpaid loan amounts due from related parties at the balance sheet date." } } }, "auth_ref": ["r26", "r60"] }, "us-gaap_LoansAndLeasesReceivableRelatedPartiesAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansAndLeasesReceivableRelatedPartiesAdditions", "crdr": "debit", "presentation": ["http://cvm.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Additional loan amount", "documentation": "Reflects the amount of new advances made to related parties in the form of loan and lease receivables." } } }, "auth_ref": ["r26", "r60"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetails3"], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": ["r150", "r151", "r152", "r153", "r181", "r219", "r253", "r283", "r307", "r308", "r314", "r325", "r326", "r383", "r384", "r385", "r386", "r387", "r391", "r392", "r402", "r404", "r405", "r408", "r409", "r410", "r411", "r414", "r468", "r507", "r508", "r509", "r510", "r511", "r512"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetails3"], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": ["r150", "r151", "r152", "r153", "r181", "r219", "r253", "r283", "r307", "r308", "r314", "r325", "r326", "r383", "r384", "r385", "r386", "r387", "r391", "r392", "r402", "r404", "r405", "r408", "r409", "r410", "r414", "r468", "r507", "r508", "r509", "r510", "r511", "r512"] }, "cvm_ModificationOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "ModificationOfWarrants", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Modification of warrants" } } }, "auth_ref": [] }, "cvm_MrKerstenMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "MrKerstenMember", "presentation": ["http://cvm.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Mr. Kersten [Member]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 23.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "[Net Cash Provided by (Used in) Financing Activities]", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r90"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 22.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "[Net Cash Provided by (Used in) Investing Activities]", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r90"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 21.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "[Net Cash Provided by (Used in) Operating Activities]", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r47", "r48", "r49"] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfOperationsUnaudited", "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "[Net Income (Loss) Attributable to Parent]", "verboseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r42", "r49", "r61", "r73", "r81", "r82", "r86", "r95", "r99", "r101", "r102", "r103", "r104", "r105", "r107", "r108", "r112", "r125", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r233", "r236", "r252", "r254", "r305", "r355", "r373", "r374", "r423", "r466"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net loss available to common shareholders", "label": "[Net Income (Loss) Available to Common Stockholders, Basic]", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": ["r87", "r101", "r102", "r103", "r104", "r110", "r111", "r113", "r114", "r236"] }, "cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted", "crdr": "credit", "presentation": ["http://cvm.com/role/LossPerCommonShareDetails"], "lang": { "en-us": { "role": { "label": "Net loss available to common shareholders - basic and diluted" } } }, "auth_ref": [] }, "cvm_NetOfDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "NetOfDiscount", "crdr": "debit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Net Of Discount" } } }, "auth_ref": [] }, "cvm_NetofissuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "NetofissuanceCosts", "crdr": "credit", "presentation": ["http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Net of issuance costs" } } }, "auth_ref": [] }, "cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvm.com/20240630", "localname": "NewAccountingPronouncementEarlyAdoptionPolicyTextBlock", "presentation": ["http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Recently Adopted Accounting Standards" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "cvm_NonEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "NonEmployeesMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetails2"], "lang": { "en-us": { "role": { "label": "Non-employees" } } }, "auth_ref": [] }, "cvm_NonQualifiedStockOptionsPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "NonQualifiedStockOptionsPlansMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Non-Qualified Stock Option Plans [Member]" } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1", "presentation": ["http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Options issued", "documentation": "The number of options issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r13", "r14", "r15"] }, "cvm_OfficerandDirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "OfficerandDirectorMember", "presentation": ["http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Officer And Director [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "[Operating Expenses]", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "[Operating Income (Loss)]", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r63", "r399", "r445", "r446", "r447", "r448", "r449"] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Lease expense for operating leases", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r501"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails1"], "lang": { "en-us": { "role": { "label": "Net Present Value Of Operating Lease Obligation", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r265"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 17.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating lease obligation, current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r265"] }, "cvm_OperatingLeaseLiabilityCurrentPortion": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "OperatingLeaseLiabilityCurrentPortion", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails1"], "lang": { "en-us": { "role": { "negatedLabel": "Net present value of lease finance lease obligations - current portion", "label": "[Net present value of lease finance lease obligations - current portion]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 20.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating lease obligations, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r265"] }, "cvm_OperatingLeaseLiabilityNoncurrentPortion": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "OperatingLeaseLiabilityNoncurrentPortion", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetails1"], "lang": { "en-us": { "role": { "label": "Net present value of lease finance lease obligations - non-current portion" } } }, "auth_ref": [] }, "us-gaap_OperatingLeasePaymentsUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePaymentsUse", "crdr": "credit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Total cash payment for oprating lease", "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r266", "r267"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating lease right of use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r264"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Weighted average discount rate operating lease", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r268", "r412"] }, "cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne": { "xbrltype": "durationItemType", "nsuri": "http://cvm.com/20240630", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTermOne", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Weighted average time of maturity of operating leases" } } }, "auth_ref": [] }, "cvm_OptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "OptionsMember", "presentation": ["http://cvm.com/role/LossPerCommonShareDetails1"], "lang": { "en-us": { "role": { "label": "Options and Warrants" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "auth_ref": [] }, "us-gaap_OtherIndefiniteLivedIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIndefiniteLivedIntangibleAssets", "crdr": "debit", "presentation": ["http://cvm.com/role/PatentsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Total", "label": "[Other Indefinite-Lived Intangible Assets]", "documentation": "Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill." } } }, "auth_ref": ["r432", "r460"] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 21.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r32"] }, "us-gaap_OtherNoncashExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashExpense", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Non-cash lease expense", "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other." } } }, "auth_ref": ["r49"] }, "us-gaap_OtherNonoperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingExpense", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 7.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Other expense", "label": "[Other Nonoperating Expense]", "documentation": "Amount of expense related to nonoperating activities, classified as other." } } }, "auth_ref": ["r45"] }, "us-gaap_OtherResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Research and development expenses", "documentation": "Amount of other research and development expense." } } }, "auth_ref": ["r496"] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Payments of stock issuance costs", "label": "[Payments of Stock Issuance Costs]", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": ["r9"] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Expenditures for patent costs", "label": "[Payments to Acquire Intangible Assets]", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": ["r46"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "[Payments to Acquire Property, Plant, and Equipment]", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r46"] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Plan Name Axis", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://cvm.com/role/CondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r35", "r165"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://cvm.com/role/CondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r35", "r335"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://cvm.com/role/CondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r35", "r165"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://cvm.com/role/CondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r35", "r335", "r353", "r516", "r517"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 23.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred stock, $.01 par value; 200,000 shares authorized; 0 shares issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r35", "r297", "r413"] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r79", "r131", "r132", "r395"] }, "cvm_ProceedsFromEquityWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "ProceedsFromEquityWarrantsExercised", "crdr": "debit", "presentation": ["http://cvm.com/role/StockholdersEquityDetails4"], "lang": { "en-us": { "role": { "label": "Proceeds From Equity Warrants Exercised" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited", "http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock", "verboseLabel": "Proceeds from issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r1"] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 19.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Proceeds from the exercise of warrants", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": ["r436"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Net loss", "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r73", "r81", "r82", "r89", "r95", "r99", "r105", "r107", "r108", "r125", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r233", "r236", "r237", "r240", "r241", "r252", "r254", "r292", "r304", "r322", "r355", "r373", "r374", "r406", "r407", "r424", "r435", "r466"] }, "cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities", "crdr": "credit", "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Property and equipment included in current liabilities" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r4", "r270", "r293", "r303", "r413"] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": ["http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Property and Equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r4", "r68", "r71", "r302"] }, "cvm_PurchaseOfNewlyIssuedSharesByInsiders": { "xbrltype": "sharesItemType", "nsuri": "http://cvm.com/20240630", "localname": "PurchaseOfNewlyIssuedSharesByInsiders", "presentation": ["http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Purchase of newly issued shares by insiders" } } }, "auth_ref": [] }, "cvm_PurchaseOfStockByOfficersAndDirectorsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "PurchaseOfStockByOfficersAndDirectorsAmount", "crdr": "credit", "presentation": ["http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Purchase of stock by officers and directors amount" } } }, "auth_ref": [] }, "cvm_PurchaseOfStockByOfficersAndDirectorsSahres": { "xbrltype": "sharesItemType", "nsuri": "http://cvm.com/20240630", "localname": "PurchaseOfStockByOfficersAndDirectorsSahres", "presentation": ["http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Purchase of stock by officers and directors sahres" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://cvm.com/role/StockholdersEquityDetails3"], "lang": { "en-us": { "role": { "label": "Range Axis" } } }, "auth_ref": ["r150", "r151", "r152", "r153", "r179", "r181", "r208", "r209", "r210", "r219", "r253", "r281", "r282", "r283", "r307", "r308", "r314", "r325", "r326", "r383", "r384", "r385", "r386", "r387", "r391", "r392", "r402", "r404", "r405", "r408", "r409", "r410", "r411", "r414", "r417", "r464", "r468", "r498", "r508", "r509", "r510", "r511", "r512"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetails3"], "auth_ref": ["r150", "r151", "r152", "r153", "r179", "r181", "r208", "r209", "r210", "r219", "r253", "r281", "r282", "r283", "r307", "r308", "r314", "r325", "r326", "r383", "r384", "r385", "r386", "r387", "r391", "r392", "r402", "r404", "r405", "r408", "r409", "r410", "r411", "r414", "r417", "r464", "r468", "r498", "r508", "r509", "r510", "r511", "r512"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative", "http://cvm.com/role/StockholdersEquityDetails3", "http://cvm.com/role/StockholdersEquityDetailsNarrative", "http://cvm.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r124", "r180", "r275", "r276", "r295", "r301", "r328", "r329", "r330", "r331", "r332", "r352", "r354", "r382"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative", "http://cvm.com/role/StockholdersEquityDetails3", "http://cvm.com/role/StockholdersEquityDetailsNarrative", "http://cvm.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Related Party Transactions By Related Party Axis", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r124", "r180", "r275", "r276", "r295", "r301", "r328", "r329", "r330", "r331", "r332", "r352", "r354", "r382", "r504"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://cvm.com/role/RelatedPartyTransactions"], "lang": { "en-us": { "role": { "verboseLabel": "RELATED PARTY TRANSACTIONS", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r272", "r273", "r274", "r276", "r277", "r319", "r320", "r321", "r358", "r359", "r360", "r379", "r381"] }, "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebtAndCapitalLeaseObligations", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Payments on obligations under finance leases", "label": "[Repayments of Debt and Lease Obligation]", "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [

"http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r221", "r394", "r400", "r513"] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Research and Development Costs", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r220"] }, "cvm_RestrictedCommonStockFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "RestrictedCommonStockFairValue", "crdr": "credit", "presentation": ["http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Purchase of restricted common stock fair value" } } }, "auth_ref": [] }, "cvm_RestrictedStocksMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "RestrictedStocksMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 26.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r38", "r54", "r299", "r312", "r313", "r318", "r336", "r413"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r72", "r96", "r97", "r98", "r100", "r105", "r106", "r108", "r126", "r127", "r147", "r228", "r229", "r230", "r231", "r232", "r234", "r235", "r236", "r244", "r246", "r247", "r249", "r251", "r262", "r263", "r309", "r311", "r323", "r516"] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://cvm.com/role/StockholdersEquityDetails2"], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": ["http://cvm.com/role/StockholdersEquityDetailsNarrative", "http://cvm.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Sale of common stock at a public offering price", "verboseLabel": "Sale of common stock at a public offering price", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": ["http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Public offering price", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvm.com/20240630", "localname": "ScheduleOfAntiDilutiveSecuritiesTableTextBlock", "presentation": ["http://cvm.com/role/LossPerCommonShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of anti-dilutive securities" } } }, "auth_ref": [] }, "cvm_ScheduleOfCompensatingBalancesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvm.com/20240630", "localname": "ScheduleOfCompensatingBalancesTableTextBlock", "presentation": ["http://cvm.com/role/StockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of Stock-Based Compensation Expense" } } }, "auth_ref": [] }, "cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvm.com/20240630", "localname": "ScheduleOfDerivativeLiabilitiesTableTextBlock", "presentation": ["http://cvm.com/role/StockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of derivative liabilities" } } }, "auth_ref": [] }, "cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvm.com/20240630", "localname": "ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock", "presentation": ["http://cvm.com/role/LossPerCommonShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": ["http://cvm.com/role/StockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of equity compensation plans", "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": ["r6", "r7", "r55"] }, "cvm_ScheduleOfStockOptionActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvm.com/20240630", "localname": "ScheduleOfStockOptionActivityTableTextBlock", "presentation": ["http://cvm.com/role/StockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of Stock option activity" } } }, "auth_ref": [] }, "cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvm.com/20240630", "localname": "ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock", "presentation": ["http://cvm.com/role/StockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of warrants and non-employee options outstanding" } } }, "auth_ref": [] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": ["http://cvm.com/role/PatentsTables"], "lang": { "en-us": { "role": { "label": "Schedule of total estimated future amortization", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": ["r403", "r459"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r426"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r428"] }, "cvm_SeriesMMMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "SeriesMMMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetails3"], "lang": { "en-us": { "role": { "label": "Series MM [Member]" } } }, "auth_ref": [] }, "cvm_SeriesNMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "SeriesNMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetails3"], "lang": { "en-us": { "role": { "label": "Series N [Member]" } } }, "auth_ref": [] }, "cvm_SeriesNNMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "SeriesNNMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetails3"], "lang": { "en-us": { "role": { "label": "Series NN [Member]" } } }, "auth_ref": [] }, "cvm_SeriesRRMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "SeriesRRMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetails3", "http://cvm.com/role/StockholdersEquityDetails4", "http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Series RR [Member]" } } }, "auth_ref": [] }, "cvm_SeriesSSMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "SeriesSSMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetails4"], "lang": { "en-us": { "role": { "label": "Series SS [Member]" } } }, "auth_ref": [] }, "cvm_SeriesUUMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "SeriesUUMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetails3"], "lang": { "en-us": { "role": { "label": "Series UU [Member]" } } }, "auth_ref": [] }, "cvm_SeriesXMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "SeriesXMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetails3"], "lang": { "en-us": { "role": { "label": "Series X [Member]" } } }, "auth_ref": [] }, "cvm_SeriesYMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "SeriesYMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetails3"], "lang": { "en-us": { "role": { "label": "Series Y [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Equity-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r2"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://cvm.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Remaining Options/shares Under Plans", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r23"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": ["http://cvm.com/role/StockholdersEquityDetails1"], "lang": { "en-us": { "role": { "label": "Options Expired", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": ["r194"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://cvm.com/role/StockholdersEquityDetails1"], "lang": { "en-us": { "role": { "label": "Options Forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r193"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://cvm.com/role/StockholdersEquityDetails1"], "lang": { "en-us": { "role": { "label": "Options Granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r191"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r201"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "presentation": ["http://cvm.com/role/StockholdersEquityDetails1"], "lang": { "en-us": { "role": { "label": "Option Exercised", "documentation": "Number of shares purchased for issuance under share-based payment arrangement." } } }, "auth_ref": ["r495"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://cvm.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r183", "r184", "r185", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r207", "r208", "r209", "r210", "r211"] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r182", "r186", "r205", "r206", "r207", "r208", "r211", "r214", "r215", "r216", "r217"] }, "cvm_ShareIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "ShareIssuanceCosts", "crdr": "debit", "presentation": ["http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Share issuance costs", "documentation": "Amount of expense for amortization of deferred issuance costs associated with an own-share lending arrangement." } } }, "auth_ref": [] }, "cvm_SharesIssuableUponExerciseOfWarrantOptions": {

"xbrltype": "sharesItemType", "nsuri": "http://cvm.com/20240630", "localname": "SharesIssuableUponExerciseOfWarrantOptions", "presentation": ["http://cvm.com/role/StockholdersEquityDetails3"], "lang": { "en-us": { "role": { "label": "Shares Issuable Upon Exercise Of Warrant/options" } } }, "auth_ref": [] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": ["http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": ["r5"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r5", "r36", "r39", "r40", "r72", "r84", "r85", "r86", "r96", "r97", "r98", "r100", "r105", "r106", "r108", "r120", "r126", "r127", "r147", "r178", "r228", "r229", "r230", "r231", "r232", "r234", "r235", "r236", "r244", "r245", "r246", "r247", "r248", "r249", "r251", "r255", "r256", "r257", "r258", "r259", "r260", "r262", "r263", "r271", "r306", "r309", "r310", "r311", "r323", "r375"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cvm.com/role/LossPerCommonShareDetails1", "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative", "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited", "http://cvm.com/role/StockholdersEquityDetails", "http://cvm.com/role/StockholdersEquityDetails2", "http://cvm.com/role/StockholdersEquityDetails3", "http://cvm.com/role/StockholdersEquityDetails4", "http://cvm.com/role/StockholdersEquityDetailsNarrative", "http://cvm.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r96", "r97", "r98", "r120", "r263", "r288", "r315", "r324", "r327", "r328", "r329", "r330", "r331", "r332", "r335", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r348", "r349", "r350", "r351", "r352", "r354", "r356", "r357", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r375", "r418"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED BALANCE SHEETS" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cvm.com/role/LossPerCommonShareDetails1", "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative", "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited", "http://cvm.com/role/StockholdersEquityDetails", "http://cvm.com/role/StockholdersEquityDetails2", "http://cvm.com/role/StockholdersEquityDetails3", "http://cvm.com/role/StockholdersEquityDetails4", "http://cvm.com/role/StockholdersEquityDetailsNarrative", "http://cvm.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r96", "r97", "r98", "r120", "r124", "r263", "r288", "r315", "r324", "r327", "r328", "r329", "r330", "r331", "r332", "r335", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r348", "r349", "r350", "r351", "r352", "r354", "r356", "r357", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r375", "r418"] }, "cvm_StockBonusPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "StockBonusPlansMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Stock Bonus Plans [Member]" } } }, "auth_ref": [] }, "us-gaap_StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockCompensationPlanMember", "presentation": ["http://cvm.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Stock Compensation Plan [Member]", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } }, "auth_ref": ["r444"] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "presentation": ["http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "401(k) contributions paid in common stock shares", "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": ["http://cvm.com/role/StatementsOfStockholdersEquityUnaudited", "http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Stock issued to nonemployees for service shares", "verboseLabel": "Common stock issued for service, shares", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Proceeds from the sale of common stock shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r5", "r35", "r36", "r54", "r317", "r375", "r388"] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan", "crdr": "credit", "presentation": ["http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "401(k) contributions paid in common stock amount", "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": ["http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Stock issued to nonemployees for service amount", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://cvm.com/role/StatementsOfStockholdersEquityUnaudited", "http://cvm.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Proceeds from the sale of common stock amount", "verboseLabel": "Proceeds from newly issued shares", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r5", "r35", "r36", "r54", "r323", "r375", "r388", "r424"] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": ["http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Equity based compensation - employees", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r24", "r35", "r36", "r54"] }, "cvm_StockOptionPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "StockOptionPlan", "crdr": "debit", "presentation": ["http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Stock options" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 28.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets", "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "label": "[Stockholders' Equity Attributable to Parent]", "periodStartLabel": "Balance, amount", "periodEndLabel": "Balance, amount", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r36", "r39", "r40", "r51", "r337", "r353", "r376", "r377", "r413", "r425", "r439", "r451", "r499", "r516"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://cvm.com/role/StockholdersEquity"], "lang": { "en-us": { "role": { "verboseLabel": "STOCKHOLDERS' EQUITY", "label": "Stockholders' Equity Note Disclosure [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r53", "r94", "r164", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r178", "r250", "r378", "r380", "r389"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://cvm.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r261", "r279"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://cvm.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type Axis", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r261", "r279"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://cvm.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r261", "r279"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://cvm.com/role/SubsequentEvents"], "lang": { "en-us": { "role": { "verboseLabel": "SUBSEQUENT EVENTS", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r278", "r280"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://cvm.com/role/StockholdersEquityDetails2"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "cvm_SuppliesUsedForRDAndManufacturingCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "SuppliesUsedForRDAndManufacturingCurrent", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Supplie used for R&D and manufacturing" } } }, "auth_ref": [] }, "cvm_SuppliesUsedForRDAndManufacturingNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "SuppliesUsedForRDAndManufacturingNonCurrent", "crdr": "debit", "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 12.0 } }, "presentation": ["http://cvm.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Supplies used for R&D and manufacturing" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cvm.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": ["r450", "r503"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cvm.com/role/SubsequentEventsDetailsNarrative"], "auth_ref": [] }, "us-gaap_TradingActivityByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradingActivityByTypeAxis", "presentation": ["http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Trading Activity [Axis]", "documentation": "Information by type of trading activity." } } }, "auth_ref": ["r56"] }, "us-gaap_TradingActivityByTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradingActivityByTypeDomain", "presentation": ["http://cvm.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit)." } } }, "auth_ref": ["r56"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://cvm.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "cvm_UnvestedRestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://cvm.com/20240630", "localname": "UnvestedRestrictedStockMember", "presentation": ["http://cvm.com/role/LossPerCommonShareDetails1"], "lang": { "en-us": { "role": { "label": "Unvested Restricted Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r18", "r19", "r20", "r66", "r67", "r69", "r70"] }, "cvm_WarrantExercisesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://cvm.com/20240630", "localname": "WarrantExercisesAmount", "crdr": "credit", "presentation": ["http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Warrant exercises amount" } } }, "auth_ref": [] }, "cvm_WarrantExercisesShares": { "xbrltype": "sharesItemType", "nsuri": "http://cvm.com/20240630", "localname": "WarrantExercisesShares", "presentation": ["http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Warrant exercises shares" } } }, "auth_ref": [] }, "cvm_WarrantsOfferingPrice": { "xbrltype": "perShareItemType", "nsuri": "http://cvm.com/20240630", "localname": "WarrantsOfferingPrice", "presentation": ["http://cvm.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Pre funded warrants offering price" } } }, "auth_ref": [] }, "cvm_WarrantsToPurchaseCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://cvm.com/20240630", "localname": "WarrantsToPurchaseCommonStock", "presentation": ["http://cvm.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Pre-funded warrants to purchase common stock" } } }, "auth_ref": [] }, "cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted": { "xbrltype": "sharesItemType", "nsuri": "http://cvm.com/20240630", "localname": "WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted", "presentation": ["http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding - basic and diluted" } } }, "auth_ref": [] }, "cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted": { "xbrltype": "sharesItemType", "nsuri": "http://cvm.com/20240630", "localname": "WeightedAverageNumberOfShareOutstandingBasicsAndDiluted", "presentation": ["http://cvm.com/role/LossPerCommonShareDetails"], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding - basic and diluted" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-8" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479024/942-230-45-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-
10-50-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r203": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r204": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r205": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r206": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r207": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r208": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r209": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r210": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r211": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r212": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r213": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r214": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r215": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r216": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r217": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r218": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r219": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r222": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" },
"r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r225": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" },
"r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-
10-65-8" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r231": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r232": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-
323-65-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r236": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-
45-25" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r240": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r241": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r242": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-
65-6" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r246": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r247": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r248": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r249": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r313": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r314": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r315": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r316": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r317": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r318": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r320":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-
20-50-6" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r323": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-
50-6" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r327": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r328": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r329": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r330": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r331": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r332": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r333": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r334": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r335": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r336": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r337": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r338": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r339": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r340": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r341": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r342": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r343": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r344": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r345": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r346": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r347": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r348": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r349": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r350": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r351": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r352": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r353": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r354": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r397": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r398": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r399": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r400": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r401": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r402": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r403": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r404": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r405": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r406": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r407": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r408": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r409": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r410": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r411": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r412": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r413": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r414": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r415": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r417": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r423": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r424": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r425": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r426": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r427": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r430": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r432": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r433": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r434": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r435": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r436": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r437": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r438": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r440": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r441": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r442": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r443": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r444": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r445": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r446": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r447": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r448": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r449": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r450": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r451": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r452": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r453": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r454": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r455": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r456": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r457": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r458": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r459": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r460": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r461": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r462": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r463": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r464": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r465": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r466": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r467": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r468": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r469": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r497": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r498": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r500": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r501": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r502": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r503": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r505": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r506": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r507": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r508": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r509": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r510": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r511": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r512": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r513": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 60 0001654954-24-010651-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-24-010651-xbrl.zip M4$L#!!0 (&Z##EG%) D7,P*N2 0 8W9M+3(P,C0P-C,P+GAS
M9.U=ZW/;-A+_#TY=*7%W/Q,{Q}/ETRG*RRR*X1@H5IT.[PO+][0O*==eFD0bA0P].DUC#OMi0=Z0Jb+S--<*0.$TI{?PKqIHcK*T?Y[%bI0[Y3<^G;fAkjS?[%Tgh9^^9^_]S--L/_[OrB$;UZRT[MO-Jn]^!7o#*:I%B[O!8n.I3G[N]NM1[!^J9DI9S[O&?]S%_]XSD]*<R.U/=H[[L%]1.M8H9A*Wg*W]%Y8Z>-B<1@^^*_*Z+6*V9S/<7N]WY#9IH^[%Y]=_
(J8EJX*_&,PLS9$8$MX##F&C3E94P,4-WR# MK@WSGY8QV""V13N&MXA*HPSS29Q%>=VZNSTCZXTPWEC?&;(88[2=#)?&C<<) MQ9P;"]?QI"K\7\
(6F>&Z3C&7$IP8XXY9D_8#K+CU@8*,<##E%^..!\[&R%V MU[W>_/SV%;*^ZP$U9+0\Q@"L?<2M.#FV MSM;N4R^D*E^%(H#H&J%=%PD12:T0?U3Y!\0>$!EY] 3@'(AQ8N47
H1$_OC% MVN1S2D["E= GS$4^LT\#]OYE][S?O>R'0A2O9805^N=]C[D.[@5LD10B$L\O M29'2+A+[>:Y E&4!#L7.U:@&Z#$61-*/U^&*O=[7^[""Q4]G2A6(!SRV/OO
MW[_O*6K(FN%,!I8D/T+MBG(&*CG"3ZBLZ5:"WTZ!%#"_[?G$!"O)97WGLY(H M<%V/"E84MSXQB8E@1R ':H0&$T7H1:1$SK9@*W9&5_D#N2;*4.9>A>-&/%R6# MK:
H14H6A4F^Q4!(,%)O]]$&.# C5B3@TA(R+NVFY$#/7.7SFHSBYB+.;#T= MU(#?9Y:[5?3S=Y?0LT0-RYW+M@.\0IX#"GCT#P\Y9$5DA<4.EEU)@B%&%HBM
ML9B@+>8[9.'BL]#]-8P/B%)7]{Y#?ZA]ZQ:RBI#[TT:SH7#WK# M*?U!_89^BH.PLD%V$H%TP'),TD*.Y3DG"!XT*Y8+4D._G>A.:F,*^=X@1[8Y MBPW&@H?^S:5I'7X!7EZ
MW#H\>ED),PLA@/CQAR;D]NAL?@T^"X7+0A'09C! M:(J#*#18$#+B&2)1"\]E27B,-XF,OVOA2L,5>9%);=9DIQ,U\DE@ MIN/6 G=5"-
QB:2Z'\,)@#:],Z:SX=Q#X7QA#'\Y&"V_MMB5-MK7JWB&_N'\>Y5,W+8=9B]ZYDQ:LU%Y^_N_'T]A=94QAA6H@*TU(3$$+7,]WT8;(<37XR9M/Q MZ'8T;
/K6X?)_&)9)MG1OU:>FN*>R^,NE:=[]/NSNG MC]9?./Z:'[,;:@1:2?1N1V>G_6OJ=O^P3 M8%0@6_[AI&WV8Z#,(&K!0SX X8?6V1=I9P>2K5O#WM3E?(:9C&B7+C8P40^Z
MU6RZUMF7F?YUNE@8,(E4(0XCGL4G9D1?G*N4%%%@*]?:+%QEYP#&F]"8=C)8HK-> MHD>G1)<=L&F!>U>IXS;>^/FV2!7/+>(%5*UN&2FV[F+8"T:J?$43"B@,L0A
M2"9I_9Z93@=CJ];7^D%6W.V%5"T"F1EV[H"KQ4/?$@VP0,0I;(I"L@Z1B\QT M.[@:$&YT(!RH0&:=H!Q<[5"\"F"I%K**@!; S#)#20#;?[YHU2W1)*;2='<
M9M88HG6WM]$[ZNY4'2DB;@'(K"BD 6@CO\P:.*(2%).U<&36$@I60=O:41:2 MO@83?:=_6>XL0-O9ES@74#!MU7%I(=*?&_@_;=#D?_*>Y1RO#'4_\UK>N?O8
MX62[<^1M2I6V45=[;EN>$_M-[#V\[&7KA!PR^R/7,Q78:0<%Y899(&9EI8186#?=54".4]]Y_.[MDX:&+/5MA?+RKVWG%I&AON<9)N=QG XY(37U "_UZ&6_=]U0Y38T3
M=2AZ8[(4!!&_^G4]".H)@]#QZZV0);KX9><@BH3+]G?P7%UI&,?YD1Y$F.DGUS4^!_O#X2SGL0W[U MZQ3G>_P$\.-O>/C^#[,Y487']\>]4#4" M1%%S>!C"_[;P=CL'1M /,$.]
<]E\8%+['E%/=AL>(W1]]X8RT,Y*G>6\OS0_M<1QY\.]C1S/3A[DM" MRXW8?B3P5K*!9[Q'+HA0SV<]Q%QO%[(28#G=W(E+]U]<$&FBT0,/+]TA3.'<
M/<8IZPIHQ\VP&+9KL./>M=4%""DU77V6:T+]WHIO22'U5%MLSW_;XL\Q9H@8 ME1&U3D]:)]76#Z&D<1!QU0K' 7*)5'1,343 M'+^1X=R3:MRZ_-!8YU).
[#O_7!MF'K,VB./@W9R;_70%0@QF7#5"#"P]^]8+ MM(F%6S616H.OE*K)4*PFTLS ##H7J;!\G.(_)&@?!D(WF.(5$3=0,S2[FD@^D]GD7#ZS%N!G/U_;LSM"I4YC#"E1
)=A;":P<2VGCPY9]I*@]70\&]LC&MR< MY3.TE]]'!E<7:Z,Y,W]'9]549XEWDEB""_F!.,|\<$/1*"!)KNEZ103=_M I65>XX\?[;[D:*@"1V^)V(3=3S36E"7[4-VKBC73?(A<4,?.FK-T;W!H
M4H[])\@UTP%^U98+$W*44:8.5))HIM%C I77EG<)H@,62_PB;IP8PA]>ZA-+ M]7#PM0CS>+4-]]=1+P[LL\H7$&O7>K3=(<)DTG0U=NEZ#&-V.^A/(VT?XZ94
MD]C=O@E^CKT^P5P*/RW%,D3,V9NVNY,9%L!VLG3M=LM'U6W/"4>]4Z6G:<&4 M+'P](&-L-9$&60C-^@Y3CH1:>U%-&=>96$]F03:&ZX,PT)FX-!S$^QC%UYMT M=I^<3X-
\.8!2G]3QNEC?IC.\G%"#K)QCRX5NW2'!"O%R@]5I!:3FJS!WQ=3= M$K5+SA4UM=08KL"*2/?\DT1:)_TE93;(QR8T[$IUN5*%+8^5"]624K7;*4?^
M6/X5F7[4=\=33EW($7(3Z9LLM7$U-P$=G;0%@4KN%%;%31*B26XLA):VW(W M?K[-&E6HUHP1*Y]QIQ.K*O@MMT&&+SOB(RM#X:!A*K76^/"O%H>]5>B]PSY3
M(;G6YB(VH%].9&6G98_+C#P>H?=,D,PWS-AMHMWV2/6M.2O$T\'A#?ALE="SO& MT$C@)EBX*Y+W[Y1+:>8:CFG;ZG@\<@X[+GD+=5]V6EOPV-0WOIN236YD(!U< M.L'/SEX-
]X)MXYO]B'(B7^W{;HP=9ZX5CSF6XPE+R*7=*CN&&_(L>+.E4M M5S.K3'P:)YR5[H-EVYG+_(*S.S[%K(T\]I6K^@3FF>4-S>-NI*W!'QBBZS*8 MEF7^7[*T$-
<*_(VT%WKBZ4IN/<3/%]03&]DIF)1ZR%$C6O#\TAU1@:%E%C.T MW^+8@<02?"?.6N59H&\;:ZE#>`\!182&0"5FVRG^9%74O+$3B],??50W@&E M+.0$NYA+1N3?H@N&
[OFT1L9>M#=IRMGA6A$'>.=R(F[4%4HJDJ=UJ@@TU6*@ MJTTQ]$!@ @$5_>VQ*-; FCK_J.TF"G-8N:?)EUSO$)#" V'N\7R$03S"1&E MS=*-#<>"-^,*3M6^)H-F#NX*S@FK 7;Z@#
O?'FP!#+=9%S;K3!3&\;Q=;\B8IT+P;%.Z5><"^9,V'5, MM89;?)3)!FZL)I<. BAY#2% 64>A:XCSPYEK:E'&LCK,L[_7WC4H_+59-[M+-
NP3L%)\@S;R1MHMBM[RM>9<,]^AKY&X(S2&4*M:L+TZ9?P+X3'UJB4'WE: M]5+,M9]3#(2, 07D6E4N".*,[C]^>OT.Q6 ^R?@[F=P %1|>\G4\I#= R2_Y M.GYID(I?\U?\VB
5[^_S=3RD-T#)25&=:5*EF<_SE3RDUZIDL!4IQYAI/7-(M35'5[SN/*)QD]%5M?X<^OF>_0$Y\&)\VH[1 Z)[LM]:4XS(A M7D1O0IS+Q:8UP_[?<"]($5R>6I4/1K5I?5/)M:KX0)\
=FRGP$^KK&&KMTUA M:W>+[4S+D4RN5<4QHK;CLHR.Z?3&5;6IV&!6IKXE&.NM=/ZE6G2X4YNI?X< M=<^@PU/P>1/F#.VO5/9#SW]YZ_E!+ P4 " !N@PY951<0]QH-!5
ME % &-V;2TR,#(T,#8S,%]C86PN>&UL5U;<^(X%G[]OT/6O9ANZN6 M$$*FI[M[-(S^^JU_1F#?G'@Q*4/K#D.@^9VXUKN/3M/AY#_<?*Y|G9/AQIU>(TP)6P$GBIEE"/AME?%SGGY^<?Q!/(\6%
M\NIZ7?\^>G[[@3V/@8KF$<S@LQ[;L[MBE:7&#_P'(IZI^@CT\NPG?L7H:!0_!HoJZJUI%(B(GpK8>B\6UKC6K8(E/O_`;]H@2*B%N/PE6CBN\%>K>G0F8H.Ot7%Y>J..%LNU+E[J%)9>%[Y9&UG

M%DN^[NN1@B+5#$CA0W "')8RUO"B(K5B!F3:&H^""C-@K8E8 E74HAFP1C5E M9\!W+9T!53>T+=O91"4>@;GQH<@!=.=.9P,=+^3HH0H-FS IRZ 9O@NY16]] MQ#4<7O$-,)X-
:+)3]6;A1B711(KAP:;%4UR>C=F*&?T(8X?+7#"/$(A*CFM. MYRU:(M]G]^Q*\Z&E*TV7_]KEO[9FZN[R7[O\U[9-D&DM=OH4F(>2:I++DY[1
MADAILT9**Q^YPID*0=B%R>F35.)NT:146N39*:?'OBYP1.HF95,8U)F.\X<3+CS4F^2>]H'&U\$'\'@^/+'PX@7+?"6(1GX] MW1IS_W"=C<,E\,N*.(H6VL_UPH+N(28 M-
P:*>$'S)7#2N3@HCE/4; Z*>SW8)D>>:QK!4AO MU 0-KMW#.E'Z2GI/3!E&1 R)M$%F(KU'$W12G3G;BH]\N":D,V,[E,-K-]I$ M"N+@)G4W!06;K#P_M/^=A%DD&QMW$3T51
DTH6))!\Z(^E]3[TUFI -H Y8 M R*I?T0 ET'(= X.2Q+!OPX'0F]N9[HD;'YQ<)((%$?Z8>G:M;YKF7N;.MX; M#-U. +7@LS1B@S:]L18 SGC]F5%LC&BCY)F30M-XLLW?%[/-
I]]=.M,&RD2=SKXKLZDZTM7^;#@>Z9BDA<'SA<'?LQ";/YW#8!Y,$:V#XP M(1(M5(4,+7XCQQ5D16:@@>IL78!* P$[^"]86R!T!)Z=U_@,(#X/N$'WR.CR MF'!]Q8D]B>0YN:F_#-
DN$C1S#D"+TLE%C^)Q))$YBPTA=<<0*788Q>&I+B3, M1??XP#5MD+]$.$_P0]$3[(_O[X>S>VTTTQ5U-(!_CV;#T6_:]#_4=L[@KUO6 MCLE
#\?!QVH<*#TQ/%#]\D\5>>5JP76>^4_EF; -!$11_Q,;34 4Y16_[03$ MHQ9@#S?0%@"]!R3#IG^)@]LE17Z'W:XC'QY=**R MM-""':!1:=Y3R[%%* M-
]2*/6,%2^97-IYOP:621"F\#;.V**4?H10:OER$O_!6P*(6A8; M%RA.Y\!:KQ3N#-=R8+LTN15A!]NRE9Q3ZI%?E*Q"DK;O -&-#C*%"3P!'#Q MUEQQMBU,-P3V4AW5&&DY
N%XC@Z>O8T;XBV_")>QKQAWEF]Q2;*0U, /@C" MB6%3TMOR4#+(&4NXV/SO\3K*'787T1AB!]\2P"42/H&#@U*E;]9"4E4@>.#7 M1 Y%6FWDN#@H>Q]?E^"Z<.F/(C!@9S-O-
P[C;O'S.1M+!GES,7)0?C.^ABJG MWT(UC"E O*4?9\!?C5U"/$25=B112Q76Q"8_1]6+IB 4!!+U:4&X DXWAHQ MREY-!*E4&%P)=L2F1E/-*!WP32&]$&^;
+NIQ<[5/"W)L,C2S!V41XTOK@(! M;--PDH(3,]\V'/QTB(>40=Q$XNO/?=YF5V>*-PW V@OL$*4H35'AIA79CRN! M+HG@2W"T%V=QE,B\"60";D3(47A7%\6XKXDZBV*^FHRWRY-
%BTN[ZK'HRT;@ MU4_IG1>@)RN28$L4VT]1Y661UKNQKBL3;1H%TXU'BOY5G6]-2I9(+RZ \>]] M',$H<+$+\NN" .0/\NL>_"IC.%(^^"4]HK%[\$O<@U^BPB]!![^$/_AUU#S&
MN"HH-7DQ#R+>GZE0<+_0P-)BP_N$PA"8!5*^],$RT"14M ,G@XK*"1ZKT0\ M$:AG6I'IQ*!>CHLWRDI/]SHVN\/T(U7M&]$ M9[[S-
#M/4WY/LS!@9]]K1F89$4$]#X_(A>"=.H8NUA:=@M(*?XQA86S%%)RH M6A-R!*FF16Y33>K)^CK7+8,ME"%;9@ACY/H^[ZE6^_I>5AD, .\%A
M(,N9H>_["T>_UW6FC3#&77H@[GV LSH?#*I84C4 \2@(HC7!+M4(XN'5 DU M5K"I[_\)_" $+NV]8P[)I2_/892R0I*$L&^M@ZMP#?M $3/,6T_!LG7@/(& M8\7FQ \1_K?#]G%8?
PW.;2?S.8B>F4-]XT<1 50&]9.I%YOBUCT74_]S,8*F M0,*#C5$UT1%XCKZ4?\]RB"Z3\O@X]C^7+AWI,R^M]\M\X8>!(H/4V5R(?2+T MSH-#576M*(DEF (3V$_H]".S]H1
X077P9=E61);$H="Y7IVU(':S#3T$^G MR@QOO&UL[7UK<^XENMUW1_@_P&W'3G>$U)7O M1\..E)25H*]5&]9]>=H>C TF"$GXA^/95T'^ ?0?7Z)P??6#X!\]MQ>W]^?P-4A M
<");H M[[U(UAY'G@D&A%X1!$*WY"=%.>Y_C[^(O^SP_4#N*'] MZ*>OD?NG[U[B>/_3AP]?OGSY\AEWYC_"&%@\4C]Z>(?NXNL&CC2]@!H03YK\M4 M])+\Z7(XNAP/?_P:V=_AU@"
M4<8>.@1.8""_BE^WV-&1>]KWB.0Z-]>0N3P MH7AA^('H?_#1,R$;^=\!(OGY\598]V6NK$3I@R34 M9H4_H- -[+6??]6CBA:+E07?Z>>W,0SC5DU>UE=<@:<@AEXKZ%E-
Q:#O4;O6 M/NFI;F5LI5&[5LYH]@ Z+@-NW+2\-O7(G^[POW(T=<8^3:R4XBD@]+2\NG MAIV6?"P[L'*E>L1V!V&YWA$NE988(>O'Y^#M@XU<.FV2?UR2?]]X__X_3K
M#L!]%\4AM.*T)%]/WW'^?U#'A"16X4I*CP%UU0LD?A@!7B"V\>77M8D.F'P MROUH4N>_\^/OWNZHSQH%?X(+,R<4HB@XA!9]U!]9K*(62O"\>EB">%'(O_R\M_>X_]
SX+97Z/_^X51*[UV\]E,W?G]$SR[YNA_?PU?$]0=?3$V'5T%,^YTG M8T#W5\ ]LH")@L[,(;N'"-7;L)=]BD_3U+^A=6*N2G$HV"$#FZ5 0,H8/ M?%P"0B3"@$H#+*Z4$ND*
[@F7R*E/_FGF+_'F4_$5+:P=>',"3@W,B" MW]\(AG@]2+9->&Z*4%213U<#]>C>">0,($,-M)+3Q\0!DP=$ 6 -0%0T3/K; M5^AYZ4Z6<.(]2*F<\+D \]-]3L0 1HA1":9Z*GK<3]3!@A?
D>=?!ZQ[Z8K\O M+Z24 QQX!0ID),QA0!F4B !$$B2B&OI_8K"9]=_CD,OL0O=4002*MD17"Q M/#6XHL9PI]=@"RI"F Z&FF3S&6/:!^$,4:TC6%\$,\B(G&EZ\=R(5E)%?6
M&.I4PA,M*A/OXZ@$F):6M>7QL$+@G KDU*XVN2"+R\Z,H4D161Q"ZOZ&>'HF'%+R^!OXV#[Q_;%\@.I3-(;9Q2]CQ$;M5E4I*?54) M^_6/M4+#-"I)@Q1YKU034%7 =$%&69/'%_6X,
M,T]0*EP4P 0U]/FM;P4A7C[1"#FR?$+7P<&/0TQL6WR$7].EDAE2%FOC]=1U7!:-66-HA/(]N54#.L\]@; Q M?*K&)V 25@)Y+7VF:F7;N%6BY/_=N3X:"BO+E55)G0]P>=IP!
(VAC!B;@"Z) MY/'_$Q4P-((KHP:U'.GFRDB6*R.#N3)]P961/]Y_W7WENHHOK($Y7+AY\ IQ:O1GL8RZON6W$+T'EX" M7F(S%5A91T\(J=G,@)]1E4*^_6B\8$A+<-
>.+]1WN\L%*WBX+DD]?;@7@"T>'!?$#. %]7(A ?W1_$D2%#/ MM;.0^I%+-L]KZ5$657P=30"U=#6M(&<00P30Q%?6CO(Z.)*>]6&20BMVW] - MC&$2V%IQ-
,@@75WON6@6Y>.#*DS6 ,Q+PA$>L1QT28 K38.0.R>/ :$?K<8@N MGR'<,P8A+X[2OYRHE/SA=[KC16B]<3ZZ/O0M%R^3 D9O00]$9]K]4ZQ-50C= MFNB1OOU] 9=SN-#(P/:
(2_L:F_N;]?UV?0.N5G>K^LUV/YYO7[:;F:C*HI0 M'"4CHX9^ EEU?*L$FR485Y#VSV#G#.'$ $9)0!1=Y814]2?-S+F&T0OYO_4_M#^X;]#"PZ!'A:KA6C&SRP\JW\W_(2 H:Y
C1'KKV^NL>^1'B^X8ULN]X6PDVRTFN(.T@ M"TWFPX$!7). 6.10H@(0TSF3.M;;*Z7#8#8>4$K@/_R^/>SWGHNBSQ&R/P;A MXPUF_"?H'QQ($D.Z_C.?(CQ=0 QC6
6N3<4=58UCV$ M <88OS]@W#%VPLGNP)[LO=X+25>MHG)I70\]O\(6R]-NW"%K[BP-8)P\TO)Z MFVG2%1!*U2Z CW2?Q&#SZ\;HSGU#]]T?8\SNSF-#*!)3K4Y)Z70[;\PHU9H
MT&X<#P?.P)!)51IKB7(P)GZ[%43$;=-/M/R2[QYW;8/E=E9)!C(T$3RKP$GHW"B#C2\7M-Y(6\NC].*U2ED6R MNLGVR70\->%@NQW]TH67V]75[=WMT^UZ"U;W-V#
[M+G^RY\W=S?KQ^T?P/]O MGV^??C6'K7*1054*6A@I$2,DE],-T+6>&'")K4L3E&TD"?2UQTRM+(LDN(F M>H#O$*_F:@XS!.(*9\%*N+E9D2O)]D5VUG0&#>"1#,;2HQ*)#M@S)?
W\"0_(_M+H\(<95%\DI95 VZ0"2^..LG:V(O30B[D83)H1-1ZS/TYN: GH+UZ]X+WI' MP(C%U"R3]R"FZV&>#%M#SF:HD\>]4=)VHRI"O6H,=5-]+P= V@'Y-L-8=]K:BH-*5D=R*B-
5Z/+"1*@^V M=F.O#F1U*%=F,63<&ENZPGK7U V8,QH9,*ZKL)5V"S/"1L9['#TU[@[S)9;68FH9Z"'GT?%=8R-=XO]].7*'I>@P,V #"8[9)[9'&6(IG,.\Q^P,4@//.P _N_0>]0S 57
M*:GT?K6(:.%6=E&,!1P,!];^A(VT6H"<&]E,4$XP+\CQ\'0[^"(?@CRG\$ M^+L7@\$ 1.P))GD(7X+0_1>R_PB.?W2CB!PMD8"YH)DE8-],4W$MNGD8C2=7RP6$T]T MR?QB,AI=C
>3:A8"&(/_=? 1& \N "$)%=CBGD$DX6WZY_$%P&7L$4U9Y77Y M%&:KPW;;INF-H/< 7?O6OX9[%_N+HA-AD;3"@_9]P+EC=KYH,K=92R.VE:1 MEH[8CT] 9+FX='U@,3W-
='I$,71]9*]AZ.,A$;TLZ_!Z\&",[!ODN)8KOLNUCVOB/NDML9ZUW4-]#,VX>"K"EMI(V";(PH3!ZLX M#MW=(2:A?R1\YP'6G(>IV8/A!E_7;,QP=5BB]/EH-U%UQ;;)YIT$Y-*@WSRM
M[L"W%6%>V9L-6\>D^P^M"3G^%NXZG)!6[2G2=0Y3T+VIF-^5P)9L$]*DKC9= M,SZ@D+]O++6E(5;6M5E45QWQ_I%(D^T9#V9S(V*SVF"NW64Z+ON-8B9]6GQU
MW"20:I&RDBXFBN"+&5C42%86$VMGPB*\"=9:QI5VE QDWBW=P6K0&]F"7L;E M8=>QC4G3WK.'T!F:L(TIBU.696PKTD"&;4X;HPV:(]>EEVN<"M01+].2S%*3
M!3(CKT\#L++4,_( ]]'+)Z6IY9BFB;,GH<:N; VF9F0V:PRX^GS'%!\O4RU) M!Z]20PO09%R["G'6;:/!?[U>?;VZ?UC<_Z+XDD%YK2)X,B6I(5B&OX;]*"#3WFDI1 MF-V3G$SLR=
]DG"%%]+29-(Z$Y]\X@BA%N0O&IT@]Z0%]#\MDFMA/$5E3H] MPUDDP.'B.+8)<5.-P!9)ERA3SL&T0)8E*)DL!]/>EVU+UB,^_M>B;'>I5S@118?O]
I%=TSP6Y*+!@DPE#NQ9@>.*@[,F]I-Z='N<. MVZ]*3HGP.Z#C.V%I6]&KG7H*O 5&Q^+FN#$<9N\]E8]AV<+/I@08\1'51I] MA $Y!ZWY-9/6:8,_!;;KN!;-;[1Q?
H%A"/W2>QO5@FI?!U?#3),'\Z78&OG# M@:5U^U\67Y$=61V2>NI+H]7?+]_]->H.L1ACX%F8/9Y++$%8QM 8BZP]@6A 9]U9R7$W.]9.R3)H>Y'O^O*;3-L6HH_;0A"/)
MUL!EIK(LKY,PC&R)%X"6V)2:)B,@I]Y3@YV.N=5 M2[/P]\' MG7Z0TUQ"HTD7IWD;".X!#M2$#NN9$7U0*1?$'DK&-FK-[PZ>D;W
M!Y*\9.,DPZ,8B53/LS/+4T/#3BJ=LO2LPMANQ'@^F>@*^FX&D6.IT5C1X"6 MG>-Y+E>M-)WD-H@"9S:."VRV4GI]DR-T* R^9P(%$HK,'1P/+,>$^Z4M().Y<'JWB?
XJVP"B"&@A2@LDER5&*'1$NQG,CK@K4X:L@"]$ M5,48QC!;B5V ?>#C_XQ67]U:\O!U-/"H"CR74CP%=C+EC$=#$YZ-; "U2+0D M^\])!?
Q&E'13+;,_T3S)@]SI'3^N#:R(R6E2P3">O+ M7"GF%5^2'=PMQ@O;A%!-&8SE]'ZF U(E\TV4662V;)B<=:G*U)S^;5TF70^ M6:"YJL.@/0K=P,8N11A7'0F)01:[X@IZY-6C]
ZB;B>V_]]TKOO1C7EA1.9) M']ARRDD]=0&8G)X(F[.R?"Z'4V>@:B4I.P1KH H'(GPE+WWW<6K 3NK77U%H MN1&*6+?S=I4%@HKV^2MA'C?PN5+,/YXMK:&]1X"$._2^$I;
[DP'H%2I$Z,L MQ845)9U$/5)!/5S(PQ1Q@4DQ9W8YGBYU/L,EBZ^>"UW8A6YR1K-YXN80LO-3 M; UI6]#T'!799,,"^1&-$:HRCPT+4IQSNE4U2[-5HU*29*ZV,S?A$N6Y^ 7;
M63NB18X3CVK@TI@'Z05U9N9[G8"\0CY>HL0/N';-F]ZB&.WDK]VB!+6%95!B M.,YT.C=A$^0\]$5:3P;#[__Q R:TSX)DRW*;]]DU\$?@W"+PC?7$M[<;E](=FK7 M5$_;
<)=*8,=3B\'$B+WK<["7SW)9Y-7PN(^(%_=$& $X0@8L68;[//9+6H M#.VDK]ZFM&];3#=X]]V29H4"@4#=Y ;(UNXSU0C MKV:+00ITNM-0*Z"=3NY.6T-^&E "R<%^]
M1EXK=_B[5)7"["WVQ7*]]='AAC ;D+NTHN9W@LS1 ?H" VIE3.>4=;NKPB]^U\'S59I.I@.%X8[W0+ M,)>?)P@LA&SLAN"&/!/$+M@WOO^3VZ+>U/=*2]T5=]53E5!;6IZ.&%
[]XY0EV%V-Z6ZD]41#!EMI M/M44O]+F) F9 5'7)O76?/^#ZO< ()1=>KMXWCH-7:6%$+V]%R,+%1%OXPE]" M-=)6PY(6%4KITT"5]9TS&$"=D^19H$O6)RF(V!MF:';O^-
^LL.1R75(:2?.+)H=G;7Z1?,&CQV[#:R3' MC47[:*=?V>2RA$/4^SF+?"Y+$3Q#<^"5VUI8'[5/<3;@@ EA\!Q(]9F"+LA_ M>@>:X>(A"&F<6C$/WCUN+!
(9$7@>RVK,LM'[O]"YLO_S$,7$ D5/P2,B7>IZ M*+>#_!00TX0;YLVUD7WU_CE"]JU_3-"\LF+WC3TZ7SV;]/IE7?]^FN]_!7!
MIK_#HLD'R!GI7'2HJV'Y0N+QBV0PANDW20YHEI^)'(/C?UOX]^! HDY=/_.@ M!#Q^3 ?313=HC]&[-!B6O%GR2NS-OZKBIRLUU T?">#945 AGAPM3B;#->Y%-@Y2?79KSE
>8FO,V+L'&HY62(33&(MP)+? M&?B7U%AYB.R\F)$^/=TS3W:4\'(,\5F8I,VX,4'76&:FH9E*'Q(H4WEF@SX#,/2RY9#<[IO"=SB)'!R+\K=%F^*]3#F4,[*>@_C9$8VTU9QXM*I2>>310
M36(^1H[V/.;M05<]RWRZ\\#B:9.;$'NL +[':Y]03-$_?+ 1^Q=96L H0G'5 M8]]+/B2Q!=)/@N?4?0D0N:E0X4'4Z;/DUG\T7O6_9R^_A-0-=#O&@L]8\)BC;
M:PW;0/'3V_T0SP@7219H:3\QU03?[H_$!.1\D_KEF(I1L2)??PW^+K_XPU=S]]"_^! *Z8A M9L99#TX_-FD8O7;C;!(:\=]U)$Q9@Y%1-L58W*!]$+FQ9">ETDGPTQA9]L[
M):+]9>%RMOFHE'$&H-@WTO75._3/H)01+Y;(8)0=\;FF[E/UWVNXU"D]L OLY4=861D?OK>S//9.Y9BR)%Y9
M%@G:BA[@NRBC?:U2LKX](H];S6.5]$LG]8DPV;LETL99'D"-6T%O?:E M,_8-3;@8U@"]],QWI&%2@BD.+\85'O!Z\V30I/NNH,?.9+F;38UV@NN <^P'
MD3=W5TW<@RW:0KL5Z92.)F2:;X:V@3FAK,P48HI%24\F'A%->=VX,\?ZM)D& MNX4]497VLI6%D:U+.S9[2-7LO3,VF')]2S,X=:UB*E98&D
M,/VFZ1[%DC&9O#Z6UV:7:N8#M%"5=DGFW>16X'F7!6HC3/4_E]RPFULWEN)' MDM6Q=V+$T;S-R[#]04D!9#KG9^_YG1]P=P+ R<2M.]&2FH-SD=B1I=6&A3
MD'9"2U13@M@5I;_;M]/=;F'";O]Y^$MA/:?KKZ MZ?9OMT^WZZV>+Q2O'*MTDR]?QO5THN 2MEK0K[. M-IA+TV]:"%G()L6 M)P+0$NZH/0]%]9G;5"]]*T?XX]X.P^M:*2C5*\6E=C!
M^F*$)KW]4V>8HFK4I6AELN]IN_$A3'*M[O$'.;B+]$'=VQY1+S9M$]V6ICL] M#DV(,VP 5^CG(N_;G?AX^W]ZOY:>G=!5289FMGCT(^;#Z=IGYMZ4R"^IUU.: M=T:N$H5T-
-5*S+.RK/G$A)/PAG"K,]@>DY<6,MAJ74TFMXV%>61EY)G+--\- MH$$$7T^0!EWHM]>"/]1:[3#O;V0]RJN<:M(6.=6-GI!N9$'HGAU*\4,0T8Z_% MI)]]IH1"-S0.3X9=*69E,TRD0:5)?
C@KFRV'_3+MKZLU]4)]%O.I?"I7 MP^)IY,AP5F/]C*E1PO61"7Y-6]Q2D34D*(R2?9/E=+9 W0O,K%M7? Y:PA,L
M]^CQND7010YW49]ESD+#*3(D+:0DTGH3F[]334SLER2+CI;I]!'MCI[!#=]1 M,ZEKN'?);B49+)N=YS[31"KG2/6,V[^_6;:;2ZBBE\:-'L[750UNM':?2ZO_:15&
M)H1;ZIW:08C15^P.2SSA0MP^CA@(L3;+OPOK\%0 K.["] M_O/ZYO=FK#U?G-_2:F=Q#9!4W(3@+F4ZO%=F?R:XO]Q^B.%V!EW@E M=-0D_Y8&GZ;\KE5@&1EFL]UHIY%
[+;"6TM10]>-QN-W#?CZ73UF(ITU8]KP8 MV4VISF[5]@0U7&M9L91Y#=59IO:)/=:_^ILX$56?LS2+W/KE:>Z71_"$/\B3FQR9EF*GH4^M[+'1Z+;%L222NR&E]/[M^82.]L Y).?-
%%6ZB9719/O+NQFT=1O0MICYKBNA(;VGT._F0R[>R3.6%Z04AD>S 68C__-B; PMHGE3$TXK]D$5YIW:1@+,5EO\%T1#KFIV+SL]6^$S MK%TV1N[AUBX*9EZ=-7'&T
#]]U"EXH"Y6FUOMW0O_W&]\7NF3[>;->[HONOW\ MZ=/]\5?RV_;VY_O:C[?7]_LGL+]^WGR^I[NG#YN[V^O;=46@0H\\NH*1&VV< M;#.0>'_WV7<=UR)V>=UR)Y M-)-
XRM/<*7SG/+8!]$|FRE+^R&1 M'K>["]GEC!*3W 5[.FQOE0;8N(%CP]V-3BI1&B>D4++&SQ;+;A&="@:GDD%: M-/B-% YHZ6=>.N(NL^YN__KY]N;VZ5>!1:S7PZ5Q6_ M(5H"U4
K$N0HKG0&I4#=?QYK)WRVM6@D4A=1X%'U[6 M1\A+T!:"%H*6"-M=_^?/F[F;]N*4148I-=XHY>PN9X;\/8E0S
M4AKLKLPC",1K/5>T#22QK6[*OZLD_U':EDE'>N%/;MHQ*VZ"0]2:L(YHC+A$S M4\(? "L#D$+ F90.UP<=?!6FCXX\P#!^?P]A'Y'K@H%?MV]9KZ;R6K!<%?*7 M@;MUV*[;KI_4-
>%@]/OT*GAY7]UL2*KFYU[/S)Z], MI%%IH,X"3:>C\4*5HR(Q ;;&WT6W:C4I\E-AHQ+T&Y]>F&O"A-@&:[KN6_=]K//:BRE]YUU<-F$&; E['}$Z;$8>H24*\C0M6'QO8E]
M%!]O(_\BN7'RX_* M/!<*^T_2!DFHL0"U^<09].HM]:>2&^)NW%=:#(K\Q"BE]<]\=$P_$^:]DEB+ M;"N]-&3H!+>&H8 -'LD*LGV!(:H]HA.**SRL]X&<.[83R#(GVX)_VDZ90[P
MI%"6COLWVRU)8 #(FF!S#[9_7CVNM4Q%1?R5%D HS-:VDY%M&W18)XGVS+[1 M,M3K)IP*>7V#_0Q]F3"EU",LO:&8:) ,28#]F#1[; ^["/WS@-=TZS>)6'^Q MN,+SW!K(N>-
;@2SS-!VTVYGP[H4(0R^L;Y&?0RH1IHQYAB45'#K*7G#H7DH_K?P*'Y8.@#]]E<,U*TE%=7.5%@.)=!/\$^T%&:7'#U&:[]U&:[]U&)Z5Q;:6\7(=[@K4P,=B]"^8TW\AR!]
M.C6%SEWG0UY/R&-%^6>5;6?.]8D%E2#F79"=SO/7*X2A]))_D$'O\-ON[_MF/I?#27:*_0/#]IN#R'V ;23+;_E_M'UW1C=N6_(9C67W*KGZ.DI&A%6HNI@ MI*3$">-)\1R)MI+
M\4AW>CP)>*5=<1->!]-]]%/$HN)&A5VFV6 !@L3[&(CL+P7]^Z"B!U+LD2-['12^P+" M"E[1$_P]NUH5B2M]_;H2_KQ8#LEJY.&2+CU2%(T+,W&ZW.$-
LXZBMU7O#P6/0%:%%)G]/CPLN8I+\'V MXP<[9V#^VGV&8:V@V-R&;BI)*"(^_*>;*\!Z/H:+\J!.LM.-9]/+!-,5H# M+VT)6B_(/GC4:W
.;;GD\>KZ]NOAE;Q,Q.X\=O^]UMF$OB[46;/0HA&6UG M$+M52>H?D9%MLT1O40R[)"S)G.=K\1U5H'VQ_2CYI!_13XQN%?#ZRLV'V3 M?PT;PA0>!IU5W=QY4*N26"SA;NYH?
7]FRSI4C03$DIY9F2+!GAPO];"0S-2% MG$LEYUHR[&VLK6;)V*)"Z3]Q@2K;)UK,%U!WVI?6H*L82(L";%D)8%)8K^P[
MC1__M"/!2Q,F)&M!/1ETU_^2K5"9@O2Z+E7#@TE*5>;]>@4U1UU*0_$\:%)MS:'."(])+B2#1C:MDC5K#VOZF4FMRLO MN;L\'$UUOX[<;4V]&/E*9^>Q N!?XF23R2&.
+!Z2.]TO\&A>X;)%$MF4?+ M&G!=2E\UL1M4]LQB"66VQ%_.!B/=QUUGP*[BIWTLS*#GYU* @9.)(2V%E)*E MY>HU".ID-:ED$FFT/.OF$^H7;5TV#6\IUT7YS$!.H;74ZJ:M#QE]?]M-
G7 W7RF\X1>;ZVK M!G28PT*'^ L"_A$.=?3L#*'49$B.#[B!=!?XA(G&Q3#79VZ7*@&B#WYA^'TGCI?I"MH+*8F,I)=!(!^-ODA!+S[]D4*8/ MSMP'_E\/T'.=%]F9(PV*.1(R1TI+4="B?
6.$8KU*BSN:3)%0]TG3HW!EH*T M O_R6$)"+E8&%95?4IT7*CP$QGP1RBKS5*I"IY0GQ(]XIF-<9=V^9ST\]LW(MC)GIB@C=O$R7/8023F)2&HI?GZL&7GIOCB_.%@=39S@TX?*9-%
^Q7+GB9I\ M(+'][5/0Z@4)C%&U-)L.]M/=!)KI"W%Q*G>A>T!.+'BL\T!/K]_23RP +L MZ/+M_D#@); #=)+T-NA]9@O@8A#^3(TG1*.SM<[K3"379/6Y$,[_5HOP)K;
M)MAF);4LWV=YA2ZYD)QXDM$'NET:@<\T?/3A /_Y?,SJ1%MA>C6?T"A&]@_MAT$DVN3]Y4O?P)BL;ZA.A]/X,VPU/;20UK 5914L#L)$#U!%9' CXPT;'@>Y MY SVV
8]-33W2]_>*MH]"[&^1@EO9[8?9" M4UU$@IK,=DE4/X54>8C E528P4X,->UKBS&1OA@,9]I/*N4!EAZ-"M1Z"5Q MS^GF2.5A=DE(V=FU %[F]+H@P4;@>&?/=8>!UF'C'42C;C]I.
[. PC?70H]Y MUZ,?IY&M)-+UV7?_16-6\;1*LW9>P[T;0X_\=?5*L]#4C8FNOE]//738%P3 MU^VGV&8:V@V-R&;BI)*"(^_*>;*\!Z/H:+\J!.LM.-9]/+!-,5H# M+VT)6B
$3"+%1C-QQ:)FQE2\(LO=I#U,#& 8DBV(2_J@*BVP>YHC#.$_Q_UXE4 M^#]^?R3+)@"]U"K_U3Q8N&$*,W ^T=0>CQ6*],U58!:32,2 1ZZUS&UB.1^21 M2QPU/;(S?GS#U(I)%
:]KK]ZSOU28DB8%]$RNWK1;^1SKLMK).=-TL31AR[$M M[O(A-94&5!QD2P)7[R#_Z_D0B<_M6S/MEZS%L$I.#A4%]]W&M=)O?/YZ(^2I< M@L[]_+G_WOU[3>?^74??
_KV];_^>O9]"G^G^7#5B6(*._7O_!?IK3;_^]]-? M?ZWHJJUU^SVVC3X71AC7FPA/TZZ_]]^NG3S4=>Q)0V;-%6/FN37]E@V/HC&PS
M^I;/2]"YGS[UW[OWM4Z4'B^JVHW*.BRCX1#.=1[NU.$2.5(*/"G'QYK>/0FH M[-TBK'SOIK\F:^3I,&&&)\7')>C=Q\=>P^EK-F@^L?2SW,[G_*YFHX8+*MVL MR?
W(%B(3R)Z:%L#]]CQB6B?@_H:K[$/7DSB687CFB.C9F@+P:6CNR20"I/ MX$QW>KP:;*4-V9.XUE$.OU:/\OSOBD8Y#]1QE&=_9)O>$X0LG;MC-;!*HYR) M*AKE+
(Q(9]SG)96/>!Y0SKC/BB71"X/91.=]'VF 538@C?;]_YE%!W0#8S1 MD%.![(^*[E66X!SO4!Y_85ER9\/=5'<&(1&FTMU((@>(8!\>.0W<)9\@]\$^ M[TFF/1:.>SH19#SB>:-
E!5Y\HVK<_3RI36390?L].WSX.X^')%EN#SQ,O_80N]>VR52U\+L:-G%!I83)_<@>!(.SVU]]YD0% MK%(L7MK#5+:73DT#E(GUXH+-"ZC]5AZL4[!]F2%6>"G"BG&5>S:5
M[6W>H!L*VVW-3LY)0.5.3A%6?BUVO *78"=GN^W3KUO35U+2 MI.S"'SH\5HHD%0WE;]#';PMFU2K]XM4#1@AG*VK MI'4R@S^3BT79GOEB9 UU/U0]#5*6);W-
^@A8"%D1Q]Q7\@:$BDM-=1I4(&4 M0A(JM)[>-68(N42@L I 30DQDZ.TSP*83D-8_TO::K]YKTM17RZH(M:T%G8_Z$PBRL9K:$"Q.RUDC"++(L40.IGAE7S$BV9[N4[7G]U?(.-
K+)@,BD M-[\X:QB2S#E1FOO\ZIU?0%5:Y3Z_]#!)<.\-ETOYW-_GD]"UD6W$@QK**EI* M1YW1 R=%D'Z:S0Z9CY.=I/3S '\4 D/%=4E ']YP2]U3U\K9HX\B+]1A0/
M6G8(9'JGX0$S!!2]9EXC<.\.L?0U\37B1IH] M%SS2%:\5)2F=Q ME(1(4 V']F&F?.%+L?6"XZ"%[HA&&7SENR.I3IK,H)8,9H6K+^?+W4Z5]U_S MD$(-POZC5]K"%\@RY#E$-
+M*;,025UAI$$,%W (A.)(LFM=>CH>Z]=E,0]X M01>!1T75+-G$+RAL1)6Z4Q(WABH"VH>L])R4/Z M+>B1:_LWY,/VC?OFVLCG[?S6R"M+25X/.I.17"S,WG"SYLC2O<_9 "8G'WF]
M"BRLISM55]?99G]!Y)H^LE=X)NT?B/B/Y(CHD_0C?\&_0.Q1,=;2B^G91V+1NX MOY3)M1 2KPS9"Q,2I&BM?"PI^H_GWP3/-;V+@$X. BP!LI0]-N,>DAM'+
M)B17VI/_6%EX;1RYI$62OWQT?>A;+O0V(5LWW-IX]7,@S4=F1VP)69A(THPT MU-_N!G.J^:2ZP:ZBZ;(CN_O,0=ZX(R,>)] 74U%]2U=*MSKTN C(CFD+6P"
M[(<0[;%K)PF5>"&RS,CG:V;KQ>%8BR)Y>LR=Q1M8R7 MZ#XIK)7]E#P^TX6E/W]A=D]82\,ITE-5$7>%X@J7.C60<^9"(,MNHZ&!/3(A
M@9TB[(ID*>Q2Z/QR/'A%S[\DA+82X9S0[V H7W* F3"1SNR,_N:HIE MU=VRK 2;O73)%60N^,2VH.X%@R1$WI5,:GD('[HU/UQ^W*,X<-P,5MY2DR>D M*+.Y$-
XQLWE)@MURV8U^Z?>LCH.I=>W?B8A M9KT7)5&$%G5NFH"]96GYTG3N%LI/;,Y_G(14]U9,T4@#&-8_,"YVMP5:V M3;<H9<"$#4WS]$]+%MDL!30U.TT_S-K6LO;V;I?
[*X$QG].H),_[1LW1!96$D:B475&0\]Z]*D5$LFQ'1=[.)]]SG @A['T\I>TP,]W M0:]G+X"WXSB]X7+D*+O#5Q/8VP!MO^%4_%O'1R_F'GWQWIF+S-SE*W+ 3$Z5 M>:MF23U%-
X^;5.)X]UA&B9V#.=B@ZDY[U0)N>>O^Y'/Z])#T["XY&MKA/R0% M]7]=(^,OBV+G9!147^^H@EV^YL&39CNF]PG4GA6G"O9M8M M;EX*6_L,IHNE"2[RN?A+[C(F(0*8U?

%+!/!L379ZMK@GJ),$QH,+0/AF,L-O M#N@>?8V?OB#O#7VB%6G3=MQB#&%W116END; M1L9LI1K3D2BSNT##G;,TX2Y$2]@<2LZ_4I^Q&UW1D,P=;,(F:U24SX2769] MG*4-
=:ZNSD/-8>/B6V"C^W:.?63]AK$Q4Z7&;,2Z[-Z%A<9C$S+'M$/-8>/2 M<#:VK+])[&O#.I;+$C]3@<[GE=JAY1]2.8?X$.+%=_(0CX?HCM/.6 MB&-
NO3[[MAM9Y%UY9*^_6BB*V"OSTMTH*H"%4RT7NW'O00]+U[<^>B8'C+R3 MC Y[4.SG.RP"7)+F#-G Q;ID,Q$$/G#8-T]KOOXO%7WG]-^V]U2O]PV(5BL M'>HBE7]+B@&TG
MP+.D"9,L"K##-2M.=DI-;]2;-I)V>TC1,' MR N>W6,<>)EQRKD\,5)P_&;6,J>CLFX=;H^A"%&_$!N @2E^"X)%;94WSDS MU/M5O/HIL!5F[]3G-^Q-< DL]@VP9Q_IX7RV00\V:Q!5)
[4]4G"H.Z%3(Z"E MV:DCTO61]8E;,9+PH!7Q.(H:N2>L1B7]2EHL1MUQX%CWO1!R#!";+.G>3;\YS,/V]N7Q@[W'+@;][H#)'%%M:O]?)-G\.43L99P=5D%QG%O'.*G"V!236
M#FQ\9+:%]P@(.E@$2P*$T'*GZ]BQ0_O&K8.!<4(MN_6\5C'1B'7,6Q/> FJ+ MNQM+A4O\!BR5*%]L<2%LHQLY#C(HP=*9M3 PB*QUYY[;,L;:K&X9;,)!4GOD M'5DN4J;YMDL46-
BTC"2YD;,8?:-^5KD2!L8;MNW9,]O%5+/5*7EU'B"<#;P; MFT6*_9,EB#ZM&D9+)KMI@XW^#6%[\2!@:EMNW9,]O%6)/5)7E-N'W7&GA'
M)@L7]3M83+8)5DZ,PHYX7BC+/+)S*]N&\;F"6 S^.&Q9)KQ-T4$5RD>Z*$2D M-R"\CI#ZS:4RD[CEL39Z/L*2P>5]6LF4 M-VJ(,9]PZ6->M_PD+^T%-N'&9M\EEA-QT,L+&+\
[44FS0;[P:WDIH698A M9DW-(!B]V]YN;>S]X;?R1\V]P2!H!T';":75T;@&<):H M'D1>]Y=&#"P9D4 M2%XZ,2 4K338&-T\K,]A3+*ZA4=22YE!(+\EI"9]A]H(;<=886]*7B>5D4 MK_
>GY+[#(VZL6F;*,M2VB\7AS]#)EM +'DCSVO$&+*[\] *+RWBZ.K]$_S/(+SV(%Z.E*G4]@2EUXZ; M5]QP&5E6G?G,V&F>F'"1H37P(F5909>T) J"K"R2,IA6A]@Q75"9NYLO Z?
M@U=D"[/1%WY7,Z]R0:639^Y'-M\,ATOM#EL%K&+7)Z(22>5;="L=]&TO",7] M6A10T[%\6&G/YG]E;3B#RY'NVYU5N$K;I8EL1YW;P68H]]=6SR&BZ?(C+A]] M9%5N9E:
S6]6<@391)T=X$'+ M#O_L[\S+6]+YU(3 8S&R\A,FR5$:?#6 #/GU??5[5P)978<%%:]9<079IMD8 M+AP3(J@D(/*GB>2M*N#@-4)P/".@VR>ZT\'EZY1&&GR6)%1.7A>I.*#%Q,H(
MLR#RL;,@%[)E.PK(LR?IXT]/W#]"C;SOA#SP%)V/*@'-F MWWH51:]Z2D(_/NM9(\]N?=KSG:-[Y[<9TM+#GE0;N(DZ">$\)K1,N-7'DTIY MXO^"W.>7&-FK-
_S79\3R0*0_/[T'P=>/SGEE]4XB..?0,B40/MYM[.F M"]U/-)V+O9PGP^*YQT,TT/T> M>#VZ(B]2#1 Q%1 3G=[2:V*&K<(0 Z ;KC=H'T1N3%Z0?L3_R0T,;]BK,LEF M@\KD\VQ**+*-
ZPF<.WW.\ S(G.[7)+$F/)6#)U=:$-B1M0]--ZG;G=-SQ(YK M&,;NOV#F??,F;UF>6RQKVO';FAMT>;S>GV3"3<]$WW[6M(@(H1H\< EZ[+ MNO->?A#'MUP 4BA]'3G]=-
R=#9K(,G'5L\HD>VU36;(4142T;G=K:Z2@5D[MN^% IVUFKAE5- 1,R:;9434ZLIMZ,WLV:XO]!W^;%\3:0N::RH5#PX3;I)T6)5FYC2ZR)E1 MD'SA-B3? '04Z3:N-
;+WUK>1(VXG821SC1YMN,%D/!ZK"KR7,)#-@7,O&>D. M7&[0;2T:0'DD?9\,-"(&N0G8DIVAVN"D+K(XNE,V9.T=28,DQ<CLI">4"A&Q13)Q3D+*@ MYS.]F8F ;E$*.Z@?.].!
[LMP7>"OO9P!L\3=TQ+HC>]C'NZP'F/XEO?"E[1 M71!%]S?HXL([]!18(B24L$E"?YW M+7,7CA6MV1]8PY",X@@/W2U!6]CX:A?%(.1$M^]DM=5Y" TKE'45)%595.ET
MO%B:L/_8"GOIZP=A+[:]C*V=LY1KA0NW .X/Y*;#Q]&5V!SB",\WY!8$K4]4 M:8-;EZ3& I]9T=3^MBR&[33CN7B@\UVCSBI0ZTY0!D<@.!78O=7E\ODTLWS$
M?7\=^+'K'_#GD]NM@4^&:&%TTKKS4H^<4Y@:5I]?W938[4MBP5Z6 Z0<;V_DLVNHAM;^7!61V4KW+;LLC%RNYM=%,R.DYWI#.G,!]9CERIE5;S+(T$X/1QF@I1-
F,@9[;0&1+3"&0IOQ%1 M!$=-D*CVF>G]4_@7%&(_U[JB"V MJ';L]3+_52*(J8.;%+O[X;#S7 L$CH-"L]^Y)Z5H]C+.ZODNFDREEV(S4U(M[7,>^E+H%'N$*G#2+2\0A(
JD6AW5BB@I69DH]-0+P]7'=$G0XU^GG>DP9=3 M=*Y4!?]X:L038GT!T6BB_4RH'E[)"H8(. ?21C;X6TQ/..BV)HP! M!/MF,V"?W4U L9K='"AS:>02?5G['GVAO_!W0F04V9;#._
I24FY[8]VO*GX $WR@N,4";35VO9*T$4;SO5F M2\,)?#+3O;1I)-C\R^+-C\,L#E@Y>0LA>XW\0)LY5:^33-91X_(0NX;"0E[M1!YY$_X!AF2K63#$9)45OIK7]#]Y9_2D-%ENB\%TL=-
Y&'<.9DX@-DDU3AZ? MQ]5]$VQ0+;5B>]KC0 M,E8B^]9:+A8>_V8C[.B&>-9S$WT\T^$" %XP!Y9+.AA\<6/R=@<(OOB7U(<" M7?I(^.I-[,=2'V;_<(?_A?^8_@G_#TE1_A__%U!+ P04_"
!O@PY9+0BY MQCTT-"3O (% &-V;2TR,#(T,#8S,%]P&ULY7WM<^.XT>?W]]K_M0;?WX?)4WW>SPG50]>9]2V]-*4\):VFRV?N" DG0YA.9@CP*&\Y??P E6I0(
M@N"+!'"2]NRN;0#$K]L!=#>Z&W-ZK^_/V\DK2M(PCO[\D_]S\M,$15[LA]'C MGW-:I1]@ZH7A3Y,T@Y$/MW&$_OS3&TI_^J___)__XT__Z\'OW]ZN)O/$^UG_6?%>?_]YCB7G&4
M]\%_5-__]U^?A_K)GYY2\+'IVSR M!^_)N0SD\6'Y7PS^;1+PPBEZ60=;W=D*NG_G2PB[^?);+N=/) >Z>0!I2AY M1?YAN&T8->./Y!\NQC?!A([2/WY/PS__]1E+W_\^/';MV_?]-_CI-
'C$=1 M/_[]R[W:>\+S^A!&A.^-]GH14:A]5.GT^G'_*]%TTK+[VZR+;ZA?RRF@YNG MX1_3_'-WL9<3EZ/;1+8%^>E#T>P#^=+'S]_3_V?,#4FDST]DGB+'E P M(?
_^^K!X_Z;W^ORS%S]_)+__>!-CD<13S'L])2CX\T_X[Q\(.Q1+5\B8__ND M3?;V@B4S#9]?MAC:Q_;?BWP482'\!+>$[NLGA+*T<0*L3A>9T3V6\BA[0EGH
MP6VGZ5%'&&JNZPPO5[(3I*M@]8*27*K2KQ'<^7A9^KP3YARFYZS+7UEGL?>/ MIWCKXPUJ_L]=F+WQ3KKE*)>@] U,GSYOXV_]"%T_2L\YX\T]Q./?)WASC+*<
ME[/(7^^>GV'RAHF&]^@PP-(893//BW=1AG?]^W@;>B%J6H%##-T3W=WBUZ^+ MV\7F]X:I5MKUEMYS66I4U+H./6?R@+;DT,<;2 :V26"40B]?KPWS:>K6>Z4\
M/X=9+MM8)+#$$]YCS:99]#AZ]IS;_6PS7V[6#?,X:]573N,TO4<) 1='!ZP" MH2:!K>W05W)W;HK^N+-!R/GF@]U]>#KD6L]3=T&Y]4MRF"X;<^LLWZ7FI?:=6+]
MI6>F=9V9=NF9Z5UGIE]Z9D;7F1F7GMD2)L0,>6TZ-?D'N)#6U7*^;8>YW)G% MM]'P#W#QF39M/2U&N/A<><6APTC#G,-\W*3?G;EIEN"SHAAI"UVTS<<'N,U9DX\7G],<
M;U39VP-Z#,DWHVP)GQ%]:O26IS,LLW*6>),XP<&'%A]? M@2-TRW3#[\]>M1^ :C2>!V@67Y^U_1&XO$E:9< M-%:%T;@&VE6)7*SN#1Z13MO3%EPDU020E
;DJI2#V=P23>>23B]F:S;^V-1>)#0$D;@(H8*==/\/M MMKAS9NVS9PVY:&P*VV6IL$20]PEMMU@;?8$1]Q0[;<=%7$L<<2F@!-!V_HR2
M1VPW_I+$W[(G#B+7=."BMBV,VDR8(G2S_2;V@%[BA)CMY')WQ]PZZGIP$=X1 MIZDQ@0I1V+!I&8^\UBL:I<;\U%;I/E7@T_$ MX;AW/)+;F=S[F*YV61]3BL\/YA')[,?' 1%&
(S]]05OYTH2,?\<79E%RX!?!C [\O M? PP#P@BCNC@3E(%1 M"HIK[2BN\5)C^SB+B!9**][W4,F MDR!83^;3%GR$%6&'TI!LF@<0SL'Y[=N,MG:9G3?@(*L(TI&(1(]3S M[]X3C!Y1?
4P2O24?;#8?*QD0ORH'Y@D]%D^[;_$V+[42N-^0@MPLIKP"$.CS$KK;FH[8("Z)H1"7'F8[";3[8OC]Z#C^SB3#TV
MT@KI__2Q@@,;X_^X1#PN,\F_%*"K33Y,WA.]27SN:GD[7Z[GMY-/L[O9\F8^ M6?]E@M^L^T;H!C!U9:<9#;0Y4)8 .;%HI%7D<=KUT MH?CIBN+">(RV%<$N4F]
_)\D2+W"+9Y@^H#P#$,O0S[YPRSR3W]1:EG/UE[# M@NG4]Q1)V,]F'I7?PX_A@R+D(O[!+W-T]_?R$[;OUA=VA/;0X,Z$&[[E91NB]"L^XC['R<,MEI,O,-H%D%11PA94/1MP M=]
[>P/)4P[#&QY4N&(^!S"(6T2W66?%!D9Z@K%]$U.9 "UQ?#<;'+BY0QR!H MX;H*IXX";,5W#'>T_*"#.<9+8R !PG_T[_9T]\UH/LLLSN V:RF@XWN-#-TA MF**\\-
LJP'M#CK&>GXQ.0#%\S:V(XVBXRP/M&*TM@F.'(F+18SN>,;L!%P6* M.\(CK16X8["W&(4PQK/,WNZWI*!.Y!.5]86814L6VUB]@#X-+!+M.U*N<6$[M1HT+V/A[##-V%K\A?8))&CZ&
[W4M5RF0;NQ\(5$<+*CK5:!C'B:X4CRY>>5S& MD==.?SSV (%C*:@B@]/A5R.N4C3]U6PQ/(U^YMAQ *#[MCYMO&:2CS\=89;" MX<5I_4W]/C TSX;C=5ZOI'2
MA\V>%&I[8)E.8$FR\#B(3M]OV=!*:0&"&)7L\(Y? /[\LHW?$&.QX*:TEL T-4>1Q//8FNY-H$KY!*(=B06V MM\8UPN]%D7F.++=?79<)%\!2/Q8#1V!K[A3IW+O/BZ&\V(LI6Q(M+?R
M<+&Q*T#&U)DV)AK*S4=^E*5,$2&A*XE+N$+MF*>4\ M%.$G(]>1"!S%-KS&;&FYV4+#4TI?&=(D['W\ZAXN+V'H;^(;N!+F$%;]F+AA*-W *[] MZIHDNUQ7)C5A*Z7YB.#5
RF]'R%_#L(:Z_IS/-VS[O\ 9);%(1>R#B?FOL" M,]",Z]7$N#C8 F81"R[(@5+_GB"/<@%_UF&)!'&79G%@%4P9W0.E*9;Q,Y7 MWEA!"P)%DLO2KBSG!ED(@-9? 3G.M)?#"XE/N]G0 MK?
CP11@1F-RK))^SG^ML]R@Y>@^U/3EL8.O00?:6C%YDR6G!OMSTR.SF#] M0-V6Y-:I/U/;(!:;;%DI@,US5#(Z 0WY4)9P]$$968OTF*4I!0.;3LB:#L#W MW:G^(ZY
*DJQZ98MB^W782]?$Y]].DK%Q?S#L(\&]3SU\OIN@'>@2HXQ!S$ M4?HU@CL_S(XCE7T!1]TO8+V9;>9?YLO>K+Z/%G=SQ]FF\5]N9[\X>MR]O5V
ML9G?"O$(D.KQS^A]SLU.@)H.P#)]5=2=_7M$R*%N2-H,H[8+-G0US9?D(K&) MV-3EU0Q-K_W_@"F)J4!*\MRB5]2-\PS>PV195R",L"#IBE+8G,S VHN/W@ MBK7:?
T$1QK;%4YSYSV&4/\M+BM8UP5\)BA*LSVD SV8-23]>@##FT);$IVF(X<;L8FUU// UF4/;9DV; !6DN_(5+O#OFS5SSIQ\-C-JQ@($_G M3EDN5O4:$KB>]4PE26[]P.EAP%>]-%W-
Z5WV=5?#^I@^;_/,YWWJZ5YO5C=__M_IN1V3]F5F#[OU(%!8X?I@67]UH@?^38414VP(-H]":HR682:<49G.C M"N6]%()PENS%"V :+W%$]L+9]Y"':
[1NP$*Z.Y4D+;03HYBH!)>O.)O;;?P, M0]KKKX:VU.9Y*4M;-@XQ]4YE$/<N#<8$:5#)0Q].8)R&I4P+XIT)%A*Y(D#K*I M3&5,/:!2?1&)D@:;&,3L!E3?G#]2: \=F,4'3G!ID//TN":.T=L#7T?
0DN2N MM0.K&E)+OK!%Z=W$K9F*(Y;K>0E^""]ZFET=8$&Y!A?TL[KA.WN,"9Q5TDF M5?T(E@Y828&S%"603]W@Y68]G&/TGU8>__V_#M*O#!%Z5X4:YQ3U+9@ MBEQ=%]\3-
Z^:X0S_3M,Y!V?/I/(J'ZWW;<%4"PQ?DCNP/K0^@R,V=2-?L/O= M]S:O_7Z?+[<\&:'P*2.?'*\H2G,B-^QEK<8"CN%ILE01[K37=8,K-]NC9N+[M/:"H]?H)12@(,_)02FN.UXX$
LE61EB1*_D#\;@8K-K"$):9#,+MN(&#;NN[) MENLSP-IF816;,.*4T/WO/\?)&B6OH<>*VVPW#O#M0)>EKN"@B[H>]MAWO5C2 MV9_-J&& X?O*5+8$Z0&6$OQD@
M_[8;%1U)*:RCG>_D%25NG"+1OK"Z\W6)ON5-Z]]*O/<'EC]U])'RO"7$T]M@ M$C$T/T[[_T.W =SPPJP2^C9F<-PG[O>=&?022"0SY#:I#=Q&E=''.U'3"0 MC:IW4Y+3G0VEWVM;5
+?[Q+O";,H$%KTZ6T5!%AQ3-(\(B]!'AXF7<.G6IVN MQ0! 5Z;],K:ET!%COP>WNO.*I?VU& "HNF6]8SN%.F+L][26B%M2RU90]5)7 MW^IRI3:/1*9!];PDU737UL?
L7*3#*3W+-01+Q=8\N8'IT^=M_(U= M\L3B+'ER,UO_9?+Y;O6;\)(GI=CB=XBMPKXK08"N!D[U;O,Z<.Z3. @SMH5] M;_/0U%*\;-LHBZ;4-4@!U#KH1)]4TIG_W[LTRU?=)GY
7AQYX1:=^!(V,2$0 M1OT:X@7]Z8V_;V(WA-59EX6ON[+,C<*\B6^!]#BFA+F#K24]HN21FSAEEN$ MF>&%>U9Q^89.&-&B("&)V XZF&+4G]W47Y1I44'LH(KO-
R2,'W,&SN6@2E MQD"W#0@EL8:NSV 61<2& !1^DH.UAZ6O2/0N78*MDILM#%FY1:V& 8;G&NC? M5ABZT4IPE%#;Z"]ZR!.TIDB6NES79WP#47I%!E']7:6<$6R394GHD@3AXQ/>
M[$@?/$*+ 8"&;5Q3$B/\BKSM2"6QL4&8# EY[O06[?^]B.X3])#O_%L;^H) MH**%IU6>4?G@Q:$N>U]5NI+$OJQ 7T2LF<9PP'SEE=@-PB]:]]/%$,D@-C3;'
M"*3QBPRV>$B1YU;R4O0!"E&))'$/R" L%<)T+M0C/D2DBN]X0"]IN3">PM(M MQ@&&9OFZ)*D',H@4%]$$QX-59SWS/"(MF=[#-W:MDL:NP-,@%DBBS79D#R>K MZY"/.,Z,"C+9X?
GS/.?.TQO8 41($DOVXO)1![X4?39^$2FLM0>4OQ#;453] M1P&*9D]M25YIO:S(4O2++NP?9@'?#@K^S/OG+DP0 MQH#])D+T1)V$VBWP2"I2_V,$(P^>_^^ZGF5)Y!M$/6&,!4S?.*
D_MPKB1$/.0076\13]A#RT\^8 M1,>0A=)=)S-_E-T5>)H.)5=(>%A$/VFXT0NNW%@GG?^6Z12TS] M0SW;.R+3*W<;/N9L8#"8?PPP=77H2%*3?FAV=R!#P7Q^GZP$_]88P)X!A
MFX;U@QXD'$XP>T0->&O,@0"Q+]KKS -!W#4UN9TIG\15$RF()/MY M?X0E<"&)'K9FF_'M>V&H4PA;QUS\$67*!E2=2]:>80229!C!+@74%90]I&ZA, MP)5UQ'U2W-
&_&OGOY,RK)W!XG'F'_A#]BM)E/G@&F)K*A09I0,65-S?I!45 M9/RO$?[?A8H-W!]2B U=@.[X^N*+#>3K2E]RK!6@ LF#?A:9_E#1XL3ZU=8 MGR(BV!Q%BT=I.0BP-.1Z/PX#N\(OV-
DM;Y]>U.H0[E".="@D*SW.Z&:7)'E5 M&E98(RG_U'4X$$#=D>8VN#^+^Q.B8/: +V?6#]MS![XKVB MR_,56PT"#&0B)(OBWY^Q7>$7[!RP.N,AMKHZHTW\"16S:N1GVU&;[N*)XM:
M/?)C+F\5\+:)BW2IYA-&AO!#9,S%FOR!/F5]KX" (<'LLY-=LC@\R/$"* MZTP%%3NID1R6P&RP7'[;.H.B^HP*K !!65*>AV4P=3<9A%9=WVXVD91A=;=>Z M6_SZ=7&[V/Q.VX*
<\RWHV'H@]>5]0,8ZQ^T]S8#K394AZY;?A=CF\L/L[8B7 MM<;(G!@]@(%5!D5TO"&3N:T1SC*Q7?(R;V'2?:V26"48L*48[=*2U!5SI?@P_QNMIG?3NYG#YO?
M)YN'V7(]NR%]KQ!%M@Y*\]ILZ@EFTQ"-"@H1B2K%ANSE#7 M%451CNZKJ^4*^67WYLMCLRZD3B_5FE=NE\V5' MH[2V_&#-)-G])4='X.K8@!"T0AGS:
[5(VXT#%.1INN@"$BW90X][Z(9[E"OU M'A^8>)715]5VOB]+MF)\F2?9L$N4O4?8_1+'_K=PN^6INL4_"K#5:>)6L'G M$VVU;#DZ \OP#%F<\YVX4N?
EY48^RM5*BJO=H^1P643]]=(6KE]QPZS6Z\G] M_"$_5U?+R?HOLX>Y$,,4)A'F*L&0SY[#3*WI 4P#*I:@FY?S7$LRMHN(%!L
M6Y;G(!NI35UVS=A&N=C6.S=%_]SAD>:OY1#2\E(S*EZ@KY_6\U^_XG-R,O^; MJ-/R?.8<#_[4] #(<'0DRB]T-BD>/U!=%V##]>M($N'52&VZ!Z@1VTB7<^5
M)^/]4S6KBY#W@G/RAV)@(;]S57%R/&E4VP>XK]^C;D_#Q*=G^<+GB;'D"F^ M\=B:/-V!9UF6*]K$Y.<#W;ILA?2XI 6E2]-K57'SE7<$X&B>/I4D^+TK:UN# M%?
M,5E"%_8V;FW4]@&'I4UN2&,RNW&L$) ,-]W/C]G,8A1FZ"U^1OY\POT>@ MTA6HEJL[DM0+[LX_7I2]WK2BQP/D:1'-ZXACG$[2PB#],BPG9MM.FM=1A, "1B:HOIHZ$N0/@[O5TU
7EBG")*URUZ M1=LX/Y(/+]XTL9NC,U U7U"NG8]X!3[.-2YMXE;>6GH"!RD[<(=1A>C.?W MG025\H]?T09^;?%XTGN]:I;]B2Y(MT5EP9PQZ>5AM)7%L\O,$SV]P;?Q:2V M-
=:2#FF?[Y-PZY48_O[-1VS^@;+2#C4#6KI@2,1R^MKBE;!/,W"9YBQBA>= MM@.>XBC&6!G%AM3O*2#]"EJB;Z5))G&$_]/+@\CQ'KQ]F_EQKAIQF03=Q@*F
M;RI0DKKY75963]BE%X#$E^KF_UA7^_^W-J.!*"K!+*4I^VZ4CN+KW]T]4 MVX:DT5,O)ZQ6L6V3/^Q'ZG;(U[*MD]DD-=^B>TWYP>VV]5)V@-"&RL@X^7%XFXA%:#_!.)S!,26Z6
MN+C6$5^O]]P&-AVE)7K\!+?D]$[:\:EY!&#HYM20Q(O=GE$M /:ZQFW@U*%(M.CF=E_'[0Y-[4I7NRS-8$3BFMMQK]NHP+45:$IR[=2>HSU!#W_'>YS:+4K" M5TANNTIE7]]QE&,
(@%3?TR2)=FK/OS8(S^^KY?^ K,]E+)6GZS4-#@DP0C5 M(05DPUB*!PU!_NQ"IN*@%-)1B?,88>,%S9[C)#L4_SA<7K;52H?X"LD)LP-) M/'2=^,S49 K>;B\!+0-> MR\\ *
(&NF17R29;14_"8<8)?D527-')G41;F,*[U1IYQ,756EWC&0/H4P,% MLC@H>O"]%5B)O(*W*(/AEK9_:Y52(52WX&&,?D%3:A#K9(]>"6]K"B;M]DI MQ%VH#2?ML
1"Y$I2+*Z&FG3MAP[C/=A#E'9<3 NO)927Q.3@Q'M;$ 2!KDKB M)*BA;]L;52CO+].*8LGL&TS\#?[[O(X,9),^!,[5$R@HY'"\.O -9YVXE%Z MW <9?'H[MCD\G9HC.
<*)?!++O(3/Z#9^AF'4-B;\W]> Z6]*)XD62> MDA;]I(H>"5D$KN?ZQ*((XOCG[=P6T8A,@OW?;D,T]94L#1$2"$())D#5]7%MI0[_0H]6#6 MWXD$,OE(;0H\WS$]T=$^0CC'ID?
I[6=AI4++5&#NU>_:3&TG8#F&*DM&^17Y MW((R_9YW;G/F,IR)7&X2W'JGA.F]%"SE IY'4F6.P+C$#N3SEYA MN"4VR>C0,AU)PNX95G W[;PO483=YM2Z U6:/[!2<93E
M#YRH8_((6C8*@HIX2K[*#]IA+DOI(M[_]?Q+$]Z+#.]0 0K)E?0[O,N)%.5C !]>I\I2W^^*(L6BA=BZ-YV1[0^__M]W=1,<+\UQ>0IYHO 34P[*H*]P,+4Q,AQ-;DZ,M#YM]?
PF1_,7]YS8GR,6#; MOE>])?F!Y8F#%N>1H^)56(VFPE;*F2@](8Z*H:2,,M?K)3V<;"5[I2'O!:N/ABTRWP63M@(MTT)5$%.E.= M#:W?C>UP"V/_D'J-,;#-/YY'+I-(YLDXQU_?P-
[QOX$F9P2WX]>R:% M2#@6U[?! 9"BBG++7.][L%>D!>BB7PW"3K-#*L\ML(TP_0QF6$]FH[]2>AF MAGG^-*B679/"#"NHR6.&%3!&;H;IH6@*]#7=:RC,X854(2;83=;F*;OV=&K
MY"%\?,K89EAM%X#\]2U+<88V#&L\%)AUITZPR?YB= "]KFN.))I"_7YF78& M]Q]L2Y.LQ#+\TY%=^ ?P0%S&-0L(__W]SR" 4R\0702]S6*ASK[P;E^;PK5&
M5#'+@XGA6E"!HCU#5,K1B7LV[4N0M\6^4_?"\>W\E_8QP7_& ":P11*LBNU M.3\Z0"Q]V$O V*9SI-H6:+:&7$F2BSHOOY\&)9S#[,8L>48YM5I0NF9'DY28
M>LCW):E,SG/T5OP_=#@%:8=,U"TZZC516PT='V'$Y!VB'K?N4?^KV9M($<3D'- M(8MMY1_Z\]69MD4;H/]V[4A2P*X'<2MX"NIVB]QG'68\IUFQ_RN*Z]]B]?(! MCK-S/
5UNSU.Q*#NPT,S=8LV &F*94CBB.E!W0]>@KI#5]YML#;_A%'XO'MF MV9LG38")H"X\YKO&G*S8G/2I%V3N%C-54S@^2G?;C(2%L^2XT@QXNF],)3GC
M&"9"18+KD134'?)EW28AAM\;A;CK%LV(#&FTEGNX#/SE% MN=P8>)KERV)K=!1H*IZ"W@-;QEZEH>$I7MV"WL17>L*92E>]B82=FE07?@V.
MD8>]F+X/'4D4QAH*I[E1A?)CA;W84]>01:-OPZ!F1()?'AT\[,75\.$IB;]4 M3'U^IIW'JZ\>VH9R0FNOHKB2:%_5FIR0!9X+O/ZZ_])ZW4S=H@UP?,0]1/$ 3&%[T%*CB1Y-;PRL*;)EH3?
C9*W:!0UXAOEG//564L_1$1B*XLA2>:0-*]@ M.W=!B#>7EV2N!X;S6PV6YG-[T.-R7QV#,VN:A%2F\^6;>M327R@-=3D,9\+ M&",WGSW%@;($R=10F-=\+]#\6.8S<@)7EF#2-
@Q]1O2CF<^Z&_BRU)]NIGYK M#\F)YAMFP22M]2*!V(_O165\NN95ML%^-K4'./B:D94]&HR<:EI<3$Z 4]5 M'$!$]2=TDS]?F=@9/-O(8U1^Y3&[_0.R"0E@-
)9)_@5^#)L4[L%+)&L\+,$T]@08-W9#DANX:G&PA0A0]"9:#*V?1 M.OB!UHP:L"+ MKP>49DGH98?7P@9Y)O2VP$(.A))$!7!KMA5>-(K2#]@C&WGS)ZIBH\P24+V M&6I+A<3U2
KJ&G*\17B8*%G/CPG:/Q7%P2)*>Z"0:R-)SHR:P[6.3RPX!<,& MS(6E?765/;&D+>5+G4@TMQU(A_PT3 4/!LR8741>DG\0;DE5R%OR=?\6 MGV@^BFH"()A= (2.7TTZE2;TH;@7K/"
#]6X7^0Y?6OH-T0T2.3/\)8*'U^ M1Y(0\1F&R=_@=L>ZQ;_N1,!4T71?$M.&6Z@$TTKL2S_+./)@^K1*B)YP^&'F
M8>TW#0F]PV\^AQ&,O!N5\E>,UY$6"?:$1*0/1&0O7V>SH$4>0:@3\MP/'SV MDE\%NNV9FKSQ=4PAO IAAD]*.QZ,GQ%YS,K#
N[?)^@%AO[\.UE,]"8/DZU73LB"9M6>T&YQ;99]+C?QHXYI/G+4H=*ULQHI3;C M-MS+"B)$M]ZP.@&M;BYN;I!U3_XYNC^*(-D!-[0.P#7<[$I.DZN-V$]K@3& MQ]
[22PAY4'=QF\E8[#4]@!_H5K5>T#@8W-BJ] HAZ-*AY)/,<_LC#T^W))6, M>XBFKL#Q/,L8*=_XT17F^?B6Z.PY3K+P7X>P@X,:&#WF[T0P0B\8O8!M>)XA
M6S0=)\NY@!VXW:TT46T-%R)=Y#M-2^]0#X7:"B^Y[.QF:+.Z>'$5?!BR+"]YP-X[0^X> M:F(<3AL!SW8=3Y++Q39TKL-1T%60Q^/P\!;RZ8[?@W^&H55Q]0>8*O98/1PM M(18,?9?
1]Z6:UH7Z\22<6N<)IP_SN]EF?CNYGSUL?I]L'F;+]>QFLU@MUY2\ MTXF0Q-,ZO,VI]$T] 0ITU:EXSZ_EA.R4G(I\PPTDB0[FIF^2Y$*;3I]KX9 M0%GX4T-A-C>]4(2G]UXY #\P5$>6F-
4V+.P 47"]9,\ ?&5]:[H4MW=B=_(MQ#.8%_SK((@]!">KG\;)LC#G5AA3G6M =*0]DD27\,@8$5;;P1T@5I1@PC>?%9RPA)5*(K,* MLSR>=!;A.48D9@1%7H@*$Y9FN=KGENO-
ZLN7Q>;+?+E93V;+6_SS"W91%7<>F 7&\#+G/CM M#BWQTMY)0]M7] 53Y8EA8[4=">@N,]JY+#+\;UG(Q0;$-DV;2.GF6]R=XXR8_M>1KW3# MU%S3^6&9W B[=9SK=.^-B-
C<1<+C'.EXFTI%!/]80_F=WC#Q[=2OW>S M2PC.>Q)Q2XWIPSTY.@+54QQ;=$V*7EQI";1T177E9]_-P'T/-,5THYO2ZPTAS$ MC=Q]3&!#VYJ.Q'HIV$8[!P>@@;"KT^L(52O7=-<1
5(PCT:B5O<7*!8%C]]] M'U6<&MW=+0<"G])-A=<$OZ;PG_,NK[_;)EAN]!;#P4\QT;5F*,?76Y.H!]= MZC^RY+#=\FU' M#7D3828V0PN3E!/MZ"$ZT@,UW];4<"EF=HIN@*IE<7FS+R
M\1:RX(4"S*4#"<[)\,!S=(<;21^KD$$B Y?[*T#[]S[,Q\$'G2-?R>]]AWQ M\9I!.A:WOV#]-]Q0W:DV'4F<1W?F-(_7D6,[<*I!G&IG-1T !%9C"22R>F M)#0!O$3F#?
V3/#=/7%V!HNE(%YU!WXLYK:&6[B5DN"VJF3SG_1-O;^#X*H(_M**/KT58*ADAT!\5,P9]VO(O]]?KS]>^D=&A_*$@3]OKNLZHHU3?&Y%Q(!7FI MQUD-KI%GUGLNM#39:B*=4IC-
C2H4X9GU'1[5,H)I(#S.K_.,]"_$Y[]W?%1K M:KB:+@D+]&1E,N_,Q"58D"99B?SXIR/I\0]@0X[C5;#)MYKZ,_@MD;\<5M] M4X!TQW=$^[O:K(%&\)=XUKY_437@*7S;Q'!]IC,H0-
%3L08!C MF$8U5.;*G&OD1C/S.&$*?]WY< MY__(L4^?%H,_Q42Z=#5].0ZG+A@%OXK+F/)QPCR'6\N!@.N;MBDZQ*L'W]H* M),(_82__FAB\A@_(Y_Y-&*Y"0@,(ZB^VBC%ZU:%DE'Q-]
1%-0ATZ%V#7X"FH+2G[./4T<+^N]WQ90F@-5L11/M N\ MYQY2"-!?FIS4%@[;XN.OZK(T_8B,36 M43B=6Q$?')6?0:4NP%!44Q%]O__")![]7]40Z'7136%U]]/ WQ+ MGD?
OVW"K!U2QY0CRIWX?,'DQ;9YFD7^+7M$V?B&PFP^GQK[ ]]=V]0%YR?G9 M'I[8B$"F\!4;Z_,&?X\2#+[$BQ=J.!'1540W1(<6#"(MP/8#*]]?T>,&H0>W MAX<5-
TD(MS5W\I26P(8Z&IV]T03F4C4 R$OGQP>0;]%+G(89>0?B ?]8&TKY MGCW-T1U,D3TU):F3W(8?I1%6;O6N%IYSCV&1H-W:4]*Z?M]-"J &J/<0'2->B(CN04+'*U1!EO M^GD[

O#47&T_" UQ[+_S;>ST9>+MEG@P^/+@^X\-/(@"69QOP@Q(%F&.SO&Q25Y^_[# AG%03XV& MZY&&WF![(L.0),1\..EI!;UU25^&? AR/[(R-76UR0_9+^=OC!Y)TS9@(*C& M?
GG[(E&/O,N9W0\@WPW0&"VD@A?4A@##4!6SV]OF=?&YBPA3'A&B-MSUXQB4A:RR8N/3+X%&_),X^?8!IZ)"XBW.XR5+/V.@\'7.A!*,GR:Z1^9:GU-MQRTV4O@<\=DLVPMLS0
NE8@BV>Q)9L[(AW^5=2SV)7EC@3QKX)-JM=EN*M MGAP4^<32IA7;<3 0V+[OBBZKT)$EE>7;EPB]XICKWL^["-;?_=I]M8@=GL(A MBBF."-@SG/N'>>EL[CX><#3/5"5=LJTY/0
=SF.AQ>M%M-<1=+V=8M3M5029 M5"-HNI1ZI]>!T,4VS52?6I*4?&BD*-4TK-$T\[TC@%M6931&@JSN5&%(KPH
MS0QOM3[94+$]ND;>+@FS$*5[LQ;Y^]WX^667'9P/E9W^C3X N\K !3*/$TW M?$E\N6V$Y!HT$5R!ASY#GK(%33V!]C@/E"1!\AJ<;"%"%"I=I,1FK]:Q,N]/ MFN*SRYP*+P[3EG
5Q96.J?)F5W_Z?HU>48[UW@?\SR3TB/Y+W!C.[%WW M'5GB'[O3GP]CI7ZE#/L>]X;05%EZD.&!H>F:+V\24:$P7>+1/*/ N<-O:I;D M>N>FZ)\
[DMKVRGNO:9S;D^NOG];S7[_.EYO)_&\RW7">HVNV*>MZ@$!1+;]; M3I(HFU*]B7\E2%>NO+8E 6@D=N4NA\$MB2V?@V%>6W*-HIPF_),OC;X4VQ[ML*8#\"PSF,J6N,S#G-8\
[QR2AC]-!EAM%X 1.98D>GP3W7F9=09-,+OR*F#(MOX=)[K9)8)3BK9H8'9->RG]AKS#^,8!A(DN1Y&*AS:+K %%PQ<[RO)H68+4M MT#73KU;/$\.H#L1O9.
(93!F]YK:M71S82+,D2:W@6DN-2(IKMA^]=K%GV:XG M,J"\D1O-S..$>0FV=M=(FLI#4IL#R_1\75Y-Y$RIX-%%SH 53!HR&JEA[=T\ MA2B8?T=>[EM9!4'HH:26/;@'HP.
9"N71)UG'#251<6#]>#-@ %%7Y*_HB3- M4,1R\IXU BY2M3'6LRTVHHJ'MPY@07!!50KS^[ZKX#?B4HNR5?) 0I6PC"1> MF*+[!$O(^Q_3PU^/
2'5':W3<%B54ORIO"4H"X<$=:OKAUA8.0QZZ%\QSP!/ M)8P>\^C?7!/;1F@)+5UU-DF1);D8VHA%;Y'4-R0:47P>=1-ZFBS3=D=C[DIW" M4#5:C-)ZAW>YRT!/?
[Q+O"::H%/"/WI>I78"A&X'$%18;]V2A\)1Z*DH8>LI8B7W^@.HXA2VI@V[78$]+88K9\ MDYWY?IB; GT9^SX0ULQ@+ L !C=FU?,3!Q+FAT;>R]>W?BR-4W
M^O_Y%#]>)TGW6L+6A:N[QV?1-IXAL<%C<)+)/UD"%4;30F(D83?Y]&=7E00" M->8BB9)46>_S3AN$ZK)_^U][[O[Z__V8F,(;OU MY[\U>[?M]M_^OYO_Y^O8@\?@4]589F&A?[I[?
GA8O&XM_GYY:-7G]-9[LAV)IH'T\!QJH0DI:140R\IN6BX M\B+X^_+5?QOP/?62*@?O&<*V\^15?P!'*,X>('MK7';VRKM/8[!XVV[DKU"KY=_,ZU
MRXIKV_*V)"K\^W)H3\CW4E65+FZ^CI&FWWSU#,]$-_#U?V7ISTM@PZ]7!*.O M_V^I=&2>]PZ2/.0+@SF I8-CYKK(;=4NODZ09XFX#%*Z,^9\?;SQ:UM
M>?"+4A]6>2$,Z5_7WCHAW=%F/S]YNL5'7I@ZW/!]>8FHM^7---XM:[_F+F> M,9I_&<%OKV5IZ@F>,4&N8*%WP;$GF@5SUXVWX)>ZX4Y-;8Y1C+X<\IHO%X*A
M_WR!UW/7_B>\U/AQC2>&'/I/0]>11?X)K^Y0Z N6-L%C(N.Z9<$^S6]A=8YF MMBT=_?@'FOLK_N$]8]ZXAW%@P]62C&GMV7CS2U*U!-M/AC9^O)5]-:EQ<2/!
M_VI*1:V]7Z]6!MP^?A,(HV/BW)O:Z_[C4H&.Q_;N!S:PDF:--!,+N^6,9(' M^7^OR=P28>_=&^Y0,W]'FM.R]#M S#!?SI?M#OW*_L
V0O)3F89S"Q@R9*1VG.O+'M&/]#^IX3C$YN=0LK>-OQ M_V*87-MU9[%-K H%L.5LE*IU>OEI"=W^-.:!]"_7RHJB M2H=.CKSY&W@..DQSBBR7>$Y-!QRI5X15Q+?
Y\I$G;8X_;KYKCDZG]#1SAF/\ MU;WMD(_W5R%[+TX]G*52616LI'S\]LJ,KDH-K4H]>%451E>EA!!X^*H.4(/@ ME5P'4^J..NC=G%.-3,?X-F],K@'V^F9:;P.D_HO]G.YH9 P1[(A^9SAHZ.
G. M(YH,D'/ &D!C5NK[2\:\CF?D>F#*>80R@0B[UPR'Z*:X%P#*_OL0:W6I:IR M*+;Z4QC3 K\$(@(_>K1\87@<8^/O-#?2I2I36Y6G3\['MOFR9XFX,[YHB]IV/ MG:(W1@X 5R$X;@)Y$-
OR+2G>**[MG/#7 D.6LZK/4'Z0<170?7*6V=_M>KW M$B,/64/DWGS%0;%KEX3>8!"!Q-.N<2CCYPO7F$Q-'/TBGXU)6 CF5PIB#9<_M7)VX_6NO)'^Z-C X_HM$V:
[]Y9,9[T!3\#@B3GCP%\@'^'MD($<@,T4;0YRW M[7^L.MSK/]X)/EI]^Y1XE<%?8'0X'G9Q,Y93#'ZW_&XQ33UXU%_!<@CZ3?!W M,,C5RG;LV!UX7RVT.]627/^OCI?
_]F8#%_TYP_!Z@_^/ H5 Y]'Y!XA-#UD^ M>!+>3W];T"N&.OU3A\%^3$UC:/CS$G0#OB61\Z4Z6UT CBDU?QCNQ0^"DTW1/.&&2
MGPZGI2T/!Y_@!#LTW]QQP8:M7Z@XFYK5T29H2;"5;2=) MK_*9!.O^(5Q.+U:TXB9Z!8XO.5]HOC][(*@QKB'O#M.2NYS&*9'5|+Y*B,;P M[S*G<4)\7-F?
QI@.B4<;;F%_9B;.N83"VO!O],&]X\>DQ7$*<\K(7E>*-DT MZ-_Z-K($U0W&\PKV-S99H'<9OW6UV2 M8G]?!>X3)?D ""=XS]SRU2M9G,A)$'DUE2M,M^-3N1:WU5C15:%%KJF?DQ?)
MCKFR2DDEC:2\M;PB-Y24[QNP&O.V=^)I%YLW:2L/[SWQ0YW\"$5R=0BV>D.6 M^X"'*@$U*%81GWSDCCD36OF#^!>7Y5R6;W;T6(OO<:1RI&Y *H-G@USA92;6 M\
$ENH3V(%4W\D#.T$+RSIU**.NO!R]"[O,SVR0D M^;7=T;\T7&O)ZSK/QNO86]DS=1$LL*02,T"^<.:/#OC-/@Y24' M1 @6D5DJY$(Q9X,&.X("Q,/4?
N3!PPRO(F<>YMGC$A\AB,Y]AXO&X0(;)QP,*F29?+JR6/!-O<\)_Q[9:DZEISQ%B MU,<,U[,W=$-SYO@Z9'=$L@N7%(PN)$$R,I<-S\F8]53Q;6F;G(RYR-GD9,R8 M;MQ>,S58?
@,*"NR@9?#(AM7DD:"[:AUS@F92T$:M5T[0G-FQG*!9M&@WI":T MK2&>\AM=\S?;FKGX.@CCIA#I#KU:B6?W0N(D8PI)(XLN=W@MX5[:>$F9(LV" M^[:O)&.T(6&TC#-
+'GC$=!Y^FVDFWB!Z@]7OF)1-]NRQF@S2:(M@SAQU=]XC M8W0)],LS\C3#0GIP3BN7>MET7_<@+1>7!2$T ME[-9(NA26:HE56:N]*X:]G8>AT6 W\>U39RV0:
(4XDHC6_3BLO_,=%G]9SFD MGQD1[>O*;M\V)VN[$X?ULKX[7"?$;\>P2%]N3 I":*Z%LD3098<3A0TUM=KA M1(G37O+?Q[5-C#T6D]405QK9HA>7_6>FR^96[8R(]F-
3:]=V)^Y&]EPGG"]K M.DW2B=\V2)1"7&EDBUY<]I^9+DO]+(?T,R.B?5W9[9N\H\:< MC;5A=[A.B->.89&T7)D4A-!<"V6)H+XIH3"3=A/2RTK,^5*SYZ)V7)*FD)<
M:62+7ESVGYDN&\IQLB/:5Y3=85WF8\W&VK [7">-IH[)93LA3B2B-;].*R_\QTV=X0@_'1?]RR2Z$8 M.VN[<\:*81OR6UC;G?,FB[!G*,6==))';?(F670%;[T M[A;+FB#-
G3GHQG#MLB+7KN&[X.?!5\'?^/>1=_7&FH/P-;!PAZ\$;/#Y[_UGV:SV7OG7[_>[CM5"9_A!< MVS3T+Q=7\'[R[*]GE>CS5_XX5V1>-U^G&Z8F3;TOY,^1-C',^;4'\IHK6.A= M
"6D65\FFO-[6-?2],?%S5]_D]O2EZ]7T]"K[KN=?]G7_D_K6B#O$L@'|\W' MJL/OU\+ZVX3'YO,O[^-ZCFV]WKQTVOW6 MG=#K_-NMWMV_UV]R4__+E#3F>,=1,?
W#/GF)2GBIF/J3P;S,P,Y%CSI_1U':_8D]LIV)YF&" MP[S0\'I@V^9_,TT;EOYC!0L53(A&K5S]$H7#%$M4/;PAR>S#;R_-YW[K^>%W MX;GUU'WN"T\OS[V79]3P-.7)O.X(W1L*?
40$:]D)X&\@?=@H9LA[=#2T M'=+!+!Y0]\]I=)6&@/*#Z1M[>H,W,4$*!U' "!WXUU;3Y'8/A8*TBL7MS\?68A M095$;_B+,(I51IVGU-; Y*KYK3T2R7A$*3$ZPU7['6SRA8^_-3]]-Q.=Y
M)"O#]G<@0+T%%@().H)7"/!=_9_@V6L?7>; &,7!9L/%<6KAW@#Y C%T>N] ME48@B;?Q6XN$("KZ9N/LE;K.-XAEV2Y7F]LT F!,O"50\;D*45]"3]UKAWXYBAL M-8 '6@^EWFT;?-
YGD)#-/G%Z][\SFM7[L;?FMC=(%_VQEV]DBSN?%.@\I=4 MX.;OX&Y#PC;UWZT_3CYD!#W>*W4D"]NZO!Y0ZZ] MY4VNRD9)L9U?$MP<@F !K!T;S!U'^&/F&*YN#
(G%8X2A'B9P]FA*<+!/]>?> M9\'Q$.T(]^3W]9V4Q?FYXHU[2;ZFKCO(=?W_/(^1)Q_%' HPAZ(TA&^V*0[] M-WMFHC?-T=?91-P>X]PV'^6H^;C !3,#N* N*;MY-2TZG!]66=F?
6_AGU^G; M[]91NU.^N/FG@2Q+.Y8^1,)TG2?0;2!0$E*1%3Q+;*,8D7GN.8 M'];'0W.H7MPHBES?A*'40U/^H@1[)$P=V'9CJID"H&&,]SM%CX&*8>/%K,> M)#N.
<3YMA01FE];#M*-!4+NX]4G].@0^;P?A@PU^U=,81.$)]@9XP17XM%&N M2BR@;^E[_L3++) $=L5Y@R["X(&6PWKU5'Z2#PR^-0#%G(,SX ' M'+)*Y"!=F,X<=P;+Q8$@>(*8#
[+R:? 9,R".(S6'WG4LX\?@Y9&@0SRAVCTM M?#5A%R20 GW#,[%P$UK:<"S% M3_^(*3@SD!&NF,;9QX$IV;>6//6Y_ZNK#/V !^''R)/P&3\)_#3Z]=
MT!^9]]!QR#=G+=V"T3,&-7S/(GV?P MH[)4P3@&^.U,&M[KE?K"]POM2^*JESZ#WACPX7):U,8^7,LB'>V(YY.?3'O M!:21^_E#P(;V!F^F-C]^C *MRP.XC:P$8FF"""/D""-@2?"6=T
QTQO<"IU:R- MGPJPHZ6-7[@30#],X@0B!T@W 5=]CN4RO VD&58]K*K8[]]X^#;2Q#3B$Q- M1R/#(KD)),[SUY_JBB)]V39!\K7\)7@I\H#_O1@\L'5ZP8LP:OUGMTPU>-*P M*
^"_5E2 F43UC#7Z8$I*T>C2X=G[>Q]8'N>/8G#'7O 2*%;$T(#_8! 8KL_ MJ["0YK[" V3AZHKO29'HK/O NMR2,Q3>A/9)YG%O8NU?,F9]@_I.7D8T?^B]; M\P3*X EL$JQ'9-
/%3*W]%R'507M43E.L+H0U_=,7PZG.YP.$D.E^F]F&A=P#R MS,]RMKTCXIZ_O',)+PR6./GB5&R]F9FO$LGF 2NJGMDJ.8G M0R!D(X]V&*/X+&>C"6V.-
KE[Q,D#46W9Q#&;N=20A6'IO80-V;9@"^.QS#D> M_-V H;&%C%=@8]OTS7"]Z+'=^2X#@/((U_@AU*;4APZ]]5 KZL+W9E'9!Q0 MGN_6^F[ABVA,G<[YAV?
9/ NY)U%'6$HDA+XL3D01&@+H]DA?]WBQ<@_0FDUT MV)/1T-!/X4+_)0?(;_P;#8+_C?OS1;MSOR+BZQ_:')$?+)HG@;"QA]1-
]RI];WAQ:^KW@+)!@AYZ:SWVA+=RW.\W.,;OY((#H[#X_^M>94E_P&6Q=/R:?U)WB MMH'3S-)FNN$AG6;@]-#4HY5+_4?4KU=:X@;UGGL3MY!1 M&4+?B/PO,?
1=9>S%1>3++!S@_0D&E1?Y6W, MSYB#PTR>8VXN%X>;_ C.5"\/]-^YS[(%ME0Y[*!X7=R'R0;LBR/=RBH8/_@_/WEO+H?I'|MY1,:W5!@L." M8@@<66((?ESBL&B-I,6UAN(?
CBJ7ZPR7YA0>-4M[)9+A;ZYP9[C#&:UKBRV1 MIJ69<]<@QLQ2E&#Q0C.1\3//R)V9Z]&./$N01G$D2%$"%]GQF^]SO'H^EH&5MAE+$3 M8T+.V/%Q5=EG[/+Y&+M,
A%@S)LN8>HGQQXB?4;:I'&FS8$VSLH[69 !(5(D MS(!!KMV"$:=@5-.LTC9EO W9>)R4G*LR2(HS:-:IPH"?3"?Q8H7*FO8T$Q&G MUS_\"Q4(P\KWQ255$HD.1G]>-;#*
(VK,O:.XL]+BRXK*.64%3*)+[HZW+7I] MC_2(X*_2P!^BI<;25/U)4WVG))(&)M'Z,38&AL=-#"Y@"FQB9/GXWC5>+VYZ M\&K-
RWFT3I538.2T;QUGZ%K]VG75@0FL%+]T*D2NW6\,M>XU9&B_X[B-_Q5- M0IQ"[Z<3(N#T.MAODM!"& 8_R (4NL(#3(0W\K_^:)Q<29NWM@-=$_",C#] M
VLCD'NB7KZU6OQ=NHGL@D\0NTM_'AH<((-&U8-GO MCA;+NMHP8""6=(S>BR5%E<5&4H@W$KZ,G[Z*^18GNV+,-]LTW5PY=*.P2U!, MTN.KO[]T6CA/?7=U">
[UQFT(ZI^ECH#1Z-P(2'_I?-/3 M7C]+)Z="\'I4#)!KT3A):HC_@0LNO&DF#>2>S_JM_^#!6IT MS=I06AK'(D>&_M]]':.ZTS/W-*KIDVO\<;B_VLMM_09@=8U<&
<)_$73TE<__M"#VYK0QUI)O UC+4+[V[< UJZ>)&K9?%;D794'";:2)S>*W#2TT>7FI):IP MK[(HERMB3:TP!S 6<]77I/"3@Z:;H0OHQQ3?%6=5^)[-8DB H\KK'.73H$5)
ML+%/:3R"N%*1156M,<:A5CH?:B4*YHDBB6]TS!]4,&,;]V71]XAL$ M,]*YRW:$Y[]]D^F7.V(MPT]G(]A,TG>9$2#GF86] 0L-WR;7 6E>@#+WMO-\ M!
[;.8Y@@"0IO1:Q4*]2WM2XY>QT*.+(R6.O%AOV3I3F"N"N+DHU]GRX#)C8 M=VA]NP9K<8T/3]$8X*08SLD^9K'ZNH444<M)@L=)&N.R*&_LPK7'D5]1Q"S'
M:QBOC>)O>G*812E_'&)A :XLWAXH%,M^8!GE;;E%'+E()&;1QKRXZ=N>9@K# ME;-N%G:+95B>KH ;TKH"3MQ05,5*61'5*H_,;C)R\B"3#P?9B=9=56S(=;&L
M2,R!C%MS;,,]:\LMXLA%(C&;UARM]XP$$VDN$HB&P)=;9 -'-^U2TK]13"]? M*_^8)L_XY]W1BXN(+D["T*N)=4D2&Q(_X6%DY.0A%\FN.A1R)Y[]#5%69;%1
M9\^W8/&@_N+&KVUOO7)!?4:NB610+OBY+,GKM4T)&3!UTDE^IP-MT)THK&6QVJB+2EEE#G1LVM1/C@TD\N8D;PI?,)CB_B8B/.TQ@MH\\TLUFGM(MR?
%D:L7M/160)%.;C*Z+E9E553E*G/L4M"1D\=<[63,G2]B)5&NUT5980]T M.;K43QHNW@64@V72^9TN"22>ZSNP7A#>MOR-.O5&)C4C'$3DLUR314E MA;WT\
(*.G#SF(GE+1V#N5-G#4RTU 1QUESZ:+AX='$D\X&Z;(D$!LJB5*V+ MZAXIX>OJ5N4&8WX@%\E[V &Y$ZT[51(K2EU4*MF '+?PN/HOQD9S$C,G3U*S M\!
[:S6_MAW;_W>H)S*XPU>;X]3 +V[9A9#8;%-2D2#9SL]]/=#L3S*>01,7:$,ME]G*9F!]95>1$ MI?[1:+RP-F;_(#5&2LW%=BB.7
M&>1&]B@=@=P8:G64U8_#+RP@EQ>H9]N2RMMRBSARD4B<=MTM?=0*'^*A?UC M&;@Q:=(OD,Z9W 5L2)5197G.K
R4EV1D9.7G@17K/"0>\TYL:510LU9D#7@:L\ZXW1@ZJ\5=^GDH8 M+=]N#I,M%$Q+6+0K%5&2#B^IQ;_"HW::+^[PU![JE[($&IY7)AM8REORRWB
MR$4B,8N69W#HSZRQR1XF8U#"D232D/Y-Q%:LB)5&152]]/68+>C(R6,LDN[Y M$<9.M>Q]HHH;LU;9:Y[-#3FVT9ZWY19QY"*1F$U#[M:>3 P/=T%V21,Q+.(-
MZQ590]QG].#1LC!-_@[MH>$UF<6-I(CM@@;S4G,G%#B1@X'&Q^9DSAS1@YO M4U!P6!9TY"*1._Y=T_$FW(0'M,>?A>%_]L:B"M'$G(6/^[AWSYI3M?I>9]' MJ']]Y@P]
(:Q:2^32W:_UM%UWEM@Z MMJ_(,,23]Z>>:X'_V"N&3A[@O#TP+D:28A>!05ATOW1[#_DV+KFCG?&SDO, MA^+KHW",QE%%XN^Q9]&Q]%4(-R'ZKT2?!TEUG4]95(2F-H
M+2DI]BI5[*[(#U7UBHJU6?MO-8).7V&7F:82&I3D6.$ANB))WE))R'?!A>G^?%$" M02_5Q;(DX'9VIUVX,]35VV>.2]9P&3GF.!*7IZF![+]9HH-611;7Q<#"YN M7/(T*9-
G;PMMX@C%XG$+-J/P:4^[?!/3GS/ 8"[<62D-O5]"1 MDJR]$.5:A&Y]57M31:GR<;,W%]]C<[RR@M=RI%3AGG@]]8JA*BIR6:PW>/V[M[+$,,QR23SNDH",7B<2,FIK=?O-!>&@WO[4?
VOUVJR-IZR0#ZX;SZV'WZ_%M8G+3PVGW]I=Z[Q.?<7(:17A@A4 M@_O[B$$&^/!KSP;*P8=62]2A1$I3V^0*(F+5+OXG)MP5?>P-;G^+\;*+58 M=Y6\,7C=P'9
>Q$]&M;KM41>2%X=6:]/>$GZ"V@YP-U4TW'.+-%17_WI;]33 M11BSX^E@["SGLYO"%SLLC($)U]\%AX1^Z]_]4KMSU^KT*4TVD43=:\C0?D^U M5U0:.$C[7M)&\(YK03/?
M;D+S^T!4?]M:'+S51/&#E;P/X%? 3X'(8(]$FZQ MO0 ^'JEP8OP@PR (+1S)AIY"8+B[#QZVWHH]6[,PFWW^:G[W.RWNYV]"TCSM=3$1W7"GIC:_%@S+-"QT0
MT+T7ND\MN@&]KU?XM?LCG(&-Z+0[+>$1W0%K3VC!^NZ$O[_)RN)_-@6S]*: M/KUTFB]W[7]K[O,!PB9!U9^V@3/6]8&S((62MK&3NC')MSAM,S*_;!/?5H@
MDL(P252K>8YMO=Y@R0VZB/ZQ:6LW"I(5AF?S0%^55?]>4V"9N=[YC%RD.<,Q\=UU[(9, M>X]#I2QLWX:1XSS>C/$0LQHYQ SVM6GI=\M=;5%IN'J">0\[04XP9:DDR9X=
M0R,'5:S6RZ*RH38#S3E:%I'4Z02P^%H4D)H4D]$4PV0I(KUK-?/\^US%^0 M!;:02>2KID\,RP!73,-%3=AB"IZS3%@O4I["IQ]P7G.%>BF)\]I8*=?$>O7$ M*W
%DNXM26:PI)]XQ9E&QI&2Y!_>U[(ASS1F000:,_ME-)8!$5\CG.3UAV*)"]XGD8M&Q=A.':9P6ZD1,5^V(U17>#L<*DN5BI*)K#+ M$W+9"C'F,JQ8T)&+1&
(V[<_EL8YINXQ9G>P!,H:-/-5(39X%"=K6T)Z@!Z!# MPF;DLB#/ ?9DUFM"Y1--D0(2^Z(J/L,N+,]+;S4*CEQRXRK;3XR)W'F++,V M3OI#KA>$!$5XCM4S?&9P&8-*K45JW
24H!K5#Y=TD)>:E5:IR:(L):M4.9Z2 MPE.D-,-!>$K"3BLW5+&BL&FD)>SN>F.D!!*5$0@6,4Z]@UTB>5>$9AW;LM<" MUDF?
M=3$^H9^2@>%]C,JASD4*10C25L'03'.DW89Y'6%ETSFUDE^O;""CEPD M$K-I$X+ES0_4O*%(KF8L/GG.?:HRY+8]!V0_YQ16RZ?.(JD0GZ,HX0./"I5 M*4;'Z=
GL.2U9N/MJZ,8+7$M+8(^%=&0'C[4C\9B$&)=K\NEIB?P@.WLC%\GY*NC(M12(QFW9BX%\+VIMFF*2(JGKB7M$T[]R?BUH%&6%<546+PQ@I3(]-2/U6. MU!<\]$EI/R-,,"^G^]5GW)%PM;
[^6ZS51:LBBVOBXBB*_*)VL*%).%$7'"AE9 M%16Y+-8;!W2 8=&AX+?B4G<.\K;<HI,29S[D3F)B.RM*PW(BLE54XD""W7Q)K"_1"_ MC)P\6NM[HO6?FCE#9P3KANA K<9ARL;
(R9^M5#:'H!+$:3)A\]I84]F+9A5T MY.1A&^WBE31L[PG'Q]1!IE!8R3-*]VFA] 2QV9#8T_9L%E EM!,,0CQ^66L1C726WNG*T@_O[>='B70MOY@Z3B"];I8]?'# M?49&3ARKM8,,[+-!-
:H;ZO4#$@2*)7\@A3<0#5=E";B!"]2+):5 QK]%@$[M>49MXZ @V^FHY3Y@WD9.P0=,!Z/'RTR<&)]Q@%S"UX\ GQX:A='#WX#O!&R/! MU6AY6GX6F*91W=C77*$>6
>]DZ_Z_@I8KDAB9+$P]2,CR\\(]V1=TE_%.' MZ09U4!8;'*"LC)R"WU=.!Z#')]D]C4I%E#E>61DY!8^OD0Y>N:>7MY%3\/22 MQ>8)4K+.IMG)YC$?
Q7:%>Q\BW!MG,D66]Q%2!VT1%Z=^C$ [^TQ58F M11PY M<4>]?)!]&?2'1?!MB._B]H:XWL]2R"GX0/MF$\2)T40<(EE4ZRHX\ >T-RX" MA'(,7OFP"%-
.X.7>4=Y&]E*UE($:O[D)YO'881*)"-2LX:XH;SK<9^(^T39 M:CF%4Z%:N(4Z8:*VST.WF(6XPU/DD1,O404>3S5F_";AS81*5M4D45$,4,I9
M+U>5/;#M<%#DF+'&G8^\C9R"Q*O%A,);R#(VSU4ZR!-,VV7,0?B@HP<#?!!# MSY&M+L7&GA]%$CU%1,'VLMV15*7@V;8UM"?H 1B74;>$8YAC.%1^-Y(9?!]&
M#_!L.)XYGH_%\XYZTC$+Y83*2E?%FM00*WM4N-]\]XQZ]ARKM)YU/,(WPV!D M\YPFW_GKG7KM\.166R'LX93%7"]V[.!B9AEI<@4XRD-?TP+G>3N+E4D49+K
M8E7Z^;U.DNIW'[9AN0XVQ*D@\KCFULD=&&I(DFBO$>E"H[*_*)2/;Z-1@I) M>16I(C9 ?C8:AYLC'*690^EVZUB-2W@FU1FHH8IU$*<-Y>.K(CN!F@\G+DN@
MVX]Y\HFB\>A,.D6L@LQ3]B="*L&M@.;3Q8% MW'LMA0EJ@=P5Z??N]XLD_06(!F":]"QK%>RY5_]Z3/G??(;^JQD8S3V MKO9\6 W]K0==J#TC6#*4T:CQ5@^,C)S"
M!;)$RCSOPFDRCBKN"LFK)S(R=@]F8FT?M@%6YZZF;>14[@WEA9*3Q"Y7]% M.4"RF03*.^@SPEB-:O2 \?0:^FDY@G)5$6ME;F(S,G+R1?03*$^>BA\HBU6%
MO>*Z!1TY!4\P@6+/]?N!;]TA*F4>9F-DY!0RWB)15Y&OUA8)4K+"R^CS,OHL,Q4O&9EM^FTOHY]4B?(3O"&NM]T<@KM;Y(]\)RZ0R2+ M9541*V7V5'U!1T[!
(3]'@,7>4=Y&3L$2A&H"9.?,!Z'#]+3*ZW"?*W<@IG K5 MCZCIRQV>9HR<0E'IZC%%I=/V9I;U'6IR3;P]!USPRF@8>#!GJLQ= Y67T.0IV%4D\HF+S^=T2CF&.X5"MNB,J
M.9IF7T<\-5LOQ"-\,@Y'-VP=Z,2N*U7*DEA7/ZY3P5%97U1N*0UI."J3]4TH@R$B-<2]S%%:)1NMXVW MU-H\"*8).7 521:E1%]5G(Q&I5]2]$<7$2-'(K@5$NJE(@7"LJHIB@\:8.-
D9.O\WG0 MM9PS@C6]_\H57CJ1D9%3N#Z65)WGK3A-Q%&M2]*\1_^L0H$GO["5I:1Z/VR% M+4_DCA(&1DY!3$P;[-NSY=FI9^%U"EIXV=,_M_E3]3 MY4P+.G+R%%74@U'G(!T\]
[G^E7]')^,C)R"ZU=."Y^).'UU2908+'E6T)%3 M\/D::<&5>WMY&SD%;R]I=)X@)L),DBP>=+'B^CS@I%%&3GY(OK]=CP_HG3N ML:X05]M9&CD%'RC!\L[IND,ULU,
<]>S8C7Q.0HV%7SY+CR:V=V]SB&.89#I2>.*\L6A]O%\$W,W& UFA=^%%8S#$8V3ZC"-3'__M)I":K$ M*V(R7!&S<4Q%S.12$,NB4]F]?]?K'-WQ8]'"4$21GKL!697-$;J\"6PDE'I85
ML5+C=5H+CONN]V^]5>^S\M\#+QNP3R MP7WSL?WP^W6D_B7N7?!+NW,MP/N^""&R#Q'0RX&=Z"$$V^+!KSP;4U%"%DY M'!F69@T-S81Q-0]-X"WA)EI/!V,G>5\=OO=%SO8
M?&""3QZ*A0C]UK_[I7;GKM7ITYW?M/"5O88,[?=4>T6E@8.T[R5M!.^X%C3S M79N[\-P>9[;^V]#DY]LFC!W,A!_,-K)O M6P^EWFU;N.T^/W6?
F_UVMY,P*_6;_=8C$+TG=-.^%'NSN/W[@/!2>B2>M_9% M;/WVTN[_+GS"TM*PP O_G.R,/KUTFB]W[7]K+N&!6"K=N\XW\1NU;4>/QCI5
M^T/;A%'U%*BR3(75^>9(M^Q3;.W)AP;A@]>3DQ9?7^<OK=>;I:A]G#8^>,\Q6C)KX^NNR@E]9%8ZUU5+)?KHBJSU^F,J9'CS(>-$TV;NWU] MG/4:$Z8V=,A5RV)YC\M3#-"4HVD-
3;7-#6\/1U,BUTO*]:I852IB7:YR=+&+ MKNW70K:T_#P<7@E="RE7RF*]41.EAKH_P#)Z!801L&S%2OU$472LD%$54:Z] MHB*Q9P\=>]L^Y[*.&=\@;\LMXLB?

*U@_X/X[H:R8TI)EH*R8_!OI:3*B423%;DF MUBH*^H".GT$RTG 8DXEDERNB M+/,S$D9&3]&_0Q)RDC<:R=O(R0-1K<<'Q..E7TU4&C)SH&.SFBWOMY@^__!^
MB]FFW_9^BTGU63K!G^$J.DLCI^#&)-5O,74W1Q9KDBHV5/94?4%'3L'1*9\! MO-P1RMO("3A"T:X#B0$U?_*3S1.ILB1_^OZ9$,4Q!C.\4ZXP!7TF&!9VG7!E M)9=65F("Y?
GEKT9Y=G]40.=-:"Q+H]+RZZ:,C)P\5B/M MIW?I@+-!=8-)+?&D6T9&3L$-W#>X%A-*$W$"&[*H*#S$QLC(*3B!!\4N3@_L[8L_Z*(DB05L_!+GK"VK!:S VMG MOHX6
AI'6191!HY7/3F8)>%D+2$GRZ)4Y[!C&'8[/*=:1DY!#);C MU[9Q"#@Y8>N-S8.N#O($TW89N_SU03,0!C@BAG8E6Z^+;6P74B0A5$04;*_1 M'#E4 IX%J6E/T
,P+J/WR3B&.89#I7O5>#%|@+?#\=]2BCEDH)U22 MNB;6*ZI8D1JGX3NC[CS'*]V%'8_PS3 8V3QB"K?2N6O=^IUT9!8[Z:SA5 6< MZO9L8")F62DRQ7C*RA_3?
2?!]$)5K"D5L;I'BN$Z2ZGEUL2&6Q4?VXQ"=':>91NMTZ;L0E/)/] M*E15Q%I%$]M[I&CO!&H^G+@L@6YKOHETHF@\^K9W5:R0+,"/$Z=9D'F\8Q';
MA\%Y6VX11^8DSOW(G,2Y'YF3./2EM7D]J*",G7^'OH+MR!Q30 M5$N2')Q:M$EY*FQ7^:I3WU0.'E=(^P04^G\D4NTU=;^P4@;I^G$^=J' DV?8
MU@^*;,0!6^X1YFWD%#S"1/HQ.@.@MBL,]B!@,UC,UY*FQ'&:E0WIQV>5DH[M+4=0K8N5*]]2S,C(R6/U($OE;%"-Z@:USMU 1D9.P0U,H.)K^H>#DB0]9>X% M,C)R\JAM'!2\.!VUW
?,V\@I^(_'!8*/QN@I,K.J9MP%Y$7FBE,>A!>9XRC8 M54+@B'I&Y\^TY!CF& [=Y#ZBSE%,SA;',\=S_(6[&C$+Y80]%-1%M;R(=5YD MKL!8;4CQ"-\,@Y'-
T[=PD;G'YO/MKX(J"Z3$G,]TS"]]B;F&='B)N22/W7") MN7I-K"L?QSI8*!F2$21GKV+-L562$CMGPR7FZGOT,^>HS"\JY6/K**5RKE9N M2&"(J**L?MQTD;,T\RC=;AO+
<0G/I$K,U611;]AB63ZQ+E@^7+@L@6XKYI03 M1>/1MR D42[7Q,H>S918D'F\Q!S;)\EY6VX11^8DSOW(G,2Y'YF3./8DY7F*N*",G7_EBW^M.1Q26*8?.+;LE5>
(EYO(X<@H72,Z!T81*S%4J MLJC*_!X)(R.G<(\DP1J>6\'++Y/D;>04+I-$;=TIXB3E6^*M1 MWO>N]L$EYHXULP]*<9(5L5YA[RI704=.OL3<0P%?-H\#GQP;O$T=W#WX3O#&2'
U$PGVB)\%IFI4[YT30CVP#GHG M7YW7\6O(]]CP(#4K(R]"ABBKO/8](R.GX/,=5/SV>'PFE0A: M5D4>HV!FY!2\O8-B%,?CE7MY>1LY!2_OH$8B!V/SE'1/12PWV&MMRN81GR+)
M9:%M#9'E&6](H"=^X(V/$&R*S@B:L\]'VXO8U!8GYL.WR?6"$H00"SH$WM7Y M?+EE51M%E/8H0I+UVC6YQ%]]O ?6FA,01-[9?+(0T#C*LH@R<+.JR<$L"==]
M"3E9%]4ZAQW#L-OA+%620QUWD/(V<@IBL"+%#I@X!)RZH.7^LCVR,DK56E%]1(F:OL\=(M9B-?Q*/+(:?@2M9@!F*P#H=1D ML5'|N'HZ|R 8%':-
:LQ8XVY#WD9.PVV0XT%A)F09FX(1OAL'(YCE-N*_JWU\Z+4&5>%O56/@HH0:6T330/=]])G;CJ%P6 M:^6Z6%8_SO]DH4U61I"P]3G^KP94B'60Q;ONNYU^J=?^3PO|
M3/PN@7QPWWQL/_Q^+:R_37AL/Q_2[EP+\+XO0HCN..41.; 3/81@6SSXE6=C M,NK(P]VX1H:E64-#,V%-R]7)W)Z8LBVQ2\;F [@"A"*1!)UQ)Y(7EU M9%4^<27I+X
\X(BI!FK7>B6X^>K38*/_?!'FIO%T,':6\]GM>5_LX/.!"5YY M*!HB]%O_[I?:G;M6IT]W?M/&U-8:,K3?4^T5E08.TKZ7M!&\XUK0S'=M[L)S M>UQE\]^&)C=?-6'L8*;
[J=^]O;CI$R+8(^$6\["%DR\U>!%^,!5D[P9!:.=,_M-/(2!(5MP]B@QQH+^?I!'"5N3KQM/91ZMVWAMOO\U'UN]MO=SMZ$96#Z7_'X M
6]IGO:ZF(ANN%-3FU\+AF6"U7%!E,MP!"ON8A]IM>Z$7K_9;ST"Q_2$[KUP MV^S]*MP_=/_5^W]%W[H_P!G8ATZ[TQ(>X1V_]H06K.\NB):18%E9T"Q]+6K& M_IH^O72:+W?M?
NON\P&R)D&_(NT WEBGEM>"%$K:W4)3=]WX%]=]VSR_;!/? M^5$@DL(P252I>8YMO=Y@R0VZB/ZQ:6LWG@$5AF?S0%^55?]>4V"<_<3L?-]@
M2$'3HFXZ3W(^@C9QAC#CS,^7Y4@CGB?"AG>CK0160K21LJGA2L52:S+DMBH M'=!-(:-1[@P_(9)"]_$0E! 03HQ;*V6Q4E7%RAYQZ[SE" G!_U';I*G_,7,] M$CG&L64'P<8/#1/!;ZE\
(XUKX-]#S1T+,QQU-BS!GB)'\PSK5<"[]F9X!G*O M&%96$Y\XCR]=2+NC(12(QBW;70G]I9,IW: H2RR"=L$G,5IO8,.C_R Z#%C=Y.I(:.#A8,!4 MF]/@0:B?
+:LQT5RQ4.3B4%#EI#LBN9]@_/Q+::W5 MZF*EQIXE5-"1D\=C-.O]=#S&*.S+-56L,=A$.0.6.]\7]T)Y@YY)SV .C%*;G%1]T]]B]W MU(^0W;>A)].$3HXQF'D@QSU;*$ORI^^?
A:FI6<*GMC5T<.#E\Q5L/OD7/N8# MC"&/'^REP6U]N&IAZ-KT[9)H?;LUF9KV'*%OR$(CPWL"TB4M^>6J(C:XW&=E
MY!206(X3B7'&:RHUL295F4,B\R8\I;^!+PW26UFX+36::H8>A-EYP":%?*?H M'=U Z=[Y*K=M^71)*>HN5X"ASF]7?68*"=G'X X(1HY+CX)@?$(]W*VL+I9E M]NP,YHW\#=*]-YM.30-
^3-+U<&#^^:_:9/KEC]3(P+MF(]A=TF.4$>AGG^EV M"?[("6N4Z]K6&]#/=HRM;2KCB^5(95$ZI,%KUC.@\P6FR-'IX6"*-Y&ZW#C@ MF"=O2=1;)/
=FM]NP5MDI<(1T9/0"$<$]$A8MH:*+%7%^A[EZKB,91%1:O0L M\S!$)6(@BVH99Q@R)&S/$],.:'U*0A5?\:Q:M/0!H,);Z(4[H"04!8+^|@R8&-1W)$SZZCB#NCR1,F2FD58:8 &K_'FZ
PC M:P>P(G>5CP-6C)YWM2I6Y8R?AC$2+P7*.3/$3\/29*CR7@R%R?*P-.R33W:H MB95#6C86 0RYAN$>9[)[PC#6H"HN)7^_J<"B;&?$#+^;(9SLAOQ\%<9D>Z&Z
M2>U@PSW.I8.,HV=D:EZZ6D%MB,"2O)T?!_5!H-[CV/=_4,>I8^]BO$<9+!8P M?:Q+D4_N8H:)\AE]+.C(12(QTV9L50]*2WY8<(V%O2RHUM\5@]]4Q?<6:/GD
MV&^&CO1O\Q<@:MO]!B1M+BB:6C!:5L5&HRQ6I,-;0/$FOCG";B1UYD2L)I'X M(-?$N]2*M3U2%L_:XY=;GMPLX2-S$F?,\KRX639R$NZ?NX]"N_//5]\/3ZD]$DX+.G*12,ST.3TM3?
XTS3(SNW%)BJ"R2U@W?!F#](5'J<: M[CX+F^^R=KF)QW1\KHJV55GGJK;E:=:K,3!DQ3X2?X 753DC^^M\$ACQE&Y M Y21=+_C0/FAA/\?Z2@(Q>)Q"R:G-'S[OMVI]FYY>?
=Q<5I04% P_/8Y^/![&"KCS\)FLHS:.*+5D13N@#38YE_V-0H51T_\"$41:ZHD M2@S>"B[HR"G ,)*=?1P,XZS!+U8]BE@^I'HLB_+]/(?IP9$7ENBT(\M"QC-X
MGIYAEMH1_]E$2CL&5/';U 5L=8LIDKA4QW=PQ4]-%V/.*)]VIL;MC:8XKW3+ M^);_26A\E8?=),9[8V1,/4329>"=S"'?X^,(7)K;#97#R9DWE
MPR)]=S.$N:/K4ZAIZ829QK:IPY_IG19)8E7A]C8C(Z<-S_^+_!T!S+0REKB] MO8T73A)]^A_;[97*7]S)D\)RC-!(MJ;X3$1IKR!TWOE5KZ2/T6!_9[8*LU92WI9;Q)&+1&*FCH\7U+
[IT"%$WM#L*-+(F](HNURHE9W440BAS5*ZC>MTC?O]B_MLPF-4A>KRHFF*8OJAYNSW-;A(W,29\RROL(,LTI4".); P_-:%BTA6U)D]'-'GCH=/LC5PD0Z2@(Q>)Q&S:
MFEMM2U'XUQJEW>G@.[7=>^&I]=SNWK&PCSRXM*[X(\FX)RG^53W>=+LCJKL; MI^3.B'*Y(M;42B:B3!S;[& [DL\;/[:5T["M*&*UHBR^K$YR@*XN5G+;9YB M;#0G,7/RA
6SM@6?9L.@54&EZO9L8*+CN3D0OPH_\6!? MK9?%ZA&G^BHW3G.$T\AM@T3^S\M\-'QE 7RP7WSL?WP^[6P/FGAL?G\ M2[MSC9-0OP@AI3,$18
<>';/(=@8#W[EV5@OZ,C"U;'|K%3-A'$U#Y&["I=K M"[[R!K8^Q__50./%NJODC<'K!K:C(X=0T;!>KR7R0O+]R'I]PDO27T#) ->ZF MFHZ/!(F*^NI/=R.=+L*8'4\'8V8"N2KW;MG#;?
7[]/C?[I6XG MX0&[F.2]UIW0ZS?[K4?L[F%/;UDK--GQ.^U.2WB$=_S:PTXFS./O+_")*HD" M=E%(D1)L R8[BT\OG>;+7;O?NON<[$![^Y+0CTTT\A(3+(G]NK0U^EB/.]@>
M$&ZI#I4D5=Y7\(MLZ_4&0__KE?_'|]W=&!1/W73C]#V>OB]K]-W3GD@F!-E[M>7IZ(%]H^2#T;G]MW;T\M+_^ZG0[):*30DV:.W=,E[!>\OO0^%R(7]Q,_W M*9)88[
L+E,C,PNE^NE0XG7>TFSA<1^6G*&R0()AX1QSVCQ.&PYAS:=,^.?847CPGH4GTY\R8XB.(%0$\G#D._LPTM(%A,E@W@WU>D<.\
M$FQYT]);P88'=H]]9)E;NNT/RUU/W/@5:WOD%3! YR*,G (JE>10R>WH5%OA MV98L,TF#91G]PX1#X?.#.%\HZA$]FQA@$)R MF99R^_0T%S)-
FES^9M_C++K2]L4,KSC+"C$*+3;MX44J/ M=N;C48UX.:46C0#"7I,F:><,8S1DL5'[^)HY Y3EF(I@JAXCIF*4NY6Z*-?8 MN]1$]C[H"=& ZPN-<1R@SVKGM]P MYN]Y&!O-2UW(
=UPIZ8VOP;7R30L=$'L.L*I%S>=;K_5$_I=87EUVK^%A]^L+2Y1PUK@ M[3L9H_G]W6=]DG9F$^08P[#1'"G'_DUS M#;
<[>@+#&=9*L[,S[0UK!G2FV!TXS_^6RE71KH2@_)]7@H4=?YKR$:!V6X[9&G7Y'X4@=S- MMV:O3:[B/SVW>OA").800L#>RR/L]N_XNU[[ET[[OGW;[/2%YNUM]Z5#KD8^
M=1_:M^W6$H1I$3:605;E]*52,:PM(^^]EQA%6)B&<93%S5G^WZYMZ8\1N00R M@?7-Z6'>+MN":)E &MO.U-] X9,'[_GK3W5%D;[1O^0OGP7-0>!\:C,= M;#R=I$(/P7;2#'P3A?]K^
WX\Y%M>UAT"B!4AZ;MSAR\.OR(:+ M3+R'WTXVHED>A@[0T) X0LP9X8'GYF.G-P%I&'C33\4V>&7XV7Y]#7F>FW MY897X"][:#ASR $+>2+H^"#@$V_#=>'12^%?8P-4.Y 6+
>2.^[_UM]C&-TT MT!NV"L>:1[X);]V40ACO.M! T]&?,U@#GMQ$^X[(XV$2+!\'(@@P!Q-IV"H3 M\9,NHL%!8_(11-RQ/3-UG(X#E@X]#K:M/V86#7L0$N"1-_X6;P0U<]>I'4*5
M7/OB!M0'.MN.AQN?W\,Z@$=*_R"!3/R3.=(<-5GX)3U,T"S=_NP^4+G7)1/1%DH %;Y@-B.R= M8#_-1]]2[# E8#A$<0S3GEF^[O/FEP+8FH 'F!7FB1F1^%C:=;_&_)9'!.QK
M@_5FDPF6"IB]EN:[L+3?A<" OT[=,MO]CT2.@/P*INM]G_#,YZV : O('0!C09$_]I-)]9 +0WZAR, MX!\8*BZ8Y18Q00&GY.KNV :KV)C@MNF!M0NZ+#PR>349&,,>_NV;/QM&&Z'@
M2PW78A!\.X9PBO\%N?B/M>)OHQ MI38081=@8IPE!@;2KGU^.] [7A489P)X'GA%P)(#XF!CK8?P;/'.&B.B4\.# MTLV!W8*YPS@,.EDD_M0&(6-YMC/])%/U9M.IB7W1&7$#
$_/?]4FTR]W/G"L MV4@;8I$)O.$S&>6XQ0\QPY1H7YYTO!=[.Q@/<$&K1Q29@" M#<>6;=JO<_PZ&_L]PM!PAK,)=E7P+24]S\BOP7R8D6&C@XF"-@4M_;82CM:L M>!IV2"S3-^
MF9)>HL3YHOCA]0<'#K200C4S[W5WN("G5CV>F;NJ/43]S^&OL>^-CTM\EUTD$PP; M6YC8CD-B$_[VA%Y$K3U8X&P9!EM?U'L0>:*1L!'X5PCKN@'RWG&<;E69DG!# M="
R83S7U@DO"&8@/[KOYCFV& 0FN ;B.(P-';7V;112FV![&3+BT7(C4T$(LA5>(N1L% M\5E_#L39T(+8$ZU/)\RFM, 2:#T2OPTOPG\D"'X["'"0-(E$&$=AT. ;1Y<"< M3&V
76*P(T*SPI"T1^ 'H_6IOFD4HW3"H!\?EZ:4&]3-"X4N0.61.6/%:! 1 M!2P"Y,"D)AC)$*\-!_OX0OPCH!I]7T[U,PAB63C XI+16ZY!-$BND8O@VW M%LBE/R*&*K4E?6M1U@]\-
<.S0#^0,#7B#.P/SU1^(;K2! MFRGCG8&-A3UT['<\20F'>;5%HFWX:'[#H;T^ MK(Y&PXL=FC;29*L'#@;ZAN4$%D_,V2P[M1/.VA;F#!@F..0BYLEXYPLK$16
M)H27MF]MA[^AGAVQ#C&HM,-3E";O5NA)M=%@<0GP[,)IDCN#&]8PB?_G-I_0W!.[N M#HD;&=9TA@U[D*O %>YUX-P8WQ%Y(3U@"W0X/=(+[MK2N9*GZ!?$<*'^KT$-
M%=&WDMSOI1$.;#I47_F!GS<;]W5\4D*G&R;D,$+N5?_A U=,"*9>&5D96# M)X""(@Y89>$P[=*:R>,92-@B',.^+ 2%CU"V(O WD1V)7V")]::'/B90"'BGZ,5:1&M(YPD"4P
M!,&SP4ZX_U+_A,47-_0)(I;A^X7QO>#BQ?!D>>HN+.6EB\NU$_$>\#@^3#?\ M-!C+G(LK!C[F!RIOL/L-1M5L0K%.K-&E? N)]F"&1&;Z=;ATL-'!C3!MU_Q
M&:+%ZC:2@,][I5P,;L%1WR$TCW77X.6R![]UB&Z;^T][*SM&U=I"AQ$[&]?A MF$$L9Q%+"<>!;-]]A-T